<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Mol Cancer</journal-id><journal-id journal-id-type="pmc-domain-id">117</journal-id><journal-id journal-id-type="pmc-domain">molcanc</journal-id><journal-title-group><journal-title>Molecular Cancer</journal-title></journal-title-group><issn pub-type="epub">1476-4598</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11748575</article-id><article-id pub-id-type="pmcid-ver">PMC11748575.1</article-id><article-id pub-id-type="pmcaid">11748575</article-id><article-id pub-id-type="pmcaiid">11748575</article-id><article-id pub-id-type="pmid">39827147</article-id><article-id pub-id-type="doi">10.1186/s12943-024-02214-5</article-id><article-id pub-id-type="publisher-id">2214</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="M">Man</given-names></name><address><email>wangman@qdu.edu.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yu</surname><given-names initials="F">Fei</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="Y">Yuan</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/026e9yy16</institution-id><institution-id institution-id-type="GRID">grid.412521.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1769 1119</institution-id><institution>Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, </institution></institution-wrap>38 Dengzhou Road, Qingdao, 266021 China </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>24</volume><issue-id pub-id-type="pmc-issue-id">478187</issue-id><elocation-id>26</elocation-id><history><date date-type="received"><day>24</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>25</day><month>12</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>21</day><month>01</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-29 02:25:49.533"><day>29</day><month>01</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12943_2024_Article_2214.pdf"/><abstract id="Abs1"><p id="Par1">Clinically, multimodal therapies are adopted worldwide for the management of cancer, which continues to be a leading cause of death. In recent years, immunotherapy has firmly established itself as a new paradigm in cancer care that activates the body&#8217;s immune defense to cope with cancer. Immunotherapy has resulted in significant breakthroughs in the treatment of stubborn tumors, dramatically improving the clinical outcome of cancer patients. Multiple forms of cancer immunotherapy, including immune checkpoint inhibitors (ICIs), adoptive cell therapy and cancer vaccines, have become widely available. However, the effectiveness of these immunotherapies is not much satisfying. Many cancer patients do not respond to immunotherapy, and disease recurrence appears to be unavoidable because of the rapidly evolving resistance. Moreover, immunotherapies can give rise to severe off-target immune-related adverse events. Strategies to remove these hindrances mainly focus on the development of combinatorial therapies or the exploitation of novel immunotherapeutic mediations. Nanomaterials carrying anticancer agents to the target site are considered as practical approaches for cancer treatment. Nanomedicine combined with immunotherapies offers the possibility to potentiate systemic antitumor immunity and to facilitate selective cytotoxicity against cancer cells in an effective and safe manner. A myriad of nano-enabled cancer immunotherapies are currently under clinical investigation. Owing to gaps between preclinical and clinical studies, nano-immunotherapy faces multiple challenges, including the biosafety of nanomaterials and clinical trial design. In this review, we provide an overview of cancer immunotherapy and summarize the evidence indicating how nanomedicine-based approaches increase the efficacy of immunotherapies. We also discuss the key challenges that have emerged in the era of nanotechnology-based cancer immunotherapy. Taken together, combination nano-immunotherapy is drawing increasing attention, and it is anticipated that the combined treatment will achieve the desired success in clinical cancer therapy.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cancer immunotherapy</kwd><kwd>Nanomaterials</kwd><kwd>Antitumor immunity</kwd><kwd>Nano-immunotherapy</kwd><kwd>Tumor immune microenvironment</kwd><kwd>Clinical cancer care</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par144">Cancer remains a major public health challenge globally, and the future burden of cancer is expected to increase because of population growth and lifestyle changes [<xref ref-type="bibr" rid="CR1">1</xref>]. According to the global cancer observatory data (GLOBOCAN), over 19.3 million new cancer cases were reported, resulting in approximately 10 million deaths in 2020 [<xref ref-type="bibr" rid="CR2">2</xref>]. Conventional cancer therapies, such as chemotherapy and radiotherapy, show limited efficacy and applicability, hence highlighting the urgency for seeking more effective therapeutic measures [<xref ref-type="bibr" rid="CR3">3</xref>]. The body immune defense system is the most powerful weapon against cancer [<xref ref-type="bibr" rid="CR4">4</xref>]. Over the past decades, cancer immunotherapy has emerged as a beneficial treatment strategy for cancer and rejuvenated the field of cancer immunology [<xref ref-type="bibr" rid="CR5">5</xref>]. Several immunotherapeutic methodologies, including cancer peptide vaccines, monoclonal antibodies and immune checkpoint inhibitors (ICIs), have changed the classic cancer care landscape [<xref ref-type="bibr" rid="CR6">6</xref>&#8211;<xref ref-type="bibr" rid="CR9">9</xref>]. These immunotherapies have achieved remarkable clinical responses. Nevertheless, their efficacies vary, and only a small proportion of cancer patients can benefit from these immunotherapies. There are many reasons for the limited efficacy of immunotherapy in the clinical setting. First of all, immunotherapeutic approaches have some kinds of disadvantages including low targeting ability and unwanted adverse effects that hinder their clinical application [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Secondly, immunotherapies work by releasing the brakes on the host immune system, allowing it to destroy cancer cells [<xref ref-type="bibr" rid="CR12">12</xref>]. However, this can also cause the immune system to mistakenly attack normal cells and tissues, resulting in severe or even fatal immune-related adverse events [<xref ref-type="bibr" rid="CR13">13</xref>]. Thirdly, cancer immune escape and resistant mechanisms may overpower immunotherapeutic modalities under certain conditions and contribute to unsatisfactory outcomes of cancer immunotherapy [<xref ref-type="bibr" rid="CR14">14</xref>]. In addition, it is challenging to deliver therapeutic agents or immune cells into tumor sites through an immunosuppressive tumor microenvironment (TME) [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Particularly, application of immune cell therapy to solid tumors has proven far more arduous, as solid tumors usually exclude immune cells [<xref ref-type="bibr" rid="CR17">17</xref>]. Thus, the rational design and development of advanced cancer immunotherapies remain a huge challenge.</p><p id="Par145">At present, the medical and research communities have attempted alternative strategies to address the aforementioned limitations. One of the emerging area in this field is nano-immunotherapy, which potentiates anticancer immune responses and sensitizes tumors to immunotherapy [<xref ref-type="bibr" rid="CR18">18</xref>]. Specifically, targeted or stimuli-responsive nanocarriers are generated to transport bioactive agents in their native conformations to the target site, which amplify their anticancer efficacy and extend the survival of cancer patients [<xref ref-type="bibr" rid="CR19">19</xref>]. Nanodrug delivery platforms offer numerous advantages in cancer treatment, including high stability and biocompatibility, enhanced permeability and retention (EPR) effect, reduced adverse effects, and precise targeting of cancer cells [<xref ref-type="bibr" rid="CR20">20</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref>]. With the deepening and expansion of research, nano-immunotherapy has become a new hotspot and trend in recent years. In this review, we summarize recent research advances in nano-immunotherapy and focus on the mechanisms by which nanodrug delivery systems enhance the anticancer effects of conventional immunotherapies. We also discuss the challenges of nano-immunotherapy and critically analyze the outlook for this emerging field. Gaining insights into the roles of nanotechnology in increasing the efficacy of immunotherapies will provide valuable insights for the development of nanomedicine-based therapies aimed at improving patient outcomes.</p></sec><sec id="Sec2"><title>Types of cancer immunotherapy</title><p id="Par146">The cancer-immunity cycle is composed of a series of functional stepwise events that are required for immune-mediated control of cancer growth (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR23">23</xref>]. The cancer-immunity cycle is initiated by the liberation of antigens from dead cancer cells [<xref ref-type="bibr" rid="CR24">24</xref>]. Cancer-derived antigens are taken up by antigen-presenting cells (APCs), such as dendritic cells (DCs) [<xref ref-type="bibr" rid="CR25">25</xref>]. APCs process cancer-associated antigens into smaller peptides [<xref ref-type="bibr" rid="CR26">26</xref>]. These peptides are exhibited on the surface of APCs, along with major histocompatibility complex (MHC) molecules [<xref ref-type="bibr" rid="CR27">27</xref>]. Afterwards, these APCs migrate to the nearest draining lymph node (DLN), where they present cancer-specific antigens to T cells [<xref ref-type="bibr" rid="CR28">28</xref>]. Effector T cells are primed and activated after recognition of peptide/MHC complexes by T cell receptors (TCRs) [<xref ref-type="bibr" rid="CR29">29</xref>]. Activated T cells then move to the tumor through the circulation, infiltrate into the tumor and eliminate cancer cells [<xref ref-type="bibr" rid="CR24">24</xref>]. Effector T cells can directly kill cancer cells through the perforin/granzyme-dependent granule exocytosis mechanism or the extrinsic death receptor pathway [<xref ref-type="bibr" rid="CR30">30</xref>]. Once cancer cells die, additional neoantigens are released to actuate a new round of the cancer-immunity cycle [<xref ref-type="bibr" rid="CR31">31</xref>]. The cancer-immunity cycle highlights the tremendous potential of immunotherapy in cancer treatment. Immunotherapy has recently gained considerable attention due to its high efficacy and low toxicity. Based on the critical mechanisms of the cancer immune cycle, current cancer immunotherapies mainly include ICIs, adoptive cell therapy, antibody-based targeted therapy, cancer vaccines, oncolytic viruses and cytokine therapy (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR32">32</xref>].<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>The cancer-immunity cycle. The cancer-immunity cycle comprises a series of functional stepwise events that are required for immune-mediated control of cancer growth. The cancer-immunity cycle is started by the extravasation of antigens from dead cancer cells. Cancer-derived antigens are absorbed by antigen-presenting cells, such as dendritic cells. Antigen-presenting cells then process cancer-associated antigens into smaller peptides. These peptides are displayed on the surface of antigen-presenting cells, along with MHC molecules. Afterwards, these cells move to the draining lymph node, where they present cancer-specific antigens to T cells. Effector T cells are primed and activated after recognition of peptide/MHC complexes by T cell receptors. Activated T cells migrate to the tumor through the circulation, infiltrate into the tumor and destroy cancer cells via the perforin-granzyme pathway. Once cancer cells die, additional neoantigens are released to initiate a new round of the cancer-immunity cycle. APC, antigen-presenting cell; MHC-I, major histocompatibility complex class I; MHC-II, major histocompatibility complex class II; TCR, T cell receptor</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="12943_2024_2214_Fig1_HTML.jpg"/></fig><fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Types of cancer immunotherapy treatments. Current immunotherapeutic strategies used in clinical cancer care mainly include immune checkpoint blockade, adoptive cell therapy, antibody-based targeted therapy, cancer vaccines, oncolytic viruses, and cytokine therapy. PD-1, programmed cell death-1; TIM-3, T cell immunoglobulin and mucin domain-containing protein-3; CTLA-4, cytotoxic T lymphocyte-associated antigen-4. ILs, interleukins; IFNs, interferons; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; DR4/5, death receptor 4/5; FasL, Fas ligand; TCR, T cell receptor; MHC-I, major histocompatibility complex class I; DC, dendritic cell; CTL, cytotoxic T lymphocyte</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="12943_2024_2214_Fig2_HTML.jpg"/></fig></p><sec id="Sec3"><title>Immune checkpoint inhibitors</title><p id="Par147">Immune checkpoint molecules are a series of inhibitory and stimulatory molecules expressed on cancer cells and immune cells [<xref ref-type="bibr" rid="CR33">33</xref>]. They act as physiological brakes of the immune system, which are required to maintain immune homeostasis and prevent autoimmunity. Cancer cells have evolved to utilize immune checkpoints to evade immune surveillance [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Therefore, checkpoint molecules represent prospective therapeutic targets for cancer management. ICIs can enhance antitumor immune responses by suppressing negative modulators of the immune response. Programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) are the most well studied among immune checkpoint molecules, and their inhibitors have been used as a therapeutic regimen in the clinical intervention of several cancers [<xref ref-type="bibr" rid="CR36">36</xref>]. Other potential molecules and their ligands, including B and T lymphocyte attenuator (BTLA), lymphocyte activation gene-3 (LAG-3) and T cell immunoglobulin and mucin domain-containing protein-3 (TIM-3), are also considered as prospective targets for immune checkpoint blockade therapy [<xref ref-type="bibr" rid="CR37">37</xref>]. Despite the fact that ICI treatments exhibit durable clinical efficacy against a wide range of cancers, checkpoint inhibition has not fulfilled its early promise. This is due to the common occurrence of severe adverse events in various organs and low efficiency associated with ICIs [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Low counts of tumor-infiltrating T cells, aberrant regulation of immune checkpoints in both cancer cells and T cells, and acquired resistance to checkpoint blockade may contribute to limited responsiveness to ICIs.</p></sec><sec id="Sec4"><title>Adoptive cell therapy</title><p id="Par148">Adoptive cell therapy has emerged as one of the most promising cellular immunotherapies, which involves the intravenous adoptive transfer of autologous or allogeneic tumor-infiltrating lymphocytes (TILs), TCR-modified T cells, or chimeric antigen receptors (CARs) into patients [<xref ref-type="bibr" rid="CR40">40</xref>]. Early studies exploring the application of adoptive cell therapy for cancer treatment primarily concentrated on TILs. TILs are able to recognize antigens on the surface of cancer cells. In TIL therapy, naturally occurring TILs are collected, genetically activated, and undergo ex vivo expansion. Subsequently, the TILs are transplanted back into the TME of cancer patients, where they elicit robust antitumor responses, contributing to cancer regression [<xref ref-type="bibr" rid="CR41">41</xref>]. Although TIL therapy holds great promise for cancer treatment, it still faces many challenges [<xref ref-type="bibr" rid="CR42">42</xref>]. The frequencies of TILs are very low in cancers, and thus they require extensive ex vivo expansion [<xref ref-type="bibr" rid="CR43">43</xref>]. The success rates of ex vivo TIL expansion vary among cancer patients [<xref ref-type="bibr" rid="CR44">44</xref>]. In some patients, TILs cannot reach the necessary quantities for therapeutic use [<xref ref-type="bibr" rid="CR45">45</xref>]. To surmount these constraints and harness the full potential of adoptive cell therapy, innovative strategies utilizing peripheral lymphocytes have emerged. The instinctive anticancer potential of these cells may be further enhanced through genetic engineering. In most clinical studies, peripheral blood T cells are genetically modified to express a specific TCR or a synthetic CAR [<xref ref-type="bibr" rid="CR46">46</xref>]. TCR-modified T cells can specifically recognize cancer antigens in a MHC-dependent manner [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. TCR gene therapy specifically targeted various cancer antigens, such as melanoma differentiation antigens, C/T antigens, and carcinoembryonic antigen (CEA) [<xref ref-type="bibr" rid="CR49">49</xref>&#8211;<xref ref-type="bibr" rid="CR51">51</xref>]. It demonstrated clinical efficacy in patients with melanoma, synovial sarcoma, or colorectal adenocarcinoma. Nevertheless, engineered TCR-T cells cannot differentiate between cancer cells and normal cells expressing target antigens/epitopes, thus TCR gene therapy may damage the corresponding normal tissues. For instance, patients with metastatic colorectal cancer (CRC) that received CEA reactive TCR-T cells were reported to develop inflammatory colitis, which was induced by T cell recognition of CEA in colonic mucosa [<xref ref-type="bibr" rid="CR51">51</xref>]. TCR-T cells targeting MART-1 and MAGE-A3 caused fatal cardiotoxicity in patients with metastatic melanoma, owing to the high abundance of these two antigens in heart tissue [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. Anti-MAGE-A3 TCR gene therapy resulted in severe mental disorders in patients with metastatic melanoma due to the cross reaction of TCR-T cell with MAGE-A12 in normal brain tissue [<xref ref-type="bibr" rid="CR50">50</xref>]. Identifying antigens restricted to tumors can help improve the efficacy and safety of TCR gene therapy [<xref ref-type="bibr" rid="CR54">54</xref>]. The emergence of CAR-T treatment has revolutionized the field of cellular immunotherapy. CARs are synthetic membrane immune receptors that harbor an antigen recognition domain and an intracellular signaling domain [<xref ref-type="bibr" rid="CR55">55</xref>]. CARs are capable of inducing lymphocyte activation and costimulation [<xref ref-type="bibr" rid="CR56">56</xref>]. CAR-based immunotherapy has the potential for broad therapeutic applications in cancer treatment, as CARs interact with surface antigens on target cells in a manner similar to antibodies [<xref ref-type="bibr" rid="CR57">57</xref>]. Moreover, CARs not only target proteins but also recognize lipids and carbohydrates, making them an ideal tool for adoptive cell therapy [<xref ref-type="bibr" rid="CR57">57</xref>]. Reportedly, CAR-T therapy contributes to durable tumor growth control in patients with relapsed and refractory hematologic malignancies [<xref ref-type="bibr" rid="CR56">56</xref>]. The undeniable toxicity and high costs associated with personalized T cell formation are likely to limit the widespread feasibility of CAR-T therapy. Additionally, antigen escape and early exhaustion of the CAR-T cell population are significant obstacles to the effectiveness of CAR-T-based immunotherapy [<xref ref-type="bibr" rid="CR58">58</xref>].</p><p id="Par149">As stated above, adoptive cell immunotherapy has shown clinical activity in several tumor types. However, the clinical benefits of this treatment modality in solid tumors appear to be limited. Some factors contribute to the suboptimal performance of T cell immunotherapy, including low efficiency of T cell transfer, limited activation and short persistence of infused T cells, and challenges in overcoming the hostile TME. Attempts to tackle these barriers have led to new approaches involving the blockade of inhibitory signals, optimization of cell culture, supplementation of cytokine costimulation, regulation of T cell metabolism, and integration of new genome-engineering technologies into cellular immunotherapies [<xref ref-type="bibr" rid="CR59">59</xref>]. Ongoing research efforts will hopefully broaden the clinical application of adoptive cell therapy to various cancers.</p></sec><sec id="Sec5"><title>Antibody-based targeted therapy</title><p id="Par150">In recent years, monoclonal antibody-based immunotherapy has emerged as a potent clinical tool for the treatment of numerous cancers (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>), complementing chemotherapy, radiotherapy and surgery [<xref ref-type="bibr" rid="CR60">60</xref>]. Three classes of monoclonal antibodies are used to enhance the immune system of cancer patients, including naked monoclonal antibodies, conjugated monoclonal antibodies, and bispecific monoclonal antibodies [<xref ref-type="bibr" rid="CR61">61</xref>]. On the one hand, most naked monoclonal antibodies directly recognize antigens on cancer cells to activate antitumor immune reactions [<xref ref-type="bibr" rid="CR62">62</xref>]. For instance, Alemtuzumab is a humanized monoclonal antibody that specifically targets the lymphocyte-specific surface marker CD52 and has been used in the treatment of chronic lymphocytic leukemia (CLL) [<xref ref-type="bibr" rid="CR63">63</xref>]. On the other hand, naked monoclonal antibodies (e.g., cemiplimab, nivolumab, atezolizumab and avelumab) interact with immune checkpoint molecules (PD-1 and PD-L1) to suppress cancer immune evasion [<xref ref-type="bibr" rid="CR64">64</xref>].</p><p id="Par151">Conjugated monoclonal antibodies are paired with chemotherapy or a radioactive agent [<xref ref-type="bibr" rid="CR65">65</xref>]. Monoclonal antibodies that are linked to chemotherapy are known as antibody&#8211;drug conjugates (ADCs) [<xref ref-type="bibr" rid="CR66">66</xref>]. ADCs bind to specific antigens on cancer cell surface after they reach target cells. The ADC-antigen complex is subsequently taken up by cancer cells to form an early endosome through endocytosis [<xref ref-type="bibr" rid="CR67">67</xref>]. The early endosome matures into a late endosome that eventually fuses with the lysosome. The chemotherapeutic drug is discharged from ADCs via either a chemical reaction or proteolytic enzyme-mediated degradation in the lysosome [<xref ref-type="bibr" rid="CR68">68</xref>]. The released cytotoxic agent acts to induce apoptosis or cell death in cancer cells [<xref ref-type="bibr" rid="CR69">69</xref>]. Monoclonal antibodies in ADCs exert immune-related cytotoxic effects, including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [<xref ref-type="bibr" rid="CR70">70</xref>]. Radiolabeled antibodies (radioimmunoconjugates) consist of a monoclonal antibody attached to a radionuclide [<xref ref-type="bibr" rid="CR71">71</xref>]. In contrast to ADCs, radiolabeled antibodies may not require internalization. Once radiolabeled monoclonal antibodies recognize and bind to specific surface antigens on cancer cells, the emitted radionuclide leads to DNA strand breaks through the synthesis of free radicals, contributing to apoptosis and programmed necrosis in cancer cells [<xref ref-type="bibr" rid="CR71">71</xref>]. Radiolabeled antibodies can achieve high response rates with low toxicity compared to other cancer therapies [<xref ref-type="bibr" rid="CR72">72</xref>].</p><p id="Par152">Bispecific monoclonal antibodies are engineered artificial antibodies with two binding sites directed at two distinct epitopes of one antigen simultaneously or two distinct antigens [<xref ref-type="bibr" rid="CR73">73</xref>]. Bispecific monoclonal antibodies can target both cancer cells and immune cells [<xref ref-type="bibr" rid="CR74">74</xref>]. They act directly on cancer cells to induce apoptosis and enhance the anticancer activity of immune cells, such as tumor-infiltrating T cells [<xref ref-type="bibr" rid="CR75">75</xref>]. Bispecific monoclonal antibodies offer several advantages, including high specificity, low toxicity, and improved efficacy [<xref ref-type="bibr" rid="CR74">74</xref>]. To date, several bispecific monoclonal antibodies, such as Amivantamab, Blinatumomab, and Candonilimab, have been approved for the treatment of cancer patients [<xref ref-type="bibr" rid="CR76">76</xref>]. However, monoclonal antibody-based therapies have several limitations, including poor pharmacokinetics, inadequate target accessibility, high production cost, potential resistance and mutation, and the risk of side effects (e.g., cardiac toxicity, hypertension and thrombosis) [<xref ref-type="bibr" rid="CR77">77</xref>&#8211;<xref ref-type="bibr" rid="CR80">80</xref>]. These challenges faced by monoclonal antibodies restrict their use in clinical cancer care.</p></sec><sec id="Sec6"><title>Cancer vaccines</title><p id="Par153">The TME in different cancer patients is unique, and cancer cells express their own antigens to help differentiate themselves from noncancerous cells [<xref ref-type="bibr" rid="CR81">81</xref>]. Some cancer antigens are ordinary proteins synthesized in large numbers [<xref ref-type="bibr" rid="CR61">61</xref>]. Cancer antigens can also be novel ones due to gene mutations and solely expressed by cancer cells, which would be the target for directed vaccine responses [<xref ref-type="bibr" rid="CR82">82</xref>]. Therapeutic cancer vaccines are capable of eliciting long-lasting antitumor immune responses by immunizing cancer patients against cancer-specific antigens [<xref ref-type="bibr" rid="CR83">83</xref>]. Cancer vaccines enable the body&#8217;s immune system to recognize cancer-derive signals, thereby amplifying and diversifying the repertoire of tumor-specific T cells [<xref ref-type="bibr" rid="CR84">84</xref>]. The most commonly used vaccines are peptide-based, consisting of immunogenic epitopes derived from tumor-associated or -specific antigens [<xref ref-type="bibr" rid="CR85">85</xref>]. Synthetic long peptide (SLP) vaccines consist of 25&#8211;35 amino acids, encompassing various epitopes or a large fraction of the target protein [<xref ref-type="bibr" rid="CR86">86</xref>]. Thus, SLP vaccines are expected to induce stronger immune responses compared to vaccines consisting of 8&#8211;12 amino acids derived from cancer antigens. The inclusion of cytokine adjuvants can further enhance the immune-activating effect of SLP vaccines. For instance, in a phase 1/2 trial involving 11 CRC patients, the addition of interferon-&#945; (IFN-&#945;) to a p53-SLP vaccine was well tolerated and induced stronger p53-specific T cell responses compared to p53-SLP alone [<xref ref-type="bibr" rid="CR87">87</xref>]. The cell-based cancer vaccine is a type of cancer vaccine that utilizes the patient&#8217;s own immune cells. DCs, known as the most effective APCs, are considered an ideal carrier for cancer vaccines. DC vaccination can work by either directly targeting antigens to DC receptors or by generating antigen-loaded DCs ex vivo. Monocyte-derived DCs loaded with cancer cell lysates exhibited good tolerance and efficacy in patients with metastatic renal cell carcinoma (RCC) [<xref ref-type="bibr" rid="CR88">88</xref>]. Although studies on cancer vaccines are ongoing, their practical applications are still limited due to various challenges, including identification of optimal candidates, development of antigen delivery platforms, assessment of immune responses, and the large-scale manufacturing of vaccines. So far, only one therapeutic DC-based cancer vaccine Provenge&#8482;, an autologous peripheral blood mononuclear cell (PBMC) product, has been approved for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) [<xref ref-type="bibr" rid="CR89">89</xref>]. New attempts combining DC-based cancer vaccines with conventional cancer therapies are underway and early evidence appears promising [<xref ref-type="bibr" rid="CR90">90</xref>]. Concerted efforts are being devoted to improving their anticancer benefits.</p><p id="Par154">In the case of DNA vaccines, plasmids harboring cDNAs encoding cancer antigens are administered to cancer patients [<xref ref-type="bibr" rid="CR91">91</xref>]. These antigens are expressed in cancer patients and induce T cell-mediated immune responses against them [<xref ref-type="bibr" rid="CR92">92</xref>]. DNA vaccines demonstrate significant therapeutic efficacy in clinical trials. For instance, the DNA vaccine GX-188E was administered to patients with human papillomavirus (HPV)-positive advanced cervical cancer, and it exhibited a favorable safety profile [<xref ref-type="bibr" rid="CR93">93</xref>]. Among the treated 26 patients, 11 patients achieved an overall response, with four experiencing complete remission and seven experiencing partial remission. In a phase 1 non-randomized clinical trial, the DNA vaccine encoding the intracellular domain of human epidermal growth factor receptor 2/neu (HER2/neu) induced long-lasting antigen-specific T cell responses in patients with advanced HER2/neu-positive breast cancer [<xref ref-type="bibr" rid="CR94">94</xref>]. DNA vaccines must overcome multiple barriers to reach the cell nucleus, which poses a challenge for DNA-based antigen delivery vehicles. Moreover, DNA vaccines have shown limited immunogenicity in cancer patients [<xref ref-type="bibr" rid="CR95">95</xref>]. DNA may be integrated into the host genome. mRNA vaccines demonstrate superiority over DNA vaccines in terms of a low risk of genome integration [<xref ref-type="bibr" rid="CR96">96</xref>]. The personalized mRNA vaccine BNT122 triggered neoantigen-specific T cell responses and extended recurrence-free survival (RFS) in patients with pancreatic ductal adenocarcinoma (PDAC) [<xref ref-type="bibr" rid="CR97">97</xref>]. Technical barriers to mRNA vaccines focus on their sequence design, in vivo stability and delivery approaches, as well as translation efficiency [<xref ref-type="bibr" rid="CR98">98</xref>].</p></sec><sec id="Sec7"><title>Oncolytic viruses</title><p id="Par155">Oncolytic viruses are viruses that selectively replicate in and kill cancer cells while causing no damage to their normal cellular counterparts [<xref ref-type="bibr" rid="CR99">99</xref>]. The anticancer effect of oncolytic viruses is mainly achieved in two ways: direct oncolysis and induction of antitumor immune responses [<xref ref-type="bibr" rid="CR100">100</xref>]. Oncolytic viruses can be divided into naturally attenuated viral strains and genetically engineered viral vectors [<xref ref-type="bibr" rid="CR101">101</xref>]. Modulating the viral vector or genome can potentially enhance the clinical efficacy of oncolytic viruses. In particular, oncolytic viruses armed with exogenous immune-stimulating molecules have shown significant tumor-antagonizing effects by synergistically activating antitumor immunity. Several oncolytic virus products have been developed for the clinical treatment of cancers. Rigvir, an unmodified enteric cytopathic human orphan virus type 7 (ECHO-7), was the first approved oncolytic agent for the treatment of melanoma [<xref ref-type="bibr" rid="CR102">102</xref>]. In 2005, the China Food and Drug Administration (CFDA) approved Oncorine (H101), an engineered human adenovirus, for the treatment of advanced head and neck cancer [<xref ref-type="bibr" rid="CR103">103</xref>]. However, the therapeutic efficacy of these two oncolytic drugs mainly depends on their oncolytic actions rather than immune-stimulating effects. Talimogene laherparepvec (T-VEC) is an attenuated herpes simplex virus-1 (HSV-1) encoding granulocyte&#8211;macrophage colony-stimulating factor (GM-CSF) and was approved for the treatment of melanoma in 2015 [<xref ref-type="bibr" rid="CR104">104</xref>]. Delytact (G47&#8710;), a triple-mutated oncolytic HSV-1, is used for the treatment of residual or recurrent glioblastoma [<xref ref-type="bibr" rid="CR105">105</xref>]. Oncolytic viruses are an emerging class of immunotherapy in cancer. The overall performance of genetically modified oncolytic viruses is not as good as expected. Intratumoral injection, the common delivery approach for oncolytic viruses, may pose a risk of bleeding and unwanted metastasis at the lesion site [<xref ref-type="bibr" rid="CR106">106</xref>]. Moreover, delivering therapeutic viruses into deep tumor tissues through intratumoral inoculation is arduous. Intravenous injection can be a feasible choice. Viruses administered intravenously may be exterminated by neutralizing antibodies in the circulation. In this case, incorporating or loading oncolytic viruses into special biomaterials is an effective solution. Normal human cells (e.g., mesenchymal stem cells (MSCs)) are potential carriers for oncolytic virus transportation [<xref ref-type="bibr" rid="CR107">107</xref>].</p></sec><sec id="Sec8"><title>Cytokine therapy</title><p id="Par156">Cytokines are capable of regulating the immune system that mediate communication between immune cells. Three primary types of cytokines (IFNs, interleukins (ILs) and GM-CSFs) have been extensively investigated in clinical settings [<xref ref-type="bibr" rid="CR108">108</xref>]. IFN-&#947; exerts an inhibitory effect on cancer cell proliferation and enhances antitumor immunity by promoting antigen presentation and strengthening the function of cytotoxic T lymphocytes (CTLs), macrophages and T helper 1 (Th1) cells [<xref ref-type="bibr" rid="CR109">109</xref>]. ILs induce T cell growth to enhance antitumor immune responses [<xref ref-type="bibr" rid="CR110">110</xref>&#8211;<xref ref-type="bibr" rid="CR112">112</xref>]. GM-CSFs trigger adaptive immune responses by supporting T cell homeostasis and facilitating DC differentiation [<xref ref-type="bibr" rid="CR113">113</xref>]. GM-CSFs have been used as medication to promote granulocyte recovery following chemotherapy [<xref ref-type="bibr" rid="CR114">114</xref>]. These cytokine-based therapies induced the expansion and functionality of immune cells, thereby leading to good clinical outcomes in patients with melanoma and hematological malignancies [<xref ref-type="bibr" rid="CR115">115</xref>, <xref ref-type="bibr" rid="CR116">116</xref>]. Additionally, immunotherapeutic strategies targeting cytokine signaling have been developed. Inhibitors of the transforming growth factor-&#946; type I receptor (TGF&#946;R1), such as SD-208, functioned to reinvigorate T cell function [<xref ref-type="bibr" rid="CR117">117</xref>]. Stimulator of interferon genes (STING) agonists effectively triggered the production of proinflammatory cytokines and elicited type I IFN (IFN-I) responses [<xref ref-type="bibr" rid="CR118">118</xref>].</p><p id="Par157">Notably, due to the short half-life of cytokines, effective cytokine-based therapies generally require high-dose infusions, which can lead to vascular leakage and cytokine release syndrome [<xref ref-type="bibr" rid="CR119">119</xref>]. This further restricts the long-term benefits of cytokine treatments. Moreover, cytokine-based therapeutics may result in autoimmune attacks against the body&#8217;s own tissues by supporting the survival of regulatory T (Treg) cells and inducing the death of activated T cells [<xref ref-type="bibr" rid="CR120">120</xref>]. Therefore, current research is investigating combination treatment strategies, including the combination of two or more cytokines (e.g., IFNs coupled with ILs), and the combination of cytokines with other immunotherapies or chemotherapies, aiming to attenuate the side effects of high treatments dosages required for cytokine-directed monotherapy [<xref ref-type="bibr" rid="CR121">121</xref>].</p></sec></sec><sec id="Sec9"><title>Clinically approved nano-based therapeutics for cancer therapy</title><p id="Par158">Nanoparticles, which are defined as particles with diameters in the size range of 1&#8211;100&#160;nanometers (nm), are composed of various biodegradable materials, such as lipids, metals, or polymers [<xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR123">123</xref>]. Nanoparticles possess several advantages, including a high surface-to-volume ratio, significant carrier capacity, high stability, and the feasibility of scalable production [<xref ref-type="bibr" rid="CR124">124</xref>]. Nanotechnology-based formulations have potential applications in disease prevention, diagnosis, treatment, therapeutic monitoring, and drug discovery [<xref ref-type="bibr" rid="CR125">125</xref>]. Despite the improvements in convention anticancer therapies (e.g., chemotherapy, surgical resection and radiotherapy), the clinical outcomes are still unsatisfactory owing to the limited efficacy and serious adverse effects of these treatment modalities [<xref ref-type="bibr" rid="CR126">126</xref>]. Nanotechnology is expected to address and surpass the shortcomings of current cancer therapies. Nanoparticles have been considered as one of the excellent tools for targeted drug delivery in a controlled manner [<xref ref-type="bibr" rid="CR127">127</xref>]. Nano-based therapeutic systems promote drug stability, absorption and therapeutic concentration, and they have deep tissue penetration to augment the EPR effect, contributing to effective drug targeting and few side effects [<xref ref-type="bibr" rid="CR128">128</xref>]. The targeting mechanisms of nanomedicine formulations can be generally grouped into two types, passive and active targeting [<xref ref-type="bibr" rid="CR129">129</xref>]. In passive targeting mode, the accumulation of therapeutic nanoparticles into the tumor site is attributed to the characteristics of the tumor. Excessive proliferation of cancer cells leads to neovascularization. The new blood vessels have large pores in the vascular walls that facilitate passive targeting [<xref ref-type="bibr" rid="CR130">130</xref>]. Due to rapid and defective angiogenesis, nanoparticles can diffuse from leaky blood vessels and eventually accumulate within the tumor site [<xref ref-type="bibr" rid="CR131">131</xref>]. Moreover, poor lymphatic drainage enhances nanoparticle retention contributing to EPR effects on cancer cells [<xref ref-type="bibr" rid="CR132">132</xref>]. In contrast, the high interstitial fluid pressure in the TME results in decreased uptake and heterogeneous distribution of drug nanocarriers [<xref ref-type="bibr" rid="CR133">133</xref>]. Active targeting mechanism relies on specific ligands (e.g., folate, glycoproteins and transferrin), which interacts with surface receptors overexpressed in tumors [<xref ref-type="bibr" rid="CR134">134</xref>]. This targeting is achieved by surface modification of drug-loading nanoparticles with specific ligands capable of binding to antigens/receptors in target cancer cells [<xref ref-type="bibr" rid="CR135">135</xref>]. Nucleic acids, antibodies, peptides and proteins may be specific ligands grafted in the surface of nanocarriers [<xref ref-type="bibr" rid="CR136">136</xref>]. Ligand-receptor interaction induces uptake and absorption of nanoparticles via receptor-mediated endocytosis [<xref ref-type="bibr" rid="CR129">129</xref>]. Multiple factors, including nanoparticle size and structure, ligand density and ligand-receptor chemistry, affect the efficiency of active targeting scheme [<xref ref-type="bibr" rid="CR137">137</xref>]. So far, several nanoformulations have been developed for clinical use in cancer treatment (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Clinically approved nanomedicines for cancer treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Product</th><th align="left" colspan="1" rowspan="1">Material</th><th align="left" colspan="1" rowspan="1">Active pharmaceutical ingredient</th><th align="left" colspan="1" rowspan="1">Indication</th><th align="left" colspan="1" rowspan="1">Approval (Year)</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1"><bold>Lipid-based nanoparticles</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Caelyx</td><td align="left" colspan="1" rowspan="1">Liposome; PEG</td><td align="left" colspan="1" rowspan="1">Doxorubicin</td><td align="left" colspan="1" rowspan="1">Kaposi sarcoma, metastatic breast cancer, multiple myeloma, ovarian cancer</td><td align="left" colspan="1" rowspan="1">EMA (1996)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Doxil</td><td align="left" colspan="1" rowspan="1">Liposome; PEG</td><td align="left" colspan="1" rowspan="1">Doxorubicin</td><td align="left" colspan="1" rowspan="1">Kaposi sarcoma, multiple myeloma, ovarian cancer</td><td align="left" colspan="1" rowspan="1">FDA (1995)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Myocet</td><td align="left" colspan="1" rowspan="1">Liposome</td><td align="left" colspan="1" rowspan="1">Doxorubicin</td><td align="left" colspan="1" rowspan="1">Metastatic breast cancer</td><td align="left" colspan="1" rowspan="1">EMA (2000)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;DaunoXome</td><td align="left" colspan="1" rowspan="1">Liposome</td><td align="left" colspan="1" rowspan="1">Daunorubicin</td><td align="left" colspan="1" rowspan="1">HIV-associated Kaposi sarcoma</td><td align="left" colspan="1" rowspan="1">FDA (1996)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Lipusu</td><td align="left" colspan="1" rowspan="1">Liposome</td><td align="left" colspan="1" rowspan="1">Paclitaxel</td><td align="left" colspan="1" rowspan="1">Breast cancer, lung cancer, ovarian cancer</td><td align="left" colspan="1" rowspan="1">China (2006)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Marqibo</td><td align="left" colspan="1" rowspan="1">Liposome</td><td align="left" colspan="1" rowspan="1">Vincristine</td><td align="left" colspan="1" rowspan="1">Acute lymphoid leukemia</td><td align="left" colspan="1" rowspan="1">FDA (2012)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mepact</td><td align="left" colspan="1" rowspan="1">Liposome</td><td align="left" colspan="1" rowspan="1">Mifamurtide</td><td align="left" colspan="1" rowspan="1">Osteosarcoma</td><td align="left" colspan="1" rowspan="1">EMA (2009)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Onivyde</td><td align="left" colspan="1" rowspan="1">Liposome; PEG</td><td align="left" colspan="1" rowspan="1">Irinotecan</td><td align="left" colspan="1" rowspan="1">Metastatic pancreatic cancer</td><td align="left" colspan="1" rowspan="1">FDA (2015)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Vyxeos</td><td align="left" colspan="1" rowspan="1">Liposome</td><td align="left" colspan="1" rowspan="1">Daunorubicin, cytarabine</td><td align="left" colspan="1" rowspan="1">Acute myeloid leukemia</td><td align="left" colspan="1" rowspan="1">FDA (2017); EMA (2018)</td></tr><tr><td align="left" colspan="5" rowspan="1"><bold>Polymeric nanoparticles</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Eligard</td><td align="left" colspan="1" rowspan="1">Poly(lactic-co-glycolic acid)</td><td align="left" colspan="1" rowspan="1">Leuprolide acetate</td><td align="left" colspan="1" rowspan="1">Prostate cancer</td><td align="left" colspan="1" rowspan="1">FDA (2002)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Genexol-PM</td><td align="left" colspan="1" rowspan="1">Micelle</td><td align="left" colspan="1" rowspan="1">Paclitaxel</td><td align="left" colspan="1" rowspan="1">Metastatic breast cancer, pancreatic cancer</td><td align="left" colspan="1" rowspan="1">South Korea (2007)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Kadcyla</td><td align="left" colspan="1" rowspan="1">Maleimidomethyl cyclohexane-1-carboxylate thioether linker</td><td align="left" colspan="1" rowspan="1">Trastuzumab, DM1</td><td align="left" colspan="1" rowspan="1">HER2-positive breast cancer</td><td align="left" colspan="1" rowspan="1">FDA (2013); EMA (2013)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Oncaspar</td><td align="left" colspan="1" rowspan="1">PEGylated protein</td><td align="left" colspan="1" rowspan="1">Asparaginase</td><td align="left" colspan="1" rowspan="1">Acute lymphoblastic leukemia</td><td align="left" colspan="1" rowspan="1">FDA (1994)</td></tr><tr><td align="left" colspan="5" rowspan="1"><bold>Protein-based nanoparticles</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Abraxane</td><td align="left" colspan="1" rowspan="1">Albumin</td><td align="left" colspan="1" rowspan="1">Paclitaxel</td><td align="left" colspan="1" rowspan="1">Lung cancer, metastatic breast cancer, metastatic pancreatic cancer</td><td align="left" colspan="1" rowspan="1">FDA (2005); EMA (2008)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Pazenir</td><td align="left" colspan="1" rowspan="1">Albumin</td><td align="left" colspan="1" rowspan="1">Paclitaxel</td><td align="left" colspan="1" rowspan="1">Metastatic breast cancer, metastatic pancreatic adenocarcinoma, non-small cell lung cancer</td><td align="left" colspan="1" rowspan="1">EMA (2019)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Ontak</td><td align="left" colspan="1" rowspan="1">Engineered fusion protein</td><td align="left" colspan="1" rowspan="1">Denileukin diftitox</td><td align="left" colspan="1" rowspan="1">Cutaneous T-cell lymphoma</td><td align="left" colspan="1" rowspan="1">FDA (1999)</td></tr><tr><td align="left" colspan="5" rowspan="1"><bold>Metallic-based nanoparticles</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">NanoTherm</td><td align="left" colspan="1" rowspan="1">Iron oxide</td><td align="left" colspan="1" rowspan="1">Not applicable</td><td align="left" colspan="1" rowspan="1">Glioblastoma multiforme, prostate cancer</td><td align="left" colspan="1" rowspan="1">EMA (2011)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">PEG</italic> polyethylene glycol, <italic toggle="yes">EMA</italic> European Medicines Agency, <italic toggle="yes">FDA&#160;</italic>U.S. Food and Drug Administration</p></table-wrap-foot></table-wrap></p><sec id="Sec10"><title>Lipid-based nanoparticles</title><p id="Par159">Lipid-based nanoparticles have the most typical configuration of a spherical system, containing at least one lipid bilayer surrounding an internal water chamber. Lipid-based nanoparticles show various advantages, such as simple formulation, biocompatibility, high bioavailability, self-assembly, and the capability to carry diverse payloads [<xref ref-type="bibr" rid="CR138">138</xref>]. Therefore, lipid-based nanoparticles are one of the most common types of nanopharmaceuticals. Liposomes are a subtype of lipid-based nanoparticles that are still most frequently used to date [<xref ref-type="bibr" rid="CR139">139</xref>]. Liposomes are capable of encapsulating and delivering hydrophilic, hydrophobic and lipophilic agents [<xref ref-type="bibr" rid="CR140">140</xref>]. Liposomes carrying anticancer drugs for chemotherapy or immunotherapy can reduce non-specific adverse and toxic effects of these drugs on normal tissues [<xref ref-type="bibr" rid="CR141">141</xref>]. The stability of liposome-based systems can be controlled by adjusting their size, composition, and surface charge and modifications [<xref ref-type="bibr" rid="CR142">142</xref>]. Reportedly, surface modifications of liposomes can enhance the circulation time and promote drug delivery, which allow for drug accumulation in tumor tissues [<xref ref-type="bibr" rid="CR143">143</xref>]. Currently, several liposomal pharmaceuticals have been approved for clinical cancer therapy. Caelyx, Doxil and Myocet were formulated to deliver doxorubicin (DOX) and are indicated for the treatment of ovarian cancer, myeloma and breast cancer, respectively [<xref ref-type="bibr" rid="CR144">144</xref>&#8211;<xref ref-type="bibr" rid="CR146">146</xref>]. These nanoformulations protect DOX from chemical and enzymatic degradation in the blood, and reduce drug-induced cardiotoxicity [<xref ref-type="bibr" rid="CR147">147</xref>]. DaunoXome prepared by encapsulating daunorubicin in a non-PEGylated liposome is applicable for patients with human immunodeficiency virus (HIV)-associated Kaposi sarcoma [<xref ref-type="bibr" rid="CR148">148</xref>]. Lipusu is a non-PEGylated liposome formulation carrying paclitaxel for the treatment of breast cancer, non-small cell lung cancer (NSCLC) and ovarian cancer [<xref ref-type="bibr" rid="CR149">149</xref>]. Marqibo, a liposome preparation of vincristine, has been approved for the treatment of leukemia [<xref ref-type="bibr" rid="CR150">150</xref>]. Mepact, a liposomal mifamurtide, is mainly used for the treatment of osteosarcoma [<xref ref-type="bibr" rid="CR151">151</xref>]. Onivyde, a PEGylated liposomal irinotecan, is mainly administered for the treatment of metastatic pancreatic cancer [<xref ref-type="bibr" rid="CR152">152</xref>]. Vyxeos is a formulation of cytarabine and daunorubicin in liposomes that has been granted for the treatment of acute myelogenous leukemia [<xref ref-type="bibr" rid="CR153">153</xref>].</p></sec><sec id="Sec11"><title>Polymeric nanoparticles</title><p id="Par160">Polymeric nanoparticles, engineered nanostructured materials, have been widely applied in the field of drug delivery due to structural versatility for controlled drug release, high kinetic stability, possibilities for surface functionalization, and the ability to protect drug against the environment [<xref ref-type="bibr" rid="CR154">154</xref>, <xref ref-type="bibr" rid="CR155">155</xref>]. According to their internal architectures, polymeric nanoparticles can be divided into nanospheres and nanocapsules [<xref ref-type="bibr" rid="CR156">156</xref>]. Polymeric nanospheres consist of a solid polymeric matrix and commonly display a regular sphere structure, in which drugs are distributed throughout the matrix [<xref ref-type="bibr" rid="CR157">157</xref>]. Polymeric nanocapsules are composed of an inner core containing therapeutic compounds and enveloped by a polymeric shell [<xref ref-type="bibr" rid="CR158">158</xref>]. Polymeric nanoparticles can carry and deliver hydrophobic and hydrophilic substances, as well as substances with varied molecular weights [<xref ref-type="bibr" rid="CR159">159</xref>]. Thus, polymeric nanoparticles may be a useful platform for joint delivery of different therapeutic drugs. Altering the characteristics (e.g., composition, stability, and surface charge) of polymeric nanoparticles can regulate their loading efficiency and release kinetics of payloads [<xref ref-type="bibr" rid="CR160">160</xref>, <xref ref-type="bibr" rid="CR161">161</xref>]. Clinically approved polymeric nanoparticles include Eligard, Genexol-PM, Kadcyla, and Oncaspar. Eligard, a polymeric matrix formulation of leuprolide acetate, increases the efficiency and prolongs action duration of the loaded drug [<xref ref-type="bibr" rid="CR162">162</xref>]. Moreover, this nanoformulation was approved for the treatment of advanced hormone-dependent prostate cancer. Genexol-PM, a polymeric micelle nanoparticle formulation of paclitaxel, has controlled drug release and is applicable for the treatment of breast cancer and pancreatic cancer [<xref ref-type="bibr" rid="CR163">163</xref>]. Kadcyla, also called Ado-Trastuzumab emtansine or T-DM1, is a protein-based nanocompound consisting of the anti-HER2 antibody transtuzumab conjugated via a non-cleavable maleimidomethyl cyclohexane-1-carboxylate thioether linker to the cytotoxin DM1 [<xref ref-type="bibr" rid="CR164">164</xref>]. Kadcyla selectively delivers DM1 to HER2-positive cancer cells, resulting in cancer cell death [<xref ref-type="bibr" rid="CR165">165</xref>]. Moreover, trastuzumab also exerts an anticancer activity via blockade of HER2 signalling, and the binding of transtuzumab to HER-2 receptor also induces antibody-dependent cell-mediated cytotoxicity. Kadcyla is indicated for the adjuvant treatment of HER2-positive breast cancer [<xref ref-type="bibr" rid="CR166">166</xref>]. Oncaspar, a PEGylated formulation of the enzyme asparaginase, inhibits tumor growth by decreasing the level of the amino acid asparagine in the blood [<xref ref-type="bibr" rid="CR167">167</xref>]. This nanopharmaceutical extends half-life of encapsulated drugs and attenuates the risk of adverse reactions. Oncaspar has been approved for the treatment of acute lymphoblastic leukemia.</p></sec><sec id="Sec12"><title>Protein-based nanoparticles</title><p id="Par161">Protein-based nanopharmaceuticals can be formulated using proteins such as albumin, fibroin, gelatin, and lipoprotein [<xref ref-type="bibr" rid="CR168">168</xref>]. Protein-based nanoparticles are used to carry anticancer drugs, genetic materials and growth factors. Protein nanoparticles exhibits many advantages, including high safety, favorable biocompatibility and biodegradability. Abraxane and Pazenir are albumin-bound paclitaxel nanoparticles for the treatment of metastatic breast cancer and NSCLC [<xref ref-type="bibr" rid="CR169">169</xref>]. In terms of mechanism, these nanopharmaceuticals improve the tumor-targeting ability of paclitaxel and enhance antitumor T cell responses. Ontak represents a Denileukin diftitox (engineered fusion protein combining IL-2 with diphtheria toxin) nanoparticle that is administered to treat cutaneous T-cell lymphoma [<xref ref-type="bibr" rid="CR170">170</xref>]. Ontak acts as an IL-2 receptor antagonist designed to direct the cell-killing effect of diphtheria toxin towards IL-2 receptor-overexpressing target cells [<xref ref-type="bibr" rid="CR171">171</xref>].</p></sec><sec id="Sec13"><title>Metallic-based nanoparticles</title><p id="Par162">Iron oxide nanoparticles are made up of an iron oxide core that responds to clinical magnetic devices and coated with biocompatible molecules [<xref ref-type="bibr" rid="CR172">172</xref>]. In vivo, iron oxide nanoparticles can be selectively heated by alternating magnetic fields, leading to the temperature-dependent liberation of drugs [<xref ref-type="bibr" rid="CR173">173</xref>]. For instance, NanoTherm, an iron oxide nanoparticle with aminosilane coating, was approved for the treatment of glioblastoma multiforme (GBM) and prostate cancer [<xref ref-type="bibr" rid="CR174">174</xref>].</p></sec></sec><sec id="Sec14"><title>Mechanisms of action of nanodrug delivery systems in improving immunotherapeutic efficacy</title><p id="Par163">In recent years, nanoparticles have emerged as a new research hotspot in the field of oncology. Various nanostructures have been introduced as novel adjuvant approaches to enhance the efficacy of cancer immunotherapy (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Furthermore, nanoparticles can be equipped with diverse ligands (e.g., antibodies and aptamers), thereby promoting their interaction with target molecules, including surface receptors on cancer cells. Consequently, nanoparticles can be used as efficient targeting drug delivery systems that result in drug accumulation at therapeutic doses in tumors. Nanoparticles have a relatively high depth of tissue penetration to promote the EPR effect. In addition, manipulation of nanoparticle characteristics can optimize the release rate of loaded therapeutic drugs. Taken together, nanoparticles have the ability to improve drug bioavailability and decrease the dosing frequency, forming a solid basis for better cancer treatment.
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>An overview of studies that evaluate feasibility and efficacy of nanomaterials in cancer immunotherapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Treatment</th><th align="left" colspan="1" rowspan="1">Formulation</th><th align="left" colspan="1" rowspan="1">Nanoparticle name</th><th align="left" colspan="1" rowspan="1">Active substance</th><th align="left" colspan="1" rowspan="1">Study type</th><th align="left" colspan="1" rowspan="1">Targeted tumor</th><th align="left" colspan="1" rowspan="1">Delivery route</th><th align="left" colspan="1" rowspan="1">Key findings</th><th align="left" colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td align="left" rowspan="17" colspan="1"><bold>Immune checkpoint blockade therapy</bold></td><td align="left" colspan="1" rowspan="1">Polymeric nanocapsule</td><td align="left" colspan="1" rowspan="1">PMPC-b-PApm/Glu</td><td align="left" colspan="1" rowspan="1">nBSA-PBA-IgG</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Breast cancer, melanoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Significantly inhibit tumor growth with no evident side effects</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR175">175</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Liposome</td><td align="left" colspan="1" rowspan="1">PpIX-NLG@Lipo</td><td align="left" colspan="1" rowspan="1">Protoporphyrin IX, NLG919</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Induce immunogenic cell death, amplify PDT-induced immune responses</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR176">176</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">N/PGEM/dp</td><td align="left" colspan="1" rowspan="1">Gemcitabine, NLG919</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Pancreatic cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Show a significant tumor inhibition effect</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR177">177</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PLGA nanoparticle</td><td align="left" colspan="1" rowspan="1">PLGA (PD-L1 siRNA&#8201;+&#8201;PD-1 siRNA)-NP</td><td align="left" colspan="1" rowspan="1">PD-L1 siRNA, PD-1 siRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Lung cancer and lymphoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Trigger CD8<sup>+</sup> T cell responses, significantly inhibit tumor growth</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR178">178</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanocapsule</td><td align="left" colspan="1" rowspan="1">SiNC</td><td align="left" colspan="1" rowspan="1">PD-L1 siRNA</td><td align="left" colspan="1" rowspan="1">Cell experiment</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Promote T cell survival</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR179">179</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">LYiClustersiPD-L1</td><td align="left" colspan="1" rowspan="1">LY2157299, PD-L1 siRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Pancreatic ductal adenocarcinoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Promote intratumoral infiltration of CD8<sup>+</sup> T cells, inhibit tumor growth</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR180">180</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">NIC</td><td align="left" colspan="1" rowspan="1">Anti-CTLA-4 antibody, anti-PD-1 antibody</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Glioblastoma multiforme</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Amplify antitumor immune responses, prolong animals&#8217; survival</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR181">181</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Protein-based nanoparticle</td><td align="left" colspan="1" rowspan="1">C-RNA-NP</td><td align="left" colspan="1" rowspan="1">Chemotherapy-induced tumor RNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Colon carcinoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Activate robust immune responses, enhance the efficacy of immune checkpoint blockade treatment</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR182">182</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PLGA nanoparticle</td><td align="left" colspan="1" rowspan="1">CCM-PLGA/GA NP</td><td align="left" colspan="1" rowspan="1">Gambogic acid, cancer-specific neoantigen</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Colorectal cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Activate DC maturation, induce antitumor immunity</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR183">183</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid-polymer hybrid nanoparticle</td><td align="left" colspan="1" rowspan="1"><sup>TK</sup>HNP-C/D</td><td align="left" colspan="1" rowspan="1">Chlorin e6, doxorubicin</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Induce antitumor immune responses, synergize with anti-PD-L1 antibody to exert abscopal tumor-suppressive effects</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR184">184</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PLGA nanoparticle</td><td align="left" colspan="1" rowspan="1">M&#934;-SDNP</td><td align="left" colspan="1" rowspan="1">SD-208</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Suppress cancer metastasis, inhibit M2-type macrophage differentiation, exert antitumor effects in combination with anti-PD-1 antibody</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR185">185</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">NP-siZDHHC9</td><td align="left" colspan="1" rowspan="1">ZDHHC9 siRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Pancreatic cancer</td><td align="left" colspan="1" rowspan="1">Intratumoral injection</td><td align="left" colspan="1" rowspan="1">Delay tumor growth in conjunction with anti-PD-L1 treatment</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR186">186</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid-polymer hybrid nanoparticle</td><td align="left" colspan="1" rowspan="1">MAN-OVA-IMNP</td><td align="left" colspan="1" rowspan="1">Imiquimod, monophosphoryl lipid A, ovalbumin</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Lymphoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Inhibit tumor development and prolong animals' survival</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR187">187</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Self-assembled polyelectrolyte nanocomplex</td><td align="left" colspan="1" rowspan="1">CpG ODN-loaded nano-adjuvant</td><td align="left" colspan="1" rowspan="1">CpG-ODN</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Collaborate with CD16-CAR-T cells to produce enhanced targeted antitumor effects</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR188">188</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Iron oxide nanoparticle</td><td align="left" colspan="1" rowspan="1">mIONPsp-Xcc LOS, mIONPsp-HyNic-4FB-OVA</td><td align="left" colspan="1" rowspan="1">Lipooligosaccharides, ovalbumin</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Induce antigen-specific cytotoxic T lymphocyte responses, provide long-term protection against tumor challenge in combination with PD-L1 blockade therapy</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR189">189</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">SCNPs/R837</td><td align="left" colspan="1" rowspan="1">Imiquimod</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Prostate cancer</td><td align="left" colspan="1" rowspan="1">Intradermal injection</td><td align="left" colspan="1" rowspan="1">Augment antitumor immune responses, collaborate with anti-PD-1 antibody to generate enhanced antitumor effects</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR190">190</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">PAI nanovaccine</td><td align="left" colspan="1" rowspan="1">2BXy, TAT-P6-GWWWG peptide</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Lymphoma, melanoma, colorectal cancer</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Induce strong antitumor immune responses in combination with immune checkpoint inhibitor therapy</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR191">191</xref>]</td></tr><tr><td align="left" rowspan="9" colspan="1"><bold>Adoptive cell therapy</bold></td><td align="left" colspan="1" rowspan="1">PLGA nanoparticle</td><td align="left" colspan="1" rowspan="1">522GGNP</td><td align="left" colspan="1" rowspan="1">Imidazoquinoline-based small molecule 522</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Lung adenocarcinoma</td><td align="left" colspan="1" rowspan="1">Peritumoral injection</td><td align="left" colspan="1" rowspan="1">Promote NK cell activation, improve the antitumor efficacy of cetuximab and an anti-HER2/neu antibody</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR192">192</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Chiral gold nanoparticle</td><td align="left" colspan="1" rowspan="1">L-type NP</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Lymphoma</td><td align="left" colspan="1" rowspan="1">Intratumoral injection</td><td align="left" colspan="1" rowspan="1">Induce cancer cell apoptosis, prolong animals&#8217; survival time</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR193">193</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Liposome</td><td align="left" colspan="1" rowspan="1">LAM&#934;-m7/8a</td><td align="left" colspan="1" rowspan="1">TLR7/8 agonist</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="1" rowspan="1">Intratumoral injection, intravenous injection</td><td align="left" colspan="1" rowspan="1">Promote M1-type macrophage activation, induce effective antitumor efficacy</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR194">194</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">SHP-1 and Cbls siRNA&#8208;loaded NP</td><td align="left" colspan="1" rowspan="1">siRNAs targeting SHP-1, Cbl-b, and c-Cbl</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">B-cell lymphoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Unleash NK cell activity to eradicate tumors</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR195">195</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Cationic nanoparticle</td><td align="left" colspan="1" rowspan="1">cNP</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Triple-negative breast cancer</td><td align="left" colspan="1" rowspan="1">Intratumoral injection</td><td align="left" colspan="1" rowspan="1">Enhance the tumor-killing effects of NK cells</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR196">196</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">T-cell-targeted DNA nanocarrier</td><td align="left" colspan="1" rowspan="1">CAR transgene</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Leukemia</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Program CAR lymphocytes to mediate cancer regression</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR197">197</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">pEGFRvIII-CAR@SNP<sup>G1/800</sup></td><td align="left" colspan="1" rowspan="1">EGFRvIII CAR-expression plasmid vector</td><td align="left" colspan="1" rowspan="1">Cell experiment</td><td align="left" colspan="1" rowspan="1">Hepatocellular carcinoma</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Efficiently deliver pEGFRvIII-CAR into T cells that enables them to specifically bind to target cancer cells</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR198">198</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Hydrogel nanoparticle</td><td align="left" colspan="1" rowspan="1">IL-15Sa-NG</td><td align="left" colspan="1" rowspan="1">IL-15 super-agonist</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Enhance T cell expansion, promote tumor regression</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR199">199</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PEGylated immunoliposome</td><td align="left" colspan="1" rowspan="1">TGF-&#946;I-loaded liposome</td><td align="left" colspan="1" rowspan="1">TGF-&#946; inhibitor SB525334</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Increase granzyme expression in T cells, induce tumor regression</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR200">200</xref>]</td></tr><tr><td align="left" rowspan="7" colspan="1"><bold>Antibody-based targeted therapy</bold></td><td align="left" colspan="1" rowspan="1">Gold nanoparticle</td><td align="left" colspan="1" rowspan="1">CTX-INS-GNP</td><td align="left" colspan="1" rowspan="1">Cetuximab</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Glioblastoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Efficiently deliver antibodies into target cancer cells, improve the efficacy of standard of care treatment</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR201">201</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">PDA-ICG@CAT-DTA-1</td><td align="left" colspan="1" rowspan="1">Catalase, anti-GITR antibody</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Block tumor immune suppression, suppress cancer progression</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR202">202</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">imNA<sub>&#945;PD1&amp;&#945;PDL1</sub></td><td align="left" colspan="1" rowspan="1">anti-PD-1 antibody, anti-PD-L1 antibody</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Breast cancer, melanoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Promote the interaction between T cells and cancer cells, amplify T cell-mediated antitumor immune responses</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR203">203</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">CCM-MPLA-aCD28</td><td align="left" colspan="1" rowspan="1">Monophosphoryl lipid A, anti-CD28 antibody</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Lymphoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Stimulate tumor-specific CD8<sup>+</sup> T cells, significantly retard tumor growth</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR204">204</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">mRNA-LNP</td><td align="left" colspan="1" rowspan="1">Pembrolizumab mRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Colon cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Inhibit tumor growth, improve animals&#8217; survival</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR205">205</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Iron oxide nanoparticle</td><td align="left" colspan="1" rowspan="1">FH-MPLA</td><td align="left" colspan="1" rowspan="1">Monophosphoryl lipid A</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Trigger tumor necrosis and eradication in conjunction with agonistic &#945;-CD40 monoclonal antibody</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR206">206</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PLGA nanoparticle</td><td align="left" colspan="1" rowspan="1">PTEN D<sub>m</sub>-NP</td><td align="left" colspan="1" rowspan="1">PTEN mRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Inactivate the PI3K/Akt signaling pathway, reverse trastuzumab resistance, inhibit tumor development</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR207">207</xref>]</td></tr><tr><td align="left" rowspan="39" colspan="1"><bold>Cancer vaccines</bold></td><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">TLS/LZnP</td><td align="left" colspan="1" rowspan="1">Monophosphoryl lipid A, melanoma cell-derived tumor lysate</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Intradermal injection</td><td align="left" colspan="1" rowspan="1">Prime DCs, induce cytotoxic T lymphocyte responses, suppress cancer progression and extend animals&#8217; survival time in combination with d-peptide antagonist</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR208">208</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Magnetic liposome</td><td align="left" colspan="1" rowspan="1">Ag-ML</td><td align="left" colspan="1" rowspan="1">Mouse melanoma lysate, CpG-1826</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Activate DCs in lymph nodes, increase the accumulation of cytotoxic T lymphocytes within tumors, exert tumor-suppressive effects</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR209">209</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">CaCO<sub>3</sub>@TCL/CpG</td><td align="left" colspan="1" rowspan="1">Tumor cell lysate, CpG oligodeoxynucleotide 1826</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Induce cytotoxic T cell-mediated responses, inhibit tumor growth</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR210">210</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">EnS@PDA@CL</td><td align="left" colspan="1" rowspan="1">Tumor cell lysate</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Pancreatic cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Promote DC maturation, elicit antigen-specific cytotoxic T lymphocyte responses</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR211">211</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Ti<sub>3</sub>C<sub>2</sub> MXene-based nanoparticle</td><td align="left" colspan="1" rowspan="1">MXP@OC</td><td align="left" colspan="1" rowspan="1">Ovalbumin, CpG-ODN</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Intratumoral injection</td><td align="left" colspan="1" rowspan="1">Promote DC maturation, collaborate with photothermal therapy to generate antitumor effects</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR212">212</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Porous Silica Nanoparticle</td><td align="left" colspan="1" rowspan="1">OVA@PS3</td><td align="left" colspan="1" rowspan="1">Ovalbumin</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Induce tumor-specific cell-mediated and humoral immune responses, lead to tumor regression in prophylactic and therapeutic vaccination</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR213">213</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">PEG BR647-NP</td><td align="left" colspan="1" rowspan="1">Ovalbumin, STAT3 siRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Promote TADC maturation, enhance anticancer T cell immunity, facilitate cancer cell apoptosis</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR214">214</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Magnetic nanoparticle</td><td align="left" colspan="1" rowspan="1">MNP-CpG-COVA</td><td align="left" colspan="1" rowspan="1">CpG, ovalbumin<sub>257&#8211;264</sub></td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Present favorable stability in the blood, enhance CD8<sup>+</sup> T cell antitumoral response</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR215">215</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Graphene oxide nanosheet</td><td align="left" colspan="1" rowspan="1">nsGO/PCP/OVA</td><td align="left" colspan="1" rowspan="1">Ovalbumin, <italic toggle="yes">Poria cocos</italic> polysaccharides</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Lymphoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Induce antigen-specific Th1 and Th2 immune responses, suppress tumor growth in prophylactic and therapeutic vaccination</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR216">216</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Self-assembled protein-based nanoparticle</td><td align="left" colspan="1" rowspan="1">N-Ac PamCS-MAGE conjugate</td><td align="left" colspan="1" rowspan="1">MAGE-A1 peptides, N-Ac PamCS</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Promote DC maturation, enhance CD8<sup>+</sup> T cell activation, induce cancer cell death</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR217">217</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Chitosan nanoparticle</td><td align="left" colspan="1" rowspan="1">Chitosan-rCD44v nanoparticle</td><td align="left" colspan="1" rowspan="1">Recombinant CD44v</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="1" rowspan="1">Oral administration</td><td align="left" colspan="1" rowspan="1">Induce both humoral and cellular immune responses, reduce tumor growth</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR218">218</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">FAP<sub>PEP</sub>-SLNP nanovaccine</td><td align="left" colspan="1" rowspan="1">FAP<sub>PEP</sub>-SLNPs</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Lymphoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Downregulate the population of FAP<sup>+</sup> CAFs, reduce ECM production, inhibit tumor growth</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR219">219</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">8FN</td><td align="left" colspan="1" rowspan="1">FK-33</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Induce DC activation, trigger robust tumor antigen-specific CD8<sup>+</sup> T cell response, exhibit significant therapeutic and prophylactic efficacy</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR220">220</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Self-assembled protein-based nanoparticle</td><td align="left" colspan="1" rowspan="1">DCNP</td><td align="left" colspan="1" rowspan="1">CD4<sup>+</sup> T cell epitope, CpG ODN</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Induce neoantigen-specific CD8<sup>+</sup> T cell responses, significantly inhibit tumor growth</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR221">221</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">Bi-adjuvant/Ag NV</td><td align="left" colspan="1" rowspan="1">Resiquimod, CpG, Ovalbumin<sub>257&#8211;264</sub></td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Colorectal cancer, glioblastoma multiforme</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Induce robust antitumor T cell response, improve the therapeutic efficacy of anti-PD-1 antibody</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR222">222</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">OVA/PGA-IMDQ NP</td><td align="left" colspan="1" rowspan="1">Imidazoquinoline-based TLR7/8 agonist</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Lymphoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Induce cytotoxic T lymphocyte responses and strong immunological memory, prevent cancer progression</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR223">223</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Liposome</td><td align="left" colspan="1" rowspan="1">PMRL@IR780</td><td align="left" colspan="1" rowspan="1">Resiquimod</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Activate DC maturation and cytotoxic T lymphocytes, inhibit the distant recurrence and metastasis of tumors</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR224">224</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Mesoporous silica nanoparticle</td><td align="left" colspan="1" rowspan="1">MSN@TheraVac</td><td align="left" colspan="1" rowspan="1">HMGN1, resiquimod, anti-PD-L1</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Colon cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Facilitate tumor eradication, induce the generation of tumor-specific protective memory</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR225">225</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PLGA nanoparticle</td><td align="left" colspan="1" rowspan="1">CpG-NP-Tag NP</td><td align="left" colspan="1" rowspan="1">Whole tumor cell lysate, CpG</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="1" rowspan="1">Intranasal instillation</td><td align="left" colspan="1" rowspan="1">Induce T cell-mediated antitumor mucosal immune responses, provide protection against lung metastasis of cancer cells</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR226">226</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Aluminum hydroxyphosphate nanoparticle</td><td align="left" colspan="1" rowspan="1">Alum-CpG@Fe-Shikonin NP</td><td align="left" colspan="1" rowspan="1">CpG-ODN</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Induce the immunogenic cell death of cancer cells, activate antitumor immune responses, selectively eliminate primary tumors, exhibit a robust abscopal effect on suppressing distant tumors</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR227">227</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DNA nanoparticle</td><td align="left" colspan="1" rowspan="1">CpG NP</td><td align="left" colspan="1" rowspan="1">CpG-ODN</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Intramuscular injection</td><td align="left" colspan="1" rowspan="1">Remodel the tumor microenvironment, enhance anti-tumor immunotherapy</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR228">228</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">CDNP</td><td align="left" colspan="1" rowspan="1">Resiquimod, CpG</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma, colorectal cancer</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Facilitate antigen presentation, inhibit cancer progression</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR229">229</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Liposome</td><td align="left" colspan="1" rowspan="1">L2, L2DC1, L2M2</td><td align="left" colspan="1" rowspan="1">8Qm</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Cervical cancer</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Extend animals&#8217; survival, inhibit tumor growth</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR230">230</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PLGA nanoparticle</td><td align="left" colspan="1" rowspan="1">E7-MDP-NP</td><td align="left" colspan="1" rowspan="1">Muramyl Dipeptide, HPV E7 peptide</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Cervical cancer</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Inhibit tumor growth, enhance the responses of tumor-specific effector adaptive immune cells</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR231">231</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">gDE7 mRNA-LNP</td><td align="left" colspan="1" rowspan="1">gDE7-encoding mRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Cervical cancer</td><td align="left" colspan="1" rowspan="1">Intramuscular injection</td><td align="left" colspan="1" rowspan="1">Activate antigen-specific CD8<sup>+</sup> T cells, stimulate memory T cell responses, induce tumor regression</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR232">232</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">HPV mRNA-LNP</td><td align="left" colspan="1" rowspan="1">HPV E7 protein-encoding mRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Oropharyngeal squamous cell carcinoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection, intravenous injection</td><td align="left" colspan="1" rowspan="1">Stimulate CD8<sup>+</sup> T cell immune responses, synergize with anti-LAG3/anti-CTLA4 to exert antitumor effects</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR233">233</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PLGA nanoparticle</td><td align="left" colspan="1" rowspan="1">IM-CS-NPs/E7</td><td align="left" colspan="1" rowspan="1">HPV16 E7<sub>44&#8211;62</sub> peptide</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Cervical cancer</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Promote DC maturation, improve antigen lysosome escape, enhance the accumulation of tumor antigen in lymph nodes, elicit antitumor immune responses</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR234">234</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Virus-like particle</td><td align="left" colspan="1" rowspan="1">V-scVLP</td><td align="left" colspan="1" rowspan="1">Tumor-specific neoantigen, ODN-1826</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Hepatocellular carcinoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Activate lymphoid DC maturation, promote robust CD8<sup>+</sup> T cells and central memory T cells responses, suppress tumor growth, metastasis and recurrence</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR235">235</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">pDNA-NP</td><td align="left" colspan="1" rowspan="1">Tumor neoantigen-encoding DNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Hepatocellular carcinoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Induce neoantigen-specific T-cell immunity, inhibit tumor growth, improve the antitumor efficacy of anti-PD-1 treatment</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR236">236</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">C2@mLMP2</td><td align="left" colspan="1" rowspan="1">LMP2 mRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Colon cancer</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Induce CD8<sup>+</sup> T cell responses, exert a synergistic anti-tumor effect in combination with anti-PD-1 therapy</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR237">237</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">p53 mRNA/ICG NP</td><td align="left" colspan="1" rowspan="1">p53 mRNA, indocyanine green</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Lung cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Promote cancer cell apoptosis, induce photodynamic therapy</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR238">238</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">PHTA-C18/mOVA</td><td align="left" colspan="1" rowspan="1">Ovalbumin mRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Efficiently deliver mRNA cancer vaccine, induce robust CD8<sup>+</sup> T cell-mediated antitumor immunity</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR239">239</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">mOVA LNP</td><td align="left" colspan="1" rowspan="1">Ovalbumin mRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection, Intramuscular injection</td><td align="left" colspan="1" rowspan="1">Trigger strong Th1 and Th2 immune responses</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR240">240</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">R18D mRNA nanoparticle</td><td align="left" colspan="1" rowspan="1">Ovalbumin mRNA, CpG, poly(I:C)</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma, colon adenocarcinoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Induce robust antigen-specific CD8<sup>+</sup> T cell responses, inhibit tumor growth</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR241">241</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">mRNA-LNP<sub>ssPalmE</sub></td><td align="left" colspan="1" rowspan="1">Ovalbumin mRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Lymphoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Elicit antigen-specific cytotoxic T cell responses, have an antitumor effect</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR242">242</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">Pam-LNP</td><td align="left" colspan="1" rowspan="1">Pam3, ovalbumin mRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Lymphoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Induce CD8<sup>+</sup> T cell responses, prevent tumor growth</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR243">243</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">mmPE-LNP</td><td align="left" colspan="1" rowspan="1">Bacterial toxin-encoding modified mRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Intratumoral injection</td><td align="left" colspan="1" rowspan="1">Induce antitumor effects, improve animals&#8217; survival</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR244">244</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">Rituximab mRNA-LNP</td><td align="left" colspan="1" rowspan="1">Rituximab-encoding mRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Lymphoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Slow down lymphoma growth, extend animals&#8217; survival</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR245">245</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">DAL4-LNP-IL-12, DAL4-LNP-IL-27, DAL4-LNP-GM-CSF</td><td align="left" colspan="1" rowspan="1">mRNAs encoding IL-12, IL-27 and GM-CSF</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Intratumoral injection</td><td align="left" colspan="1" rowspan="1">Induce intratumoral infiltration of immune effector cells, suppress tumor growth</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR246">246</xref>]</td></tr><tr><td align="left" rowspan="7" colspan="1"><bold>Oncolytic virotherapy</bold></td><td align="left" colspan="1" rowspan="1">Oncolytic adenoviral nanosphere</td><td align="left" colspan="1" rowspan="1">Ad nanosphere</td><td align="left" colspan="1" rowspan="1">Ad5</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Lung cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Attack cancer cells, induce T cell immune responses</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR247">247</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Oncolytic virus nanoparticle</td><td align="left" colspan="1" rowspan="1">Lipo-Cap-Ad5</td><td align="left" colspan="1" rowspan="1">Ad5</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Reduce tumor growth, extend animals&#8217; survival in combination with anti-PD-1 antibody</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR248">248</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Oncolytic virus nanoparticle</td><td align="left" colspan="1" rowspan="1">ExtraCRAd</td><td align="left" colspan="1" rowspan="1">Ad5-D24-CpG virus</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma, lung cancer</td><td align="left" colspan="1" rowspan="1">Intratumoral injection</td><td align="left" colspan="1" rowspan="1">Reduce tumor growth in preventive and therapeutic setting</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR249">249</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Oncolytic virus nanoparticle</td><td align="left" colspan="1" rowspan="1">SAG101</td><td align="left" colspan="1" rowspan="1">AdGFPLuc, AdNuPARmE1A</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Pancreatic ductal adenocarcinoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Exhibit increased oncolytic activity, enhance antitumor efficacy</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR250">250</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">vRNA/LNP</td><td align="left" colspan="1" rowspan="1">Synthetic Seneca Valley virus</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Small cell lung cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Promote immune cell infiltration, remodel the tumor microenvironment, enhance the activity of anti-PD-1 treatment</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR251">251</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Magnetic nanoparticle</td><td align="left" colspan="1" rowspan="1">MAG-OV</td><td align="left" colspan="1" rowspan="1">HSV1716</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Promote the intratumoral recruitment of activated immune cells, enhance antitumor immunity, induce tumor shrinkage, improve animals&#8217; survival</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR252">252</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Self-assembled protein nanoparticle</td><td align="left" colspan="1" rowspan="1">Nov-S-Catcher003-antigen NP</td><td align="left" colspan="1" rowspan="1">Genetically engineered Norovirus S domain</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma, cervical cancer</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Trigger robust tumor-specific T-cell immunity, reshape the tumor microenvironment, inhibit tumor growth</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR253">253</xref>]</td></tr><tr><td align="left" rowspan="30" colspan="1"><bold>Cytokine therapy</bold></td><td align="left" colspan="1" rowspan="1">Porous nanoparticle</td><td align="left" colspan="1" rowspan="1">BALLkine-2</td><td align="left" colspan="1" rowspan="1">Recombinant IL-2</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Peritumoral injection</td><td align="left" colspan="1" rowspan="1">Enhance intratumoral lymphocyte infiltration, improve the therapeutic effect of PD-1 blockade</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR254">254</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">5FU/IL2/CD2 nanoplex</td><td align="left" colspan="1" rowspan="1">5-FU, IL-2</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Colorectal cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Inhibit tumor growth and metastasis</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR255">255</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PEGylation</td><td align="left" colspan="1" rowspan="1">NKTR-214</td><td align="left" colspan="1" rowspan="1">IL-2</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Induce durable immunity, suppress tumor rechallenge in combination with anti-CTLA-4 antibody</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR256">256</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PEGylation</td><td align="left" colspan="1" rowspan="1">NKTR-214</td><td align="left" colspan="1" rowspan="1">IL-2</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Pancreatic cancer, hepatocellular carcinoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Favor activation of CD8<sup>+</sup> T cells over Tregs in the tumor microenvironment, prevent tumor development</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR257">257</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PEGylation</td><td align="left" colspan="1" rowspan="1">NKTR-214</td><td align="left" colspan="1" rowspan="1">IL-2</td><td align="left" colspan="1" rowspan="1">Clinical study</td><td align="left" colspan="1" rowspan="1">Solid tumors (e.g., melanoma, breast cancer, colorectal cancer)</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Present good tolerability, induce tumor regression and durable disease stabilization</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR258">258</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PEGylation</td><td align="left" colspan="1" rowspan="1">NKTR-214</td><td align="left" colspan="1" rowspan="1">IL-2</td><td align="left" colspan="1" rowspan="1">Clinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Show unsatisfactory anticancer efficacy in combination with nivolumab</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR259">259</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PEGylation</td><td align="left" colspan="1" rowspan="1">NKTR-214</td><td align="left" colspan="1" rowspan="1">IL-2</td><td align="left" colspan="1" rowspan="1">Clinical study</td><td align="left" colspan="1" rowspan="1">Renal cell carcinoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Show unsatisfactory anticancer efficacy in combination with nivolumab</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR260">260</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PEGylation</td><td align="left" colspan="1" rowspan="1">THOR-707</td><td align="left" colspan="1" rowspan="1">IL-2</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Promote drug retention in the tumor tissue, activate CD8<sup>+</sup> T cell-mediated immune responses, inhibit tumor growth</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR261">261</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PEGylation</td><td align="left" colspan="1" rowspan="1">THOR-707</td><td align="left" colspan="1" rowspan="1">IL-2</td><td align="left" colspan="1" rowspan="1">Clinical study</td><td align="left" colspan="1" rowspan="1">Solid tumors (e.g., pancreatic cancer and prostate cancer)</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Demonstrate a tolerable safety profile and initial clinical activity as monotherapy and in combination with pembrolizumab</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR262">262</xref>, <xref ref-type="bibr" rid="CR263">263</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Proteoliposome</td><td align="left" colspan="1" rowspan="1">Oncoquest-L</td><td align="left" colspan="1" rowspan="1">IL-2</td><td align="left" colspan="1" rowspan="1">Clinical study</td><td align="left" colspan="1" rowspan="1">Follicular lymphoma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Have a manageable safety profile, elicit tumor-specific type I cytokine response, induce a persistent complete response in one patient</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR264">264</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Liposome</td><td align="left" colspan="1" rowspan="1">PLE-IL-12-NP</td><td align="left" colspan="1" rowspan="1">IL-12</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Ovarian cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection, intraperitoneal injection</td><td align="left" colspan="1" rowspan="1">Show low toxicity and increased antitumor efficacy</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR265">265</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PLGA nanosphere</td><td align="left" colspan="1" rowspan="1">rmIL-12&#160;ns</td><td align="left" colspan="1" rowspan="1">IL-12</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Osteosarcoma</td><td align="left" colspan="1" rowspan="1">Intraperitoneal injection</td><td align="left" colspan="1" rowspan="1">Inhibit cancer progression</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR266">266</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Porous silica nanoparticle</td><td align="left" colspan="1" rowspan="1">mRNA/L-PPSN</td><td align="left" colspan="1" rowspan="1">IL-12 mRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Colorectal cancer</td><td align="left" colspan="1" rowspan="1">Intratumoral injection</td><td align="left" colspan="1" rowspan="1">Induce immunogenic cancer cell death, enhance anticancer activity of anti-PD-1 antibody</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR267">267</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Protein-based nanoparticle</td><td align="left" colspan="1" rowspan="1">INS-CAR T biohybrid</td><td align="left" colspan="1" rowspan="1">IL-12</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Lymphoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Augment CAR T cell antitumor capabilities, eradicate solid tumors, minimize unwanted side effects</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR268">268</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Calcium carbonate nanoparticle</td><td align="left" colspan="1" rowspan="1">IL-12 mRNA@cRGD-CM-CaCO3 NP</td><td align="left" colspan="1" rowspan="1">IL-12 mRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Glioblastoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Traverse through the BBB to specifically target cancer cells, synergize with acousic cavitation-mediated necroptosis to exert enhanced antitumor effects</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR269">269</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">HC/pIL-12/polyMET</td><td align="left" colspan="1" rowspan="1">Cisplatin, plasmid encoding IL-12 gene</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Lung cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Increase drug accumulation in tumor site, significantly retard cancer growth, prolong the overall survival of tumor-bearing mice</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR270">270</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticle</td><td align="left" colspan="1" rowspan="1">TNP</td><td align="left" colspan="1" rowspan="1">Doxorubicin, IL-12</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Hepatocellular carcinoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Show prolonged circulation in the blood, efficiently accumulate in tumor tissues, polarize macrophages toward the M1 phenotype to reduce tumor growth</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR271">271</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipopolymer-based nanoparticle</td><td align="left" colspan="1" rowspan="1">GEN-1</td><td align="left" colspan="1" rowspan="1">IL-12</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Significantly inhibit tumor growth</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR272">272</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipopolymer-based nanoparticle</td><td align="left" colspan="1" rowspan="1">GEN-1</td><td align="left" colspan="1" rowspan="1">IL-12</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Glioma</td><td align="left" colspan="1" rowspan="1">Intracranial injection</td><td align="left" colspan="1" rowspan="1">Present good tolerability, increase animals&#8217; survival time</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR273">273</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipopolymer-based nanoparticle</td><td align="left" colspan="1" rowspan="1">GEN-1</td><td align="left" colspan="1" rowspan="1">IL-12</td><td align="left" colspan="1" rowspan="1">Clinical study</td><td align="left" colspan="1" rowspan="1">Epithelial ovarian, fallopian tube or primary peritoneal cancer</td><td align="left" colspan="1" rowspan="1">Intraperitoneal injection</td><td align="left" colspan="1" rowspan="1">Show limited activity and unfavorable tolerability in platinum-resistant recurrent ovarian cancer patients</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR274">274</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipopolymer-based nanoparticle</td><td align="left" colspan="1" rowspan="1">GEN-1</td><td align="left" colspan="1" rowspan="1">IL-12</td><td align="left" colspan="1" rowspan="1">Clinical study</td><td align="left" colspan="1" rowspan="1">Ovarian cancer</td><td align="left" colspan="1" rowspan="1">Intraperitoneal injection</td><td align="left" colspan="1" rowspan="1">Present favorable tolerability and safety profiles, have no impact on the clinical efficacy of carboplatin/docetaxel chemotherapy</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR275">275</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipopolymer-based nanoparticle</td><td align="left" colspan="1" rowspan="1">GEN-1</td><td align="left" colspan="1" rowspan="1">IL-12</td><td align="left" colspan="1" rowspan="1">Clinical study</td><td align="left" colspan="1" rowspan="1">Epithelial ovarian, fallopian tube or primary peritoneal cancer</td><td align="left" colspan="1" rowspan="1">Intraperitoneal injection</td><td align="left" colspan="1" rowspan="1">Exhibit clinical efficacy in combination with PEGylated liposomal doxorubicin</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR276">276</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">MEDI1191</td><td align="left" colspan="1" rowspan="1">IL-12 mRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Melanoma, lymphoma</td><td align="left" colspan="1" rowspan="1">Intratumoral injection</td><td align="left" colspan="1" rowspan="1">Significantly inhibit tumor growth by activating systemic immune responses</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR277">277</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">MEDI1191</td><td align="left" colspan="1" rowspan="1">IL-12 mRNA</td><td align="left" colspan="1" rowspan="1">Clinical study</td><td align="left" colspan="1" rowspan="1">Solid tumors (e.g., breast cancer and melanoma)</td><td align="left" colspan="1" rowspan="1">Intratumoral injection</td><td align="left" colspan="1" rowspan="1">Have a favorable safety profile, show initial antitumor effects in combination with anti-PD-L1 treatment, promote the recruitment of CD8<sup>+</sup> T cells into the tumors</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR252">252</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">JCXH-211</td><td align="left" colspan="1" rowspan="1">IL-12 mRNA</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Colorectal cancer, melanoma, breast cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Induce antitumor immunity, facilitate tumor regression in conjunction with anti-PD-1 antibody</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR278">278</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Exosome</td><td align="left" colspan="1" rowspan="1">IL-29-loaded exosome</td><td align="left" colspan="1" rowspan="1">Recombinant IL-29</td><td align="left" colspan="1" rowspan="1">Cell experiment</td><td align="left" colspan="1" rowspan="1">Cervical cancer, hepatocellular carcinoma, breast cancer, glioblastoma</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Present sustained drug release and high targeting efficiency, demonstrate dramatic cytotoxic effects against cancer cells</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR279">279</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Liposome</td><td align="left" colspan="1" rowspan="1">Lip-F1, Lip-F2</td><td align="left" colspan="1" rowspan="1">IFN-&#947;</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Colon cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Promote drug accumulation in the tumor site, stimulate significant antitumor responses</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR280">280</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Chitosan nanoparticle</td><td align="left" colspan="1" rowspan="1">TGF-&#946;1-loaded chitosan NP</td><td align="left" colspan="1" rowspan="1">TGF-&#946;1</td><td align="left" colspan="1" rowspan="1">Cell experiment</td><td align="left" colspan="1" rowspan="1">Cervical cancer</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Inhibit cancer progression through activation of the TIM-3 signaling pathway and downregulation of miR-155</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR281">281</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Protein-based nanoparticle</td><td align="left" colspan="1" rowspan="1">AMD3100-SPNP</td><td align="left" colspan="1" rowspan="1">AMD3100</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Glioblastoma</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Induce persistent antitumor immunological memory response, sensitize cancer cells to radiotherapy</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR282">282</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PLGA nanosphere</td><td align="left" colspan="1" rowspan="1">ImmunoBait nanoparticle</td><td align="left" colspan="1" rowspan="1">CXCL10</td><td align="left" colspan="1" rowspan="1">Preclinical study</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="1" rowspan="1">Intravenous injection</td><td align="left" colspan="1" rowspan="1">Increase the infiltration of effector immune cells into the metastatic sites, block cancer metastasis</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR283">283</xref>]</td></tr></tbody></table></table-wrap></p><sec id="Sec15"><title>Nanotechnology for immune checkpoint blockade therapy</title><sec id="Sec16"><title>Nanocarrier-mediated alteration of immune checkpoint molecules</title><p id="Par164">Nanoparticles can be engineered to directly modify immune checkpoints on cancer cells or immune cells, inducing innate and adaptive immune responses (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). For instance, a core&#8211;shell structure of an immunomodulating nanoparticle was formed by synthesizing and coating bovine serum albumin nanocapsule (nBSA)-phenylboronic acid (PBA)-immunoglobulin G (IgG) with glucose-modified poly(2-methacryloyloxyethyl phosphorylcholine)-<italic toggle="yes">b</italic>-poly(<italic toggle="yes">N</italic>-(3-aminopropyl)-methacrylamine) (PMPC-<italic toggle="yes">b</italic>-PApm/Glu) [<xref ref-type="bibr" rid="CR175">175</xref>]. Once they enter tumor tissues, PMPC-<italic toggle="yes">b</italic>-PApm/Glu disassembled from the immunomodulating nanoparticle to release the bifunctional core nBSA-PBA-IgG. The glyco-immune negative checkpoint sialic acid (SA) expressed on the cancer cell surface competitively bound to PBA on nBSA-PBA-IgG, replacing the PMPC shell due to the strong binding affinity of SA to PBA. The discharged bifunctional core tightly coupled with cancer cells and presented IgG on the surface, contributing to the in situ modification of cancer cell surface with immune-activating signals (IgG). Subsequently, the recognition of the fragment crystallizable (Fc) region of IgG by the Fc receptor bearing on NK cell surface led to the activation of tumor-infiltrating NK cells, which induced the apoptosis of target cancer cells. Immunomodulating nanoparticles effectively activated NK cell-mediated immunity and showed marked anticancer efficacy in melanoma-bearing mice. The liposome system was used as a nanocarrier for the drug conjugate protoporphyrin IX (PpIX)-NLG919 (termed as PpIX-NLG@Lipo) [<xref ref-type="bibr" rid="CR176">176</xref>]. PpIX-NLG@Lipo demonstrated a strong ability to generate reactive oxygen species (ROS) for the purpose of destroying breast cancer cells through photodynamic therapy (PDT). Moreover, PpIX-NLG@Lipo reduced the activity of the immune checkpoint indoleamine-2,3-dioxygenase (IDO), thereby enhancing PDT-induced immune responses. Consequently, this resulted in an increased infiltration of CD8<sup>+</sup> T lymphocytes into the tumor site, ultimately leading to regression of both primary and distant tumors. Photosensitive polydopamine-coated nanoparticles co-loaded with the chemotherapeutic agent gemcitabine and the IDO inhibitor NLG919 (N/PGEM/dp) efficiently transferred the loaded agents to both primary and remote pancreatic cancer cells [<xref ref-type="bibr" rid="CR177">177</xref>]. N/PGEM/dp promoted the infiltration of NK cells and tumor antigen-specific CTLs, as well as the release of cytokines (e.g., granzyme B (GzB) and IFN-&#947;) by these immune cells. As expected, N/PGEM/dp demonstrated a significant tumor inhibition effect in a murine pancreatic cancer model.<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Nanomedicine-based strategies for enhancing the efficacy of cancer immunotherapy. Due to their prominent molecular encapsulation efficiency, prolonged circulation in blood and superior targetability, nanoparticles have emerged as a multifunctional platform that induces systemic antitumor immunity and potentiates the anticancer efficacy of conventional immunotherapies. Various types of nanoformulations, such as mesoporous silica nanoparticle, liposome, micelle, polymeric nanoparticle, gold nanoparticle and virus-like nanoparticle, have been developed and manufactured for cancer immunotherapies. PD-1, programmed cell death-1; CAR, chimeric antigen receptor; IL-2, interleukin-2; IL-12, interleukin-12</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="12943_2024_2214_Fig3_HTML.jpg"/></fig></p><p id="Par165">Nanocarrier-based systems incorporating small interfering RNAs (siRNAs) for silencing immunosuppressive immune checkpoints have a high efficiency of intracellular delivery of loaded siRNAs to the TME, resulting in more intense immune responses compared to antibody-based blockades (e.g., anti-PD-L1 antibody and anti-PD-1 antibody) [<xref ref-type="bibr" rid="CR178">178</xref>]. Several siRNA-loading nanoplatforms have been reported for immune checkpoint silencing (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). A silica nanocarrier loaded with PD-L1-targeting siRNAs efficiently delivered siRNAs into T cells, resulting in the downregulation of PD-L1 and promotion of T cell survival [<xref ref-type="bibr" rid="CR179">179</xref>]. PD-L1 siRNA-loaded nanocarriers have the potential to improve the efficacy of adoptive T-cell immunotherapy in cancer patients. Likewise, acidic tumor extracellular pH-responsive nanoparticles encapsulated with a TGF&#946;R inhibitor and PD-L1-specific siRNA stimulated CD8<sup>+</sup> T cell-mediated antitumor immunity to retard PDAC growth [<xref ref-type="bibr" rid="CR180">180</xref>]. Poly(lactic-co-glycolic-acid) (PLGA) nanoparticles carrying PD-L1 siRNA and PD-1 siRNA cooperated with PLGA nanoparticles encapsulating tumor antigen (ovalbumin (OVA) or E7 peptide) and adjuvant (poly I:C) showed synergistic antitumor effects against thymoma by eliciting CD8<sup>+</sup> T cell-directed immune responses [<xref ref-type="bibr" rid="CR178">178</xref>].<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Nanoplatform-mediated immune checkpoint modulation to enhance antitumor T cell immune responses. Anti-CTLA-4 or anti-PD-1 antibody-loaded nanoparticles, as well as PD-1/PD-L1/CTLA-4 siRNA-encapsulated nanoparticles, can activate T cell-mediated immune responses and result in cancer cell death through blockade of immune checkpoint molecules. PD-1, programmed cell death-1; CTLA-4, cytotoxic T lymphocyte-associated antigen-4; PD-L1, programmed cell death-ligand 1; PLGA, poly(lactic-co-glycolic-acid); PD-1-NP, anti-PD-1 antibody-loaded nanoparticle; CTLA-4-NP, anti-CTLA-4 antibody-loaded nanoparticle; APC, antigen-presenting cell; MHC, major histocompatibility complex; TCR, T cell receptor</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="12943_2024_2214_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec17"><title>Combined treatment of nanotechnology and immune checkpoint inhibitors</title><p id="Par166">It has been established that nano-immunotherapy can improve the therapeutic outcome of conventional ICIs. Accumulating evidence shows that the enhancing effects of nanocarriers on ICI efficacy are mainly attributable to their activity in promoting antigen presentation and stimulating CD8<sup>+</sup> T cell immune responses. A natural nanopolymer poly(&#946;-L-malic acid) (PMLA) with covalently conjugated anti-CTLA-4 and anti-PD-1 antibodies was capable of crossing the blood&#8211;brain barrier (BBB) to penetrate GBM cells [<xref ref-type="bibr" rid="CR181">181</xref>]. PMLA-based immunoconjugates increased the populations of CD8<sup>+</sup> T cells, macrophages, and NK cells and decreased the populations of Treg cells in the GBM tissue. Importantly, this combination of immunoconjugates possessed stronger anticancer effects than single ICI-bearing PMLA or free anti-CTLA-4 and anti-PD-1 antibodies in vivo. Trans-BBB transfer of tumor-targeted nanopolymer-conjugated ICIs may represent a valuable therapeutic strategy for GBM. Chemotherapy-induced tumor RNA nanoparticles (C-RNA-NPs) synergistically acted with PD-1 blockade to suppress colon carcinoma development and prolong the survival of cancer-bearing mice [<xref ref-type="bibr" rid="CR182">182</xref>]. This was achieved by increasing intratumoral T cell infiltration and enhancing the intratumoral ratio of CD8<sup>+</sup> T cells to Treg cells. Cancer cell membrane (CCM)-coated PLGA/gambogic acid nanoparticles (CCM-PLGA/GA NPs) had a high tumor-targeting ability and functioned to promote DC maturation [<xref ref-type="bibr" rid="CR183">183</xref>]. The combination of CCM-PLGA/GA NPs with anti-PD-1 treatment significantly inhibited colon carcinoma growth in vivo. A ROS-sensitive nanocarrier, <sup>TK</sup>HNP-C/D, was developed to carry two immunogenic cell death (ICD)-inducing agents, chlorin e6 (Ce6) and DOX [<xref ref-type="bibr" rid="CR184">184</xref>]. <sup>TK</sup>HNP-C/D-based therapy efficiently synergized with anti-PD-1 treatment to exert an abscopal effect, which repressed primary mammary tumor growth and restricted metastatic spread. Macrophage membrane-coated nanoparticles loaded with a TGF&#946;R1 kinase inhibitor (M&#981;-SDNP), combined with anti-PD-1 antibodies, had a significantly strong antitumor effect in breast cancer-bearing mice [<xref ref-type="bibr" rid="CR185">185</xref>].</p><p id="Par167">A nanoparticle loaded with siRNAs targeting zinc finger Asp-His-His-Cys-type palmitoyltransferase 9 (NP-siZDHHC9) enhanced infiltration and activation of CD8<sup>+</sup> T cells while reducing infiltration of myeloid-derived suppressor cells (MDSCs) [<xref ref-type="bibr" rid="CR186">186</xref>]. It also increased production of proinflammatory cytokines and chemokines (e.g., IFN-&#947;, IL-2, and tumor necrosis factor-&#945; (TNF-&#945;)). NP-siZDHHC9 combined with anti-PD-L1 treatment efficiently inhibited pancreatic cancer development and prolonged the survival of tumor-bearing mice by transforming the immunosuppressive TME into a proinflammatory state. DC-targeted nanoparticles comprising Toll-like receptor 4/7/8 (TLR4/7/8) agonists were able to increase cytokine production, promote DC maturation and enhance the population of antigen-specific CD8<sup>+</sup> T cells [<xref ref-type="bibr" rid="CR187">187</xref>]. The DC-targeted nanoparticles synergized with anti-PD-1 therapy to suppress T-cell lymphoma progression. Nanoparticles (CNPs) incorporating a TLR9 agonist, cytosine phosphate guanine (CpG)-oligodeoxynucleotide (ODN), enhanced the therapeutic activity of the anti-PD-1 antibody in melanoma-bearing mice [<xref ref-type="bibr" rid="CR188">188</xref>]. Pathogen-mimicking magnetite nanoparticles efficiently elicited antigen-specific CTL effector and memory responses [<xref ref-type="bibr" rid="CR189">189</xref>]. The nanovaccine system in conjunction with PD-L1 inhibition conferred 100% long-term immune protection against various melanoma challenges. This nanovaccine combined with checkpoint blockade of PD-L1 may be a suitable option to improve TLR4 agonist-based immunotherapy in cancer. Surgically derived CCM-coated imiquimod (R837)-loaded poly(2-oxazoline) nanoparticles (SCNP/R837) efficiently migrated to the DLN and were absorbed and presented by plasmacytoid DCs (pDCs) to induce attraction and activation of NK cells and CTLs at tumor sites [<xref ref-type="bibr" rid="CR190">190</xref>]. The nanoformulation remarkably retarded the progression of prostate cancer and extended animal survival. When combined with anti-PD-1, SCNP/R837 demonstrated improved therapeutic efficacy in mice bearing prostate cancer. The inflammasome-activating nanovaccine platform elicited antigen-specific CD8<sup>+</sup> T cell responses characterized by increased production of GzB and IFN-&#947; [<xref ref-type="bibr" rid="CR191">191</xref>]. This nanovaccine, along with ICIs (anti-CTLA-4 and anti-PD-L1 antibodies), effectively decreased tumor burden and extended animal survival in murine lymphoma, melanoma and colon carcinoma models.</p><p id="Par168">In the past decades, ICIs have emerged as a powerful treatment modality in the field of cancer immunotherapy. However, ICIs are associated with immune-related toxicities that dampen their clinical activity. Applying nanotechnology to deliver ICIs may be a feasible solution to address critical issues in ICI treatments. The advantages of utilizing nanotechnology rely on the prominent features of nanoparticles, including formulation simplicity, biocompatibility, self-assembly, high bioavailability, practical accommodation of nanoparticle size, highly adjustable surface/morphological properties, and the ability to carry specific payloads [<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR284">284</xref>]. In vivo studies have demonstrated that nanoparticles preferentially accumulate within tumors due to their leaky vascular system and poor lymphatic drainage [<xref ref-type="bibr" rid="CR285">285</xref>]. Nanoformulations can be designed as rational systems for controlled release of ICIs in response to diverse stimuli within the TME. Combination treatment of ICIs and nanotechnology overcomes tumor immune tolerance and enhances systemic antitumor immunity, which may benefit patients with poorly immunogenic tumors [<xref ref-type="bibr" rid="CR286">286</xref>]. Further research efforts are required to establish the most effective protocols for integrating nanomaterials into ICI immunotherapies, including administration route, time and intervals, as well as potential off-target effects and adverse reactions. More accessible animal models must be developed to evaluate the effects of nanoparticle-based ICI therapy. Another area that warrants urgent attention is the elucidation of the pharmacokinetic property and systemic toxicity of nanoparticles. A better understanding of tumor immunology will contribute to optimizing the effectiveness of nanoparticle-based immune checkpoint therapies, ultimately boosting the likelihood of their successful translation into clinical practice.</p></sec></sec><sec id="Sec18"><title>Nanotechnology for adoptive cell therapy</title><sec id="Sec19"><title>Innate immune cell-based immunotherapy</title><p id="Par169">TLR7/8 agonist-loaded nanoparticles selectively transported TLR7/8 mixed agonists to the endosome/lysosome of DCs [<xref ref-type="bibr" rid="CR192">192</xref>] (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). The nanoparticle-induced TLR7/8 activation favored the secretion of proinflammatory cytokines (IFN-&#947;, IL-12 and IL-18) and increased the expression of costimulatory molecules (CD40, CD70, CD80 and CD86) by DCs, both of which resulted in NK cell hyperactivation and degranulation. These immunostimulatory molecules further induced T cell-mediated immune responses. Furthermore, TLR7/8 agonist-loaded nanoparticles dramatically potentiated the therapeutic efficacy of monoclonal antibodies targeting epidermal growth factor receptor (EGFR) and HER2 in lung adenocarcinoma-bearing mice. Chiral nanoparticles facilitated the activation of NK cells and CD8<sup>+</sup> T cells by mobilizing DCs [<xref ref-type="bibr" rid="CR193">193</xref>]. Chiral nanoparticles induced the apoptosis of lymphoma cells and extended the survival of tumor-bearing mice. Liposome-anchored macrophages armed with TLR7/8 agonist (LAM&#934;-m7/8a) maintained an antitumor M1 phenotype and exerted killing effects on cancer cells [<xref ref-type="bibr" rid="CR194">194</xref>]. Moreover, LAM&#934;-m7/8a enhanced the infiltration of antigen-specific CD8<sup>+</sup> T cells and attenuated the population of MDSCs. LAM&#934;-m7/8a in combination with DOX-loaded liposomes exhibited effective anticancer efficacy against breast cancer in vivo. LAM&#934;-m7/8a may provide an appropriate alternative to adoptive cell-based therapy. The non-viral lipid nanoparticle (LNP)-based delivery system encapsulating siRNAs against intrinsic inhibitory NK cell molecules (SHP-1 and Cbls) efficiently unleashed NK cell activity to kill B cell lymphoma cells in vivo [<xref ref-type="bibr" rid="CR195">195</xref>]. Treatment with cationic nanoparticle (cNP) enhanced the cytotoxic activity of NK cells by stimulating the expression of C-C motif chemokine receptor 4 (CCR4) and C-X-C motif chemokine receptor 4 (CXCR4) and promoting their interaction with triple-negative breast cancer (TNBC) cells [<xref ref-type="bibr" rid="CR196">196</xref>]. cNP-activated NK cells demonstrated superior ability to suppress TNBC growth in vivo compared to control NK cells. The cNP-mediated activation of NK cells holds promise for NK cell-based cancer immunotherapy.<fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Nanoparticle-based therapeutics to improve adoptive cell therapy. Nanotechnology holds immense potential for improving adoptive cell therapy. TLR7/8 agonist-loaded nanoparticle selectively transports TLR7/8 agonist to the endosome/lysosome of dendritic cells, which promotes the secretion of proinflammatory cytokines (IFN-&#947;, IL-12 and IL-18) and increases the expression of costimulatory molecules (CD40, CD70, CD80 and CD86). These immunostimulatory molecules activate NK cells and further induce T cell-mediated immune responses. Chiral nanoparticle facilitates the activation of NK cells and CD8<sup>+</sup> T cells by mobilizing dendritic cells. Liposome-anchored macrophages armed with TLR7/8 agonist maintain an antitumor M1 phenotype and exert killing effects on tumor cells. SHP-1/Cbls siRNA-encapsulated lipid nanoparticle efficiently unleashes NK cell activity to kill tumor cells. Cationic nanoparticle also enhances the cytotoxic activity of NK cells by stimulating the expression of CCR4 and CXCR4. Polymeric nanoparticles carrying CAR genes modify T cells to initiate antitumor immune responses. Nanogel-mediated delivery of IL-15SA facilitates T cell expansion and contributes to CAR-T cell-mediated tumor inhibition. Likewise, TGF-&#946;I-loaded liposome also induces T cell expansion, thus triggering robust T cell-mediated antitumor immune responses. TLR7/8, Toll-like receptor 7/8; PLGA, poly(lactic-co-glycolic-acid); LNP, lipid nanoparticle; CAR, chimeric antigen receptor; EGFRvIII, epidermal growth factor receptor variant III; IL-15SA, IL-15 super-agonist; TGF-&#946;I, transforming growth factor-&#946; inhibitor; NK cell, natural killer cell; CCR4, C-C motif chemokine receptor 4; CXCR4, C-X-C motif chemokine receptor 4; IFN-&#947;, interferon-&#947;; IL-12, interleukin-12; IL-18, interleukin-18; MHC, major histocompatibility complex; TCR, T cell receptor; TNF-&#945;, tumor necrosis factor-&#945;; IL-1&#946;, interleukin-1&#946;; IL-6, interleukin-6; IL-23, interleukin-23</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="12943_2024_2214_Fig5_HTML.jpg"/></fig></p></sec><sec id="Sec20"><title>T cell-based immunotherapy</title><p id="Par170">Polymeric nanoparticles carrying leukemia-specific CARs selectively modified circulating T cells [<xref ref-type="bibr" rid="CR197">197</xref>]. Nanoparticle-edited CAR-T cells induced leukemia regression with efficacies comparable to adoptive T cell therapy in preclinical models. Plasmid DNA-loaded self-assembled nanoparticles (pDNA@SNPs<sup>G1/800</sup>) efficiently shuttled the EGFR variant III (EGFRvIII) CAR-expression plasmid vector (pEGFRvIII CAR) into T cells, thus resulting in transient expression of EGFRvIII CAR in transfected T cells [<xref ref-type="bibr" rid="CR198">198</xref>]. The presence of EGFRvIII CAR on T cell surface empowered T cells to recognize and kill EGFRvIII-positive cancer cells. pDNA@SNPs<sup>G1/800</sup> can be useful in engineering CARs in T cells and may hold considerable potential for CAR-T cancer immunotherapy. Nanogel-mediated delivery of IL-15 super-agonist (IL-15SA) complexes facilitated the expansion of T cells infiltrating the tumor tissue and contributed to CAR-T cell-mediated melanoma regression in vivo [<xref ref-type="bibr" rid="CR199">199</xref>]. Incubation of T cells with immunoliposomes encapsulating a TGF-&#946; inhibitor and a T cell targeting receptor CD45 or CD90 induced the expansion of granzyme-expressing T cells in vitro [<xref ref-type="bibr" rid="CR200">200</xref>]. Upon adoptive transfer, T cells incubated with CD90-loaded immunoliposomes triggered strong T cell-mediated antitumor immune responses and suppressed melanoma growth in preclinical models.</p><p id="Par171">Adoptive cell therapy is a promising approach for treating cancer, as evidenced by numerous clinical trials in hematologic and solid tumors. Despite its great potential in cancer intervention, the efficacy of adoptive cell therapy remains limited, particularly in the context of solid malignancies. In addition to restrictive anatomical barriers that hinder adequate delivery of T cells, the aberrant vasculature of solid tumors prevents T cell infiltration into the TME, thereby diminishing their local bioavailability and functionality. The immunosuppressive TME of solid tumors further blunts the antitumor effect of T cells. Nanocarriers offer a means to penetrate anatomical barriers and deliver therapeutic cargos to the target site. Thus, nanotechnology holds immense potential for improving adoptive cell therapy (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). However, multiple hurdles remain for the clinical utility of nanoparticles in adoptive cell therapy. The effects of nanoparticle size, composition, structure and surface charge on T cell activity must be thoroughly determined. In vivo tracking and visualization technologies are critically required to explore how adoptively transferred T cells enter target cells, expand, and exhaust. It is necessary to develop improved targeting approaches, such as multi-ligand modifications, to ensure specific uptake and low toxicity. The density and patterns of surface modifications and nanomaterial surface topology should be assessed to optimize nanocarrier synthesis for immune cell binding and activation [<xref ref-type="bibr" rid="CR287">287</xref>]. Strategies that favor controlled drug release from nanocarriers need to be employed in nanotechnology-assisted adoptive cell therapy. Nanoparticles act as a versatile delivery system that can transfer antibodies, genes and small molecules. However, the appropriate cargos that act synergistically with existing adoptive cell therapies remain to be established. A significant challenge in adoptive cell therapy lies in the lack of precise control over T cell behavior in vivo. Innovative technologies must be employed to achieve remote regulation of T cell function in vivo [<xref ref-type="bibr" rid="CR288">288</xref>]. Before applying nanotechnology to adoptive cell therapy, the anticancer effect of nanoparticle-enhanced T cells must be validated in further clinical studies.</p></sec></sec><sec id="Sec21"><title>Nanotechnology for antibody-based targeted therapy</title><p id="Par172">Radiosensitive gold nanoparticles were used to deliver tumor-targeting antibodies (Cetuximab) into the brain [<xref ref-type="bibr" rid="CR201">201</xref>] (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>). Furthermore, Cetuximab-loaded nanoparticles specifically accumulated within the glioblastoma tissues. This nanoparticle-based therapy combined with standard of care treatment, comprising temozolomide (TMZ) and adjuvant radiotherapy, resulted in a significant inhibition of glioblastoma growth in vivo. The anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, DTA-1, is capable of abrogating tumor immunosuppression by transforming Treg cells into Th1 cells [<xref ref-type="bibr" rid="CR289">289</xref>]. Catalase (CAT) and DTA-1 were loaded onto polydopamine (PDA)-indocyanine green (ICG) nanoparticles, generating a versatile nanoplatform, abbreviated as PDA-ICG@CAT-DTA-1 [<xref ref-type="bibr" rid="CR202">202</xref>]. PDA-ICG@CAT-DTA-1 reversed tumor immunosuppression by decreasing the population of intratumoral forkhead box P3 (FOXP3)<sup>+</sup> Treg cells and increasing the population of CD4<sup>+</sup> effector T cells. In vivo, PDA-ICG@CAT-DTA-1 exerted growth inhibition effects on primary and distant breast tumors. An anti-IgG antibody (&#945;Fc) was conjugated to the surface of a nanocarrier to create an antibody immobilization platform (&#945;Fc-NP) [<xref ref-type="bibr" rid="CR203">203</xref>]. &#945;Fc-NP effectively immobilized the anti-colony-stimulating factor 1 receptor antibody (&#945;CSF1R) and the anti-CD47 antibody (&#945;CD47) to form immunomodulating nanoformulations (imNAs). The imNAs facilitated the elimination of cancer cells by macrophages and induced the expansion of cancer-specific T cells. In a murine model of melanoma, intratumoral injection of imNAs resulted in more significant antitumor effects than the combination of &#945;CSF1R- and &#945;CD47-loaded nanoparticles. Anti-CD28 antibody-conjugated CCM nanoparticle (CCM-MPLA-aCD28), along with the adjuvant monophosphoryl lipid A (MPLA) incorporated into the nanoparticle, activated tumor-specific CD8<sup>+</sup> T cells and demonstrated remarkable therapeutic efficacy in mice bearing colon cancer [<xref ref-type="bibr" rid="CR204">204</xref>]. LNPs efficiently delivered the mRNA that encoded a commercial PD-1 antibody pembrolizumab [<xref ref-type="bibr" rid="CR205">205</xref>]. Furthermore, pembrolizumab mRNA-encapsulated LNPs reduced colon cancer growth and prolonged animal survival by inducing both CD4<sup>+</sup> and CD8<sup>+</sup> T cell-mediated immune responses.<fig id="Fig6" position="float" orientation="portrait"><label>Fig.&#160;6</label><caption><p>Nanotechnology for therapeutic antibody delivery in cancer treatment. Nanoplatforms with customized functionalities have been used to deliver tumor-targeting antibodies. For instance, radiosensitive gold nanoparticles can deliver Cetuximab into tumor cells. CAT and DTA-1 are loaded onto PDA-ICG nanoparticles, generating a versatile nanoplatform (PDA-ICG@CAT-DTA-1). PDA-ICG@CAT-DTA-1 reverses tumor immunosuppression by decreasing the population of Treg cells and increasing the population of CD4<sup>+</sup> effector T cells. Anti-IgG antibody-conjugated nanoparticle (&#945;Fc-NP) efficiently activates macrophages and induces T cell expansion. Anti-CD28 antibody-conjugated CCM nanoparticle (CCM-MPLA-aCD28) can activate CD8<sup>+</sup> T cells. In addition, pembrolizumab mRNA-encapsulated lipid nanoparticle functions to motivate both CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells. CAT, catalase; PDA, polydopamine; ICG, indocyanine green; Treg cell, regulatory T cell; CCM, cancer cell membrane; MPLA, monophosphoryl lipid A; LNP, lipid nanoparticle</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO6" position="float" orientation="portrait" xlink:href="12943_2024_2214_Fig6_HTML.jpg"/></fig></p><p id="Par173">Emerging evidence indicates that nanoplatforms with customized functionalities improve the therapeutic outcomes of antibody-based therapies (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). The vaccine adjuvant MPLA-loaded iron oxide nanoparticle (FH-MPLA) induced macrophage transition into an antitumor M1 phenotype [<xref ref-type="bibr" rid="CR206">206</xref>]. In the immunotherapy-resistant model of murine melanoma, FH-MPLA combined with anti-CD40 (&#945;-CD40) monoclonal antibodies resulted in cancer necrosis and regression. FH-MPLA may represent an adjunctive therapy to existing antibody-based cancer immunotherapy. Trastuzumab is the first monoclonal antibody approved for treating HER2-postive breast cancer [<xref ref-type="bibr" rid="CR290">290</xref>]. However, resistance to trastuzumab treatment remains a significant hurdle that limits its therapeutic efficacy. A previous study revealed that TME PH-responsive nanoparticles effectively responded to the acidic niche, promoting the uptake of phosphatase and tensin homologue (<italic toggle="yes">PTEN</italic>) mRNA by breast cancer cells [<xref ref-type="bibr" rid="CR207">207</xref>]. Once internalized, the loaded mRNAs were released to increase PTEN expression, leading to the inactivation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling cascade and reversing trastuzumab resistance in breast cancer cells. Consequently, the combination of <italic toggle="yes">PTEN</italic> mRNA-loaded nanoparticles with trastuzumab resulted in a dramatic inhibition of tumor growth in an orthotopic mouse model of trastuzumab-resistant breast cancer.</p><p id="Par174">Despite the advantages of antibody-incorporated nanomedicines, their anticancer activity merits further verification in clinical studies. Moreover, the limitations of antibody-based nanoparticles include high production costs and absence of suitable antibody conjugation methods. More cancer-associated targets that are appropriate for the development of antibody-incorporated nanomedicines should be identified. It is also important to assess the tumor penetration ability of targeting nanocarriers. The functionalization of nanomaterials with targeting ligands may impair their stealth properties, ultimately accelerating the in vivo clearance of nanoparticles by the host [<xref ref-type="bibr" rid="CR291">291</xref>]. Integration of targeting ligands into nanoparticles may curtail their penetration and diffusion capacities in vivo by increasing the size of nanoparticles. Antibody-modified nanoparticles may not necessarily have enhanced tumor accumulation due to the complexity of in vivo environment [<xref ref-type="bibr" rid="CR292">292</xref>]. To realize the clinical translation of antibody-incorporated nanoparticles, their features including pharmacokinetics, biodistribution, stability, and toxicity must be optimized [<xref ref-type="bibr" rid="CR293">293</xref>]. This necessitates a thorough evaluation of various factors of nanoparticles, such as particle size, type of antibody, ligand density and conjugation strategy.</p></sec><sec id="Sec22"><title>Nanotechnology for cancer vaccines</title><p id="Par175">Cancer vaccines represent a promising cancer immunotherapeutic approach. Nanomedicines hold tremendous potential to increase vaccine effectiveness as they offer several advantages (e.g., nanoscale size, high stability and controlled antigen presentation) [<xref ref-type="bibr" rid="CR294">294</xref>]. Particularly, nanocarriers can deliver molecule vaccines to the target lymphoid tissues or immune cells, which increases the effect and durability of antitumor immunity with minimum side effects and toxicity [<xref ref-type="bibr" rid="CR295">295</xref>]. Due to their roomy cores or large surface areas, nanoplatforms can load multivalent antigens and/or adjuvant molecules, thus improving the immunogenicity of vaccines and intensifying antigen-specific adaptive immunity for cancer treatment. Nanovaccines consist of three main components: antigens, nanocarriers, and adjuvants. Nanosystems serve as a crucial bridge for efficiently delivering antigens to the TME, thus inducing effective immune responses. Antigens encapsulated in nanomaterials can be in the form of tumor cell lysates, peptides, and mRNAs encoding tumor antigens [<xref ref-type="bibr" rid="CR296">296</xref>, <xref ref-type="bibr" rid="CR297">297</xref>] (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>). The therapeutic mechanisms of cancer vaccines involve expanding the repertoire of antitumor cells and reducing tumor immunosuppression [<xref ref-type="bibr" rid="CR298">298</xref>, <xref ref-type="bibr" rid="CR299">299</xref>].<fig id="Fig7" position="float" orientation="portrait"><label>Fig.&#160;7</label><caption><p>Different types of nanotechnology-based cancer vaccines. Nanotechnology-based cancer vaccines are generally classified into tumor lysate nanovaccines, peptide nanovaccines, tumor antigen-based nanovaccines, viral nanovaccines and mRNA nanovaccines. TLS, tumor lysate; TLR, Toll-like receptor</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO7" position="float" orientation="portrait" xlink:href="12943_2024_2214_Fig7_HTML.jpg"/></fig></p><sec id="Sec23"><title>Tumor lysate nanovaccines</title><p id="Par176">Nanovaccines that deliver tumor cell lysates not only increase the repertoire of tumor-derived antigens as immune targets but also induce ICD to enhance antitumor immunity [<xref ref-type="bibr" rid="CR296">296</xref>]. Tumor cell-based nanovaccines will open the door to individualized cancer vaccination and immunotherapy. Currently, several nanoplatforms loaded with tumor cell lysates have been fabricated. For instance, lipid zinc phosphate hybrid nanoparticles (LZnP NPs) were used to deliver a TLR4 agonist and melanoma cell-derived tumor lysate (TLS) for vaccination [<xref ref-type="bibr" rid="CR208">208</xref>]. TLS-loaded LZnP NPs were able to induce DC maturation and CTL response. The TLS-loaded LZnP nanovaccine, in collaboration with the immune checkpoint antagonist d-peptide antagonist (<sup>D</sup>PPA-1), exerted antitumor effects in both prophylactic and therapeutic melanoma models. Magnetic liposomes containing melanoma lysate (Ag-MLs) significantly accumulated in lymph nodes and increased the infiltration of DCs and CTLs into the tumor, which correlated with effective anticancer efficacy in a murine melanoma model [<xref ref-type="bibr" rid="CR209">209</xref>]. PH-sensitive nanovaccines encapsulating cancer cell lysates and immune adjuvant CpG altered the acidic TME, contributing to the activation of CTLs and inhibition of breast cancer development in vivo [<xref ref-type="bibr" rid="CR210">210</xref>]. Engineered <italic toggle="yes">Salmonella</italic> (EnS) was wrapped with tumor cell lysate-coated PDA nanoparticles to produce the cancer vaccine EnS@PDA@CL [<xref ref-type="bibr" rid="CR211">211</xref>]. EnS@PDA@CL was able to deliver autologous antigen-containing nanoparticles to tumor hypoxia regions through the circulation. The particles induced antitumor immunity by activating DCs and increasing the infiltration of CTLs. Therefore, EnS@PDA@CL delayed pancreatic cancer progression in vivo.</p></sec><sec id="Sec24"><title>Tumor antigen-loaded nanoparticles</title><p id="Par177">Encapsulation of cancer antigens within diverse nanomaterials significantly enhances their persistence in the circulation, lymphoid tissues, or APCs. It is increasingly recognized that extending the persistence of cancer antigens increases their immunogenicity, and a number of nanovaccines have been investigated to achieve this objective. For instance, Ti<sub>3</sub>C<sub>2</sub> MXene-based nanoplatforms (MXP) codelivering OVA and a TLR9 agonist (CpG-ODN) enhanced DC activation and induced CTL immune responses [<xref ref-type="bibr" rid="CR212">212</xref>]. MXP-based immunotherapy and photothermal therapy efficiently eliminated melanoma in vivo. OVA-loaded porous silica nanoparticles (PSNs) recruited APCs and elicited sustained T cell activation [<xref ref-type="bibr" rid="CR213">213</xref>]. OVA-loaded PSNs also triggered strong antigen-specific antibody responses compared to OVA alone. OVA-loaded PSNs elicited melanoma regression in both prophylactic and therapeutic vaccination. Polyethylene glycol (PEG)-lipid polyester nanoparticles (PEG BR647-NPs) incorporating OVA and the signal transduction and activator of transcription 3 (<italic toggle="yes">STAT3</italic>) siRNA were taken up by tumor-associated DCs (TADCs) [<xref ref-type="bibr" rid="CR214">214</xref>]. Following this, OVA and <italic toggle="yes">STAT3</italic> siRNA were released into the cytoplasm, where OVA was presented by MHC-I to activate T cells, and <italic toggle="yes">STAT3</italic> siRNA promoted TADC maturation to induce antitumor T cell immunity. PEG BR647-NPs also reversed the immunosuppressive TME by depleting MDSCs and Treg cells. Collectively, PEG BR647-NP-based nanovaccines remodeled the TME and thus induced antitumor effects in melanoma-bearing mice. Magnetic nanoparticle modified with the OVA<sub>254&#8211;267</sub> antigen and CpG (MNP-CpG-COVA) promoted DC activation and induced systemic tumor-specific effector CD8<sup>+</sup> T cell responses [<xref ref-type="bibr" rid="CR215">215</xref>]. Therefore, MNP-CpG-COVA treatment slowed down melanoma growth and prolonged mouse survival in vivo. Graphene oxide nanosheet (nsGO) loaded with OVA and the adjuvant <italic toggle="yes">Poria cocos</italic> polysaccharides (PCP) was effectively captured by DCs, which induced the activation of DCs [<xref ref-type="bibr" rid="CR216">216</xref>]. Accordingly, nsGO/PCP/OVA nanocarriers triggered robust OVA-specific Th1 and Th2 immune responses. Vaccination with nsGO/PCP/OVA nanoformulations dramatically inhibited lymphoma growth in both prophylactic and therapeutic tumor models. Self-assembled vaccines based on cancer-specific antigen peptide (MAGE-A1 peptide) and a TLR2 agonist showed an increased ability to induce DC maturation and CD8<sup>+</sup> T cell activation, leading to the inhibition of tumor growth in a murine breast cancer model [<xref ref-type="bibr" rid="CR217">217</xref>]. Chitosan nanoparticles encapsulating recombinant CD44v (rCD44v) antigen efficiently elicited specific antibody responses and increased the production of IFN-&#947; and IL-17 by splenocytes [<xref ref-type="bibr" rid="CR218">218</xref>]. As a result, rCD44v-loaded nanoparticles not only suppressed breast cancer growth but also reduced metastatic burdens in a murine model.</p></sec><sec id="Sec25"><title>Peptide nanovaccines</title><p id="Par178">Peptide vaccines incorporate key amino acid sequences of tumor antigens, which trigger CTL antitumor immune responses and alleviate cancer immunosuppression [<xref ref-type="bibr" rid="CR300">300</xref>]. LNP-based vaccines, which displayed fibroblast activation protein &#945;-specific epitope peptides (FAP<sub>PEP</sub>), resulted in significant growth inhibition of desmoplastic tumors by eliminating FAP<sup>+</sup> cancer-associated fibroblasts (CAFs) and inhibiting extracellular matrix (ECM) generation in the TME [<xref ref-type="bibr" rid="CR219">219</xref>]. The combinatorial therapy of FAP<sub>PEP</sub>-displaying nanovaccines and the chemotherapeutic agent DOX increased drug accumulation within the tumor and led to synergistic anticancer effects that were far better than each monotherapy. Antimicrobial peptide FK-13-loaded nanoparticles (8FNs) reversed the immunosuppressive TME and induced antitumor CD8<sup>+</sup> T cell responses [<xref ref-type="bibr" rid="CR220">220</xref>]. Thus, 8FNs exhibited marked prophylactic and therapeutic efficacy against melanoma growth, suppressed cancer cell metastasis and extended the survival of tumor-bearing mice. DNA-coupled nitrate T helper cell epitope nanoparticle (DCNP) induced the activation of neoantigen-specific CD8<sup>+</sup> T cells that inhibited melanoma growth in vivo [<xref ref-type="bibr" rid="CR221">221</xref>]. Su et al. [<xref ref-type="bibr" rid="CR222">222</xref>] developed pH-responsive polymeric micellular nanoparticles to deliver TLR7/8/9 agonists and peptide neoantigens to DLNs for efficient antigen presentation. These nanoparticles increased the immunogenicity of peptide neoantigens, induced strong antitumor T cell immunity, and limited tumor immunosuppression. As expected, the nanovaccine, especially when combined with anti-PD-1 antibody, exerted a significant therapeutic effect in murine models of CRC and GBM.</p></sec><sec id="Sec26"><title>TLR agonist-conjugated antigen nanoparticles</title><p id="Par179">Redox-responsive antigen nanoparticles conjugated with TLR7/8 agonists induced CTL immune responses and long-term immunological effects [<xref ref-type="bibr" rid="CR223">223</xref>]. The prophylactic and therapeutic anticancer effects of this nanovaccine were established through in vivo murine lymphoma models. Likewise, TLR7/8 agonist resiquimod (R848)-loaded acid-responsive liposome-coated PDA nanoparticles selectively targeted DCs and released R848 for efficient antigen presentation [<xref ref-type="bibr" rid="CR224">224</xref>]. PDA nanoparticles prevented the metastasis and recurrence of breast cancer. The therapeutic vaccine comprising high-mobility group nucleosome-binding protein 1 (HMGN1), R848 and anti-PD-L1-loaded ROS-responsive mesoporous silica nanoparticle (MSN@TheraVac) was previously developed for the treatment of colon cancer [<xref ref-type="bibr" rid="CR225">225</xref>]. MSN@TheraVac promoted the maturation of DCs by increasing the surface expression of CD80, CD86 and CD103 and facilitating the production of proinflammatory cytokines (e.g., IL-1&#946;, IL-12 and TNF-&#945;). MSN@TheraVac treatment resulted in complete tumor regression and elicited tumor-specific protective memory responses in colon cancer-bearing mice. This therapeutic vaccine holds potential for being translated into a clinical treatment option for colon cancer patients.</p><p id="Par180">A TLR9 agonist (CpG)-coated tumor antigen-encapsulated nanoparticle-based vaccine decreased lung colonization by breast cancer cells through the induction of humoral and cellular immune responses [<xref ref-type="bibr" rid="CR226">226</xref>]. Moreover, the nanovaccine enhanced tumor-specific generation of GzB and IFN-&#947; by lung-derived CD8<sup>+</sup> T cells. In addition, intranasal delivery of CpG-coated nanoparticles promoted the accumulation of tumor-specific lung resident memory T cells in the lungs of breast cancer-bearing mice. This nanovaccine may be used as a prophylactic measure to prevent the pulmonary metastasis of existing tumors. Shi et al. [<xref ref-type="bibr" rid="CR227">227</xref>] designed and constructed a therapeutic nanovaccine, Alum-CpG@Fe-Shikonin NPs, which consisted of CpG-ODN-loaded aluminum hydroxyphosphate nanoparticle covered by Fe-Shikonin metal-phenolic networks (MPNs). Upon internalization by breast cancer cells, the shell of Fe-Shikonin MPNs disassembled into Fe<sup>2+</sup> and Shikonin, triggering ferroptosis and necroptosis in cancer cells. Autologous cancer cell lysates were taken up by Alum NPs and codelivered with CpG-ODN to APCs to stimulate antitumor immune responses. Alum-CpG@Fe-Shikonin NPs selectively eliminated primary breast cancer and exhibited a robust abscopal effect on suppressing distant tumors. Importantly, they also induced a persistent antigen-specific immune memory effect to prevent cancer cell metastasis and recurrence. Self-assembled CpG nanoparticles modified the TME by favoring the production of proinflammatory cytokines, promoting the conversion of macrophages from an immunosuppressive M2 type to an immunoactivated M1 type, and inducing T cell activation [<xref ref-type="bibr" rid="CR228">228</xref>]. CpG nanoparticles with a pompon-shaped nanostructure synergistically acted with OVA to suppress melanoma growth in vivo. This study indicates that CpG nanoparticles hold great promise as a prospective immunological adjuvant in cancer immunotherapy. Cyclodextrin-based polymer nanoparticles (CDPN) encapsulating two epitope peptides (the TLR7/8 agonist R848 and the TLR9 agonist CpG) had increased cancer targeting capability [<xref ref-type="bibr" rid="CR229">229</xref>]. This nanovaccine significantly promoted antigen capture and cross-presentation by APCs, thus exerting antagonistic effects against different tumors in preclinical models.</p></sec><sec id="Sec27"><title>Viral nanovaccines</title><p id="Par181">Considering the association between viral infection and carcinogenesis, viral antigens provide an important resource for the development of cancer nanovaccines. Nanoparticles bearing a peptide (8Qm) derived from the HPV E7 protein conjugated to polyleucine markedly repressed cervical cancer growth and prolonged mouse survival [<xref ref-type="bibr" rid="CR230">230</xref>]. Mechanistic investigation showed that nanoparticle-mediated delivery of the 8Qm conjugate stimulated CD8<sup>+</sup> CTLs and enhanced IFN-&#947; production. Muramyl dipeptide (MDP) and HPV E7 peptide, encapsulated by PLGA nanoparticles along with an immune agonist &#946;-glucan, efficiently eliminated cervical cancer in a murine model by promoting tumor-specific effector adaptive immune responses [<xref ref-type="bibr" rid="CR231">231</xref>]. The PLGA nanoparticles provide a promising delivery platform for the design and development of cancer nanovaccines. LNP-encapsulated mRNA vaccines encoded a chimeric protein derived from the fusion of the HSV-1 glycoprotein D and the HPV E7 oncoprotein (gDE7) [<xref ref-type="bibr" rid="CR232">232</xref>]. These vaccines showed potential therapeutic efficacy in cervical cancer-bearing mice by activating E7-specific CD8<sup>+</sup> T cells. The gDE7 mRNA-LNP vaccines also induced memory T cell responses, which prevented tumor relapses. LNP loaded with mRNA encoding the HPV E7 protein, referred to as HPV mRNA-LNP, stimulated CD8<sup>+</sup> T cells and improved their functionality [<xref ref-type="bibr" rid="CR233">233</xref>]. The combined treatment of HPV mRNA-LNP and anti-LAG3/anti-CTLA4 enhanced HPV-specific CD8<sup>+</sup> T cell immune responses and prevented the growth of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). Chitosan-coated PLGA nanoparticles encapsulating HPV16 E7<sub>44&#8211;62</sub> peptides were decorated with cellular membrane derived from cancer cells undergoing ICD [<xref ref-type="bibr" rid="CR234">234</xref>]. The PLGA nanoparticles promoted DC maturation and facilitated the accumulation of tumor antigens in lymph nodes. Immunization with this nanovaccine contributed to in vivo tumor inhibition in thyroid cancer-bearing mice. Spike nanoparticles delivered a hepatocellular carcinoma (HCC)-specific neoantigen and a TLR9 agonist (ODN-1826) to DCs, inducing CD8<sup>+</sup> T cell responses that retarded HCC in vivo growth and inhibited lung metastasis [<xref ref-type="bibr" rid="CR235">235</xref>]. Polymeric nanoparticles encapsulating the HCC neoantigen preferentially accumulated in the spleen, facilitating neoantigen expression by APCs [<xref ref-type="bibr" rid="CR236">236</xref>]. This led to the induction of robust antigen-specific T cell immunity and inhibition of HCC development in vivo. Furthermore, the personalized neoantigen vaccine combined with anti-PD-1 resulted in complete tumor regression and induced long-term tumor-specific immune memory, which inhibited cancer recurrence and metastasis. LMP2-mRNA LNP (C2@mLMP2) promoted the expansion of CD8<sup>+</sup> memory T cells [<xref ref-type="bibr" rid="CR237">237</xref>]. C2@mLMP2 improved the anticancer efficacy of anti-PD-1 therapy in mice with Epstein-Barr virus (EBV)-related tumors. These findings provided theoretical evidence for future clinical studies that could extend the application scenarios and effectiveness of nano-immunotherapy in EBV-related tumors.</p></sec><sec id="Sec28"><title>mRNA nanovaccines</title><p id="Par182">mRNA-based approaches show therapeutic potency in cancer immunotherapy. To achieve optimal therapeutic outcomes, mRNA molecules must precisely reach target cells and produce desired proteins [<xref ref-type="bibr" rid="CR301">301</xref>]. Since targeted mRNA delivery and endosomal evasion pose significant challenges, it is of great importance to develop safe and efficient delivery vehicles. A number of nanomedicine delivery platforms, such as polymeric nanoparticles and LNPs, have been fabricated for therapeutic mRNA delivery [<xref ref-type="bibr" rid="CR302">302</xref>]. Among these, LNPs are the most widely used mRNA delivery system [<xref ref-type="bibr" rid="CR303">303</xref>]. LNPs have various advantages over other delivery vehicles, including excellent biodegradability, superior safety, high encapsulation efficiency, rapid, cost-effective and mass production, low toxicity, and inherent ability to induce immune responses [<xref ref-type="bibr" rid="CR304">304</xref>]. LNPs act as a versatile delivery system that ensures mRNA stability, improves cellular uptake, and fosters cytoplasmic release upon internalization [<xref ref-type="bibr" rid="CR305">305</xref>]. Due to these unique properties, LNPs have attracted considerable attention as an optimal choice for delivering therapeutic mRNA vaccines.</p><p id="Par183">The therapeutic potential of several mRNA nanovaccines has been evaluated in preclinical studies. A ROS-responsive polymeric nanoparticle platform was generated for co-delivery of <italic toggle="yes">p53</italic> mRNA and the photosensitizer ICG [<xref ref-type="bibr" rid="CR238">238</xref>]. The disassembly of nanoparticles induced by ROS enhanced the translation of <italic toggle="yes">p53</italic> mRNA, thereby facilitating apoptosis of lung cancer cells. In a preclinical model, the co-delivery of <italic toggle="yes">p53</italic> mRNA and ICG mediated by nanoparticles showed anticancer effects against lung cancer. PHTA-based polymeric nanoparticles facilitated effective migration of OVA-encoding mRNA (mOVA) to lymph nodes and allowed persistent protein translation in vivo [<xref ref-type="bibr" rid="CR239">239</xref>]. mOVA-loaded PHTA-based polymeric nanoparticle (PHTA-C8/mOVA) favored DC maturation and induced strong CD8<sup>+</sup> T cell-mediated antitumor immunity. PHTA-C8/mOVA also reduced the growth of melanoma in tumor-bearing mice. mOVA-loaded LNPs suppressed melanoma growth and prolonged mouse survival by inducing Th1 and Th2 immune responses in both prophylactic and therapeutic vaccination models [<xref ref-type="bibr" rid="CR240">240</xref>]. Moreover, mOVA-loaded LNPs combined with an anti-CTLA-4 antibody showed enhanced anticancer efficacy in vivo. Engineered nanoparticles codelivering mOVA and CpG induced antigen-specific CD8<sup>+</sup> T cell responses and exhibited efficient anticancer efficacy in vivo models of murine colon adenocarcinoma and melanoma [<xref ref-type="bibr" rid="CR241">241</xref>]. Another study showed that LNP-based vaccines containing mOVA activated CD8<sup>+</sup> T cell responses and exhibited significant anti-carcinogenic effects against lymphoma in vivo [<xref ref-type="bibr" rid="CR242">242</xref>]. Tripalmitoyl-S-glyceryl cysteine bound to a pentapeptide (PAM3CSK4, Pam3) was incorporated as an adjuvant within OVA mRNA-LNPs [<xref ref-type="bibr" rid="CR243">243</xref>]. Pam3-incorporated LNPs effectively induced antigen-specific CD8<sup>+</sup> T cell immune responses, and prevented tumor growth in lymphoma-bearing mice. LNPs entrapped a modified mRNA encoding for a bacterial toxin (pseudomonas exotoxin A), inducing anticancer effects and prolonging overall survival (OS) of melanoma-bearing mice [<xref ref-type="bibr" rid="CR244">244</xref>]. Three LNP-encapsulated mRNA vaccines encoding a chimeric protein fused by HSV-1 glycoprotein D and HPV-16 E7 oncoprotein (gDE7) were fabricated [<xref ref-type="bibr" rid="CR232">232</xref>]. gDE7 mRNA-LNP vaccines induced memory T cell responses that restrained the recurrence of HPV-associated tumors and inhibited subcutaneous tumors in mice. LNP encapsulating rituximab-encoding mRNA dramatically eradicated lymphoma cell growth and extended animals&#8217; survival [<xref ref-type="bibr" rid="CR245">245</xref>]. IL-2-mRNA-LNP induced robust antitumor immunity and showed therapeutic efficacy in melanoma-bearing mice [<xref ref-type="bibr" rid="CR246">246</xref>].</p><p id="Par184">Recent years have witnessed the rapid development of mRNA-LNP technology, which opens up a new avenue for cancer treatment. The composition and structure of lipids markedly affect the physical properties of LNPs, including particle size and surface characteristics [<xref ref-type="bibr" rid="CR303">303</xref>]. Accordingly, the safety, efficacy and drug distribution of LNPs can be optimized by modulating their lipid composition. Given that cationic lipids are a key factor determining the delivery efficiency of mRNA-LNP formulations, cellular uptake and endosomal escape of LNPs can be improved by regulating lipid head groups and hydrophobic tails. Furthermore, tissue/cell-specific delivery may be achieved by tuning the lipid structure of LNPs. To maintain the therapeutic efficacy, repeated injections of mRNA-LNPs are necessary, which may induce unwanted immune responses. This in turn attenuates the efficacy of mRNA-LNP therapy. Strategies that aim at prolonging mRNA expression or identification of cancer type-specific mRNAs can be possible solutions. mRNA cancer vaccines have immense potential for precision cancer therapy [<xref ref-type="bibr" rid="CR306">306</xref>]. Heterogeneity is a fundamental principle in designing personalized cancer vaccines, which can prevent tumor immune evasion and improve the efficacy of cancer vaccines [<xref ref-type="bibr" rid="CR307">307</xref>]. Personalized cancer vaccines targeting a broad spectrum of epitopes expressed across distinct tumor regions can induce diversified antitumor immune responses to overcome clonal evolution and the consequent tumor heterogeneity [<xref ref-type="bibr" rid="CR308">308</xref>]. However, this strategy burdens cancer vaccine development, and increases the cost and timing of vaccine manufacturing [<xref ref-type="bibr" rid="CR96">96</xref>]. Artificial intelligence (AI)-powered technologies, including quantification of mutated transcript abundance, prediction of MHC-binding affinity, and clonality of mutations to identify neoantigens based on tumor genomic data, may significantly enhance the precision and efficiency of vaccine design processes. At present, AI-driven mRNA vaccine development remains underexplored, and it constitutes a vital and compelling area for future in-depth investigations.</p></sec></sec><sec id="Sec29"><title>Nanotechnology for oncolytic virotherapy</title><p id="Par185">Oncolytic virus-based cancer vaccines have emerged as a promising approach in the field of cancer immunotherapy. Oncolytic adenoviral vector (Ad) nanospheres targeted and attacked lung cancer cells partially by triggering T cell immune responses [<xref ref-type="bibr" rid="CR247">247</xref>]. Oncolytic Ad nanospheres may be used as a multifunctional drug delivery platform for virotherapy. Oncolytic adenovirus nanovesicles combined with anti-PD-1 antibody showed anticancer efficacy and prolonged animals&#8217; survival in a murine melanoma xenograft model [<xref ref-type="bibr" rid="CR248">248</xref>]. Mechanistic investigation indicated that this combination treatment promoted the intratumoral infiltration of CD4<sup>+</sup> and CD8<sup>+</sup> T cells and facilitated the production of TNF-&#945; and IFN-&#947;. Combined immunotherapy of oncolytic virus nanovesicles and ICIs has the potential be translated into clinical applications for cancer patients. ExtraCRAd was a nanoparticle platform consisting of an oncolytic adenovirus artificially coated with cancer membranes carrying cancer-specific antigens [<xref ref-type="bibr" rid="CR249">249</xref>]. ExtraCRAd exhibited enhanced infectivity and oncolytic activity. This nanoparticle system inhibited the growth of melanoma and lung cancer by inducing robust CD8<sup>+</sup> T cell immune responses in both murine prophylactic and therapeutic models. The oncolytic adenovirus AdNuPARmE1A was coated with PEGylated oligopeptide-modified poly(&#946;-amino ester)s (OM-pBAEs) to generate nanoparticle formulations [<xref ref-type="bibr" rid="CR250">250</xref>]. The nanoparticles protected the oncolytic viruses from elimination by neutralizing antibodies. Systemic administration of OM-pBAEs showed increased oncolytic capability and efficiently reduced PDAC growth in vivo.</p><p id="Par186">LNP-encapsulated synthetic Seneca Valley virus (SVV) promoted the recruitment of CD8<sup>+</sup> T cells and led to dramatic inhibition of tumor growth in a murine xenograft model of small cell lung cancer (SCLC) [<xref ref-type="bibr" rid="CR251">251</xref>]. Intravenous administration of synthetic SVV formulated with LNPs was well tolerated and increased the anticancer activity of PD-1 blockade in mice bearing neuroblastoma. Coassembling HSV with biocompatible magnetic nanoparticles improved tumor targeting ability and protected the virus from clearance by neutralizing antibodies [<xref ref-type="bibr" rid="CR309">309</xref>]. The nanoparticles increased the intratumoral infiltration of CD8<sup>+</sup> T cells and enhanced antitumor immunity, thereby causing breast cancer regression and extending animal survival in a murine model. Engineered nanoparticles derived from Norovirus (Nov-S-Catcher003) promoted the maturation of bone marrow-derived DCs and induced strong tumor-specific T cell immune responses [<xref ref-type="bibr" rid="CR253">253</xref>]. Immunization with Nov-S-Catcher003 prevented the growth of cervical cancer in vivo. The engineered Norovirus-derived delivery platform may contribute to the development of nanoparticle-based cancer vaccines.</p><p id="Par187">Oncolytic virotherapy has been identified as a promising immunotherapy approach in recent studies. However, some limitations still need to be overcome. Tumor immune evasion and compromised immune surveillance are the main challenges in oncolytic virotherapy [<xref ref-type="bibr" rid="CR310">310</xref>]. Mechanistic investigations are necessary to reveal how oncolytic viruses interact with the host immune system. A thorough understanding of the action mechanisms of oncolytic viruses will provide new insight into the development of tumor-specific oncolytic virotherapies. The pre-established antiviral immunity induced by infection or treatment can effectively limit the replication of oncolytic viruses, diminishing their efficacy in destroying tumor cells [<xref ref-type="bibr" rid="CR311">311</xref>]. Injection of high doses of oncolytic viruses may result in exacerbated inflammation, non-specific infection and organ failure [<xref ref-type="bibr" rid="CR312">312</xref>]. Oncolytic viruses and infected cells can be eradicated by the host immune system, leading to the insufficient viral loads for elimination of cancer cells [<xref ref-type="bibr" rid="CR313">313</xref>]. The employment of nanotechnology-based approaches can reduce unwanted immune responses against oncolytic viruses, mitigate adverse immune effects and enhance the treatment efficacy. It is expected that nanotechnology advancements are poised to bring oncolytic virotherapy to a new landscape. However, translation of nanotechnology into clinical practice encounters substantial obstacles, such as feasibility of large-scale manufacturing and toxicity concerns [<xref ref-type="bibr" rid="CR314">314</xref>]. Continual efforts should be invested to explore the safety and effectiveness of nanotechnology-based oncolytic virotherapy.</p></sec><sec id="Sec30"><title>Nanotechnology for cytokine therapy</title><sec id="Sec31"><title>Interleukin-2</title><p id="Par188">The IL-2-loaded porous nanoparticle (BALLkine-2) minimized systemic adverse effects of IL-2 and increased the half-life of IL-2 compared to free IL-2 [<xref ref-type="bibr" rid="CR254">254</xref>]. BALLkine-2 treatment increased infiltration of CTLs into the melanoma and resulted in more significant tumor control than conventional IL-2 treatment. BALLkine-2 produced an effective synergistic therapeutic outcome with anti-PD-1 treatment in an orthotopic melanoma model. In vivo experiments indicated that the anticancer activity of 5-fluorouracil (5-FU) and IL-2-loaded cyclodextrin nanoplexes was superior to free 5-FU in CRC-bearing mice [<xref ref-type="bibr" rid="CR255">255</xref>]. Linking the PEG polymer chains to the protein structure is able to extend the half-life by increasing its molecular weight, reducing protein clearance by kidneys and non-specific interactions. PEGylation of proteins can increase the solubility and protect them from protease-mediated degradation. PEGylation of IL-2 is a promising strategy for systemic delivery of this cytokine. NKTR-214 is a PEGylated IL-2 that is formed by conjugating six PEG chains to the lysine residues of a mutated IL-2 protein (aldesleukin) [<xref ref-type="bibr" rid="CR256">256</xref>]. High level of PEGylation conceals the bioactivity of IL-2 and improves its pharmacokinetic profiles [<xref ref-type="bibr" rid="CR315">315</xref>]. Upon internalization, the PEG chains gradually detach from IL-2 via hydrolysis, unleashing bioactive IL-2. The density and position of PEGylation affect the interaction of IL-2 with its receptors. In NKTR-214, the position of PEG chains on IL-2 are predominantly located in the interface of IL-2/IL-2 receptor &#945; (IL-2R&#945;) complexation, thus, the PEG chains significantly reduce the affinity of IL-2 to IL-2R&#945; [<xref ref-type="bibr" rid="CR257">257</xref>]. NKTR-214 promoted the expansion and activation of NK cells, CD4<sup>+</sup> T cells, and CD8<sup>+</sup> T cells while inhibited Treg cell expansion [<xref ref-type="bibr" rid="CR258">258</xref>]. NKTR-214 administration was tolerated in patients with advanced or metastatic solid tumors. Importantly, NKTR-214 induced tumor regression and durable disease stabilization. Several clinical trials were conducted to investigate the efficacy of the combined therapy of NKTR-214 with ICIs in patients with solid tumors. However, clinical studies showed that NKTR-214 in combination with nivolumab was not superior to nivolumab monotherapy in patients with advanced melanoma and RCC, and the objective response rate (ORR) of the combinatorial therapy didn&#8217;t meet the statistically significant expectation [<xref ref-type="bibr" rid="CR259">259</xref>, <xref ref-type="bibr" rid="CR260">260</xref>]. In addition, the combination therapy showed higher toxicity than the monotherapy in treated patients. NKTR-214 treatment-associated toxicities resulted in the termination of these trials on the combinatorial therapies. Another PEGylated IL-2, THOR-707, promoted drug retention in the tumor tissue, activated CD8<sup>+</sup> T cell-mediated immune responses, and thus retarded tumor growth in melanoma-bearing mice [<xref ref-type="bibr" rid="CR261">261</xref>]. THOR-707 monotherapy and combination therapy with ICIs showed a tolerable safety profile and beneficial clinical activity in patients with different solid tumors [<xref ref-type="bibr" rid="CR262">262</xref>, <xref ref-type="bibr" rid="CR263">263</xref>]. IL-2-containing proteoliposomal vaccine (referred to as Oncoquest-L) was safe and induced tumor-specific type I cytokine response in patients with follicular lymphoma [<xref ref-type="bibr" rid="CR264">264</xref>]. It also induce a persistent complete response in one patient. Currently, Oncoquest-L is under phase 2 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02194751">NCT02194751</ext-link>) as monotherapy in follicular lymphoma patients.</p></sec><sec id="Sec32"><title>Interleukin-12</title><p id="Par189">IL-12-loaded nanoparticles showed tumor accumulation and low toxicity compared with IL-12 without carriers [<xref ref-type="bibr" rid="CR265">265</xref>]. Delivery of IL-12 through nanoparticles induced proinflammatory immune responses and led to long-term survival of mice with ovarian cancer. PLGA nanosphere-encapsulated IL-12 demonstrated a rapid agent release and alleviated disease progression in an orthotopic murine model of metastatic osteosarcoma [<xref ref-type="bibr" rid="CR266">266</xref>]. <italic toggle="yes">IL-12</italic> mRNA-loaded polyethylenimine-modified porous silica nanoparticles (PPSNs) induced a high-level production of the target protein within the tumor and contributed to immunogenic cancer cell death [<xref ref-type="bibr" rid="CR267">267</xref>]. In vivo studies revealed that intratumoral administration of <italic toggle="yes">IL-12</italic> mRNA-loaded PPSNs remodeled the TME by elevating the ratio of CD8<sup>+</sup> T cells to Treg cells. Moreover, <italic toggle="yes">IL-12</italic> mRNA-loaded PPSNs reinforced the anticancer effect of anti-PD-1 treatment and further improved the OS of melanoma-bearing mice. Intratumoral injection of <italic toggle="yes">IL-12</italic> mRNA-loaded LNPs was more effective in retarding melanoma growth than <italic toggle="yes">IL-27</italic> or <italic toggle="yes">GM-CSF</italic> mRNAs [<xref ref-type="bibr" rid="CR246">246</xref>]. Dual LNP loaded with <italic toggle="yes">IL-12</italic> and <italic toggle="yes">IL-27</italic> mRNAs induced infiltration of NK and CD8<sup>+</sup> T cells into tumors and achieved a synergistic anticancer effect without inducing systemic adverse effects.</p><p id="Par190">IL-12-loaded human serum albumin (HSA) nanoparticles were conjugated onto CAR-T cells to generate IL-12 nanostimulant-engineered CAR-T cell (INS-CAR-T) biohybrids [<xref ref-type="bibr" rid="CR268">268</xref>]. The release of IL-12 from INS-CAR-T biohybrids increased the secretion of C&#8211;C motif chemokine ligand 2 (CCL2), CCL5, and CXCL10, effectively inducing infiltration of CD8<sup>+</sup> CAR-T cells into lymphoma. INS-CAR-T biohybrids significantly enhanced the antitumor activities of CAR-T cells and achieved efficient therapeutic outcomes in lymphoma-bearing mice. IL-12 mRNA-loaded calcium carbonate nanoparticles prevented glioma development by activating CTLs in tumors and promoting IFN-&#947; production [<xref ref-type="bibr" rid="CR269">269</xref>]. A tumor-targeted polymetformin-conjugated nanoplatform was fabricated for the co-delivery of cisplatin and IL-12-encoding plasmid [<xref ref-type="bibr" rid="CR270">270</xref>]. This nanosystem facilitated drug internalization and accumulation in cancer cells. IL-12-loaded nanoparticles activated immune effector cells (NK cells and CD8<sup>+</sup> T cells) and thus exhibited efficient antitumor efficacy in lung cancer-bearing mice. Li et al. [<xref ref-type="bibr" rid="CR271">271</xref>] developed a therapeutic nanoplatform (TNP) that co-delivered IL-12 and DOX to achieve chemo-enhanced immunotherapy for HCC. IL-12 and DOX-loaded TNPs exhibited prolonged circulation in the blood and efficient accumulation in HCC. Upon internalization by cancer cells, IL-12 and DOX were released from TNPs into the TME. The released DOX induced cancer cell death, while IL-12 promoted macrophage polarization into the M1 phenotype, thereby eliciting enhanced immune responses and augmenting the anticancer effect of DOX. As a result, TNPs inhibited HCC growth without significant side effects and improved OS in HCC-bearing mice. EGEN-001 (GEN-1) is a lipopolymer-mediated IL-12 plasmid delivery system to facilitate IL-12 delivery in vivo [<xref ref-type="bibr" rid="CR272">272</xref>]. Preclinical studies indicated that GEN-1 treatment markedly suppressed tumor growth in vivo and improved animals&#8217; survival [<xref ref-type="bibr" rid="CR272">272</xref>, <xref ref-type="bibr" rid="CR273">273</xref>]. Based on these encouraging results, subsequent clinical trials on GEN-1 were carried out. In a phase 2 clinical trial, GEN-1 monotherapy was not well tolerated in patients with platinum-resistant ovarian cancer, and limited therapeutic activity was observed [<xref ref-type="bibr" rid="CR274">274</xref>]. In contrast, GEN-1 combined with carboplatin and docetaxel chemotherapy showed good tolerability in platinum-sensitive recurrent ovarian cancer yet the clinical effectiveness remained to be further improved [<xref ref-type="bibr" rid="CR275">275</xref>]. In a phase 1 clinical trial, GEN-1 combined with PEGylated liposomal DOX presented biological activity and beneficial clinical effects in patients with ovarian cancer [<xref ref-type="bibr" rid="CR276">276</xref>]. Clinical trials currently underway are intensively focusing on enhancing the potency of this therapeutic approach [<xref ref-type="bibr" rid="CR316">316</xref>]. GEN-1 in combination with chemotherapies may be an effective therapeutic strategy for the treatment of ovarian cancer. MEDI1191, an LNP formulation encapsulating IL-12 mRNA, was found to significantly inhibit tumor growth by activating systemic immune responses in various murine tumor models [<xref ref-type="bibr" rid="CR277">277</xref>]. Moreover, MEDI1191 exhibited a synergistic effect when combined with anti-PD-L1 treatment through induction of T cell expansion. Preclinical evidence provides robust support for the feasibility of translating MEDI1191 into clinical practice. The clinical benefits of MEDI1191 in combination with durvalumab was evaluated in a phase 1 clinical trial in patients with advanced solid tumors [<xref ref-type="bibr" rid="CR252">252</xref>]. Consequently, this combinatorial treatment presented favorable safety profiles and anticancer efficacy. Another LNP formulation encapsulating self-replicating RNA encoding IL-12 (referred to as JCXH-211) in combination with anti-PD-1 antibody triggered antitumor immunity and induced tumor regression in multiple mouse solid tumor models [<xref ref-type="bibr" rid="CR278">278</xref>]. JCXH-211 is now under phase 1 clincal trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05539157">NCT05539157</ext-link>) for the treatment of solid tumors.</p></sec><sec id="Sec33"><title>Other cytokines</title><p id="Par191">IL-29-loaded exosomes exhibited a stable release of IL-29, improved the half-life of released agents, and demonstrated superior targeting efficiency [<xref ref-type="bibr" rid="CR279">279</xref>]. Therefore, IL-29-encapsulated exosomes exerted cytotoxic effects against various cancer cells in vitro. Exosomes can be used as a drug transportation system in cancer immunotherapy in the future&#160;due to its high delivery efficiency and low toxicity. IFN-&#947;-loaded PEGylated liposomes displayed efficient accumulation in colon cancer and promoted the conversion of M2 macrophages into M1 macrophages [<xref ref-type="bibr" rid="CR280">280</xref>]. Consequently, liposomal formulations containing IFN-&#947; were effective in treating colon cancer in murine tumor models. TGF-&#946;1-loaded chitosan nanoparticles were able to suppress the malignant characteristics of cervical cancer cells by enhancing the secretion of macrophage inflammatory factors [<xref ref-type="bibr" rid="CR281">281</xref>].</p></sec><sec id="Sec34"><title>Chemokines</title><p id="Par192">Synthetic protein nanoparticles (SPNPs) encapsulating the transcytotic peptide iRGD was found to inhibit the CXCL2/CXCR4 pathway in a murine model of glioblastoma [<xref ref-type="bibr" rid="CR282">282</xref>]. This led to a decrease in the infiltration of CXCR4<sup>+</sup> monocytic MDSCs (M-MDSCs) into the TME and promoted ICD, which triggered tumor-specific immune reactions and enhanced cancer cell sensitivity to radiotherapy. The combination of iRGD-loaded SPNPs and radiation therapy contributed to long-term survival in glioblastoma-bearing mice by inducing persistent antitumor immune memory responses. Overall, SPNP-based immunotherapy demonstrated significant clinical translational applicability. Nanoparticles encapsulating CXCL10 increased the infiltration of both innate immune cells (NK cells) and adaptive immune cells (IFN-&#947;<sup>+</sup> Th1 CD4 cells and effector CD8 cells) into the lungs in a breast cancer spontaneous lung metastasis model [<xref ref-type="bibr" rid="CR283">283</xref>]. This immunotherapy suppressed the progression of lung metastasis, extended animal survival, and triggered systemic immune reactions that inhibited the expansion of distant tumors following re-challenge.</p><p id="Par193">Although preclinical studies have suggested the therapeutic effect of cytokine therapy, the clinical efficacy is still not satisfactory due the poor pharmacokinetics and severe adverse toxicity [<xref ref-type="bibr" rid="CR317">317</xref>]. The nanoparticle-based delivery systems can effectively address the issue of low curative effects of cytokine therapy. Targeted delivery of cytokines through nanoparticles protects cytokines from rapid degradation, and allows their targeted and sustained release, thus bypassing unwanted immune suppression and improving the therapeutic efficacy. Nanoparticles remain stable in the bloodstream, minimizing exposure to healthy tissues and lowering the chances of toxicity. As a result, cancer patients could experience a more tolerable and effective dose, leading to improved treatment outcomes. Altogether, compared to recombinant cytokine proteins, nanoformulations have better efficacy and reduced side effects because of their higher bioavailability and targeted delivery. However, it should be noted that nanoparticles introduce the possibility of unpredictable adverse effects in cancer patients. Beyond the well-known hazards linked to poor degradation, DNA damage or metal-induced central nervous system toxicity, nanoformulations may also cause persistent, chronic, and often irreversible immune-related side effects, adding another layer of complexity to their utilization [<xref ref-type="bibr" rid="CR318">318</xref>]. Therefore, efficiently reducing nanotoxicity while preserving consistent anti-tumor benefits in patients treated with cytokine nanoformulations remains an ongoing significant challenge.</p></sec></sec></sec><sec id="Sec35"><title>Potential clinical implications of nano-immunotherapy</title><p id="Par194">The combination of nanomedicine and immunotherapy has shown encouraging preclinical therapeutic outcomes. So far, the anticancer efficacy of many nanomedicines, such as Abraxane, Doxil and mRNA nanovaccines, has been tested in clinical trials (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>) [<xref ref-type="bibr" rid="CR319">319</xref>].
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>Clinical trials of nanomedicine-combined immunotherapy in cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Nanoformulation</th><th align="left" colspan="1" rowspan="1">Treatment groups</th><th align="left" colspan="1" rowspan="1">Type of study</th><th align="left" colspan="1" rowspan="1">Cancer type</th><th align="left" colspan="1" rowspan="1">Number of subjects</th><th align="left" colspan="1" rowspan="1">Results</th><th align="left" colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td align="left" rowspan="15" colspan="1"><bold>Abraxane</bold></td><td align="left" colspan="1" rowspan="1">Placebo&#8201;+&#8201;Abraxane; atezolizumab&#8201;+&#8201;Abraxane</td><td align="left" colspan="1" rowspan="1">Randomized, placebo-controlled, double blind, phase 3 trial</td><td align="left" colspan="1" rowspan="1">Locally advanced or metastatic triple-negative breast cancer</td><td align="left" colspan="1" rowspan="1">902</td><td align="left" colspan="1" rowspan="1">Extend median overall survival by 21.0&#160;months</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR320">320</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Atezolizumab&#8201;+&#8201;Abraxane</td><td align="left" colspan="1" rowspan="1">Single-arm phase 2 study</td><td align="left" colspan="1" rowspan="1">Doxorubicin and cyclophosphamide-resistant triple-negative breast cancer</td><td align="left" colspan="1" rowspan="1">37</td><td align="left" colspan="1" rowspan="1">Lead to an improvement in pathological complete response/residual cancer burden class I rate</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR321">321</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Placebo&#8201;+&#8201;Abraxane; durvalumab&#8201;+&#8201;Abraxane</td><td align="left" colspan="1" rowspan="1">Randomized phase 2 placebo-controlled trial</td><td align="left" colspan="1" rowspan="1">Triple-negative breast cancer</td><td align="left" colspan="1" rowspan="1">174</td><td align="left" colspan="1" rowspan="1">Improve overall survival</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR322">322</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Abraxane&#8201;+&#8201;PD-(L)1 antibody</td><td align="left" colspan="1" rowspan="1">Phase 2 study</td><td align="left" colspan="1" rowspan="1">Advanced non-small cell lung cancer</td><td align="left" colspan="1" rowspan="1">29</td><td align="left" colspan="1" rowspan="1">Improve the objective response rate with a durable response of 13%</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR323">323</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Carboplatin&#8201;+&#8201;Abraxane&#8201;+&#8201;pembrolizumab</td><td align="left" colspan="1" rowspan="1">Phase 1/2 study</td><td align="left" colspan="1" rowspan="1">Advanced non-small cell lung cancer</td><td align="left" colspan="1" rowspan="1">46</td><td align="left" colspan="1" rowspan="1">Extend median overall survival by 15.4&#160;months</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR324">324</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Carboplatin&#8201;+&#8201;Abraxane&#8201;+&#8201;pembrolizumab</td><td align="left" colspan="1" rowspan="1">Single arm, phase 2 trial</td><td align="left" colspan="1" rowspan="1">Metastatic triple-negative breast cancer</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">Result in an overall response rate of 48.0%</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR325">325</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Camrelizumab&#8201;+&#8201;Abraxane&#8201;+&#8201;carboplatin</td><td align="left" colspan="1" rowspan="1">Multicenter, single-arm, phase 2 trial</td><td align="left" colspan="1" rowspan="1">Locally advanced esophageal squamous cell carcinoma</td><td align="left" colspan="1" rowspan="1">60</td><td align="left" colspan="1" rowspan="1">Achieve a pathological complete response rate of 39.2% and a complete response rate of 9.8%</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR326">326</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Abraxane&#8201;+&#8201;carboplatin&#8201;+&#8201;camrelizumab</td><td align="left" colspan="1" rowspan="1">Multicenter, single-arm, phase 2 study</td><td align="left" colspan="1" rowspan="1">Clinical stage N2-3 esophageal squamous cell carcinoma</td><td align="left" colspan="1" rowspan="1">60</td><td align="left" colspan="1" rowspan="1">Improve 2-year recurrence-free survival and overall survival</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR327">327</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Camrelizumab&#8201;+&#8201;Abraxane&#8201;+&#8201;capecitabine</td><td align="left" colspan="1" rowspan="1">Single-center, single-arm, phase 2 trial</td><td align="left" colspan="1" rowspan="1">Locally advanced esophageal squamous cell carcinoma</td><td align="left" colspan="1" rowspan="1">47</td><td align="left" colspan="1" rowspan="1">Promote tumor regression and improve survival outcomes</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR328">328</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Camrelizumab&#8201;+&#8201;Abraxane&#8201;+&#8201;epirubicin</td><td align="left" colspan="1" rowspan="1">Single-arm phase 2 study</td><td align="left" colspan="1" rowspan="1">Early triple-negative breast cancer</td><td align="left" colspan="1" rowspan="1">39</td><td align="left" colspan="1" rowspan="1">Achieve an objective response rate of 89.7%</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR329">329</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Cisplatin&#8201;+&#8201;Abraxane&#8201;+&#8201;camrelizumab</td><td align="left" colspan="1" rowspan="1">Multicenter, single-arm, phase 2 study</td><td align="left" colspan="1" rowspan="1">Locally advanced cervical cancer</td><td align="left" colspan="1" rowspan="1">85</td><td align="left" colspan="1" rowspan="1">Result in an objective response rate of 98%</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR330">330</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Tislelizumab&#8201;+&#8201;carboplatin&#8201;+&#8201;Abraxane</td><td align="left" colspan="1" rowspan="1">Single-center, single-arm, open-label, phase 2 study</td><td align="left" colspan="1" rowspan="1">Resectable esophageal squamous cell carcinoma</td><td align="left" colspan="1" rowspan="1">45</td><td align="left" colspan="1" rowspan="1">Lead to a major pathological response rate of 57.5% and a pathological complete response of 40%</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR331">331</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CAR T-EGFR&#8201;+&#8201;Abraxane&#8201;+&#8201;cyclophosphamide</td><td align="left" colspan="1" rowspan="1">Phase 1 study</td><td align="left" colspan="1" rowspan="1">Metastatic pancreatic carcinoma</td><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">Improve the median overall survival and alleviate metastatic lesions in the liver</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR332">332</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DC vaccination&#8201;+&#8201;gemcitabine&#8201;+&#8201;Abraxane</td><td align="left" colspan="1" rowspan="1">Phase 1/2 study</td><td align="left" colspan="1" rowspan="1">Advanced or relapsed pancreatic ductal adenocarcinoma</td><td align="left" colspan="1" rowspan="1">48</td><td align="left" colspan="1" rowspan="1">Lead to a 8.1-month median progression-free survival and 15.1-month median overall survival</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR333">333</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Gemcitabine&#8201;+&#8201;Abraxane&#8201;+&#8201;sotigalimab; gemcitabine&#8201;+&#8201;Abraxane&#8201;+&#8201;sotigalimab&#8201;+&#8201;nivolumab</td><td align="left" colspan="1" rowspan="1">Non-randomized, open-label, multicenter, four-cohort, phase 1b study</td><td align="left" colspan="1" rowspan="1">Metastatic pancreatic adenocarcinoma</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">Achieve an objective response rate of 58%</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR334">334</xref>]</td></tr><tr><td align="left" rowspan="4" colspan="1"><bold>Doxil</bold></td><td align="left" colspan="1" rowspan="1">Gemcitabine&#8201;+&#8201;vinorelbine&#8201;+&#8201;Doxil&#8201;+&#8201;camrelizumab</td><td align="left" colspan="1" rowspan="1">Open-label, single-arm, phase 2 study</td><td align="left" colspan="1" rowspan="1">Relapsed/refractory primary mediastinal B-cell lymphoma</td><td align="left" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">Result in 2-year progression-free survival rate of 48.2% and overall survival rate of 48.2%; lead to tumor regression in 78% of treated patients</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR335">335</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Doxil&#8201;+&#8201;GEN-1</td><td align="left" colspan="1" rowspan="1">Phase 1 study</td><td align="left" colspan="1" rowspan="1">Recurrent or persistent epithelial ovarian</td><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">Lead to a clinical benefit rate of 86%</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR276">276</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Doxil&#8201;+&#8201;IL-12</td><td align="left" colspan="1" rowspan="1">Phase 2 study</td><td align="left" colspan="1" rowspan="1">AIDS-associated Kaposi sarcoma</td><td align="left" colspan="1" rowspan="1">36</td><td align="left" colspan="1" rowspan="1">Yield a major response rate of 83.3%</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR336">336</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">IL-18&#8201;+&#8201;Doxil</td><td align="left" colspan="1" rowspan="1">Phase 1, dose escalation trial</td><td align="left" colspan="1" rowspan="1">Platinum-resistant recurrent ovarian cancer</td><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">Yield a 6% partial response rate and a 38% stable disease rate; result in a 4.5-month median progression-free survival</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR337">337</xref>]</td></tr><tr><td align="left" rowspan="10" colspan="1"><bold>mRNA nanovaccines</bold></td><td align="left" colspan="1" rowspan="1">GRT-R902&#8201;+&#8201;ChAd68&#8201;+&#8201;nivolumab&#8201;+&#8201;ipilimumab</td><td align="left" colspan="1" rowspan="1">Phase 1/2 study</td><td align="left" colspan="1" rowspan="1">Metastatic microsatellite-stable colorectal cancer, non-small cell lung cancer and gastroesophageal adenocarcinoma</td><td align="left" colspan="1" rowspan="1">29</td><td align="left" colspan="1" rowspan="1">Induce neoantigen-specific CD8<sup>+&#160;</sup>T cell responses and improve overall survival in patients with microsatellite-stable colorectal cancer</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR338">338</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">mRNA-4650</td><td align="left" colspan="1" rowspan="1">Phase 1/2 study</td><td align="left" colspan="1" rowspan="1">Metastatic gastrointestinal cancer</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Induce neoepitope-specific T cell responses</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR339">339</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Atezolizumab&#8201;+&#8201;autogene cevumeran&#8201;+&#8201;mFOLFIRINOX</td><td align="left" colspan="1" rowspan="1">Investigator-initiated, phase 1 clinical trial</td><td align="left" colspan="1" rowspan="1">Pancreatic cancer</td><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">Enhance the population of neoantigen-specific T cells in 50% of treated patients</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR97">97</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">mRNA-4157; mRNA-4157&#8201;+&#8201;pembrolizumab</td><td align="left" colspan="1" rowspan="1">Phase 1 dose escalation study</td><td align="left" colspan="1" rowspan="1">Resected solid tumors (e.g., melanoma and bladder carcinoma)</td><td align="left" colspan="1" rowspan="1">33</td><td align="left" colspan="1" rowspan="1">Induce neoantigen-specific T cell responses</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR340">340</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">mRNA-4157&#8201;+&#8201;pembrolizumab; pembrolizumab</td><td align="left" colspan="1" rowspan="1">Open-label, randomized, phase 2b study</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">157</td><td align="left" colspan="1" rowspan="1">Prolong recurrence-free survival and exhibit a favorable safety profile</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR341">341</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">mRNA-2416; mRNA-2416&#8201;+&#8201;durvalumab</td><td align="left" colspan="1" rowspan="1">Phase 1/2, open-label, multicenter, dose escalation and efficacy study</td><td align="left" colspan="1" rowspan="1">Solid tumors and lymphoma</td><td align="left" colspan="1" rowspan="1">39</td><td align="left" colspan="1" rowspan="1">Exhibit good tolerance and induce immune responses</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR342">342</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">mRNA-2752; mRNA-2752&#8201;+&#8201;durvalumab</td><td align="left" colspan="1" rowspan="1">Phase 1 study</td><td align="left" colspan="1" rowspan="1">Solid tumors and lymphoma</td><td align="left" colspan="1" rowspan="1">49</td><td align="left" colspan="1" rowspan="1">Exhibit a manageable safety profile and exert a sustained treatment effect</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR343">343</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">mRNA-2752; mRNA-2752&#8201;+&#8201;durvalumab</td><td align="left" colspan="1" rowspan="1">Phase 1, open-label, multicenter, dose-escalation study</td><td align="left" colspan="1" rowspan="1">Triple-negative breast cancer and melanoma</td><td align="left" colspan="1" rowspan="1">88</td><td align="left" colspan="1" rowspan="1">Present a favorable safety profile and drive cytokine responses</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR344">344</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">BNT111</td><td align="left" colspan="1" rowspan="1">Phase 1 clinical trial</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">89</td><td align="left" colspan="1" rowspan="1">Induce durable objective responses and disease stabilization</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR345">345</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">BNT112</td><td align="left" colspan="1" rowspan="1">Open-label, multicenter, phase 1/2a clinical trial</td><td align="left" colspan="1" rowspan="1">Prostate cancer</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">Trigger strong immune and prostate-specific antigen responses</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR346">346</xref>]</td></tr></tbody></table></table-wrap></p><sec id="Sec36"><title>Abraxane</title><p id="Par195">Abraxane is a nanoformulation of paclitaxel encapsulated in albumin nanoparticles as the delivery platform [<xref ref-type="bibr" rid="CR347">347</xref>]. Atezolizumab, a PD-L1 blocking antibody, is used in the immunotherapy of several advanced or metastatic cancers in the clinical setting [<xref ref-type="bibr" rid="CR348">348</xref>]. In phase 3 clinical trial in patients with PD-L1 immune cell-positive metastatic TNBC, Abraxane plus atezolizumab improved the median OS (21&#160;months) compared to placebo plus Abraxane (18.7&#160;months) [<xref ref-type="bibr" rid="CR320">320</xref>]. Treatment with atezolizumab and Abraxane led to an improvement in pathological complete response (pCR)/residual cancer burden class I (RCB-I) rate (46%) in patients with anthracycline (AC)-resistant TNBC compared with historical controls (5%) [<xref ref-type="bibr" rid="CR321">321</xref>]. The addition of a PD-L1 inhibitor, durvalumab, to Abraxane-based neoadjuvant chemotherapy improved invasive disease-free survival (iDFS), distant disease-free survival (DDFS), and OS in patients with early TNBC [<xref ref-type="bibr" rid="CR322">322</xref>]. Abraxane treatment improved the ORR after PD-(L)1 blockade therapy, with a durable response of 13% and acceptable adverse events in patients with advanced NSCLC [<xref ref-type="bibr" rid="CR323">323</xref>]. The disease control rate (DCR) for Abraxane-treated patients was 86.2%. The median progression-free survival (PFS) and OS were 5.6 and 11.9&#160;months, respectively, in NSCLC patients. In a phase I/II trial, 16 out of 46 patients with advanced NSCLC had a partial response after the administration of an anti-PD-1 antibody (pembrolizumab), carboplatin, and Abraxane, corresponding to an ORR of approximately 35% [<xref ref-type="bibr" rid="CR324">324</xref>]. The median PFS and OS were 5.6 and 15.4&#160;months, respectively. The combination of pembrolizumab, carboplatin, and Abraxane contributed to an overall response rate of 48.0% in patients with metastatic TNBC [<xref ref-type="bibr" rid="CR325">325</xref>]. The median PFS and OS for the patient cohort were 5.8 and 13.4&#160;months, respectively.</p><p id="Par196">The checkpoint inhibitor targeting PD-1 (camrelizumab), in combination with Abraxane and carboplatin, achieved a complete response rate of 9.8% in patients with advanced esophageal squamous cell carcinoma (ESCC) [<xref ref-type="bibr" rid="CR326">326</xref>]. The regimen of camrelizumab plus Abraxane and carboplatin resulted in 2-year RFS and OS rates of 67.9% and 78.1% in ESCC patients [<xref ref-type="bibr" rid="CR327">327</xref>]. Furthermore, patients who had a major pathologic response (MPR) achieved significantly higher 2-year RFS and OS rates. Another study revealed that intensive cycles of camrelizumab plus Abraxane and capecitabine resulted in complete and MPR rates of 33.3% and 64.3% in advanced ESCC patients [<xref ref-type="bibr" rid="CR328">328</xref>]. The 2-year DFS and OS rates were 92.3% and 97.6%, respectively. Collectively, camrelizumab plus Abraxane and capecitabine facilitated tumor regression and improved survival outcomes in advanced ESCC patients. The safety and efficacy of camrelizumab plus Abraxane and epirubicin were investigated in early TNBC patients [<xref ref-type="bibr" rid="CR329">329</xref>]. Consequently, 64.1% and 89.7% of patients had complete and partial responses. Moreover, camrelizumab plus Abraxane and epirubicin showed a manageable safety profile in early TNBC patients. In a single-arm, phase 2 trial, the administration of camrelizumab plus cisplatin and Abraxane resulted in an ORR of 98% in patients with locally advanced cervical cancer [<xref ref-type="bibr" rid="CR330">330</xref>]. No serious toxicities or treatment-related deaths were observed in these patients. Taken together, this combined therapy demonstrated promising anticancer activity and a tolerable safety profile in patients with locally advanced cervical cancer. In a prospective, single-arm, phase 2 study, patients with resectable ESCC were enrolled and treated with a PD-1 inhibitor (tislelizumab) combined with conventional chemotherapy comprising carboplatin and Abraxane [<xref ref-type="bibr" rid="CR331">331</xref>]. The rates of MPR and pCR for ESCC patients were 57.5% and 40%. Combined treatment of CAR T-EGFR cells, Abraxane and cyclophosphamide was safe in patients with metastatic pancreatic cancer [<xref ref-type="bibr" rid="CR332">332</xref>]. The combined therapy resulted in a median OS of 4.9&#160;months. Metastatic lesions in the liver were alleviated, and the population of central memory T cells was increased in pancreatic cancer patients who had stable disease following treatment. Ota et al. [<xref ref-type="bibr" rid="CR333">333</xref>] conducted a phase 1/2 clinical study to test the clinical benefit of DC-based immunotherapy combined with standard chemotherapy employing gemcitabine plus Abraxane in pancreatic cancer patients. No severe adverse cascades were observed in patients receiving the combined treatment. The median PFS and OS were 8.1&#160;months and 15.1&#160;months, respectively, in patients after vaccinations. The clinical activity of the CD40 agonistic monoclonal antibody sotigalimab, gemcitabine, and Abraxane, with or without nivolumab, was assessed in patients with pancreatic adenocarcinoma [<xref ref-type="bibr" rid="CR334">334</xref>]. This combined treatment achieved an ORR of 58% in treated patients.</p></sec><sec id="Sec37"><title>Doxil</title><p id="Par197">Doxil, a PEGylated liposomal formulation of DOX, is the first approved nanomedicine product used in cancer treatment [<xref ref-type="bibr" rid="CR349">349</xref>]. In an open-label, single-arm, phase 2 study, the combined treatment of chemotherapy, comprising gemcitabine, vinorelbine, and Doxil, plus the anti-PD-1 antibody camrelizumab, resulted in an ORR of 74% in patients with relapsed/refractory primary mediastinal B-cell lymphoma (rrPMBCL) [<xref ref-type="bibr" rid="CR335">335</xref>]. The 2-year PFS and OS rates were 48.2% and 81.5% in patients, with 78% exhibiting tumor regression. Thus, camrelizumab plus Doxil-based chemotherapy showed anticancer activity in rrPMBCL patients. EGEN-001 (GEN-1) is an immunotherapeutic agent that consists of a plasmid expressing human IL-12, formulated with a gene delivery system [<xref ref-type="bibr" rid="CR350">350</xref>]. When combined with Doxil, GEN-1 led to a clinical benefit rate of 86% in patients with recurrent or persistent epithelial ovarian cancer (EOC) [<xref ref-type="bibr" rid="CR276">276</xref>]. In a phase 2 study, the Doxil plus IL-12 regimen was well tolerated in patients with acquired immunodeficiency syndrome (AIDS)-associated Kaposi sarcoma [<xref ref-type="bibr" rid="CR336">336</xref>]. Furthermore, this combination therapy resulted in a high response rate (83.3%) in these cancer patients. The clinical benefit of IL-18 in combination with Doxil was examined in patients with platinum-resistant recurrent ovarian cancer [<xref ref-type="bibr" rid="CR337">337</xref>]. The drug combination yielded a 6% partial response rate and a 38% stable disease rate, resulting in a median PFS of 4.5&#160;months.</p></sec><sec id="Sec38"><title>mRNA nanovaccines</title><p id="Par198">Currently, many LNP-based mRNA vaccines are under clinical investigation. The neoantigen vaccine GRT-R902 (self-amplifying RNA formulated in LNPs), combined with an individualized, heterologous chimpanzee adenovirus (ChAd68), the anti-PD-1 antibody nivolumab, and the anti-CTLA-4 antibody ipilimumab, was safe and well tolerated in patients with advanced metastatic solid tumors [<xref ref-type="bibr" rid="CR338">338</xref>]. This combination treatment induced neoantigen-specific CD8<sup>+</sup> T cell responses and improved OS in patients with microsatellite-stable CRC. The mRNA-4650 vaccine is comprised of an mRNA backbone that encodes defined neoantigens, mutations in driver genes (<italic toggle="yes">TP53</italic> and <italic toggle="yes">KRAS</italic>), and HLA-I-predicted epitopes formulated in LNPs [<xref ref-type="bibr" rid="CR339">339</xref>]. This vaccine induced neoepitope-specific T cell responses in patients with metastatic gastrointestinal (GI) cancer. No severe side effects were observed in treated patients. The combination of the mRNA-4650 vaccine and other immunotherapies may represent a novel therapeutic approach for treating patients with epithelial cancers. Atezolizumab, uridine mRNA-lipoplex nanoparticles (mRNA neoantigen vaccine), and a combined chemotherapy regimen efficiently increased the population of neoantigen-specific T cells in 50% of pancreatic cancer patients [<xref ref-type="bibr" rid="CR97">97</xref>]. Patients with expanded T cells (responders) had a longer median RFS than patents without vaccine-expanded T cells (non-responders). mRNA-4157 is a lipid encapsulated vaccines encoding 34 neoantigens and can induce antitumor immune responses [<xref ref-type="bibr" rid="CR351">351</xref>]. mRNA-4157 was well tolerated and safe in patients with solid tumors [<xref ref-type="bibr" rid="CR340">340</xref>]. Importantly, mRNA-4157 combined with pembrolizumab achieved remarkable clinical responses in cancer patients, which encouraged the progression of this mRNA nanovaccine to phase 2 clinical trials. In the phase 2 clinical study, mRNA-4157 in combination with pembrolizumab demonstrated an acceptable safety profile and extended RFS in melanoma patients [<xref ref-type="bibr" rid="CR341">341</xref>]. mRNA-2416, a LNP vaccine incorporating human OX40L-encoding mRNA, was well tolerated and induced immune responses in patients with solid tumors and lymphoma [<xref ref-type="bibr" rid="CR342">342</xref>]. The mRNA-based LNP encoding OX40L, IL-23 and IL-36&#947; (mRNA-2752), alone or in combination with durvalumab, was safe and tolerable and exerted a persistent treatment effect in patients with lymphoma or advanced solid tumors [<xref ref-type="bibr" rid="CR343">343</xref>]. Another clinical study indicated that mRNA-2752 could drive cytokine responses and promote CD8<sup>+</sup> T cell expansion in patients with melanoma and triple negative breast cancer (TNBC) [<xref ref-type="bibr" rid="CR344">344</xref>]. The mRNA-LNP vaccine FixVac (BNT111) that targets four melanoma-associated antigens, alone or in combination with anti-PD-1 treatment, led to durable objective responses and disease stabilization in melanoma patients [<xref ref-type="bibr" rid="CR345">345</xref>]. Particularly, antigen-specific cytotoxic T cell responses with magnitudes comparable to adoptive T-cell therapy were observed in some responders. These encouraging results advance follow-up clinical trials on BNT111 [<xref ref-type="bibr" rid="CR352">352</xref>]. A LNP mRNA vaccine (BNT112) targeting five prostate-specific tumor-associated antigens (PSAs) had a manageable safety profile and triggered intensive immune and PSA responses in patients with prostate cancer [<xref ref-type="bibr" rid="CR346">346</xref>]. Two clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04163094">NCT04163094</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05142189">NCT05142189</ext-link>) are exploring the FixVac BNT115 that encodes three ovarian-specific antigens in patients with ovarian cancer and metastatic NSCLC [<xref ref-type="bibr" rid="CR96">96</xref>]. In addition, another personalized neoantigen-specific LNP-mRNA vaccine (BNT122) is presently under clinical investigation (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03289962">NCT03289962</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03815058">NCT03815058</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04161755">NCT04161755</ext-link>, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04486378">NCT04486378</ext-link>) in patients with solid tumors.</p><p id="Par199">Despite the great promise of cancer nanovaccines, their successful translation into clinical use still faces significant challenges. Here, we list several key issues: (1) Accurate architecture of cancer nanovaccines stands as a key prerequisite for effective immune cell engagement and stability, ensuring the uniformity and efficacy of nanovaccines. Moreover, scalable production and inter-batch quality control of cancer nanovaccines are critical for their utility in the clinical setting. Thus, standardized and reproducible synthesis procedures and strict quality monitoring technologies must be established. (2) Nanoparticles may interact with diverse biological substances within the human body, thus inducing alterations in the physicochemical properties of nanoparticles. Hence, a comprehensive exploration of the terminal metabolites is also imperative. An ongoing research endeavor is indispensable for the assessment of pharmacodynamic and pharmacokinetic properties of different nanovaccines and development of techniques that monitor antigen release rates. (3) Although many cancer nanovaccines showed therapeutic potential in preclinical studies, but the majority of them failed to offer clinical benefit to cancer patients [<xref ref-type="bibr" rid="CR353">353</xref>]. A variety of factors influence the effectiveness of cancer nanovaccines, including low delivery efficiency, rapid clearance, tumor heterogeneity, immune tolerance, and absence of suitable tumor antigens [<xref ref-type="bibr" rid="CR354">354</xref>]. Low delivery efficiency and specificity of nanovaccines can be improved by engineering and optimizing the physicochemical properties of nanomaterials. For instance, hybrid nanoparticles incorporating polymers have been manipulated to facilitate controlled mRNA release, and antibody-conjugated LNPs and selective organ-targeting (SORT) LNPs may promote drug accumulation in the target tissues [<xref ref-type="bibr" rid="CR355">355</xref>]. Modification of nanoparticle composition and improved encapsulation techniques can increase the stability of nanoparticles and promote drug retention within nanoparticles. For RNA-based nanovaccines, the inherent instability and in vivo translation efficiency of RNAs are fundamental limitations [<xref ref-type="bibr" rid="CR356">356</xref>]. Optimizing untranslational regions (UTRs) may increase mRNA translation efficiency and facilitate tissue-specific mRNA translation [<xref ref-type="bibr" rid="CR357">357</xref>]. The advancements in RNA biology and nanotechnology-based delivery systems are set to accelerate the translation of RNA-based nanovaccines towards clinical application. Tailored cancer vaccines based on neoantigens will be an excellent therapeutic option for treating cancers with high intratumoral heterogeneity. Identification of tumor-specific antigens is a fundamental prerequisite for the development of personalized cancer nanovaccines. Nevertheless, it is arduous to obtain precise antigen sequencing through current techniques. The combination of biological sciences with AI-assisted computer simulation algorithms may help to discover more vaccine candidates. Furthermore, the variations in the immune system between preclinical animal models and humans are also responsible for unsatisfactory treatment outcomes in clinical trials. Thus, the development of new animal tumor models in which disease mechanisms are more similar to humans may compensate for the differences. The establishment of patient-derive xenograft models will drive the advancement of personalized cancer vaccines. (4) The interplay between nanoparticles and the host immune system, as well as their vivo distribution, has yet to be fully deciphered. Some nanocarriers (e.g., LNP) are inherently immunogenic, which can act as an immune adjuvant. Meanwhile, they could induce effector immune cell dysfunction and impair antitumor immune responses [<xref ref-type="bibr" rid="CR358">358</xref>]. Further study is necessary to figure out how to reduce the adverse effects and to tip the balance in favor of efficient antitumor immunity. Given the TME complexity during cancer progression, the combination of cancer nanovaccines and conventional therapies (e.g., ICIs and radiation treatment) presents a promising strategy to potentiate immune responses and improve therapeutic efficacy [<xref ref-type="bibr" rid="CR359">359</xref>]. In addition, undesired adverse immune effects associated with nanovaccines can be mitigated through targeted interventions within TME or precise immunoregulation. (5) The long-term safety profile of cancer nanovaccines necessitates systemic investigation in the context of their deployment. However, the assessment of nanovaccine-related toxicity is currently in its early stages. Special attention should be paid to the emergence of autoimmune responses.</p></sec></sec><sec id="Sec39"><title>Conclusions and future perspectives</title><p id="Par200">Nanoformulations have emerged as a highly investigated topic in the field of onco-immunotherapy. Their application in clinical practice would bring about a great revolution in cancer management due to their inherent properties, including biocompatibility, low toxicity, high stability, and precise targeting [<xref ref-type="bibr" rid="CR129">129</xref>]. However, there are many hurdles encountered when aiming to translate nano-immunotherapies from the bench to the bedside. First, nanoparticles are much complicated compared to small molecule drug formulations. Several physicochemical characteristics, such as size, structure, composition, and surface properties, have an impact on the in vivo performance of nanomedicine formulations [<xref ref-type="bibr" rid="CR360">360</xref>]. The physicochemical features of nanoparticles appear to significantly differ following administration due to interactions with biological molecules (e.g., protein corona), which makes it difficult to assess their performance in vivo [<xref ref-type="bibr" rid="CR361">361</xref>]. The distribution, excretion, metabolism, pharmacokinetics, and pharmacodynamics of various nanoparticles must be thoroughly investigated in both preclinical and clinical studies. Secondly, another challenge faced by cancer nanomedicine is the rapid non-specific removal of nanoparticles by the reticuloendothelial system (RES), which is composed of phagocytic immune cells [<xref ref-type="bibr" rid="CR362">362</xref>]. This significantly reduces the bioavailability of nanoparticles at the tumor site after systemic administration and may lead to off-target toxicity to RES organs, such as the liver and spleen. Modifying nanoparticles or camouflaging phagocyte surfaces can prolong the circulation time of nanoparticles and improve their pharmacokinetic properties [<xref ref-type="bibr" rid="CR363">363</xref>]. The most effective strategies for inhibiting RES uptake include reduction of nanoparticle size and stabilization of nanoparticles with PEGs. Nevertheless, completely avoiding the RES system has not yet been achieved. Thirdly, difficulty in nanoparticle targeting and penetration in tumors is a fundamental problem that must be overcome. The delivery of nanoparticles to tumors is mediated via both active and passive targeting modes [<xref ref-type="bibr" rid="CR364">364</xref>]. In the active mechanism, ligand molecules (e.g., antibodies and peptides) on the surface of nanoparticles can specifically bind to tumor antigens, facilitating nanoparticle entry into tumors [<xref ref-type="bibr" rid="CR365">365</xref>]. For passive tumor targeting, nanoparticles predominantly accumulate at tumor sites through an EPR effect. The extent of nanoparticle accumulation varies depending on multiple factors, including the type of tumor models, the type of targeting ligands, the size of nanoparticles, the surface charge of nanoparticles, the blood circulation lifetimes, angiogenesis, and the degree of tumor vascularization [<xref ref-type="bibr" rid="CR366">366</xref>]. To address this issue, extensive research interest has been gathered around designing tumor-targeting nanocarriers that release drug payloads in response to specific chemical and biological conditions (e.g., pH or temperature) in the TME [<xref ref-type="bibr" rid="CR367">367</xref>, <xref ref-type="bibr" rid="CR368">368</xref>]. Such nanoparticles may preferentially accumulate at the tumor sites, enhancing the bioavailability and efficacy of encapsulated or conjugated bioactive agents. Particularly, nanoparticle size and surface charge are key features that can be modified to improve the targeting specificity and efficiency of nanoparticles [<xref ref-type="bibr" rid="CR366">366</xref>]. Fourthly, the concern regarding the toxicity of nanoparticles is an important area of research. Exposure to nanoparticles may lead to harmful nano-bio interactions and other downstream mechanisms that can potentially induce side effects and nanotoxicity. These effects include genotoxicity, immunotoxicity, neurotoxicity, pulmonary toxicity, and vascular dysfunction [<xref ref-type="bibr" rid="CR369">369</xref>]. Before being used in clinical settings, all developed nanosystems must undergo toxicological studies. Currently, there is a scarcity of comprehensive data on the toxicity of nanoproducts. Interestingly, the available experimental results on nanoparticle toxicological profiles are conflicting and paradoxical, which may be attributed to the intricate interactions between different physicochemical parameters and corresponding biological systems. Additionally, many variables such as exposure route, dose and duration also influence the pathological effects of nanoparticles. Therefore, it is crucial to establish standardized and unified procedures for the systematic evaluation of nanotoxicity under different circumstances in order to obtain accurate toxicological data. In order to fully assess nanoparticle toxicity, the structure and physicochemical features of nanoparticles need to be thoroughly defined and understood. Furthermore, significant attention should be given to elucidating the sophisticated mechanisms of nanotoxicity in biologically and physiologically relevant models. Improved understanding of nanotoxicology may lead to the development of innovative strategies to reduce nanotoxicity, with the ultimate goal of harnessing the full potential of nanotechnology in cancer therapy. Last but not least, there are striking differences between preclinical tumor models and tumors in patients. It should be noted that tumors in patients are more complex and heterogeneous than animal tumor models. Thus, it is of great significance to corroborate the therapeutic efficacy and outcome of nanoformulations in large cohorts of cancer patients. The effect of the TME or other therapeutics on nanoformulation performance in patents is a fundamental research subject that has yet to be fully deciphered and awaits improved understanding.</p><p id="Par201">To conclude, nanocarriers may represent a promising therapeutic regimen for cancer treatment and support the development of more effective treatments. Numerous nanomaterials have been used as efficient vehicles for chemotherapeutic agents or immune modulators, including exosomes, liposomal formulations, and virus-like nanoparticles. These nanosized carriers can be tailored to specifically transfer bioactive cargos to the tumor site. Particular research interest has focused on developing a series of tumor-targeting nanocarriers for cancer therapeutic implications. The utilization of tumor-targeting nanoproducts leads to increased drug accumulation at the tumor site, higher cancer cell penetration, and improved therapeutic effect, culminating in enhanced cytotoxicity against cancer cells while maintaining minimal toxicity toward healthy tissues. Nanoformulations combined with immunotherapy offer collaborative therapeutic efficiency and have great application potential for cancer therapy. Notably, before entering the clinic, substantial research efforts are necessary to verify the biosafety and efficacy of the developed nanocarriers for human use.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ICIs</term><def><p id="Par2">Immune checkpoint inhibitors</p></def></def-item><def-item><term>GLOBOCAN</term><def><p id="Par3">Global cancer observatory data</p></def></def-item><def-item><term>TME</term><def><p id="Par4">Tumor microenvironment</p></def></def-item><def-item><term>EPR</term><def><p id="Par5">Enhanced permeability and retention</p></def></def-item><def-item><term>APC</term><def><p id="Par6">Antigen-presenting cell</p></def></def-item><def-item><term>DC</term><def><p id="Par7">Dendritic cell</p></def></def-item><def-item><term>MHC</term><def><p id="Par8">Major histocompatibility complex</p></def></def-item><def-item><term>DLN</term><def><p id="Par9">Draining lymph node</p></def></def-item><def-item><term>TCR</term><def><p id="Par10">T cell receptor</p></def></def-item><def-item><term>PD-1</term><def><p id="Par11">Programmed cell death-1</p></def></def-item><def-item><term>PD-L1</term><def><p id="Par12">Programmed cell death-ligand 1</p></def></def-item><def-item><term>CTLA-4</term><def><p id="Par13">Cytotoxic T lymphocyte-associated antigen-4</p></def></def-item><def-item><term>BTLA</term><def><p id="Par14">B and T lymphocyte attenuator</p></def></def-item><def-item><term>LAG-3</term><def><p id="Par15">Lymphocyte activation gene-3</p></def></def-item><def-item><term>TIM-3</term><def><p id="Par16">T cell immunoglobulin and mucin domain-containing protein-3</p></def></def-item><def-item><term>TIL</term><def><p id="Par17">Tumor-infiltrating lymphocyte</p></def></def-item><def-item><term>CAR</term><def><p id="Par18">Chimeric antigen receptor</p></def></def-item><def-item><term>CEA</term><def><p id="Par19">Carcinoembryonic antigen</p></def></def-item><def-item><term>CRC</term><def><p id="Par20">Colorectal cancer</p></def></def-item><def-item><term>CLL</term><def><p id="Par21">Chronic lymphocytic leukemia</p></def></def-item><def-item><term>ADC</term><def><p id="Par22">Antibody&#8211;drug conjugate</p></def></def-item><def-item><term>ADCC</term><def><p id="Par23">Antibody-dependent cell-mediated cytotoxicity</p></def></def-item><def-item><term>CDC</term><def><p id="Par24">Complement-dependent cytotoxicity</p></def></def-item><def-item><term>SLP</term><def><p id="Par25">Synthetic long peptide</p></def></def-item><def-item><term>IFN-&#945;</term><def><p id="Par26">Interferon-&#945;</p></def></def-item><def-item><term>RCC</term><def><p id="Par27">Renal cell carcinoma</p></def></def-item><def-item><term>PBMC</term><def><p id="Par28">Peripheral blood mononuclear cell</p></def></def-item><def-item><term>mCRPC</term><def><p id="Par29">Metastatic castrate-resistant prostate cancer</p></def></def-item><def-item><term>HPV</term><def><p id="Par30">Human papillomavirus</p></def></def-item><def-item><term>HER2</term><def><p id="Par31">Human epidermal growth factor receptor 2</p></def></def-item><def-item><term>RFS</term><def><p id="Par32">Recurrence-free survival</p></def></def-item><def-item><term>PDAC</term><def><p id="Par33">Pancreatic ductal adenocarcinoma</p></def></def-item><def-item><term>ECHO-7</term><def><p id="Par34">Enteric cytopathic human orphan virus type 7</p></def></def-item><def-item><term>CFDA</term><def><p id="Par35">China Food and Drug Administration</p></def></def-item><def-item><term>T-VEC</term><def><p id="Par36">Talimogene laherparepvec</p></def></def-item><def-item><term>HSV-1</term><def><p id="Par37">Herpes simplex virus-1</p></def></def-item><def-item><term>GM-CSF</term><def><p id="Par38">Granulocyte&#8211;macrophage colony-stimulating factor</p></def></def-item><def-item><term>MSC</term><def><p id="Par39">Mesenchymal stem cell</p></def></def-item><def-item><term>IL</term><def><p id="Par40">Interleukin</p></def></def-item><def-item><term>CTL</term><def><p id="Par41">Cytotoxic T lymphocyte</p></def></def-item><def-item><term>Th1</term><def><p id="Par42">T helper 1</p></def></def-item><def-item><term>TGF&#946;R1</term><def><p id="Par43">Transforming growth factor-&#946; type I receptor</p></def></def-item><def-item><term>STING</term><def><p id="Par44">Stimulator of interferon genes</p></def></def-item><def-item><term>IFN-I</term><def><p id="Par45">Type I interferon</p></def></def-item><def-item><term>Treg</term><def><p id="Par46">Regulatory T</p></def></def-item><def-item><term>nm</term><def><p id="Par47">Nanometers</p></def></def-item><def-item><term>DOX</term><def><p id="Par48">Doxorubicin</p></def></def-item><def-item><term>HIV</term><def><p id="Par49">Human immunodeficiency virus</p></def></def-item><def-item><term>NSCLC</term><def><p id="Par50">Non-small cell lung cancer</p></def></def-item><def-item><term>GBM</term><def><p id="Par51">Glioblastoma multiforme</p></def></def-item><def-item><term>nBSA</term><def><p id="Par52">Bovine serum albumin nanocapsule</p></def></def-item><def-item><term>PBA</term><def><p id="Par53">Phenylboronic acid</p></def></def-item><def-item><term>IgG</term><def><p id="Par54">Immunoglobulin G</p></def></def-item><def-item><term>SA</term><def><p id="Par55">Sialic acid</p></def></def-item><def-item><term>Fc</term><def><p id="Par56">Fragment crystallizable</p></def></def-item><def-item><term>PpIx</term><def><p id="Par57">Protoporphyrin IX</p></def></def-item><def-item><term>ROS</term><def><p id="Par58">Reactive oxygen species</p></def></def-item><def-item><term>PDT</term><def><p id="Par59">Photodynamic therapy</p></def></def-item><def-item><term>IDO</term><def><p id="Par60">Indoleamine-2,3-dioxygenase</p></def></def-item><def-item><term>GzB</term><def><p id="Par61">Granzyme B</p></def></def-item><def-item><term>siRNA</term><def><p id="Par62">Small interfering RNA</p></def></def-item><def-item><term>PLGA</term><def><p id="Par63">Poly(lactic-co-glycolic-acid)</p></def></def-item><def-item><term>OVA</term><def><p id="Par64">Ovalbumin</p></def></def-item><def-item><term>BBB</term><def><p id="Par65">Blood-brain barrier</p></def></def-item><def-item><term>CCM</term><def><p id="Par66">Cancer cell membrane</p></def></def-item><def-item><term>ICD</term><def><p id="Par67">Immunogenic cell death</p></def></def-item><def-item><term>Ce6</term><def><p id="Par68">Chlorin e6</p></def></def-item><def-item><term>MDSC</term><def><p id="Par69">Myeloid-derived suppressor cell</p></def></def-item><def-item><term>TNF-&#945;</term><def><p id="Par70">Tumor necrosis factor-&#945;</p></def></def-item><def-item><term>TLR</term><def><p id="Par71">Toll-like receptor</p></def></def-item><def-item><term>CpG</term><def><p id="Par72">Cytosine phosphate guanine</p></def></def-item><def-item><term>ODN</term><def><p id="Par73">Oligodeoxynucleotide</p></def></def-item><def-item><term>pDC</term><def><p id="Par74">Plasmacytoid dendritic cell</p></def></def-item><def-item><term>EGFR</term><def><p id="Par75">Epidermal growth factor receptor</p></def></def-item><def-item><term>LNP</term><def><p id="Par76">Lipid nanoparticle</p></def></def-item><def-item><term>cNP</term><def><p id="Par77">Cationic nanoparticle</p></def></def-item><def-item><term>CCR4</term><def><p id="Par78">C-C motif chemokine receptor 4</p></def></def-item><def-item><term>CXCR4</term><def><p id="Par79">C-X-C motif chemokine receptor 4</p></def></def-item><def-item><term>TNBC</term><def><p id="Par80">Triple-negative breast cancer</p></def></def-item><def-item><term>EGFRvIII</term><def><p id="Par81">Epidermal growth factor receptor variant III</p></def></def-item><def-item><term>IL-15SA</term><def><p id="Par82">Interleukin-15 super-agonist</p></def></def-item><def-item><term>TMZ</term><def><p id="Par83">Temozolomide</p></def></def-item><def-item><term>GITR</term><def><p id="Par84">Glucocorticoid-induced tumor necrosis factor receptor</p></def></def-item><def-item><term>CAT</term><def><p id="Par85">Catalase</p></def></def-item><def-item><term>PDA</term><def><p id="Par86">Polydopamine</p></def></def-item><def-item><term>ICG</term><def><p id="Par87">Indocyanine green</p></def></def-item><def-item><term>FOXP3</term><def><p id="Par88">Forkhead box P3</p></def></def-item><def-item><term>&#945;CSF1R</term><def><p id="Par89">Anti-colony-stimulating factor 1 receptor antibody</p></def></def-item><def-item><term>&#945;CD47</term><def><p id="Par90">Anti-CD47 antibody</p></def></def-item><def-item><term>imNA</term><def><p id="Par91">Immunomodulating nanoformulation</p></def></def-item><def-item><term>MPLA</term><def><p id="Par92">Monophosphoryl lipid A</p></def></def-item><def-item><term>&#945;-CD40</term><def><p id="Par93">Anti-CD40</p></def></def-item><def-item><term>PTEN</term><def><p id="Par94">Phosphatase and tensin homologue</p></def></def-item><def-item><term>PI3K</term><def><p id="Par95">Phosphatidylinositol 3-kinase</p></def></def-item><def-item><term>Akt</term><def><p id="Par96">Protein kinase B</p></def></def-item><def-item><term>TLS</term><def><p id="Par97">Tumor lysate</p></def></def-item><def-item><term>DPPA-1</term><def><p id="Par98">D-peptide antagonist</p></def></def-item><def-item><term>EnS</term><def><p id="Par99">Engineered <italic toggle="yes">Salmonella</italic></p></def></def-item><def-item><term>PEG</term><def><p id="Par100">Polyethylene glycol</p></def></def-item><def-item><term>STAT3</term><def><p id="Par101">Signal transduction and activator of transcription 3</p></def></def-item><def-item><term>TADC</term><def><p id="Par102">Tumor-associated dendritic cell</p></def></def-item><def-item><term>PCP</term><def><p id="Par103"><italic toggle="yes">Poria</italic>
<italic toggle="yes">cocos</italic> polysaccharides</p></def></def-item><def-item><term>rCD44v</term><def><p id="Par104">Recombinant CD44v</p></def></def-item><def-item><term>FAPPEP</term><def><p id="Par105">Fibroblast activation protein &#945;-specific epitope peptides</p></def></def-item><def-item><term>CAF</term><def><p id="Par106">Cancer-associated fibroblast</p></def></def-item><def-item><term>ECM</term><def><p id="Par107">Extracellular matrix</p></def></def-item><def-item><term>HMGN1</term><def><p id="Par108">High-mobility group nucleosome-binding protein 1</p></def></def-item><def-item><term>MPN</term><def><p id="Par109">Metal-phenolic network</p></def></def-item><def-item><term>MDP</term><def><p id="Par110">Muramyl dipeptide</p></def></def-item><def-item><term>OPSCC</term><def><p id="Par111">Oropharyngeal squamous cell carcinom</p></def></def-item><def-item><term>HCC</term><def><p id="Par112">Hepatocellular carcinoma</p></def></def-item><def-item><term>EBV</term><def><p id="Par113">Epstein-Barr virus</p></def></def-item><def-item><term>mOVA</term><def><p id="Par114">OVA-encoding mRNA</p></def></def-item><def-item><term>OS</term><def><p id="Par115">Overall survival</p></def></def-item><def-item><term>AI</term><def><p id="Par116">Artificial intelligence</p></def></def-item><def-item><term>Ad</term><def><p id="Par117">Adenoviral vector</p></def></def-item><def-item><term>SVV</term><def><p id="Par118">Seneca Valley virus</p></def></def-item><def-item><term>SCLC</term><def><p id="Par119">Small cell lung cancer</p></def></def-item><def-item><term>5-FU</term><def><p id="Par120">5-fluorouracil</p></def></def-item><def-item><term>IL-2R&#945;</term><def><p id="Par121">Interleukin-2 receptor &#945;</p></def></def-item><def-item><term>ORR</term><def><p id="Par122">Objective response rate</p></def></def-item><def-item><term>HSA</term><def><p id="Par123">Human serum albumin</p></def></def-item><def-item><term>CCL2</term><def><p id="Par124">C-C motif chemokine ligand 2</p></def></def-item><def-item><term>TNP</term><def><p id="Par125">Therapeutic nanoplatform</p></def></def-item><def-item><term>SPNP</term><def><p id="Par126">Synthetic protein nanoparticle</p></def></def-item><def-item><term>M-MDSC</term><def><p id="Par127">Monocytic myeloid-derived suppressor cell</p></def></def-item><def-item><term>pCR</term><def><p id="Par128">Pathological complete response</p></def></def-item><def-item><term>RCB-I</term><def><p id="Par129">Residual cancer burden class I</p></def></def-item><def-item><term>AC</term><def><p id="Par130">Anthracycline</p></def></def-item><def-item><term>iDFS</term><def><p id="Par131">Invasive disease-free survival</p></def></def-item><def-item><term>DDFS</term><def><p id="Par132">Distant disease-free survival</p></def></def-item><def-item><term>PFS</term><def><p id="Par133">Progression-free survival</p></def></def-item><def-item><term>ESCC</term><def><p id="Par134">Esophageal squamous cell carcinoma</p></def></def-item><def-item><term>MPR</term><def><p id="Par135">Major pathologic response</p></def></def-item><def-item><term>rrPMBCL</term><def><p id="Par136">Relapsed/refractory primary mediastinal B-cell lymphoma</p></def></def-item><def-item><term>EOC</term><def><p id="Par137">Epithelial ovarian cancer</p></def></def-item><def-item><term>AIDS</term><def><p id="Par138">Acquired immunodeficiency syndrome</p></def></def-item><def-item><term>GI</term><def><p id="Par139">Gastrointestinal</p></def></def-item><def-item><term>PSA</term><def><p id="Par140">Prostate-specific tumor-associated antigen</p></def></def-item><def-item><term>SORT</term><def><p id="Par141">Selective organ-targeting</p></def></def-item><def-item><term>UTR</term><def><p id="Par142">Untranslational region</p></def></def-item><def-item><term>RES</term><def><p id="Par143">Reticuloendothelial system</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>Conceptualization, Supervision, Investigation, Writing - Original draft preparation, M.W.; Investigation, Visualization, F.Y.; Writing - Reviewing and Editing, Y.Z. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par202">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par203">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par204">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><collab>Global Burden of Disease Cancer C</collab><name name-style="western"><surname>Kocarnik</surname><given-names>JM</given-names></name><name name-style="western"><surname>Compton</surname><given-names>K</given-names></name><name name-style="western"><surname>Dean</surname><given-names>FE</given-names></name><name name-style="western"><surname>Fu</surname><given-names>W</given-names></name><name name-style="western"><surname>Gaw</surname><given-names>BL</given-names></name><etal/></person-group><article-title>cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019</article-title><source>JAMA Oncol</source><year>2022</year><volume>8</volume><issue>3</issue><fpage>420</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2021.6987</pub-id><pub-id pub-id-type="pmid">34967848</pub-id><pub-id pub-id-type="pmcid">PMC8719276</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Global Burden of Disease Cancer C, Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, et al. cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019. JAMA Oncol. 2022;8(3):420&#8211;44.<pub-id pub-id-type="pmid">34967848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2021.6987</pub-id><pub-id pub-id-type="pmcid">PMC8719276</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Colombet</surname><given-names>M</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><name name-style="western"><surname>Parkin</surname><given-names>DM</given-names></name><name name-style="western"><surname>Pineros</surname><given-names>M</given-names></name><name name-style="western"><surname>Znaor</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cancer statistics for the year 2020: An overview</article-title><source>Int J Cancer</source><year>2021</year><volume>149</volume><issue>4</issue><fpage>778</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1002/ijc.33588</pub-id><pub-id pub-id-type="pmid">33818764</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pineros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149(4):778&#8211;89.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.33588</pub-id><pub-id pub-id-type="pmid">33818764</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mirzayans</surname><given-names>R</given-names></name><name name-style="western"><surname>Murray</surname><given-names>D</given-names></name></person-group><article-title>What are the reasons for continuing failures in cancer therapy? Are misleading/inappropriate preclinical assays to be blamed? might some modern therapies cause more harm than benefit?</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>21</issue><fpage>13217</fpage><pub-id pub-id-type="doi">10.3390/ijms232113217</pub-id><pub-id pub-id-type="pmid">36362004</pub-id><pub-id pub-id-type="pmcid">PMC9655591</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Mirzayans R, Murray D. What are the reasons for continuing failures in cancer therapy? Are misleading/inappropriate preclinical assays to be blamed? might some modern therapies cause more harm than benefit? Int J Mol Sci. 2022;23(21):13217.<pub-id pub-id-type="pmid">36362004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms232113217</pub-id><pub-id pub-id-type="pmcid">PMC9655591</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coventry</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Henneberg</surname><given-names>M</given-names></name></person-group><article-title>The immune system and responses to cancer: coordinated evolution</article-title><source>F1000Res</source><year>2015</year><volume>4</volume><fpage>552</fpage><pub-id pub-id-type="doi">10.12688/f1000research.6718.1</pub-id><pub-id pub-id-type="pmid">33365125</pub-id><pub-id pub-id-type="pmcid">PMC7735224</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Coventry BJ, Henneberg M. The immune system and responses to cancer: coordinated evolution. F1000Res. 2015;4:552.<pub-id pub-id-type="pmid">33365125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12688/f1000research.6718.1</pub-id><pub-id pub-id-type="pmcid">PMC7735224</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications</article-title><source>Cell Mol Immunol</source><year>2020</year><volume>17</volume><issue>8</issue><fpage>807</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-0488-6</pub-id><pub-id pub-id-type="pmid">32612154</pub-id><pub-id pub-id-type="pmcid">PMC7395159</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807&#8211;21.<pub-id pub-id-type="pmid">32612154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41423-020-0488-6</pub-id><pub-id pub-id-type="pmcid">PMC7395159</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>SL</given-names></name><name name-style="western"><surname>Basu</surname><given-names>S</given-names></name><name name-style="western"><surname>Soni</surname><given-names>V</given-names></name><name name-style="western"><surname>Jaiswal</surname><given-names>RK</given-names></name></person-group><article-title>Immunotherapy: an alternative promising therapeutic approach against cancers</article-title><source>Mol Biol Rep</source><year>2022</year><volume>49</volume><issue>10</issue><fpage>9903</fpage><lpage>9913</lpage><pub-id pub-id-type="doi">10.1007/s11033-022-07525-8</pub-id><pub-id pub-id-type="pmid">35759082</pub-id><pub-id pub-id-type="pmcid">PMC9244230</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Gupta SL, Basu S, Soni V, Jaiswal RK. Immunotherapy: an alternative promising therapeutic approach against cancers. Mol Biol Rep. 2022;49(10):9903&#8211;13.<pub-id pub-id-type="pmid">35759082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11033-022-07525-8</pub-id><pub-id pub-id-type="pmcid">PMC9244230</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mizukoshi</surname><given-names>E</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Tamai</surname><given-names>T</given-names></name><name name-style="western"><surname>Kitahara</surname><given-names>M</given-names></name><name name-style="western"><surname>Fushimi</surname><given-names>K</given-names></name><name name-style="western"><surname>Nio</surname><given-names>K</given-names></name><etal/></person-group><article-title>Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8(+) T cells</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>3123</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-30861-z</pub-id><pub-id pub-id-type="pmid">35660746</pub-id><pub-id pub-id-type="pmcid">PMC9166698</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Mizukoshi E, Nakagawa H, Tamai T, Kitahara M, Fushimi K, Nio K, et al. Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8(+) T cells. Nat Commun. 2022;13(1):3123.<pub-id pub-id-type="pmid">35660746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-30861-z</pub-id><pub-id pub-id-type="pmcid">PMC9166698</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiner</surname><given-names>LM</given-names></name><name name-style="western"><surname>Surana</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name></person-group><article-title>Monoclonal antibodies: versatile platforms for cancer immunotherapy</article-title><source>Nat Rev Immunol</source><year>2010</year><volume>10</volume><issue>5</issue><fpage>317</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1038/nri2744</pub-id><pub-id pub-id-type="pmid">20414205</pub-id><pub-id pub-id-type="pmcid">PMC3508064</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10(5):317&#8211;27.<pub-id pub-id-type="pmid">20414205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri2744</pub-id><pub-id pub-id-type="pmcid">PMC3508064</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiravand</surname><given-names>Y</given-names></name><name name-style="western"><surname>Khodadadi</surname><given-names>F</given-names></name><name name-style="western"><surname>Kashani</surname><given-names>SMA</given-names></name><name name-style="western"><surname>Hosseini-Fard</surname><given-names>SR</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>S</given-names></name><name name-style="western"><surname>Sadeghirad</surname><given-names>H</given-names></name><etal/></person-group><article-title>Immune checkpoint inhibitors in cancer therapy</article-title><source>Curr Oncol</source><year>2022</year><volume>29</volume><issue>5</issue><fpage>3044</fpage><lpage>3060</lpage><pub-id pub-id-type="doi">10.3390/curroncol29050247</pub-id><pub-id pub-id-type="pmid">35621637</pub-id><pub-id pub-id-type="pmcid">PMC9139602</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044&#8211;60.<pub-id pub-id-type="pmid">35621637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/curroncol29050247</pub-id><pub-id pub-id-type="pmcid">PMC9139602</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waldman</surname><given-names>AD</given-names></name><name name-style="western"><surname>Fritz</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lenardo</surname><given-names>MJ</given-names></name></person-group><article-title>A guide to cancer immunotherapy: from T cell basic science to clinical practice</article-title><source>Nat Rev Immunol</source><year>2020</year><volume>20</volume><issue>11</issue><fpage>651</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0306-5</pub-id><pub-id pub-id-type="pmid">32433532</pub-id><pub-id pub-id-type="pmcid">PMC7238960</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651&#8211;68.<pub-id pub-id-type="pmid">32433532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0306-5</pub-id><pub-id pub-id-type="pmcid">PMC7238960</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kubli</surname><given-names>SP</given-names></name><name name-style="western"><surname>Berger</surname><given-names>T</given-names></name><name name-style="western"><surname>Araujo</surname><given-names>DV</given-names></name><name name-style="western"><surname>Siu</surname><given-names>LL</given-names></name><name name-style="western"><surname>Mak</surname><given-names>TW</given-names></name></person-group><article-title>Beyond immune checkpoint blockade: emerging immunological strategies</article-title><source>Nat Rev Drug Discov</source><year>2021</year><volume>20</volume><issue>12</issue><fpage>899</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00155-y</pub-id><pub-id pub-id-type="pmid">33686237</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Kubli SP, Berger T, Araujo DV, Siu LL, Mak TW. Beyond immune checkpoint blockade: emerging immunological strategies. Nat Rev Drug Discov. 2021;20(12):899&#8211;919.<pub-id pub-id-type="pmid">33686237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-021-00155-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weigmann</surname><given-names>K</given-names></name></person-group><article-title>Releasing the brakes to fight cancer: The recent discovery of checkpoints has boosted the field of cancer immunotherapy</article-title><source>EMBO Rep</source><year>2016</year><volume>17</volume><issue>9</issue><fpage>1257</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.15252/embr.201643038</pub-id><pub-id pub-id-type="pmid">27458238</pub-id><pub-id pub-id-type="pmcid">PMC5007568</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Weigmann K. Releasing the brakes to fight cancer: The recent discovery of checkpoints has boosted the field of cancer immunotherapy. EMBO Rep. 2016;17(9):1257&#8211;60.<pub-id pub-id-type="pmid">27458238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embr.201643038</pub-id><pub-id pub-id-type="pmcid">PMC5007568</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kichloo</surname><given-names>A</given-names></name><name name-style="western"><surname>Albosta</surname><given-names>M</given-names></name><name name-style="western"><surname>Dahiya</surname><given-names>D</given-names></name><name name-style="western"><surname>Guidi</surname><given-names>JC</given-names></name><name name-style="western"><surname>Aljadah</surname><given-names>M</given-names></name><name name-style="western"><surname>Singh</surname><given-names>J</given-names></name><etal/></person-group><article-title>Systemic adverse effects and toxicities associated with immunotherapy: a review</article-title><source>World J Clin Oncol</source><year>2021</year><volume>12</volume><issue>3</issue><fpage>150</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.5306/wjco.v12.i3.150</pub-id><pub-id pub-id-type="pmid">33767971</pub-id><pub-id pub-id-type="pmcid">PMC7968107</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Kichloo A, Albosta M, Dahiya D, Guidi JC, Aljadah M, Singh J, et al. Systemic adverse effects and toxicities associated with immunotherapy: a review. World J Clin Oncol. 2021;12(3):150&#8211;63.<pub-id pub-id-type="pmid">33767971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5306/wjco.v12.i3.150</pub-id><pub-id pub-id-type="pmcid">PMC7968107</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aktar</surname><given-names>N</given-names></name><name name-style="western"><surname>Yueting</surname><given-names>C</given-names></name><name name-style="western"><surname>Abbas</surname><given-names>M</given-names></name><name name-style="western"><surname>Zafar</surname><given-names>H</given-names></name><name name-style="western"><surname>Paiva-Santos</surname><given-names>AC</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Understanding of immune escape mechanisms and advances in cancer immunotherapy</article-title><source>J Oncol</source><year>2022</year><volume>2022</volume><fpage>8901326</fpage><pub-id pub-id-type="doi">10.1155/2022/8901326</pub-id><pub-id pub-id-type="pmid">35401745</pub-id><pub-id pub-id-type="pmcid">PMC8989557</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Aktar N, Yueting C, Abbas M, Zafar H, Paiva-Santos AC, Zhang Q, et al. Understanding of immune escape mechanisms and advances in cancer immunotherapy. J Oncol. 2022;2022:8901326.<pub-id pub-id-type="pmid">35401745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/8901326</pub-id><pub-id pub-id-type="pmcid">PMC8989557</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>X</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>New horizons in tumor microenvironment biology: challenges and opportunities</article-title><source>BMC Med</source><year>2015</year><volume>13</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.1186/s12916-015-0278-7</pub-id><pub-id pub-id-type="pmid">25857315</pub-id><pub-id pub-id-type="pmcid">PMC4350882</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y, et al. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med. 2015;13:45.<pub-id pub-id-type="pmid">25857315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-015-0278-7</pub-id><pub-id pub-id-type="pmcid">PMC4350882</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>B</given-names></name><name name-style="western"><surname>Hyun</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>LT</given-names></name><name name-style="western"><surname>Wang</surname><given-names>AZ</given-names></name></person-group><article-title>Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment</article-title><source>Acta Pharmacol Sin</source><year>2020</year><volume>41</volume><issue>7</issue><fpage>970</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1038/s41401-020-0424-4</pub-id><pub-id pub-id-type="pmid">32424240</pub-id><pub-id pub-id-type="pmcid">PMC7470849</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Sun B, Hyun H, Li LT, Wang AZ. Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment. Acta Pharmacol Sin. 2020;41(7):970&#8211;85.<pub-id pub-id-type="pmid">32424240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41401-020-0424-4</pub-id><pub-id pub-id-type="pmcid">PMC7470849</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haas</surname><given-names>AR</given-names></name><name name-style="western"><surname>Tanyi</surname><given-names>JL</given-names></name><name name-style="western"><surname>O'Hara</surname><given-names>MH</given-names></name><name name-style="western"><surname>Gladney</surname><given-names>WL</given-names></name><name name-style="western"><surname>Lacey</surname><given-names>SF</given-names></name><name name-style="western"><surname>Torigian</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers</article-title><source>Mol Ther</source><year>2019</year><volume>27</volume><issue>11</issue><fpage>1919</fpage><lpage>1929</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2019.07.015</pub-id><pub-id pub-id-type="pmid">31420241</pub-id><pub-id pub-id-type="pmcid">PMC6838875</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Haas AR, Tanyi JL, O&#8217;Hara MH, Gladney WL, Lacey SF, Torigian DA, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther. 2019;27(11):1919&#8211;29.<pub-id pub-id-type="pmid">31420241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2019.07.015</pub-id><pub-id pub-id-type="pmcid">PMC6838875</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiaie</surname><given-names>SH</given-names></name><name name-style="western"><surname>Salehi-Shadkami</surname><given-names>H</given-names></name><name name-style="western"><surname>Sanaei</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Azizi</surname><given-names>M</given-names></name><name name-style="western"><surname>Shokrollahi Barough</surname><given-names>M</given-names></name><name name-style="western"><surname>Nasr</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy</article-title><source>J Nanobiotechnology</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>339</fpage><pub-id pub-id-type="doi">10.1186/s12951-023-02083-y</pub-id><pub-id pub-id-type="pmid">37735656</pub-id><pub-id pub-id-type="pmcid">PMC10512572</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Kiaie SH, Salehi-Shadkami H, Sanaei MJ, Azizi M, Shokrollahi Barough M, Nasr MS, et al. Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy. J Nanobiotechnology. 2023;21(1):339.<pub-id pub-id-type="pmid">37735656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-023-02083-y</pub-id><pub-id pub-id-type="pmcid">PMC10512572</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Z</given-names></name></person-group><article-title>Targeted nanoparticle drug delivery system for the enhancement of cancer immunotherapy</article-title><source>J Biomed Nanotechnol</source><year>2019</year><volume>15</volume><issue>9</issue><fpage>1839</fpage><lpage>1866</lpage><pub-id pub-id-type="doi">10.1166/jbn.2019.2827</pub-id><pub-id pub-id-type="pmid">31387674</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Zhang H, Wu Y, Hu Y, Li X, Zhao M, Lv Z. Targeted nanoparticle drug delivery system for the enhancement of cancer immunotherapy. J Biomed Nanotechnol. 2019;15(9):1839&#8211;66.<pub-id pub-id-type="pmid">31387674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1166/jbn.2019.2827</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mochida</surname><given-names>A</given-names></name><name name-style="western"><surname>Choyke</surname><given-names>PL</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>H</given-names></name></person-group><article-title>Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer?</article-title><source>Bioconjug Chem</source><year>2016</year><volume>27</volume><issue>10</issue><fpage>2225</fpage><lpage>2238</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.6b00437</pub-id><pub-id pub-id-type="pmid">27547843</pub-id><pub-id pub-id-type="pmcid">PMC7397928</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Nakamura Y, Mochida A, Choyke PL, Kobayashi H. Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjug Chem. 2016;27(10):2225&#8211;38.<pub-id pub-id-type="pmid">27547843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.bioconjchem.6b00437</pub-id><pub-id pub-id-type="pmcid">PMC7397928</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palazzolo</surname><given-names>S</given-names></name><name name-style="western"><surname>Bayda</surname><given-names>S</given-names></name><name name-style="western"><surname>Hadla</surname><given-names>M</given-names></name><name name-style="western"><surname>Caligiuri</surname><given-names>I</given-names></name><name name-style="western"><surname>Corona</surname><given-names>G</given-names></name><name name-style="western"><surname>Toffoli</surname><given-names>G</given-names></name><etal/></person-group><article-title>The clinical translation of organic nanomaterials for cancer therapy: a focus on polymeric nanoparticles, Micelles</article-title><source>Liposom Exosom Curr Med Chem</source><year>2018</year><volume>25</volume><issue>34</issue><fpage>4224</fpage><lpage>4268</lpage><pub-id pub-id-type="doi">10.2174/0929867324666170830113755</pub-id><pub-id pub-id-type="pmid">28875844</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Palazzolo S, Bayda S, Hadla M, Caligiuri I, Corona G, Toffoli G, et al. The clinical translation of organic nanomaterials for cancer therapy: a focus on polymeric nanoparticles, Micelles. Liposom Exosom Curr Med Chem. 2018;25(34):4224&#8211;68.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0929867324666170830113755</pub-id><pub-id pub-id-type="pmid">28875844</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dadwal</surname><given-names>A</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>A</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>NR</given-names></name></person-group><article-title>Nanoparticles as carriers for drug delivery in cancer</article-title><source>Artif Cells Nanomed Biotechnol</source><year>2018</year><volume>46</volume><issue>sup2</issue><fpage>295</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1080/21691401.2018.1457039</pub-id><pub-id pub-id-type="pmid">30043651</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Dadwal A, Baldi A, Kumar NR. Nanoparticles as carriers for drug delivery in cancer. Artif Cells Nanomed Biotechnol. 2018;46(sup2):295&#8211;305.<pub-id pub-id-type="pmid">30043651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21691401.2018.1457039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>DS</given-names></name><name name-style="western"><surname>Mellman</surname><given-names>I</given-names></name></person-group><article-title>Oncology meets immunology: the cancer-immunity cycle</article-title><source>Immunity</source><year>2013</year><volume>39</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.012</pub-id><pub-id pub-id-type="pmid">23890059</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1&#8211;10.<pub-id pub-id-type="pmid">23890059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2013.07.012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Somarribas Patterson</surname><given-names>LF</given-names></name><name name-style="western"><surname>Vardhana</surname><given-names>SA</given-names></name></person-group><article-title>Metabolic regulation of the cancer-immunity cycle</article-title><source>Trends Immunol</source><year>2021</year><volume>42</volume><issue>11</issue><fpage>975</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1016/j.it.2021.09.002</pub-id><pub-id pub-id-type="pmid">34610889</pub-id><pub-id pub-id-type="pmcid">PMC8556351</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Somarribas Patterson LF, Vardhana SA. Metabolic regulation of the cancer-immunity cycle. Trends Immunol. 2021;42(11):975&#8211;93.<pub-id pub-id-type="pmid">34610889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.it.2021.09.002</pub-id><pub-id pub-id-type="pmcid">PMC8556351</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Prete</surname><given-names>A</given-names></name><name name-style="western"><surname>Salvi</surname><given-names>V</given-names></name><name name-style="western"><surname>Soriani</surname><given-names>A</given-names></name><name name-style="western"><surname>Laffranchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Sozio</surname><given-names>F</given-names></name><name name-style="western"><surname>Bosisio</surname><given-names>D</given-names></name><etal/></person-group><article-title>Dendritic cell subsets in cancer immunity and tumor antigen sensing</article-title><source>Cell Mol Immunol</source><year>2023</year><volume>20</volume><issue>5</issue><fpage>432</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1038/s41423-023-00990-6</pub-id><pub-id pub-id-type="pmid">36949244</pub-id><pub-id pub-id-type="pmcid">PMC10203372</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Del Prete A, Salvi V, Soriani A, Laffranchi M, Sozio F, Bosisio D, et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol. 2023;20(5):432&#8211;47.<pub-id pub-id-type="pmid">36949244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41423-023-00990-6</pub-id><pub-id pub-id-type="pmcid">PMC10203372</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blum</surname><given-names>JS</given-names></name><name name-style="western"><surname>Wearsch</surname><given-names>PA</given-names></name><name name-style="western"><surname>Cresswell</surname><given-names>P</given-names></name></person-group><article-title>Pathways of antigen processing</article-title><source>Annu Rev Immunol</source><year>2013</year><volume>31</volume><fpage>443</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-095910</pub-id><pub-id pub-id-type="pmid">23298205</pub-id><pub-id pub-id-type="pmcid">PMC4026165</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol. 2013;31:443&#8211;73.<pub-id pub-id-type="pmid">23298205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-immunol-032712-095910</pub-id><pub-id pub-id-type="pmcid">PMC4026165</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Von Rueden</surname><given-names>SK</given-names></name><name name-style="western"><surname>Fan</surname><given-names>TM</given-names></name></person-group><article-title>Cancer-immunity cycle and therapeutic interventions- opportunities for including pet dogs with cancer</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><fpage>773420</fpage><pub-id pub-id-type="doi">10.3389/fonc.2021.773420</pub-id><pub-id pub-id-type="pmid">34869014</pub-id><pub-id pub-id-type="pmcid">PMC8639699</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Von Rueden SK, Fan TM. Cancer-immunity cycle and therapeutic interventions- opportunities for including pet dogs with cancer. Front Oncol. 2021;11:773420.<pub-id pub-id-type="pmid">34869014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2021.773420</pub-id><pub-id pub-id-type="pmcid">PMC8639699</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pio</surname><given-names>R</given-names></name><name name-style="western"><surname>Ajona</surname><given-names>D</given-names></name><name name-style="western"><surname>Ortiz-Espinosa</surname><given-names>S</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name><name name-style="western"><surname>Lambris</surname><given-names>JD</given-names></name></person-group><article-title>Complementing the cancer-immunity cycle</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>774</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00774</pub-id><pub-id pub-id-type="pmid">31031765</pub-id><pub-id pub-id-type="pmcid">PMC6473060</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Pio R, Ajona D, Ortiz-Espinosa S, Mantovani A, Lambris JD. Complementing the cancer-immunity cycle. Front Immunol. 2019;10:774.<pub-id pub-id-type="pmid">31031765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.00774</pub-id><pub-id pub-id-type="pmcid">PMC6473060</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kallingal</surname><given-names>A</given-names></name><name name-style="western"><surname>Olszewski</surname><given-names>M</given-names></name><name name-style="western"><surname>Maciejewska</surname><given-names>N</given-names></name><name name-style="western"><surname>Brankiewicz</surname><given-names>W</given-names></name><name name-style="western"><surname>Baginski</surname><given-names>M</given-names></name></person-group><article-title>Cancer immune escape: the role of antigen presentation machinery</article-title><source>J Cancer Res Clin Oncol</source><year>2023</year><volume>149</volume><issue>10</issue><fpage>8131</fpage><lpage>8141</lpage><pub-id pub-id-type="doi">10.1007/s00432-023-04737-8</pub-id><pub-id pub-id-type="pmid">37031434</pub-id><pub-id pub-id-type="pmcid">PMC10374767</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Kallingal A, Olszewski M, Maciejewska N, Brankiewicz W, Baginski M. Cancer immune escape: the role of antigen presentation machinery. J Cancer Res Clin Oncol. 2023;149(10):8131&#8211;41.<pub-id pub-id-type="pmid">37031434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00432-023-04737-8</pub-id><pub-id pub-id-type="pmcid">PMC10374767</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuomela</surname><given-names>K</given-names></name><name name-style="western"><surname>Ambrose</surname><given-names>AR</given-names></name><name name-style="western"><surname>Davis</surname><given-names>DM</given-names></name></person-group><article-title>Escaping death: how cancer cells and infected cells resist cell-mediated cytotoxicity</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>867098</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.867098</pub-id><pub-id pub-id-type="pmid">35401556</pub-id><pub-id pub-id-type="pmcid">PMC8984481</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Tuomela K, Ambrose AR, Davis DM. Escaping death: how cancer cells and infected cells resist cell-mediated cytotoxicity. Front Immunol. 2022;13:867098.<pub-id pub-id-type="pmid">35401556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.867098</pub-id><pub-id pub-id-type="pmcid">PMC8984481</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>D</given-names></name><name name-style="western"><surname>Mei</surname><given-names>L</given-names></name></person-group><article-title>Symphony of nanomaterials and immunotherapy based on the cancer-immunity cycle</article-title><source>Acta Pharm Sin B</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>107</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2021.05.031</pub-id><pub-id pub-id-type="pmid">35127375</pub-id><pub-id pub-id-type="pmcid">PMC8799879</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Li Q, Shi Z, Zhang F, Zeng W, Zhu D, Mei L. Symphony of nanomaterials and immunotherapy based on the cancer-immunity cycle. Acta Pharm Sin B. 2022;12(1):107&#8211;34.<pub-id pub-id-type="pmid">35127375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2021.05.031</pub-id><pub-id pub-id-type="pmcid">PMC8799879</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>D</given-names></name></person-group><article-title>Clinical cancer immunotherapy: current progress and prospects</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>961805</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.961805</pub-id><pub-id pub-id-type="pmid">36304470</pub-id><pub-id pub-id-type="pmcid">PMC9592930</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Liu C, Yang M, Zhang D, Chen M, Zhu D. Clinical cancer immunotherapy: current progress and prospects. Front Immunol. 2022;13:961805.<pub-id pub-id-type="pmid">36304470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.961805</pub-id><pub-id pub-id-type="pmcid">PMC9592930</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name></person-group><article-title>Functions of immune checkpoint molecules beyond immune evasion</article-title><source>Adv Exp Med Biol</source><year>2020</year><volume>1248</volume><fpage>201</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1007/978-981-15-3266-5_9</pub-id><pub-id pub-id-type="pmid">32185712</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Zhang Y, Zheng J. Functions of immune checkpoint molecules beyond immune evasion. Adv Exp Med Biol. 2020;1248:201&#8211;26.<pub-id pub-id-type="pmid">32185712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-981-15-3266-5_9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardoll</surname><given-names>DM</given-names></name></person-group><article-title>The blockade of immune checkpoints in cancer immunotherapy</article-title><source>Nat Rev Cancer</source><year>2012</year><volume>12</volume><issue>4</issue><fpage>252</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1038/nrc3239</pub-id><pub-id pub-id-type="pmid">22437870</pub-id><pub-id pub-id-type="pmcid">PMC4856023</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252&#8211;64.<pub-id pub-id-type="pmid">22437870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc3239</pub-id><pub-id pub-id-type="pmcid">PMC4856023</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Flies</surname><given-names>DB</given-names></name></person-group><article-title>Molecular mechanisms of T cell co-stimulation and co-inhibition</article-title><source>Nat Rev Immunol</source><year>2013</year><volume>13</volume><issue>4</issue><fpage>227</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1038/nri3405</pub-id><pub-id pub-id-type="pmid">23470321</pub-id><pub-id pub-id-type="pmcid">PMC3786574</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227&#8211;42.<pub-id pub-id-type="pmid">23470321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3405</pub-id><pub-id pub-id-type="pmcid">PMC3786574</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Yi</surname><given-names>M</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S</given-names></name></person-group><article-title>Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4</article-title><source>Mol Cancer</source><year>2019</year><volume>18</volume><issue>1</issue><fpage>155</fpage><pub-id pub-id-type="doi">10.1186/s12943-019-1091-2</pub-id><pub-id pub-id-type="pmid">31690319</pub-id><pub-id pub-id-type="pmcid">PMC6833286</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.<pub-id pub-id-type="pmid">31690319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-019-1091-2</pub-id><pub-id pub-id-type="pmcid">PMC6833286</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>M</given-names></name><name name-style="western"><surname>Jasek</surname><given-names>M</given-names></name><name name-style="western"><surname>Karabon</surname><given-names>L</given-names></name></person-group><article-title>Immune checkpoint molecules-inherited variations as markers for cancer risk</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>606721</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.606721</pub-id><pub-id pub-id-type="pmid">33519815</pub-id><pub-id pub-id-type="pmcid">PMC7840570</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Wagner M, Jasek M, Karabon L. Immune checkpoint molecules-inherited variations as markers for cancer risk. Front Immunol. 2020;11:606721.<pub-id pub-id-type="pmid">33519815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.606721</pub-id><pub-id pub-id-type="pmcid">PMC7840570</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>CF</given-names></name><name name-style="western"><surname>Proverbs-Singh</surname><given-names>TA</given-names></name><name name-style="western"><surname>Postow</surname><given-names>MA</given-names></name></person-group><article-title>Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review</article-title><source>JAMA Oncol</source><year>2016</year><volume>2</volume><issue>10</issue><fpage>1346</fpage><lpage>1353</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2016.1051</pub-id><pub-id pub-id-type="pmid">27367787</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346&#8211;53.<pub-id pub-id-type="pmid">27367787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2016.1051</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byun</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Wolchok</surname><given-names>JD</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>LM</given-names></name><name name-style="western"><surname>Girotra</surname><given-names>M</given-names></name></person-group><article-title>Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies</article-title><source>Nat Rev Endocrinol</source><year>2017</year><volume>13</volume><issue>4</issue><fpage>195</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2016.205</pub-id><pub-id pub-id-type="pmid">28106152</pub-id><pub-id pub-id-type="pmcid">PMC5629093</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13(4):195&#8211;207.<pub-id pub-id-type="pmid">28106152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrendo.2016.205</pub-id><pub-id pub-id-type="pmcid">PMC5629093</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morotti</surname><given-names>M</given-names></name><name name-style="western"><surname>Albukhari</surname><given-names>A</given-names></name><name name-style="western"><surname>Alsaadi</surname><given-names>A</given-names></name><name name-style="western"><surname>Artibani</surname><given-names>M</given-names></name><name name-style="western"><surname>Brenton</surname><given-names>JD</given-names></name><name name-style="western"><surname>Curbishley</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Promises and challenges of adoptive T-cell therapies for solid tumours</article-title><source>Br J Cancer</source><year>2021</year><volume>124</volume><issue>11</issue><fpage>1759</fpage><lpage>1776</lpage><pub-id pub-id-type="doi">10.1038/s41416-021-01353-6</pub-id><pub-id pub-id-type="pmid">33782566</pub-id><pub-id pub-id-type="pmcid">PMC8144577</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Morotti M, Albukhari A, Alsaadi A, Artibani M, Brenton JD, Curbishley SM, et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer. 2021;124(11):1759&#8211;76.<pub-id pub-id-type="pmid">33782566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-021-01353-6</pub-id><pub-id pub-id-type="pmcid">PMC8144577</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sim</surname><given-names>GC</given-names></name><name name-style="western"><surname>Chacon</surname><given-names>J</given-names></name><name name-style="western"><surname>Haymaker</surname><given-names>C</given-names></name><name name-style="western"><surname>Ritthipichai</surname><given-names>K</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M</given-names></name><name name-style="western"><surname>Hwu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development</article-title><source>BioDrugs</source><year>2014</year><volume>28</volume><issue>5</issue><fpage>421</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1007/s40259-014-0097-y</pub-id><pub-id pub-id-type="pmid">24890028</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Sim GC, Chacon J, Haymaker C, Ritthipichai K, Singh M, Hwu P, et al. Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development. BioDrugs. 2014;28(5):421&#8211;37.<pub-id pub-id-type="pmid">24890028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40259-014-0097-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sidaway</surname><given-names>P</given-names></name></person-group><article-title>TILs show early efficacy</article-title><source>Nat Rev Clin Oncol</source><year>2021</year><volume>18</volume><issue>10</issue><fpage>603</fpage><pub-id pub-id-type="doi">10.1038/s41571-021-00555-4</pub-id><pub-id pub-id-type="pmid">34453131</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Sidaway P. TILs show early efficacy. Nat Rev Clin Oncol. 2021;18(10):603.<pub-id pub-id-type="pmid">34453131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-021-00555-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brummel</surname><given-names>K</given-names></name><name name-style="western"><surname>Eerkens</surname><given-names>AL</given-names></name><name name-style="western"><surname>de Bruyn</surname><given-names>M</given-names></name><name name-style="western"><surname>Nijman</surname><given-names>HW</given-names></name></person-group><article-title>Tumour-infiltrating lymphocytes: from prognosis to treatment selection</article-title><source>Br J Cancer</source><year>2023</year><volume>128</volume><issue>3</issue><fpage>451</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1038/s41416-022-02119-4</pub-id><pub-id pub-id-type="pmid">36564565</pub-id><pub-id pub-id-type="pmcid">PMC9938191</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Brummel K, Eerkens AL, de Bruyn M, Nijman HW. Tumour-infiltrating lymphocytes: from prognosis to treatment selection. Br J Cancer. 2023;128(3):451&#8211;8.<pub-id pub-id-type="pmid">36564565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-022-02119-4</pub-id><pub-id pub-id-type="pmcid">PMC9938191</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paijens</surname><given-names>ST</given-names></name><name name-style="western"><surname>Vledder</surname><given-names>A</given-names></name><name name-style="western"><surname>de Bruyn</surname><given-names>M</given-names></name><name name-style="western"><surname>Nijman</surname><given-names>HW</given-names></name></person-group><article-title>Tumor-infiltrating lymphocytes in the immunotherapy era</article-title><source>Cell Mol Immunol</source><year>2021</year><volume>18</volume><issue>4</issue><fpage>842</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-00565-9</pub-id><pub-id pub-id-type="pmid">33139907</pub-id><pub-id pub-id-type="pmcid">PMC8115290</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021;18(4):842&#8211;59.<pub-id pub-id-type="pmid">33139907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41423-020-00565-9</pub-id><pub-id pub-id-type="pmcid">PMC8115290</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>R</given-names></name><name name-style="western"><surname>Vilgelm</surname><given-names>AE</given-names></name></person-group><article-title>Cell therapy with TILs: training and taming T cells to fight cancer</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>690499</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.690499</pub-id><pub-id pub-id-type="pmid">34140957</pub-id><pub-id pub-id-type="pmcid">PMC8204054</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Kumar A, Watkins R, Vilgelm AE. Cell therapy with TILs: training and taming T cells to fight cancer. Front Immunol. 2021;12:690499.<pub-id pub-id-type="pmid">34140957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.690499</pub-id><pub-id pub-id-type="pmcid">PMC8204054</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quinn</surname><given-names>S</given-names></name><name name-style="western"><surname>Lenart</surname><given-names>N</given-names></name><name name-style="western"><surname>Dronzek</surname><given-names>V</given-names></name><name name-style="western"><surname>Scurti</surname><given-names>GM</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>NM</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>MI</given-names></name></person-group><article-title>Genetic modification of T cells for the immunotherapy of cancer</article-title><source>Vaccines (Basel)</source><year>2022</year><volume>10</volume><issue>3</issue><fpage>457</fpage><pub-id pub-id-type="doi">10.3390/vaccines10030457</pub-id><pub-id pub-id-type="pmid">35335089</pub-id><pub-id pub-id-type="pmcid">PMC8949949</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Quinn S, Lenart N, Dronzek V, Scurti GM, Hossain NM, Nishimura MI. Genetic modification of T cells for the immunotherapy of cancer. Vaccines (Basel). 2022;10(3):457.<pub-id pub-id-type="pmid">35335089</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines10030457</pub-id><pub-id pub-id-type="pmcid">PMC8949949</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>SA</given-names></name><name name-style="western"><surname>Restifo</surname><given-names>NP</given-names></name></person-group><article-title>Adoptive cell transfer as personalized immunotherapy for human cancer</article-title><source>Science</source><year>2015</year><volume>348</volume><issue>6230</issue><fpage>62</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1126/science.aaa4967</pub-id><pub-id pub-id-type="pmid">25838374</pub-id><pub-id pub-id-type="pmcid">PMC6295668</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62&#8211;8.<pub-id pub-id-type="pmid">25838374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aaa4967</pub-id><pub-id pub-id-type="pmcid">PMC6295668</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>June</surname><given-names>CH</given-names></name><name name-style="western"><surname>O'Connor</surname><given-names>RS</given-names></name><name name-style="western"><surname>Kawalekar</surname><given-names>OU</given-names></name><name name-style="western"><surname>Ghassemi</surname><given-names>S</given-names></name><name name-style="western"><surname>Milone</surname><given-names>MC</given-names></name></person-group><article-title>CAR T cell immunotherapy for human cancer</article-title><source>Science</source><year>2018</year><volume>359</volume><issue>6382</issue><fpage>1361</fpage><lpage>1365</lpage><pub-id pub-id-type="doi">10.1126/science.aar6711</pub-id><pub-id pub-id-type="pmid">29567707</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">June CH, O&#8217;Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361&#8211;5.<pub-id pub-id-type="pmid">29567707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aar6711</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robbins</surname><given-names>PF</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>RA</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>SA</given-names></name><name name-style="western"><surname>Yang</surname><given-names>JC</given-names></name><name name-style="western"><surname>Sherry</surname><given-names>RM</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><issue>7</issue><fpage>917</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.32.2537</pub-id><pub-id pub-id-type="pmid">21282551</pub-id><pub-id pub-id-type="pmcid">PMC3068063</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917&#8211;24.<pub-id pub-id-type="pmid">21282551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2010.32.2537</pub-id><pub-id pub-id-type="pmcid">PMC3068063</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>RA</given-names></name><name name-style="western"><surname>Chinnasamy</surname><given-names>N</given-names></name><name name-style="western"><surname>Abate-Daga</surname><given-names>D</given-names></name><name name-style="western"><surname>Gros</surname><given-names>A</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>PF</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy</article-title><source>J Immunother</source><year>2013</year><volume>36</volume><issue>2</issue><fpage>133</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e3182829903</pub-id><pub-id pub-id-type="pmid">23377668</pub-id><pub-id pub-id-type="pmcid">PMC3581823</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36(2):133&#8211;51.<pub-id pub-id-type="pmid">23377668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CJI.0b013e3182829903</pub-id><pub-id pub-id-type="pmcid">PMC3581823</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parkhurst</surname><given-names>MR</given-names></name><name name-style="western"><surname>Yang</surname><given-names>JC</given-names></name><name name-style="western"><surname>Langan</surname><given-names>RC</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>ME</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>DA</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>SA</given-names></name><etal/></person-group><article-title>T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis</article-title><source>Mol Ther</source><year>2011</year><volume>19</volume><issue>3</issue><fpage>620</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1038/mt.2010.272</pub-id><pub-id pub-id-type="pmid">21157437</pub-id><pub-id pub-id-type="pmcid">PMC3048186</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19(3):620&#8211;6.<pub-id pub-id-type="pmid">21157437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2010.272</pub-id><pub-id pub-id-type="pmcid">PMC3048186</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Berg</surname><given-names>JH</given-names></name><name name-style="western"><surname>Gomez-Eerland</surname><given-names>R</given-names></name><name name-style="western"><surname>van de Wiel</surname><given-names>B</given-names></name><name name-style="western"><surname>Hulshoff</surname><given-names>L</given-names></name><name name-style="western"><surname>van den Broek</surname><given-names>D</given-names></name><name name-style="western"><surname>Bins</surname><given-names>A</given-names></name><etal/></person-group><article-title>Case report of a fatal serious adverse event upon administration of T cells transduced with a MART-1-specific T-cell receptor</article-title><source>Mol Ther</source><year>2015</year><volume>23</volume><issue>9</issue><fpage>1541</fpage><lpage>1550</lpage><pub-id pub-id-type="doi">10.1038/mt.2015.60</pub-id><pub-id pub-id-type="pmid">25896248</pub-id><pub-id pub-id-type="pmcid">PMC4817886</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">van den Berg JH, Gomez-Eerland R, van de Wiel B, Hulshoff L, van den Broek D, Bins A, et al. Case report of a fatal serious adverse event upon administration of T cells transduced with a MART-1-specific T-cell receptor. Mol Ther. 2015;23(9):1541&#8211;50.<pub-id pub-id-type="pmid">25896248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2015.60</pub-id><pub-id pub-id-type="pmcid">PMC4817886</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linette</surname><given-names>GP</given-names></name><name name-style="western"><surname>Stadtmauer</surname><given-names>EA</given-names></name><name name-style="western"><surname>Maus</surname><given-names>MV</given-names></name><name name-style="western"><surname>Rapoport</surname><given-names>AP</given-names></name><name name-style="western"><surname>Levine</surname><given-names>BL</given-names></name><name name-style="western"><surname>Emery</surname><given-names>L</given-names></name><etal/></person-group><article-title>Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma</article-title><source>Blood</source><year>2013</year><volume>122</volume><issue>6</issue><fpage>863</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-03-490565</pub-id><pub-id pub-id-type="pmid">23770775</pub-id><pub-id pub-id-type="pmcid">PMC3743463</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863&#8211;71.<pub-id pub-id-type="pmid">23770775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2013-03-490565</pub-id><pub-id pub-id-type="pmcid">PMC3743463</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leko</surname><given-names>V</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Identifying and targeting human tumor antigens for T Cell-Based immunotherapy of solid tumors</article-title><source>Cancer Cell</source><year>2020</year><volume>38</volume><issue>4</issue><fpage>454</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2020.07.013</pub-id><pub-id pub-id-type="pmid">32822573</pub-id><pub-id pub-id-type="pmcid">PMC7737225</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Leko V, Rosenberg SA. Identifying and targeting human tumor antigens for T Cell-Based immunotherapy of solid tumors. Cancer Cell. 2020;38(4):454&#8211;72.<pub-id pub-id-type="pmid">32822573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2020.07.013</pub-id><pub-id pub-id-type="pmcid">PMC7737225</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>ZL</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YY</given-names></name></person-group><article-title>CARs: synthetic immunoreceptors for cancer therapy and beyond</article-title><source>Trends Mol Med</source><year>2017</year><volume>23</volume><issue>5</issue><fpage>430</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2017.03.002</pub-id><pub-id pub-id-type="pmid">28416139</pub-id><pub-id pub-id-type="pmcid">PMC5423782</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Chang ZL, Chen YY. CARs: synthetic immunoreceptors for cancer therapy and beyond. Trends Mol Med. 2017;23(5):430&#8211;50.<pub-id pub-id-type="pmid">28416139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2017.03.002</pub-id><pub-id pub-id-type="pmcid">PMC5423782</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruella</surname><given-names>M</given-names></name><name name-style="western"><surname>June</surname><given-names>CH</given-names></name></person-group><article-title>chimeric antigen receptor T cells for B cell neoplasms: choose the right CAR for You</article-title><source>Curr Hematol Malig Rep</source><year>2016</year><volume>11</volume><issue>5</issue><fpage>368</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1007/s11899-016-0336-z</pub-id><pub-id pub-id-type="pmid">27475429</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Ruella M, June CH. chimeric antigen receptor T cells for B cell neoplasms: choose the right CAR for You. Curr Hematol Malig Rep. 2016;11(5):368&#8211;84.<pub-id pub-id-type="pmid">27475429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11899-016-0336-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbott</surname><given-names>RC</given-names></name><name name-style="western"><surname>Cross</surname><given-names>RS</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>MR</given-names></name></person-group><article-title>Finding the Keys to the CAR: identifying novel target antigens for T cell redirection immunotherapies</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><issue>2</issue><fpage>515</fpage><pub-id pub-id-type="doi">10.3390/ijms21020515</pub-id><pub-id pub-id-type="pmid">31947597</pub-id><pub-id pub-id-type="pmcid">PMC7014258</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Abbott RC, Cross RS, Jenkins MR. Finding the Keys to the CAR: identifying novel target antigens for T cell redirection immunotherapies. Int J Mol Sci. 2020;21(2):515.<pub-id pub-id-type="pmid">31947597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21020515</pub-id><pub-id pub-id-type="pmcid">PMC7014258</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gumber</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LD</given-names></name></person-group><article-title>Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion</article-title><source>EBioMedicine</source><year>2022</year><volume>77</volume><fpage>103941</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2022.103941</pub-id><pub-id pub-id-type="pmid">35301179</pub-id><pub-id pub-id-type="pmcid">PMC8927848</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Gumber D, Wang LD. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion. EBioMedicine. 2022;77:103941.<pub-id pub-id-type="pmid">35301179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2022.103941</pub-id><pub-id pub-id-type="pmcid">PMC8927848</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Cantillo</surname><given-names>G</given-names></name><name name-style="western"><surname>Uruena</surname><given-names>C</given-names></name><name name-style="western"><surname>Camacho</surname><given-names>BA</given-names></name><name name-style="western"><surname>Ramirez-Segura</surname><given-names>C</given-names></name></person-group><article-title>CAR-T cell performance: how to improve their persistence?</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>878209</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.878209</pub-id><pub-id pub-id-type="pmid">35572525</pub-id><pub-id pub-id-type="pmcid">PMC9097681</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Lopez-Cantillo G, Uruena C, Camacho BA, Ramirez-Segura C. CAR-T cell performance: how to improve their persistence? Front Immunol. 2022;13:878209.<pub-id pub-id-type="pmid">35572525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.878209</pub-id><pub-id pub-id-type="pmcid">PMC9097681</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zahavi</surname><given-names>D</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>L</given-names></name></person-group><article-title>Monoclonal antibodies in cancer therapy</article-title><source>Antibodies (Basel)</source><year>2020</year><volume>9</volume><issue>3</issue><fpage>34</fpage><pub-id pub-id-type="doi">10.3390/antib9030034</pub-id><pub-id pub-id-type="pmid">32698317</pub-id><pub-id pub-id-type="pmcid">PMC7551545</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies (Basel). 2020;9(3):34.<pub-id pub-id-type="pmid">32698317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antib9030034</pub-id><pub-id pub-id-type="pmcid">PMC7551545</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>M</given-names></name><name name-style="western"><surname>Thangavel</surname><given-names>C</given-names></name><name name-style="western"><surname>Becker</surname><given-names>RC</given-names></name><name name-style="western"><surname>Sadayappan</surname><given-names>S</given-names></name></person-group><article-title>Monoclonal antibody-based immunotherapy and its role in the development of cardiac toxicity</article-title><source>Cancers (Basel)</source><year>2020</year><volume>13</volume><issue>1</issue><fpage>86</fpage><pub-id pub-id-type="doi">10.3390/cancers13010086</pub-id><pub-id pub-id-type="pmid">33396766</pub-id><pub-id pub-id-type="pmcid">PMC7795565</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Kumar M, Thangavel C, Becker RC, Sadayappan S. Monoclonal antibody-based immunotherapy and its role in the development of cardiac toxicity. Cancers (Basel). 2020;13(1):86.<pub-id pub-id-type="pmid">33396766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13010086</pub-id><pub-id pub-id-type="pmcid">PMC7795565</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsao</surname><given-names>LC</given-names></name><name name-style="western"><surname>Force</surname><given-names>J</given-names></name><name name-style="western"><surname>Hartman</surname><given-names>ZC</given-names></name></person-group><article-title>Mechanisms of therapeutic antitumor monoclonal antibodies</article-title><source>Cancer Res</source><year>2021</year><volume>81</volume><issue>18</issue><fpage>4641</fpage><lpage>4651</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-21-1109</pub-id><pub-id pub-id-type="pmid">34145037</pub-id><pub-id pub-id-type="pmcid">PMC8448950</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Tsao LC, Force J, Hartman ZC. Mechanisms of therapeutic antitumor monoclonal antibodies. Cancer Res. 2021;81(18):4641&#8211;51.<pub-id pub-id-type="pmid">34145037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-21-1109</pub-id><pub-id pub-id-type="pmcid">PMC8448950</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tibes</surname><given-names>R</given-names></name><name name-style="western"><surname>Keating</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Ferrajoli</surname><given-names>A</given-names></name><name name-style="western"><surname>Wierda</surname><given-names>W</given-names></name><name name-style="western"><surname>Ravandi</surname><given-names>F</given-names></name><name name-style="western"><surname>Garcia-Manero</surname><given-names>G</given-names></name><etal/></person-group><article-title>Activity of alemtuzumab in patients with CD52-positive acute leukemia</article-title><source>Cancer</source><year>2006</year><volume>106</volume><issue>12</issue><fpage>2645</fpage><lpage>2651</lpage><pub-id pub-id-type="doi">10.1002/cncr.21901</pub-id><pub-id pub-id-type="pmid">16688777</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006;106(12):2645&#8211;51.<pub-id pub-id-type="pmid">16688777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.21901</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaddepally</surname><given-names>RK</given-names></name><name name-style="western"><surname>Kharel</surname><given-names>P</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>R</given-names></name><name name-style="western"><surname>Garje</surname><given-names>R</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>AB</given-names></name></person-group><article-title>Review of indications of FDA-approved immune checkpoint inhibitors per NCCN Guidelines with the level of evidence</article-title><source>Cancers (Basel)</source><year>2020</year><volume>12</volume><issue>3</issue><fpage>738</fpage><pub-id pub-id-type="doi">10.3390/cancers12030738</pub-id><pub-id pub-id-type="pmid">32245016</pub-id><pub-id pub-id-type="pmcid">PMC7140028</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN Guidelines with the level of evidence. Cancers (Basel). 2020;12(3):738.<pub-id pub-id-type="pmid">32245016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers12030738</pub-id><pub-id pub-id-type="pmcid">PMC7140028</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pettinato</surname><given-names>MC</given-names></name></person-group><article-title>Introduction to antibody-drug conjugates</article-title><source>Antibodies (Basel)</source><year>2021</year><volume>10</volume><issue>4</issue><fpage>42</fpage><pub-id pub-id-type="doi">10.3390/antib10040042</pub-id><pub-id pub-id-type="pmid">34842621</pub-id><pub-id pub-id-type="pmcid">PMC8628511</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Pettinato MC. Introduction to antibody-drug conjugates. Antibodies (Basel). 2021;10(4):42.<pub-id pub-id-type="pmid">34842621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antib10040042</pub-id><pub-id pub-id-type="pmcid">PMC8628511</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>JM</given-names></name><name name-style="western"><surname>Morris</surname><given-names>CQ</given-names></name></person-group><article-title>Antibody-Drug Conjugates (ADCs) for personalized treatment of solid tumors: a review</article-title><source>Adv Ther</source><year>2017</year><volume>34</volume><issue>5</issue><fpage>1015</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.1007/s12325-017-0519-6</pub-id><pub-id pub-id-type="pmid">28361465</pub-id><pub-id pub-id-type="pmcid">PMC5427099</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Lambert JM, Morris CQ. Antibody-Drug Conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther. 2017;34(5):1015&#8211;35.<pub-id pub-id-type="pmid">28361465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12325-017-0519-6</pub-id><pub-id pub-id-type="pmcid">PMC5427099</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Schladetsch</surname><given-names>MA</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Balunas</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Wiemer</surname><given-names>AJ</given-names></name></person-group><article-title>Stepping forward in antibody-drug conjugate development</article-title><source>Pharmacol Ther</source><year>2022</year><volume>229</volume><fpage>107917</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2021.107917</pub-id><pub-id pub-id-type="pmid">34171334</pub-id><pub-id pub-id-type="pmcid">PMC8702582</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Jin Y, Schladetsch MA, Huang X, Balunas MJ, Wiemer AJ. Stepping forward in antibody-drug conjugate development. Pharmacol Ther. 2022;229:107917.<pub-id pub-id-type="pmid">34171334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2021.107917</pub-id><pub-id pub-id-type="pmcid">PMC8702582</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalim</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C</given-names></name><name name-style="western"><surname>Ullah</surname><given-names>S</given-names></name><name name-style="western"><surname>Liang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates</article-title><source>Drug Des Devel Ther</source><year>2017</year><volume>11</volume><fpage>2265</fpage><lpage>2276</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S135571</pub-id><pub-id pub-id-type="pmid">28814834</pub-id><pub-id pub-id-type="pmcid">PMC5546728</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Kalim M, Chen J, Wang S, Lin C, Ullah S, Liang K, et al. Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates. Drug Des Devel Ther. 2017;11:2265&#8211;76.<pub-id pub-id-type="pmid">28814834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S135571</pub-id><pub-id pub-id-type="pmcid">PMC5546728</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birrer</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Moore</surname><given-names>KN</given-names></name><name name-style="western"><surname>Betella</surname><given-names>I</given-names></name><name name-style="western"><surname>Bates</surname><given-names>RC</given-names></name></person-group><article-title>Antibody-drug conjugate-based therapeutics: state of the science</article-title><source>J Natl Cancer Inst</source><year>2019</year><volume>111</volume><issue>6</issue><fpage>538</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1093/jnci/djz035</pub-id><pub-id pub-id-type="pmid">30859213</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst. 2019;111(6):538&#8211;49.<pub-id pub-id-type="pmid">30859213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djz035</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Natsume</surname><given-names>A</given-names></name><name name-style="western"><surname>Niwa</surname><given-names>R</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>M</given-names></name></person-group><article-title>Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC</article-title><source>Drug Des Devel Ther</source><year>2009</year><volume>3</volume><fpage>7</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">19920917</pub-id><pub-id pub-id-type="pmcid">PMC2769226</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Natsume A, Niwa R, Satoh M. Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. Drug Des Devel Ther. 2009;3:7&#8211;16.<pub-id pub-id-type="pmid">19920917</pub-id><pub-id pub-id-type="pmcid">PMC2769226</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parakh</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>ST</given-names></name><name name-style="western"><surname>Gan</surname><given-names>HK</given-names></name><name name-style="western"><surname>Scott</surname><given-names>AM</given-names></name></person-group><article-title>Radiolabeled antibodies for cancer imaging and therapy</article-title><source>Cancers (Basel)</source><year>2022</year><volume>14</volume><issue>6</issue><fpage>1454</fpage><pub-id pub-id-type="doi">10.3390/cancers14061454</pub-id><pub-id pub-id-type="pmid">35326605</pub-id><pub-id pub-id-type="pmcid">PMC8946248</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Parakh S, Lee ST, Gan HK, Scott AM. Radiolabeled antibodies for cancer imaging and therapy. Cancers (Basel). 2022;14(6):1454.<pub-id pub-id-type="pmid">35326605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14061454</pub-id><pub-id pub-id-type="pmcid">PMC8946248</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gill</surname><given-names>MR</given-names></name><name name-style="western"><surname>Falzone</surname><given-names>N</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Vallis</surname><given-names>KA</given-names></name></person-group><article-title>Targeted radionuclide therapy in combined-modality regimens</article-title><source>Lancet Oncol</source><year>2017</year><volume>18</volume><issue>7</issue><fpage>e414</fpage><lpage>e423</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(17)30379-0</pub-id><pub-id pub-id-type="pmid">28677577</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Gill MR, Falzone N, Du Y, Vallis KA. Targeted radionuclide therapy in combined-modality regimens. Lancet Oncol. 2017;18(7):e414&#8211;23.<pub-id pub-id-type="pmid">28677577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(17)30379-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Mo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>M</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><etal/></person-group><article-title>Bispecific antibodies: from research to clinical application</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>626616</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.626616</pub-id><pub-id pub-id-type="pmid">34025638</pub-id><pub-id pub-id-type="pmcid">PMC8131538</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Ma J, Mo Y, Tang M, Shen J, Qi Y, Zhao W, et al. Bispecific antibodies: from research to clinical application. Front Immunol. 2021;12:626616.<pub-id pub-id-type="pmid">34025638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.626616</pub-id><pub-id pub-id-type="pmcid">PMC8131538</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Bispecific antibodies in cancer therapy: Target selection and regulatory requirements</article-title><source>Acta Pharm Sin B</source><year>2023</year><volume>13</volume><issue>9</issue><fpage>3583</fpage><lpage>3597</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.05.023</pub-id><pub-id pub-id-type="pmid">37719370</pub-id><pub-id pub-id-type="pmcid">PMC10501874</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Sun Y, Yu X, Wang X, Yuan K, Wang G, Hu L, et al. Bispecific antibodies in cancer therapy: Target selection and regulatory requirements. Acta Pharm Sin B. 2023;13(9):3583&#8211;97.<pub-id pub-id-type="pmid">37719370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2023.05.023</pub-id><pub-id pub-id-type="pmcid">PMC10501874</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosseini</surname><given-names>SS</given-names></name><name name-style="western"><surname>Khalili</surname><given-names>S</given-names></name><name name-style="western"><surname>Baradaran</surname><given-names>B</given-names></name><name name-style="western"><surname>Bidar</surname><given-names>N</given-names></name><name name-style="western"><surname>Shahbazi</surname><given-names>MA</given-names></name><name name-style="western"><surname>Mosafer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials</article-title><source>Int J Biol Macromol</source><year>2021</year><volume>167</volume><fpage>1030</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.11.058</pub-id><pub-id pub-id-type="pmid">33197478</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Hosseini SS, Khalili S, Baradaran B, Bidar N, Shahbazi MA, Mosafer J, et al. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials. Int J Biol Macromol. 2021;167:1030&#8211;47.<pub-id pub-id-type="pmid">33197478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2020.11.058</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishnamurthy</surname><given-names>A</given-names></name><name name-style="western"><surname>Jimeno</surname><given-names>A</given-names></name></person-group><article-title>Bispecific antibodies for cancer therapy: a review</article-title><source>Pharmacol Ther</source><year>2018</year><volume>185</volume><fpage>122</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2017.12.002</pub-id><pub-id pub-id-type="pmid">29269044</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Krishnamurthy A, Jimeno A. Bispecific antibodies for cancer therapy: a review. Pharmacol Ther. 2018;185:122&#8211;34.<pub-id pub-id-type="pmid">29269044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2017.12.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chames</surname><given-names>P</given-names></name><name name-style="western"><surname>Van Regenmortel</surname><given-names>M</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>E</given-names></name><name name-style="western"><surname>Baty</surname><given-names>D</given-names></name></person-group><article-title>Therapeutic antibodies: successes, limitations and hopes for the future</article-title><source>Br J Pharmacol</source><year>2009</year><volume>157</volume><issue>2</issue><fpage>220</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00190.x</pub-id><pub-id pub-id-type="pmid">19459844</pub-id><pub-id pub-id-type="pmcid">PMC2697811</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157(2):220&#8211;33.<pub-id pub-id-type="pmid">19459844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1476-5381.2009.00190.x</pub-id><pub-id pub-id-type="pmcid">PMC2697811</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohan</surname><given-names>N</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Dokmanovic</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>WJ</given-names></name></person-group><article-title>Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers</article-title><source>Antib Ther</source><year>2018</year><volume>1</volume><issue>1</issue><fpage>13</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">30215054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/abt/tby003</pub-id><pub-id pub-id-type="pmcid">PMC6131716</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Mohan N, Jiang J, Dokmanovic M, Wu WJ. Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers. Antib Ther. 2018;1(1):13&#8211;7.<pub-id pub-id-type="pmid">30215054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/abt/tby003</pub-id><pub-id pub-id-type="pmcid">PMC6131716</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Kroetz</surname><given-names>DL</given-names></name></person-group><article-title>Bevacizumab-induced hypertension: Clinical presentation and molecular understanding</article-title><source>Pharmacol Ther</source><year>2018</year><volume>182</volume><fpage>152</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2017.08.012</pub-id><pub-id pub-id-type="pmid">28882537</pub-id><pub-id pub-id-type="pmcid">PMC5785435</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Li M, Kroetz DL. Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther. 2018;182:152&#8211;60.<pub-id pub-id-type="pmid">28882537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2017.08.012</pub-id><pub-id pub-id-type="pmcid">PMC5785435</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayenga</surname><given-names>M</given-names></name><name name-style="western"><surname>Falvo</surname><given-names>N</given-names></name><name name-style="western"><surname>Mahe</surname><given-names>I</given-names></name><name name-style="western"><surname>Jannot</surname><given-names>AS</given-names></name><name name-style="western"><surname>Gazeau</surname><given-names>B</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>G</given-names></name><etal/></person-group><article-title>Cancer-associated thrombosis on bevacizumab: risk of recurrence and bleeding when bevacizumab is stopped or continued</article-title><source>Cancers (Basel)</source><year>2023</year><volume>15</volume><issue>15</issue><fpage>3893</fpage><pub-id pub-id-type="doi">10.3390/cancers15153893</pub-id><pub-id pub-id-type="pmid">37568708</pub-id><pub-id pub-id-type="pmcid">PMC10417508</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Mayenga M, Falvo N, Mahe I, Jannot AS, Gazeau B, Meyer G, et al. Cancer-associated thrombosis on bevacizumab: risk of recurrence and bleeding when bevacizumab is stopped or continued. Cancers (Basel). 2023;15(15):3893.<pub-id pub-id-type="pmid">37568708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15153893</pub-id><pub-id pub-id-type="pmcid">PMC10417508</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hollingsworth</surname><given-names>RE</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>K</given-names></name></person-group><article-title>Turning the corner on therapeutic cancer vaccines</article-title><source>NPJ Vaccines</source><year>2019</year><volume>4</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1038/s41541-019-0103-y</pub-id><pub-id pub-id-type="pmid">30774998</pub-id><pub-id pub-id-type="pmcid">PMC6368616</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4:7.<pub-id pub-id-type="pmid">30774998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-019-0103-y</pub-id><pub-id pub-id-type="pmcid">PMC6368616</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>N</given-names></name><name name-style="western"><surname>Shen</surname><given-names>G</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name><name name-style="western"><surname>Fu</surname><given-names>L</given-names></name></person-group><article-title>Neoantigens: promising targets for cancer therapy</article-title><source>Signal Transduct Target Ther</source><year>2023</year><volume>8</volume><issue>1</issue><fpage>9</fpage><pub-id pub-id-type="doi">10.1038/s41392-022-01270-x</pub-id><pub-id pub-id-type="pmid">36604431</pub-id><pub-id pub-id-type="pmcid">PMC9816309</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023;8(1):9.<pub-id pub-id-type="pmid">36604431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-022-01270-x</pub-id><pub-id pub-id-type="pmcid">PMC9816309</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saxena</surname><given-names>M</given-names></name><name name-style="western"><surname>van der Burg</surname><given-names>SH</given-names></name><name name-style="western"><surname>Melief</surname><given-names>CJM</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>N</given-names></name></person-group><article-title>Therapeutic cancer vaccines</article-title><source>Nat Rev Cancer</source><year>2021</year><volume>21</volume><issue>6</issue><fpage>360</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1038/s41568-021-00346-0</pub-id><pub-id pub-id-type="pmid">33907315</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21(6):360&#8211;78.<pub-id pub-id-type="pmid">33907315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-021-00346-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>I</given-names></name><name name-style="western"><surname>Dhandayuthapani</surname><given-names>S</given-names></name><name name-style="western"><surname>Chacon</surname><given-names>J</given-names></name><name name-style="western"><surname>Eiring</surname><given-names>AM</given-names></name><name name-style="western"><surname>Gadad</surname><given-names>SS</given-names></name></person-group><article-title>Harnessing the immune system with cancer vaccines: from prevention to therapeutics</article-title><source>Vaccines (Basel)</source><year>2022</year><volume>10</volume><issue>5</issue><fpage>816</fpage><pub-id pub-id-type="doi">10.3390/vaccines10050816</pub-id><pub-id pub-id-type="pmid">35632572</pub-id><pub-id pub-id-type="pmcid">PMC9146235</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Le I, Dhandayuthapani S, Chacon J, Eiring AM, Gadad SS. Harnessing the immune system with cancer vaccines: from prevention to therapeutics. Vaccines (Basel). 2022;10(5):816.<pub-id pub-id-type="pmid">35632572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines10050816</pub-id><pub-id pub-id-type="pmcid">PMC9146235</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farkona</surname><given-names>S</given-names></name><name name-style="western"><surname>Diamandis</surname><given-names>EP</given-names></name><name name-style="western"><surname>Blasutig</surname><given-names>IM</given-names></name></person-group><article-title>Cancer immunotherapy: the beginning of the end of cancer?</article-title><source>BMC Med</source><year>2016</year><volume>14</volume><fpage>73</fpage><pub-id pub-id-type="doi">10.1186/s12916-016-0623-5</pub-id><pub-id pub-id-type="pmid">27151159</pub-id><pub-id pub-id-type="pmcid">PMC4858828</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73.<pub-id pub-id-type="pmid">27151159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-016-0623-5</pub-id><pub-id pub-id-type="pmcid">PMC4858828</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melief</surname><given-names>CJ</given-names></name><name name-style="western"><surname>van der Burg</surname><given-names>SH</given-names></name></person-group><article-title>Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines</article-title><source>Nat Rev Cancer</source><year>2008</year><volume>8</volume><issue>5</issue><fpage>351</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1038/nrc2373</pub-id><pub-id pub-id-type="pmid">18418403</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8(5):351&#8211;60.<pub-id pub-id-type="pmid">18418403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc2373</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeestraten</surname><given-names>EC</given-names></name><name name-style="western"><surname>Speetjens</surname><given-names>FM</given-names></name><name name-style="western"><surname>Welters</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Saadatmand</surname><given-names>S</given-names></name><name name-style="western"><surname>Stynenbosch</surname><given-names>LF</given-names></name><name name-style="western"><surname>Jongen</surname><given-names>R</given-names></name><etal/></person-group><article-title>Addition of interferon-alpha to the p53-SLP(R) vaccine results in increased production of interferon-gamma in vaccinated colorectal cancer patients: a phase I/II clinical trial</article-title><source>Int J Cancer</source><year>2013</year><volume>132</volume><issue>7</issue><fpage>1581</fpage><lpage>1591</lpage><pub-id pub-id-type="doi">10.1002/ijc.27819</pub-id><pub-id pub-id-type="pmid">22948952</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Zeestraten EC, Speetjens FM, Welters MJ, Saadatmand S, Stynenbosch LF, Jongen R, et al. Addition of interferon-alpha to the p53-SLP(R) vaccine results in increased production of interferon-gamma in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int J Cancer. 2013;132(7):1581&#8211;91.<pub-id pub-id-type="pmid">22948952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.27819</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holtl</surname><given-names>L</given-names></name><name name-style="western"><surname>Zelle-Rieser</surname><given-names>C</given-names></name><name name-style="western"><surname>Gander</surname><given-names>H</given-names></name><name name-style="western"><surname>Papesh</surname><given-names>C</given-names></name><name name-style="western"><surname>Ramoner</surname><given-names>R</given-names></name><name name-style="western"><surname>Bartsch</surname><given-names>G</given-names></name><etal/></person-group><article-title>Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells</article-title><source>Clin Cancer Res</source><year>2002</year><volume>8</volume><issue>11</issue><fpage>3369</fpage><lpage>3376</lpage><pub-id pub-id-type="pmid">12429623</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Holtl L, Zelle-Rieser C, Gander H, Papesh C, Ramoner R, Bartsch G, et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res. 2002;8(11):3369&#8211;76.<pub-id pub-id-type="pmid">12429623</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>XX</given-names></name><name name-style="western"><surname>Fong</surname><given-names>L</given-names></name><name name-style="western"><surname>Small</surname><given-names>EJ</given-names></name></person-group><article-title>Prostate cancer immunotherapy with sipuleucel-T: current standards and future directions</article-title><source>Expert Rev Vaccines</source><year>2015</year><volume>14</volume><issue>12</issue><fpage>1529</fpage><lpage>1541</lpage><pub-id pub-id-type="doi">10.1586/14760584.2015.1099437</pub-id><pub-id pub-id-type="pmid">26488270</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Wei XX, Fong L, Small EJ. Prostate cancer immunotherapy with sipuleucel-T: current standards and future directions. Expert Rev Vaccines. 2015;14(12):1529&#8211;41.<pub-id pub-id-type="pmid">26488270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.2015.1099437</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filin</surname><given-names>IY</given-names></name><name name-style="western"><surname>Kitaeva</surname><given-names>KV</given-names></name><name name-style="western"><surname>Rutland</surname><given-names>CS</given-names></name><name name-style="western"><surname>Rizvanov</surname><given-names>AA</given-names></name><name name-style="western"><surname>Solovyeva</surname><given-names>VV</given-names></name></person-group><article-title>Recent advances in experimental dendritic cell vaccines for cancer</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><fpage>730824</fpage><pub-id pub-id-type="doi">10.3389/fonc.2021.730824</pub-id><pub-id pub-id-type="pmid">34631558</pub-id><pub-id pub-id-type="pmcid">PMC8495208</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Filin IY, Kitaeva KV, Rutland CS, Rizvanov AA, Solovyeva VV. Recent advances in experimental dendritic cell vaccines for cancer. Front Oncol. 2021;11:730824.<pub-id pub-id-type="pmid">34631558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2021.730824</pub-id><pub-id pub-id-type="pmcid">PMC8495208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jahanafrooz</surname><given-names>Z</given-names></name><name name-style="western"><surname>Baradaran</surname><given-names>B</given-names></name><name name-style="western"><surname>Mosafer</surname><given-names>J</given-names></name><name name-style="western"><surname>Hashemzaei</surname><given-names>M</given-names></name><name name-style="western"><surname>Rezaei</surname><given-names>T</given-names></name><name name-style="western"><surname>Mokhtarzadeh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comparison of DNA and mRNA vaccines against cancer</article-title><source>Drug Discov Today</source><year>2020</year><volume>25</volume><issue>3</issue><fpage>552</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2019.12.003</pub-id><pub-id pub-id-type="pmid">31843577</pub-id><pub-id pub-id-type="pmcid">PMC7080609</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Jahanafrooz Z, Baradaran B, Mosafer J, Hashemzaei M, Rezaei T, Mokhtarzadeh A, et al. Comparison of DNA and mRNA vaccines against cancer. Drug Discov Today. 2020;25(3):552&#8211;60.<pub-id pub-id-type="pmid">31843577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2019.12.003</pub-id><pub-id pub-id-type="pmcid">PMC7080609</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papaioannou</surname><given-names>NE</given-names></name><name name-style="western"><surname>Beniata</surname><given-names>OV</given-names></name><name name-style="western"><surname>Vitsos</surname><given-names>P</given-names></name><name name-style="western"><surname>Tsitsilonis</surname><given-names>O</given-names></name><name name-style="western"><surname>Samara</surname><given-names>P</given-names></name></person-group><article-title>Harnessing the immune system to improve cancer therapy</article-title><source>Ann Transl Med</source><year>2016</year><volume>4</volume><issue>14</issue><fpage>261</fpage><pub-id pub-id-type="doi">10.21037/atm.2016.04.01</pub-id><pub-id pub-id-type="pmid">27563648</pub-id><pub-id pub-id-type="pmcid">PMC4971375</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Papaioannou NE, Beniata OV, Vitsos P, Tsitsilonis O, Samara P. Harnessing the immune system to improve cancer therapy. Ann Transl Med. 2016;4(14):261.<pub-id pub-id-type="pmid">27563648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/atm.2016.04.01</pub-id><pub-id pub-id-type="pmcid">PMC4971375</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Youn</surname><given-names>JW</given-names></name><name name-style="western"><surname>Hur</surname><given-names>SY</given-names></name><name name-style="western"><surname>Woo</surname><given-names>JW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YM</given-names></name><name name-style="western"><surname>Lim</surname><given-names>MC</given-names></name><name name-style="western"><surname>Park</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial</article-title><source>Lancet Oncol</source><year>2020</year><volume>21</volume><issue>12</issue><fpage>1653</fpage><lpage>1660</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(20)30486-1</pub-id><pub-id pub-id-type="pmid">33271094</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Youn JW, Hur SY, Woo JW, Kim YM, Lim MC, Park SY, et al. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Lancet Oncol. 2020;21(12):1653&#8211;60.<pub-id pub-id-type="pmid">33271094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(20)30486-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Disis</surname><given-names>MLN</given-names></name><name name-style="western"><surname>Guthrie</surname><given-names>KA</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Coveler</surname><given-names>AL</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>DM</given-names></name><name name-style="western"><surname>Childs</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Safety and outcomes of a plasmid DNA vaccine encoding the ERBB2 intracellular domain in patients with advanced-stage ERBB2-positive breast cancer: a phase 1 nonrandomized clinical trial</article-title><source>JAMA Oncol</source><year>2023</year><volume>9</volume><issue>1</issue><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2022.5143</pub-id><pub-id pub-id-type="pmid">36326756</pub-id><pub-id pub-id-type="pmcid">PMC9634596</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Disis MLN, Guthrie KA, Liu Y, Coveler AL, Higgins DM, Childs JS, et al. Safety and outcomes of a plasmid DNA vaccine encoding the ERBB2 intracellular domain in patients with advanced-stage ERBB2-positive breast cancer: a phase 1 nonrandomized clinical trial. JAMA Oncol. 2023;9(1):71&#8211;8.<pub-id pub-id-type="pmid">36326756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2022.5143</pub-id><pub-id pub-id-type="pmcid">PMC9634596</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopes</surname><given-names>A</given-names></name><name name-style="western"><surname>Vandermeulen</surname><given-names>G</given-names></name><name name-style="western"><surname>Preat</surname><given-names>V</given-names></name></person-group><article-title>Cancer DNA vaccines: current preclinical and clinical developments and future perspectives</article-title><source>J Exp Clin Cancer Res</source><year>2019</year><volume>38</volume><issue>1</issue><fpage>146</fpage><pub-id pub-id-type="doi">10.1186/s13046-019-1154-7</pub-id><pub-id pub-id-type="pmid">30953535</pub-id><pub-id pub-id-type="pmcid">PMC6449928</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Lopes A, Vandermeulen G, Preat V. Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. J Exp Clin Cancer Res. 2019;38(1):146.<pub-id pub-id-type="pmid">30953535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-019-1154-7</pub-id><pub-id pub-id-type="pmcid">PMC6449928</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Pei</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name></person-group><article-title>Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1246682</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1246682</pub-id><pub-id pub-id-type="pmid">37744371</pub-id><pub-id pub-id-type="pmcid">PMC10511650</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Wang B, Pei J, Xu S, Liu J, Yu J. Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities. Front Immunol. 2023;14:1246682.<pub-id pub-id-type="pmid">37744371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1246682</pub-id><pub-id pub-id-type="pmcid">PMC10511650</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rojas</surname><given-names>LA</given-names></name><name name-style="western"><surname>Sethna</surname><given-names>Z</given-names></name><name name-style="western"><surname>Soares</surname><given-names>KC</given-names></name><name name-style="western"><surname>Olcese</surname><given-names>C</given-names></name><name name-style="western"><surname>Pang</surname><given-names>N</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>E</given-names></name><etal/></person-group><article-title>Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer</article-title><source>Nature</source><year>2023</year><volume>618</volume><issue>7963</issue><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06063-y</pub-id><pub-id pub-id-type="pmid">37165196</pub-id><pub-id pub-id-type="pmcid">PMC10171177</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144&#8211;50.<pub-id pub-id-type="pmid">37165196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06063-y</pub-id><pub-id pub-id-type="pmcid">PMC10171177</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name></person-group><article-title>Development and delivery systems of mRNA vaccines</article-title><source>Front Bioeng Biotechnol</source><year>2021</year><volume>9</volume><fpage>718753</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2021.718753</pub-id><pub-id pub-id-type="pmid">34386486</pub-id><pub-id pub-id-type="pmcid">PMC8354200</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Liu T, Liang Y, Huang L. Development and delivery systems of mRNA vaccines. Front Bioeng Biotechnol. 2021;9:718753.<pub-id pub-id-type="pmid">34386486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fbioe.2021.718753</pub-id><pub-id pub-id-type="pmcid">PMC8354200</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahman</surname><given-names>MM</given-names></name><name name-style="western"><surname>McFadden</surname><given-names>G</given-names></name></person-group><article-title>Oncolytic viruses: newest frontier for cancer immunotherapy</article-title><source>Cancers (Basel)</source><year>2021</year><volume>13</volume><issue>21</issue><fpage>5452</fpage><pub-id pub-id-type="doi">10.3390/cancers13215452</pub-id><pub-id pub-id-type="pmid">34771615</pub-id><pub-id pub-id-type="pmcid">PMC8582515</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Rahman MM, McFadden G. Oncolytic viruses: newest frontier for cancer immunotherapy. Cancers (Basel). 2021;13(21):5452.<pub-id pub-id-type="pmid">34771615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13215452</pub-id><pub-id pub-id-type="pmcid">PMC8582515</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R</given-names></name><name name-style="western"><surname>Samudio</surname><given-names>I</given-names></name><name name-style="western"><surname>Jia</surname><given-names>W</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X</given-names></name><etal/></person-group><article-title>Oncolytic virotherapy in hepato-bilio-pancreatic cancer: The key to breaking the log jam?</article-title><source>Cancer Med</source><year>2020</year><volume>9</volume><issue>9</issue><fpage>2943</fpage><lpage>2959</lpage><pub-id pub-id-type="doi">10.1002/cam4.2949</pub-id><pub-id pub-id-type="pmid">32130786</pub-id><pub-id pub-id-type="pmcid">PMC7196045</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Li Y, Shen Y, Zhao R, Samudio I, Jia W, Bai X, et al. Oncolytic virotherapy in hepato-bilio-pancreatic cancer: The key to breaking the log jam? Cancer Med. 2020;9(9):2943&#8211;59.<pub-id pub-id-type="pmid">32130786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.2949</pub-id><pub-id pub-id-type="pmcid">PMC7196045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>D</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liang</surname><given-names>T</given-names></name></person-group><article-title>Oncolytic virotherapy: basic principles, recent advances and future directions</article-title><source>Signal Transduct Target Ther</source><year>2023</year><volume>8</volume><issue>1</issue><fpage>156</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01407-6</pub-id><pub-id pub-id-type="pmid">37041165</pub-id><pub-id pub-id-type="pmcid">PMC10090134</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023;8(1):156.<pub-id pub-id-type="pmid">37041165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01407-6</pub-id><pub-id pub-id-type="pmcid">PMC10090134</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cema</surname><given-names>I</given-names></name><name name-style="western"><surname>Kleina</surname><given-names>R</given-names></name><name name-style="western"><surname>Donina</surname><given-names>S</given-names></name><name name-style="western"><surname>Isajevs</surname><given-names>S</given-names></name><name name-style="western"><surname>Zablocka</surname><given-names>T</given-names></name><name name-style="western"><surname>Rasa</surname><given-names>A</given-names></name><etal/></person-group><article-title>Stage IIA skin melanoma treatment with ECHO-7 oncolytic virus Rigvir</article-title><source>Perm J</source><year>2022</year><volume>26</volume><issue>3</issue><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.7812/TPP/21.232</pub-id><pub-id pub-id-type="pmid">35950985</pub-id><pub-id pub-id-type="pmcid">PMC9683754</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Cema I, Kleina R, Donina S, Isajevs S, Zablocka T, Rasa A, et al. Stage IIA skin melanoma treatment with ECHO-7 oncolytic virus Rigvir. Perm J. 2022;26(3):139&#8211;44.<pub-id pub-id-type="pmid">35950985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7812/TPP/21.232</pub-id><pub-id pub-id-type="pmcid">PMC9683754</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>D</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>XY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>ZN</given-names></name><name name-style="western"><surname>Bian</surname><given-names>H</given-names></name></person-group><article-title>Fighting cancer with viruses: oncolytic virus therapy in China</article-title><source>Hum Gene Ther</source><year>2018</year><volume>29</volume><issue>2</issue><fpage>151</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1089/hum.2017.212</pub-id><pub-id pub-id-type="pmid">29284308</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Wei D, Xu J, Liu XY, Chen ZN, Bian H. Fighting cancer with viruses: oncolytic virus therapy in China. Hum Gene Ther. 2018;29(2):151&#8211;9.<pub-id pub-id-type="pmid">29284308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/hum.2017.212</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andtbacka</surname><given-names>RH</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>HL</given-names></name><name name-style="western"><surname>Collichio</surname><given-names>F</given-names></name><name name-style="western"><surname>Amatruda</surname><given-names>T</given-names></name><name name-style="western"><surname>Senzer</surname><given-names>N</given-names></name><name name-style="western"><surname>Chesney</surname><given-names>J</given-names></name><etal/></person-group><article-title>Talimogene laherparepvec improves durable response rate in patients with advanced melanoma</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><issue>25</issue><fpage>2780</fpage><lpage>2788</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.58.3377</pub-id><pub-id pub-id-type="pmid">26014293</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780&#8211;8.<pub-id pub-id-type="pmid">26014293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2014.58.3377</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Todo</surname><given-names>T</given-names></name><name name-style="western"><surname>Ino</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ohtsu</surname><given-names>H</given-names></name><name name-style="western"><surname>Shibahara</surname><given-names>J</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>M</given-names></name></person-group><article-title>A phase I/II study of triple-mutated oncolytic herpes virus G47&#8710; in patients with progressive glioblastoma</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>4119</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-31262-y</pub-id><pub-id pub-id-type="pmid">35864115</pub-id><pub-id pub-id-type="pmcid">PMC9304402</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Todo T, Ino Y, Ohtsu H, Shibahara J, Tanaka M. A phase I/II study of triple-mutated oncolytic herpes virus G47&#8710; in patients with progressive glioblastoma. Nat Commun. 2022;13(1):4119.<pub-id pub-id-type="pmid">35864115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-31262-y</pub-id><pub-id pub-id-type="pmcid">PMC9304402</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ban</surname><given-names>W</given-names></name><name name-style="western"><surname>Guan</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>He</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sun</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Emerging systemic delivery strategies of oncolytic viruses: a key step toward cancer immunotherapy</article-title><source>Nano Res</source><year>2022</year><volume>15</volume><issue>5</issue><fpage>4137</fpage><lpage>4153</lpage><pub-id pub-id-type="doi">10.1007/s12274-021-4031-6</pub-id><pub-id pub-id-type="pmid">35194488</pub-id><pub-id pub-id-type="pmcid">PMC8852960</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Ban W, Guan J, Huang H, He Z, Sun M, Liu F, et al. Emerging systemic delivery strategies of oncolytic viruses: a key step toward cancer immunotherapy. Nano Res. 2022;15(5):4137&#8211;53.<pub-id pub-id-type="pmid">35194488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12274-021-4031-6</pub-id><pub-id pub-id-type="pmcid">PMC8852960</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno</surname><given-names>R</given-names></name></person-group><article-title>Mesenchymal stem cells and oncolytic viruses: joining forces against cancer</article-title><source>J Immunother Cancer</source><year>2021</year><volume>9</volume><issue>2</issue><fpage>e001684</fpage><pub-id pub-id-type="doi">10.1136/jitc-2020-001684</pub-id><pub-id pub-id-type="pmid">33558278</pub-id><pub-id pub-id-type="pmcid">PMC7871674</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Moreno R. Mesenchymal stem cells and oncolytic viruses: joining forces against cancer. J Immunother Cancer. 2021;9(2):e001684.<pub-id pub-id-type="pmid">33558278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2020-001684</pub-id><pub-id pub-id-type="pmcid">PMC7871674</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waldmann</surname><given-names>TA</given-names></name></person-group><article-title>Cytokines in Cancer Immunotherapy</article-title><source>Cold Spring Harb Perspect Biol</source><year>2018</year><volume>10</volume><issue>12</issue><fpage>a028472</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a028472</pub-id><pub-id pub-id-type="pmid">29101107</pub-id><pub-id pub-id-type="pmcid">PMC6280701</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Waldmann TA. Cytokines in Cancer Immunotherapy. Cold Spring Harb Perspect Biol. 2018;10(12):a028472.<pub-id pub-id-type="pmid">29101107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a028472</pub-id><pub-id pub-id-type="pmcid">PMC6280701</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jorgovanovic</surname><given-names>D</given-names></name><name name-style="western"><surname>Song</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Roles of IFN-gamma in tumor progression and regression: a review</article-title><source>Biomark Res</source><year>2020</year><volume>8</volume><fpage>49</fpage><pub-id pub-id-type="doi">10.1186/s40364-020-00228-x</pub-id><pub-id pub-id-type="pmid">33005420</pub-id><pub-id pub-id-type="pmcid">PMC7526126</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-gamma in tumor progression and regression: a review. Biomark Res. 2020;8:49.<pub-id pub-id-type="pmid">33005420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40364-020-00228-x</pub-id><pub-id pub-id-type="pmcid">PMC7526126</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>MA</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>LE</given-names></name><name name-style="western"><surname>Zajac</surname><given-names>AJ</given-names></name></person-group><article-title>Cytokines and the inception of CD8 T cell responses</article-title><source>Trends Immunol</source><year>2011</year><volume>32</volume><issue>4</issue><fpage>180</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.it.2011.01.004</pub-id><pub-id pub-id-type="pmid">21371940</pub-id><pub-id pub-id-type="pmcid">PMC3074938</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Cox MA, Harrington LE, Zajac AJ. Cytokines and the inception of CD8 T cell responses. Trends Immunol. 2011;32(4):180&#8211;6.<pub-id pub-id-type="pmid">21371940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.it.2011.01.004</pub-id><pub-id pub-id-type="pmcid">PMC3074938</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben-Sasson</surname><given-names>SZ</given-names></name><name name-style="western"><surname>Hu-Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Quiel</surname><given-names>J</given-names></name><name name-style="western"><surname>Cauchetaux</surname><given-names>S</given-names></name><name name-style="western"><surname>Ratner</surname><given-names>M</given-names></name><name name-style="western"><surname>Shapira</surname><given-names>I</given-names></name><etal/></person-group><article-title>IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><volume>106</volume><issue>17</issue><fpage>7119</fpage><lpage>7124</lpage><pub-id pub-id-type="doi">10.1073/pnas.0902745106</pub-id><pub-id pub-id-type="pmid">19359475</pub-id><pub-id pub-id-type="pmcid">PMC2678417</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Ben-Sasson SZ, Hu-Li J, Quiel J, Cauchetaux S, Ratner M, Shapira I, et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci U S A. 2009;106(17):7119&#8211;24.<pub-id pub-id-type="pmid">19359475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0902745106</pub-id><pub-id pub-id-type="pmcid">PMC2678417</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trinchieri</surname><given-names>G</given-names></name></person-group><article-title>Interleukin-12 and the regulation of innate resistance and adaptive immunity</article-title><source>Nat Rev Immunol</source><year>2003</year><volume>3</volume><issue>2</issue><fpage>133</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1038/nri1001</pub-id><pub-id pub-id-type="pmid">12563297</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3(2):133&#8211;46.<pub-id pub-id-type="pmid">12563297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri1001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>WL</given-names></name><name name-style="western"><surname>Shen</surname><given-names>KY</given-names></name><name name-style="western"><surname>Tien</surname><given-names>CY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YA</given-names></name><name name-style="western"><surname>Liu</surname><given-names>SJ</given-names></name></person-group><article-title>Recent progress in GM-CSF-based cancer immunotherapy</article-title><source>Immunotherapy</source><year>2017</year><volume>9</volume><issue>4</issue><fpage>347</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.2217/imt-2016-0141</pub-id><pub-id pub-id-type="pmid">28303764</pub-id></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Yan WL, Shen KY, Tien CY, Chen YA, Liu SJ. Recent progress in GM-CSF-based cancer immunotherapy. Immunotherapy. 2017;9(4):347&#8211;60.<pub-id pub-id-type="pmid">28303764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/imt-2016-0141</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>J</given-names></name><name name-style="western"><surname>Mielcarek</surname><given-names>M</given-names></name><name name-style="western"><surname>Torok-Storb</surname><given-names>B</given-names></name></person-group><article-title>Impaired induction of the CD28-responsive complex in granulocyte colony-stimulating factor mobilized CD4 T cells</article-title><source>Blood</source><year>1998</year><volume>91</volume><issue>1</issue><fpage>347</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1182/blood.V91.1.347</pub-id><pub-id pub-id-type="pmid">9414304</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Tanaka J, Mielcarek M, Torok-Storb B. Impaired induction of the CD28-responsive complex in granulocyte colony-stimulating factor mobilized CD4 T cells. Blood. 1998;91(1):347&#8211;52.<pub-id pub-id-type="pmid">9414304</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herzberg</surname><given-names>B</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>DE</given-names></name></person-group><article-title>Metastatic melanoma and immunotherapy</article-title><source>Clin Immunol</source><year>2016</year><volume>172</volume><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2016.07.006</pub-id><pub-id pub-id-type="pmid">27430520</pub-id><pub-id pub-id-type="pmcid">PMC5569887</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Herzberg B, Fisher DE. Metastatic melanoma and immunotherapy. Clin Immunol. 2016;172:105&#8211;10.<pub-id pub-id-type="pmid">27430520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clim.2016.07.006</pub-id><pub-id pub-id-type="pmcid">PMC5569887</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Im</surname><given-names>A</given-names></name><name name-style="western"><surname>Pavletic</surname><given-names>SZ</given-names></name></person-group><article-title>Immunotherapy in hematologic malignancies: past, present, and future</article-title><source>J Hematol Oncol</source><year>2017</year><volume>10</volume><issue>1</issue><fpage>94</fpage><pub-id pub-id-type="doi">10.1186/s13045-017-0453-8</pub-id><pub-id pub-id-type="pmid">28434396</pub-id><pub-id pub-id-type="pmcid">PMC5402171</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Im A, Pavletic SZ. Immunotherapy in hematologic malignancies: past, present, and future. J Hematol Oncol. 2017;10(1):94.<pub-id pub-id-type="pmid">28434396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-017-0453-8</pub-id><pub-id pub-id-type="pmcid">PMC5402171</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uhl</surname><given-names>M</given-names></name><name name-style="western"><surname>Aulwurm</surname><given-names>S</given-names></name><name name-style="western"><surname>Wischhusen</surname><given-names>J</given-names></name><name name-style="western"><surname>Weiler</surname><given-names>M</given-names></name><name name-style="western"><surname>Ma</surname><given-names>JY</given-names></name><name name-style="western"><surname>Almirez</surname><given-names>R</given-names></name><etal/></person-group><article-title>SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><issue>21</issue><fpage>7954</fpage><lpage>7961</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1013</pub-id><pub-id pub-id-type="pmid">15520202</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 2004;64(21):7954&#8211;61.<pub-id pub-id-type="pmid">15520202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-04-1013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>J</given-names></name><name name-style="western"><surname>Kanne</surname><given-names>DB</given-names></name><name name-style="western"><surname>Leong</surname><given-names>M</given-names></name><name name-style="western"><surname>Glickman</surname><given-names>LH</given-names></name><name name-style="western"><surname>McWhirter</surname><given-names>SM</given-names></name><name name-style="western"><surname>Lemmens</surname><given-names>E</given-names></name><etal/></person-group><article-title>STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade</article-title><source>Sci Transl Med</source><year>2015</year><volume>7</volume><issue>283</issue><fpage>283ra52</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aaa4306</pub-id><pub-id pub-id-type="pmid">25877890</pub-id><pub-id pub-id-type="pmcid">PMC4504692</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Fu J, Kanne DB, Leong M, Glickman LH, McWhirter SM, Lemmens E, et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med. 2015;7(283):283ra52.<pub-id pub-id-type="pmid">25877890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aaa4306</pub-id><pub-id pub-id-type="pmcid">PMC4504692</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Margolin</surname><given-names>K</given-names></name></person-group><article-title>Cytokines in cancer immunotherapy</article-title><source>Cancers (Basel)</source><year>2011</year><volume>3</volume><issue>4</issue><fpage>3856</fpage><lpage>3893</lpage><pub-id pub-id-type="doi">10.3390/cancers3043856</pub-id><pub-id pub-id-type="pmid">24213115</pub-id><pub-id pub-id-type="pmcid">PMC3763400</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel). 2011;3(4):3856&#8211;93.<pub-id pub-id-type="pmid">24213115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers3043856</pub-id><pub-id pub-id-type="pmcid">PMC3763400</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milling</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>DJ</given-names></name></person-group><article-title>Delivering safer immunotherapies for cancer</article-title><source>Adv Drug Deliv Rev</source><year>2017</year><volume>114</volume><fpage>79</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2017.05.011</pub-id><pub-id pub-id-type="pmid">28545888</pub-id><pub-id pub-id-type="pmcid">PMC5647831</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">Milling L, Zhang Y, Irvine DJ. Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev. 2017;114:79&#8211;101.<pub-id pub-id-type="pmid">28545888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2017.05.011</pub-id><pub-id pub-id-type="pmcid">PMC5647831</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>T</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Inhibition of tumor angiogenesis by interferon-gamma by suppression of tumor-associated macrophage differentiation</article-title><source>Oncol Res</source><year>2014</year><volume>21</volume><issue>5</issue><fpage>227</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.3727/096504014X13890370410285</pub-id><pub-id pub-id-type="pmid">24854099</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Sun T, Yang Y, Luo X, Cheng Y, Zhang M, Wang K, et al. Inhibition of tumor angiogenesis by interferon-gamma by suppression of tumor-associated macrophage differentiation. Oncol Res. 2014;21(5):227&#8211;35.<pub-id pub-id-type="pmid">24854099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3727/096504014X13890370410285</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joseph</surname><given-names>TM</given-names></name><name name-style="western"><surname>Kar Mahapatra</surname><given-names>D</given-names></name><name name-style="western"><surname>Esmaeili</surname><given-names>A</given-names></name><name name-style="western"><surname>Piszczyk</surname><given-names>L</given-names></name><name name-style="western"><surname>Hasanin</surname><given-names>MS</given-names></name><name name-style="western"><surname>Kattali</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nanoparticles: taking a unique position in medicine</article-title><source>Nanomaterials (Basel)</source><year>2023</year><volume>13</volume><issue>3</issue><fpage>574</fpage><pub-id pub-id-type="doi">10.3390/nano13030574</pub-id><pub-id pub-id-type="pmid">36770535</pub-id><pub-id pub-id-type="pmcid">PMC9920911</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Joseph TM, Kar Mahapatra D, Esmaeili A, Piszczyk L, Hasanin MS, Kattali M, et al. Nanoparticles: taking a unique position in medicine. Nanomaterials (Basel). 2023;13(3):574.<pub-id pub-id-type="pmid">36770535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nano13030574</pub-id><pub-id pub-id-type="pmcid">PMC9920911</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>R</given-names></name><name name-style="western"><surname>Lim</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>TW</given-names></name><etal/></person-group><article-title>Recent advances in the development of lipid-, metal-, carbon-, and polymer-based nanomaterials for antibacterial applications</article-title><source>Nanomaterials (Basel)</source><year>2022</year><volume>12</volume><issue>21</issue><fpage>3855</fpage><pub-id pub-id-type="doi">10.3390/nano12213855</pub-id><pub-id pub-id-type="pmid">36364631</pub-id><pub-id pub-id-type="pmcid">PMC9658259</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Ren R, Lim C, Li S, Wang Y, Song J, Lin TW, et al. Recent advances in the development of lipid-, metal-, carbon-, and polymer-based nanomaterials for antibacterial applications. Nanomaterials (Basel). 2022;12(21):3855.<pub-id pub-id-type="pmid">36364631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nano12213855</pub-id><pub-id pub-id-type="pmcid">PMC9658259</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandrakala</surname><given-names>V</given-names></name><name name-style="western"><surname>Aruna</surname><given-names>V</given-names></name><name name-style="western"><surname>Angajala</surname><given-names>G</given-names></name></person-group><article-title>Review on metal nanoparticles as nanocarriers: current challenges and perspectives in drug delivery systems</article-title><source>Emergent Mater</source><year>2022</year><volume>5</volume><issue>6</issue><fpage>1593</fpage><lpage>1615</lpage><pub-id pub-id-type="doi">10.1007/s42247-021-00335-x</pub-id><pub-id pub-id-type="pmid">35005431</pub-id><pub-id pub-id-type="pmcid">PMC8724657</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Chandrakala V, Aruna V, Angajala G. Review on metal nanoparticles as nanocarriers: current challenges and perspectives in drug delivery systems. Emergent Mater. 2022;5(6):1593&#8211;615.<pub-id pub-id-type="pmid">35005431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s42247-021-00335-x</pub-id><pub-id pub-id-type="pmcid">PMC8724657</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malik</surname><given-names>S</given-names></name><name name-style="western"><surname>Muhammad</surname><given-names>K</given-names></name><name name-style="western"><surname>Waheed</surname><given-names>Y</given-names></name></person-group><article-title>Emerging applications of nanotechnology in healthcare and medicine</article-title><source>Molecules</source><year>2023</year><volume>28</volume><issue>18</issue><fpage>6624</fpage><pub-id pub-id-type="doi">10.3390/molecules28186624</pub-id><pub-id pub-id-type="pmid">37764400</pub-id><pub-id pub-id-type="pmcid">PMC10536529</pub-id></element-citation><mixed-citation id="mc-CR125" publication-type="journal">Malik S, Muhammad K, Waheed Y. Emerging applications of nanotechnology in healthcare and medicine. Molecules. 2023;28(18):6624.<pub-id pub-id-type="pmid">37764400</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules28186624</pub-id><pub-id pub-id-type="pmcid">PMC10536529</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naser</surname><given-names>R</given-names></name><name name-style="western"><surname>Dilabazian</surname><given-names>H</given-names></name><name name-style="western"><surname>Bahr</surname><given-names>H</given-names></name><name name-style="western"><surname>Barakat</surname><given-names>A</given-names></name><name name-style="western"><surname>El-Sibai</surname><given-names>M</given-names></name></person-group><article-title>A guide through conventional and modern cancer treatment modalities: a specific focus on glioblastoma cancer therapy (Review)</article-title><source>Oncol Rep</source><year>2022</year><volume>48</volume><issue>5</issue><fpage>190</fpage><pub-id pub-id-type="doi">10.3892/or.2022.8405</pub-id><pub-id pub-id-type="pmid">36102321</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Naser R, Dilabazian H, Bahr H, Barakat A, El-Sibai M. A guide through conventional and modern cancer treatment modalities: a specific focus on glioblastoma cancer therapy (Review). Oncol Rep. 2022;48(5):190.<pub-id pub-id-type="pmid">36102321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2022.8405</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Billingsley</surname><given-names>MM</given-names></name><name name-style="western"><surname>Haley</surname><given-names>RM</given-names></name><name name-style="western"><surname>Wechsler</surname><given-names>ME</given-names></name><name name-style="western"><surname>Peppas</surname><given-names>NA</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R</given-names></name></person-group><article-title>Engineering precision nanoparticles for drug delivery</article-title><source>Nat Rev Drug Discov</source><year>2021</year><volume>20</volume><issue>2</issue><fpage>101</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1038/s41573-020-0090-8</pub-id><pub-id pub-id-type="pmid">33277608</pub-id><pub-id pub-id-type="pmcid">PMC7717100</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101&#8211;24.<pub-id pub-id-type="pmid">33277608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-020-0090-8</pub-id><pub-id pub-id-type="pmcid">PMC7717100</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>B</given-names></name><name name-style="western"><surname>Sui</surname><given-names>X</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cong</surname><given-names>H</given-names></name></person-group><article-title>Recent advances in drug delivery systems for enhancing drug penetration into tumors</article-title><source>Drug Deliv</source><year>2020</year><volume>27</volume><issue>1</issue><fpage>1474</fpage><lpage>1490</lpage><pub-id pub-id-type="doi">10.1080/10717544.2020.1831106</pub-id><pub-id pub-id-type="pmid">33100061</pub-id><pub-id pub-id-type="pmcid">PMC7594734</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">He B, Sui X, Yu B, Wang S, Shen Y, Cong H. Recent advances in drug delivery systems for enhancing drug penetration into tumors. Drug Deliv. 2020;27(1):1474&#8211;90.<pub-id pub-id-type="pmid">33100061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10717544.2020.1831106</pub-id><pub-id pub-id-type="pmcid">PMC7594734</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gavas</surname><given-names>S</given-names></name><name name-style="western"><surname>Quazi</surname><given-names>S</given-names></name><name name-style="western"><surname>Karpinski</surname><given-names>TM</given-names></name></person-group><article-title>Nanoparticles for cancer therapy: current progress and challenges</article-title><source>Nanoscale Res Lett</source><year>2021</year><volume>16</volume><issue>1</issue><fpage>173</fpage><pub-id pub-id-type="doi">10.1186/s11671-021-03628-6</pub-id><pub-id pub-id-type="pmid">34866166</pub-id><pub-id pub-id-type="pmcid">PMC8645667</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Gavas S, Quazi S, Karpinski TM. Nanoparticles for cancer therapy: current progress and challenges. Nanoscale Res Lett. 2021;16(1):173.<pub-id pub-id-type="pmid">34866166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s11671-021-03628-6</pub-id><pub-id pub-id-type="pmcid">PMC8645667</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durymanov</surname><given-names>M</given-names></name><name name-style="western"><surname>Kamaletdinova</surname><given-names>T</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>SE</given-names></name><name name-style="western"><surname>Reineke</surname><given-names>J</given-names></name></person-group><article-title>Exploiting passive nanomedicine accumulation at sites of enhanced vascular permeability for non-cancerous applications</article-title><source>J Control Release</source><year>2017</year><volume>261</volume><fpage>10</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.06.013</pub-id><pub-id pub-id-type="pmid">28625673</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Durymanov M, Kamaletdinova T, Lehmann SE, Reineke J. Exploiting passive nanomedicine accumulation at sites of enhanced vascular permeability for non-cancerous applications. J Control Release. 2017;261:10&#8211;22.<pub-id pub-id-type="pmid">28625673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2017.06.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torchilin</surname><given-names>V</given-names></name></person-group><article-title>Tumor delivery of macromolecular drugs based on the EPR effect</article-title><source>Adv Drug Deliv Rev</source><year>2011</year><volume>63</volume><issue>3</issue><fpage>131</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2010.03.011</pub-id><pub-id pub-id-type="pmid">20304019</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63(3):131&#8211;5.<pub-id pub-id-type="pmid">20304019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2010.03.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Estanqueiro</surname><given-names>M</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>MH</given-names></name><name name-style="western"><surname>Conceicao</surname><given-names>J</given-names></name><name name-style="western"><surname>Sousa Lobo</surname><given-names>JM</given-names></name></person-group><article-title>Nanotechnological carriers for cancer chemotherapy: the state of the art</article-title><source>Colloids Surf B Biointerfaces</source><year>2015</year><volume>126</volume><fpage>631</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2014.12.041</pub-id><pub-id pub-id-type="pmid">25591851</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Estanqueiro M, Amaral MH, Conceicao J, Sousa Lobo JM. Nanotechnological carriers for cancer chemotherapy: the state of the art. Colloids Surf B Biointerfaces. 2015;126:631&#8211;48.<pub-id pub-id-type="pmid">25591851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.colsurfb.2014.12.041</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danhier</surname><given-names>F</given-names></name><name name-style="western"><surname>Lecouturier</surname><given-names>N</given-names></name><name name-style="western"><surname>Vroman</surname><given-names>B</given-names></name><name name-style="western"><surname>Jerome</surname><given-names>C</given-names></name><name name-style="western"><surname>Marchand-Brynaert</surname><given-names>J</given-names></name><name name-style="western"><surname>Feron</surname><given-names>O</given-names></name><etal/></person-group><article-title>Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation</article-title><source>J Control Release</source><year>2009</year><volume>133</volume><issue>1</issue><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2008.09.086</pub-id><pub-id pub-id-type="pmid">18950666</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Danhier F, Lecouturier N, Vroman B, Jerome C, Marchand-Brynaert J, Feron O, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release. 2009;133(1):11&#8211;7.<pub-id pub-id-type="pmid">18950666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2008.09.086</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riaz</surname><given-names>MK</given-names></name><name name-style="western"><surname>Riaz</surname><given-names>MA</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C</given-names></name><name name-style="western"><surname>Wong</surname><given-names>KH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a review</article-title><source>Int J Mol Sci</source><year>2018</year><volume>19</volume><issue>1</issue><fpage>195</fpage><pub-id pub-id-type="doi">10.3390/ijms19010195</pub-id><pub-id pub-id-type="pmid">29315231</pub-id><pub-id pub-id-type="pmcid">PMC5796144</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Riaz MK, Riaz MA, Zhang X, Lin C, Wong KH, Chen X, et al. Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a review. Int J Mol Sci. 2018;19(1):195.<pub-id pub-id-type="pmid">29315231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms19010195</pub-id><pub-id pub-id-type="pmcid">PMC5796144</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoo</surname><given-names>J</given-names></name><name name-style="western"><surname>Park</surname><given-names>C</given-names></name><name name-style="western"><surname>Yi</surname><given-names>G</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D</given-names></name><name name-style="western"><surname>Koo</surname><given-names>H</given-names></name></person-group><article-title>Active targeting strategies using biological ligands for nanoparticle drug delivery systems</article-title><source>Cancers (Basel)</source><year>2019</year><volume>11</volume><issue>5</issue><fpage>640</fpage><pub-id pub-id-type="doi">10.3390/cancers11050640</pub-id><pub-id pub-id-type="pmid">31072061</pub-id><pub-id pub-id-type="pmcid">PMC6562917</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers (Basel). 2019;11(5):640.<pub-id pub-id-type="pmid">31072061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers11050640</pub-id><pub-id pub-id-type="pmcid">PMC6562917</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byrne</surname><given-names>JD</given-names></name><name name-style="western"><surname>Betancourt</surname><given-names>T</given-names></name><name name-style="western"><surname>Brannon-Peppas</surname><given-names>L</given-names></name></person-group><article-title>Active targeting schemes for nanoparticle systems in cancer therapeutics</article-title><source>Adv Drug Deliv Rev</source><year>2008</year><volume>60</volume><issue>15</issue><fpage>1615</fpage><lpage>1626</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2008.08.005</pub-id><pub-id pub-id-type="pmid">18840489</pub-id></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60(15):1615&#8211;26.<pub-id pub-id-type="pmid">18840489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2008.08.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>HK</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>S</given-names></name></person-group><article-title>Side effects of chemotherapy among cancer patients in a Malaysian General Hospital: experiences, perceptions and informational needs from clinical pharmacists</article-title><source>Asian Pac J Cancer Prev</source><year>2014</year><volume>15</volume><issue>13</issue><fpage>5305</fpage><lpage>5309</lpage><pub-id pub-id-type="doi">10.7314/APJCP.2014.15.13.5305</pub-id><pub-id pub-id-type="pmid">25040993</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Chan HK, Ismail S. Side effects of chemotherapy among cancer patients in a Malaysian General Hospital: experiences, perceptions and informational needs from clinical pharmacists. Asian Pac J Cancer Prev. 2014;15(13):5305&#8211;9.<pub-id pub-id-type="pmid">25040993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7314/apjcp.2014.15.13.5305</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhayalan</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Riyaz</surname><given-names>SUM</given-names></name><name name-style="western"><surname>Dinesh</surname><given-names>RA</given-names></name><name name-style="western"><surname>Shanmugam</surname><given-names>J</given-names></name><name name-style="western"><surname>Irudayaraj</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Advances in functional lipid nanoparticles: from drug delivery platforms to clinical applications</article-title><source>3 Biotech</source><year>2024</year><volume>14</volume><issue>2</issue><fpage>57</fpage><pub-id pub-id-type="doi">10.1007/s13205-023-03901-8</pub-id><pub-id pub-id-type="pmid">38298556</pub-id><pub-id pub-id-type="pmcid">PMC10825110</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Dhayalan M, Wang W, Riyaz SUM, Dinesh RA, Shanmugam J, Irudayaraj SS, et al. Advances in functional lipid nanoparticles: from drug delivery platforms to clinical applications. 3 Biotech. 2024;14(2):57.<pub-id pub-id-type="pmid">38298556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13205-023-03901-8</pub-id><pub-id pub-id-type="pmcid">PMC10825110</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakhaei</surname><given-names>P</given-names></name><name name-style="western"><surname>Margiana</surname><given-names>R</given-names></name><name name-style="western"><surname>Bokov</surname><given-names>DO</given-names></name><name name-style="western"><surname>Abdelbasset</surname><given-names>WK</given-names></name><name name-style="western"><surname>Jadidi Kouhbanani</surname><given-names>MA</given-names></name><name name-style="western"><surname>Varma</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Liposomes: structure, biomedical applications, and stability parameters with emphasis on cholesterol</article-title><source>Front Bioeng Biotechnol</source><year>2021</year><volume>9</volume><fpage>705886</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2021.705886</pub-id><pub-id pub-id-type="pmid">34568298</pub-id><pub-id pub-id-type="pmcid">PMC8459376</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="retraction-forward" ext-link-type="pmc" xlink:href="PMC10507466"/></element-citation><mixed-citation id="mc-CR139" publication-type="journal">Nakhaei P, Margiana R, Bokov DO, Abdelbasset WK, Jadidi Kouhbanani MA, Varma RS, et al. Liposomes: structure, biomedical applications, and stability parameters with emphasis on cholesterol. Front Bioeng Biotechnol. 2021;9:705886.<pub-id pub-id-type="pmid">34568298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fbioe.2021.705886</pub-id><pub-id pub-id-type="pmcid">PMC8459376</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="retraction-forward" ext-link-type="pmc" xlink:href="PMC10507466"/></mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eloy</surname><given-names>JO</given-names></name><name name-style="western"><surname>Claro de Souza</surname><given-names>M</given-names></name><name name-style="western"><surname>Petrilli</surname><given-names>R</given-names></name><name name-style="western"><surname>Barcellos</surname><given-names>JP</given-names></name><name name-style="western"><surname>Lee</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Marchetti</surname><given-names>JM</given-names></name></person-group><article-title>Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery</article-title><source>Colloids Surf B Biointerfaces</source><year>2014</year><volume>123</volume><fpage>345</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2014.09.029</pub-id><pub-id pub-id-type="pmid">25280609</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">Eloy JO, Claro de Souza M, Petrilli R, Barcellos JP, Lee RJ, Marchetti JM. Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery. Colloids Surf B Biointerfaces. 2014;123:345&#8211;63.<pub-id pub-id-type="pmid">25280609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.colsurfb.2014.09.029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olusanya</surname><given-names>TOB</given-names></name><name name-style="western"><surname>Haj Ahmad</surname><given-names>RR</given-names></name><name name-style="western"><surname>Ibegbu</surname><given-names>DM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>JR</given-names></name><name name-style="western"><surname>Elkordy</surname><given-names>AA</given-names></name></person-group><article-title>Liposomal drug delivery systems and anticancer drugs</article-title><source>Molecules</source><year>2018</year><volume>23</volume><issue>4</issue><fpage>907</fpage><pub-id pub-id-type="doi">10.3390/molecules23040907</pub-id><pub-id pub-id-type="pmid">29662019</pub-id><pub-id pub-id-type="pmcid">PMC6017847</pub-id></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Olusanya TOB, Haj Ahmad RR, Ibegbu DM, Smith JR, Elkordy AA. Liposomal drug delivery systems and anticancer drugs. Molecules. 2018;23(4):907.<pub-id pub-id-type="pmid">29662019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules23040907</pub-id><pub-id pub-id-type="pmcid">PMC6017847</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nsairat</surname><given-names>H</given-names></name><name name-style="western"><surname>Khater</surname><given-names>D</given-names></name><name name-style="western"><surname>Sayed</surname><given-names>U</given-names></name><name name-style="western"><surname>Odeh</surname><given-names>F</given-names></name><name name-style="western"><surname>Al Bawab</surname><given-names>A</given-names></name><name name-style="western"><surname>Alshaer</surname><given-names>W</given-names></name></person-group><article-title>Liposomes: structure, composition, types, and clinical applications</article-title><source>Heliyon</source><year>2022</year><volume>8</volume><issue>5</issue><fpage>e09394</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2022.e09394</pub-id><pub-id pub-id-type="pmid">35600452</pub-id><pub-id pub-id-type="pmcid">PMC9118483</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022;8(5):e09394.<pub-id pub-id-type="pmid">35600452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2022.e09394</pub-id><pub-id pub-id-type="pmcid">PMC9118483</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Priya</surname><given-names>S</given-names></name><name name-style="western"><surname>Desai</surname><given-names>VM</given-names></name><name name-style="western"><surname>Singhvi</surname><given-names>G</given-names></name></person-group><article-title>Surface modification of lipid-based nanocarriers: a potential approach to enhance targeted drug delivery</article-title><source>ACS Omega</source><year>2023</year><volume>8</volume><issue>1</issue><fpage>74</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1021/acsomega.2c05976</pub-id><pub-id pub-id-type="pmid">36643539</pub-id><pub-id pub-id-type="pmcid">PMC9835629</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">Priya S, Desai VM, Singhvi G. Surface modification of lipid-based nanocarriers: a potential approach to enhance targeted drug delivery. ACS Omega. 2023;8(1):74&#8211;86.<pub-id pub-id-type="pmid">36643539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsomega.2c05976</pub-id><pub-id pub-id-type="pmcid">PMC9835629</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stebbing</surname><given-names>J</given-names></name><name name-style="western"><surname>Gaya</surname><given-names>A</given-names></name></person-group><article-title>Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer</article-title><source>Cancer Treat Rev</source><year>2002</year><volume>28</volume><issue>2</issue><fpage>121</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1053/ctrv.2002.0262</pub-id><pub-id pub-id-type="pmid">12297120</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Stebbing J, Gaya A. Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer. Cancer Treat Rev. 2002;28(2):121&#8211;5.<pub-id pub-id-type="pmid">12297120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/ctrv.2002.0262</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duggan</surname><given-names>ST</given-names></name><name name-style="western"><surname>Keating</surname><given-names>GM</given-names></name></person-group><article-title>Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma</article-title><source>Drugs</source><year>2011</year><volume>71</volume><issue>18</issue><fpage>2531</fpage><lpage>2558</lpage><pub-id pub-id-type="doi">10.2165/11207510-000000000-00000</pub-id><pub-id pub-id-type="pmid">22141391</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Duggan ST, Keating GM. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi&#8217;s sarcoma. Drugs. 2011;71(18):2531&#8211;58.<pub-id pub-id-type="pmid">22141391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11207510-000000000-00000</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batist</surname><given-names>G</given-names></name><name name-style="western"><surname>Barton</surname><given-names>J</given-names></name><name name-style="western"><surname>Chaikin</surname><given-names>P</given-names></name><name name-style="western"><surname>Swenson</surname><given-names>C</given-names></name><name name-style="western"><surname>Welles</surname><given-names>L</given-names></name></person-group><article-title>Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy</article-title><source>Expert Opin Pharmacother</source><year>2002</year><volume>3</volume><issue>12</issue><fpage>1739</fpage><lpage>1751</lpage><pub-id pub-id-type="doi">10.1517/14656566.3.12.1739</pub-id><pub-id pub-id-type="pmid">12472371</pub-id></element-citation><mixed-citation id="mc-CR146" publication-type="journal">Batist G, Barton J, Chaikin P, Swenson C, Welles L. Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin Pharmacother. 2002;3(12):1739&#8211;51.<pub-id pub-id-type="pmid">12472371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14656566.3.12.1739</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><mixed-citation publication-type="other">DOXIL approved by FDA. AIDS Patient Care. 1995;9(6):306.<pub-id pub-id-type="pmid">11361446</pub-id></mixed-citation></ref><ref id="CR148"><label>148.</label><mixed-citation publication-type="other">DaunoXome approved. AIDS Patient Care STDS. 1996;10(4):263.<pub-id pub-id-type="pmid">11361607</pub-id></mixed-citation></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nehate</surname><given-names>C</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S</given-names></name><name name-style="western"><surname>Saneja</surname><given-names>A</given-names></name><name name-style="western"><surname>Khare</surname><given-names>V</given-names></name><name name-style="western"><surname>Alam</surname><given-names>N</given-names></name><name name-style="western"><surname>Dubey</surname><given-names>RD</given-names></name><etal/></person-group><article-title>Paclitaxel formulations: challenges and novel delivery options</article-title><source>Curr Drug Deliv</source><year>2014</year><volume>11</volume><issue>6</issue><fpage>666</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.2174/1567201811666140609154949</pub-id><pub-id pub-id-type="pmid">24909147</pub-id></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Nehate C, Jain S, Saneja A, Khare V, Alam N, Dubey RD, et al. Paclitaxel formulations: challenges and novel delivery options. Curr Drug Deliv. 2014;11(6):666&#8211;86.<pub-id pub-id-type="pmid">24909147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1567201811666140609154949</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>TS</given-names></name><name name-style="western"><surname>Lyseng-Williamson</surname><given-names>KA</given-names></name></person-group><article-title>Vincristine sulfate liposome injection: a guide to its use in refractory or relapsed acute lymphoblastic leukemia</article-title><source>BioDrugs</source><year>2013</year><volume>27</volume><issue>1</issue><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1007/s40259-012-0002-5</pub-id><pub-id pub-id-type="pmid">23329395</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Harrison TS, Lyseng-Williamson KA. Vincristine sulfate liposome injection: a guide to its use in refractory or relapsed acute lymphoblastic leukemia. BioDrugs. 2013;27(1):69&#8211;74.<pub-id pub-id-type="pmid">23329395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40259-012-0002-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>AP</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>A</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>A</given-names></name><name name-style="western"><surname>Maiti</surname><given-names>P</given-names></name></person-group><article-title>Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles</article-title><source>Signal Transduct Target Ther</source><year>2019</year><volume>4</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1038/s41392-019-0068-3</pub-id><pub-id pub-id-type="pmid">31637012</pub-id><pub-id pub-id-type="pmcid">PMC6799838</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">Singh AP, Biswas A, Shukla A, Maiti P. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal Transduct Target Ther. 2019;4:33.<pub-id pub-id-type="pmid">31637012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-019-0068-3</pub-id><pub-id pub-id-type="pmcid">PMC6799838</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamb</surname><given-names>YN</given-names></name><name name-style="western"><surname>Scott</surname><given-names>LJ</given-names></name></person-group><article-title>Liposomal irinotecan: a review in metastatic pancreatic adenocarcinoma</article-title><source>Drugs</source><year>2017</year><volume>77</volume><issue>7</issue><fpage>785</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1007/s40265-017-0741-1</pub-id><pub-id pub-id-type="pmid">28401446</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Lamb YN, Scott LJ. Liposomal irinotecan: a review in metastatic pancreatic adenocarcinoma. Drugs. 2017;77(7):785&#8211;92.<pub-id pub-id-type="pmid">28401446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-017-0741-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alfayez</surname><given-names>M</given-names></name><name name-style="western"><surname>Kantarjian</surname><given-names>H</given-names></name><name name-style="western"><surname>Kadia</surname><given-names>T</given-names></name><name name-style="western"><surname>Ravandi-Kashani</surname><given-names>F</given-names></name><name name-style="western"><surname>Daver</surname><given-names>N</given-names></name></person-group><article-title>CPX-351 (vyxeos) in AML</article-title><source>Leuk Lymphoma</source><year>2020</year><volume>61</volume><issue>2</issue><fpage>288</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1080/10428194.2019.1660970</pub-id><pub-id pub-id-type="pmid">31547736</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver N. CPX-351 (vyxeos) in AML. Leuk Lymphoma. 2020;61(2):288&#8211;97.<pub-id pub-id-type="pmid">31547736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10428194.2019.1660970</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soppimath</surname><given-names>KS</given-names></name><name name-style="western"><surname>Aminabhavi</surname><given-names>TM</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>AR</given-names></name><name name-style="western"><surname>Rudzinski</surname><given-names>WE</given-names></name></person-group><article-title>Biodegradable polymeric nanoparticles as drug delivery devices</article-title><source>J Control Release</source><year>2001</year><volume>70</volume><issue>1&#8211;2</issue><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/S0168-3659(00)00339-4</pub-id><pub-id pub-id-type="pmid">11166403</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1&#8211;2):1&#8211;20.<pub-id pub-id-type="pmid">11166403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0168-3659(00)00339-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Owens</surname><given-names>DE</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Peppas</surname><given-names>NA</given-names></name></person-group><article-title>Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles</article-title><source>Int J Pharm</source><year>2006</year><volume>307</volume><issue>1</issue><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2005.10.010</pub-id><pub-id pub-id-type="pmid">16303268</pub-id></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93&#8211;102.<pub-id pub-id-type="pmid">16303268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2005.10.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lukasiewicz</surname><given-names>S</given-names></name><name name-style="western"><surname>Szczepanowicz</surname><given-names>K</given-names></name><name name-style="western"><surname>Podgorna</surname><given-names>K</given-names></name><name name-style="western"><surname>Blasiak</surname><given-names>E</given-names></name><name name-style="western"><surname>Majeed</surname><given-names>N</given-names></name><name name-style="western"><surname>Ogren</surname><given-names>SOO</given-names></name><etal/></person-group><article-title>Encapsulation of clozapine in polymeric nanocapsules and its biological effects</article-title><source>Colloids Surf B Biointerfaces</source><year>2016</year><volume>140</volume><fpage>342</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2015.12.044</pub-id><pub-id pub-id-type="pmid">26774571</pub-id></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Lukasiewicz S, Szczepanowicz K, Podgorna K, Blasiak E, Majeed N, Ogren SOO, et al. Encapsulation of clozapine in polymeric nanocapsules and its biological effects. Colloids Surf B Biointerfaces. 2016;140:342&#8211;52.<pub-id pub-id-type="pmid">26774571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.colsurfb.2015.12.044</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>S</given-names></name><name name-style="western"><surname>Gigliobianco</surname><given-names>MR</given-names></name><name name-style="western"><surname>Censi</surname><given-names>R</given-names></name><name name-style="western"><surname>Di Martino</surname><given-names>P</given-names></name></person-group><article-title>Polymeric nanocapsules as nanotechnological alternative for drug delivery system: current status, challenges and opportunities</article-title><source>Nanomaterials (Basel)</source><year>2020</year><volume>10</volume><issue>5</issue><fpage>847</fpage><pub-id pub-id-type="doi">10.3390/nano10050847</pub-id><pub-id pub-id-type="pmid">32354008</pub-id><pub-id pub-id-type="pmcid">PMC7711922</pub-id></element-citation><mixed-citation id="mc-CR157" publication-type="journal">Deng S, Gigliobianco MR, Censi R, Di Martino P. Polymeric nanocapsules as nanotechnological alternative for drug delivery system: current status, challenges and opportunities. Nanomaterials (Basel). 2020;10(5):847.<pub-id pub-id-type="pmid">32354008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nano10050847</pub-id><pub-id pub-id-type="pmcid">PMC7711922</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frank</surname><given-names>LA</given-names></name><name name-style="western"><surname>Gazzi</surname><given-names>RP</given-names></name><name name-style="western"><surname>de Andrade</surname><given-names>MP</given-names></name><name name-style="western"><surname>Buffon</surname><given-names>A</given-names></name><name name-style="western"><surname>Pohlmann</surname><given-names>AR</given-names></name><name name-style="western"><surname>Guterres</surname><given-names>SS</given-names></name></person-group><article-title>Imiquimod-loaded nanocapsules improve cytotoxicity in cervical cancer cell line</article-title><source>Eur J Pharm Biopharm</source><year>2019</year><volume>136</volume><fpage>9</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2019.01.001</pub-id><pub-id pub-id-type="pmid">30630060</pub-id></element-citation><mixed-citation id="mc-CR158" publication-type="journal">Frank LA, Gazzi RP, de Andrade MP, Buffon A, Pohlmann AR, Guterres SS. Imiquimod-loaded nanocapsules improve cytotoxicity in cervical cancer cell line. Eur J Pharm Biopharm. 2019;136:9&#8211;17.<pub-id pub-id-type="pmid">30630060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejpb.2019.01.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kroger</surname><given-names>APP</given-names></name><name name-style="western"><surname>Paulusse</surname><given-names>JMJ</given-names></name></person-group><article-title>Single-chain polymer nanoparticles in controlled drug delivery and targeted imaging</article-title><source>J Control Release</source><year>2018</year><volume>286</volume><fpage>326</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2018.07.041</pub-id><pub-id pub-id-type="pmid">30077737</pub-id></element-citation><mixed-citation id="mc-CR159" publication-type="journal">Kroger APP, Paulusse JMJ. Single-chain polymer nanoparticles in controlled drug delivery and targeted imaging. J Control Release. 2018;286:326&#8211;47.<pub-id pub-id-type="pmid">30077737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2018.07.041</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palivan</surname><given-names>CG</given-names></name><name name-style="western"><surname>Goers</surname><given-names>R</given-names></name><name name-style="western"><surname>Najer</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Car</surname><given-names>A</given-names></name><name name-style="western"><surname>Meier</surname><given-names>W</given-names></name></person-group><article-title>Bioinspired polymer vesicles and membranes for biological and medical applications</article-title><source>Chem Soc Rev</source><year>2016</year><volume>45</volume><issue>2</issue><fpage>377</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1039/C5CS00569H</pub-id><pub-id pub-id-type="pmid">26563574</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Palivan CG, Goers R, Najer A, Zhang X, Car A, Meier W. Bioinspired polymer vesicles and membranes for biological and medical applications. Chem Soc Rev. 2016;45(2):377&#8211;411.<pub-id pub-id-type="pmid">26563574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c5cs00569h</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>D</given-names></name><name name-style="western"><surname>Ramsey</surname><given-names>JD</given-names></name><name name-style="western"><surname>Kabanov</surname><given-names>AV</given-names></name></person-group><article-title>Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval</article-title><source>Adv Drug Deliv Rev</source><year>2020</year><volume>156</volume><fpage>80</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.09.009</pub-id><pub-id pub-id-type="pmid">32980449</pub-id><pub-id pub-id-type="pmcid">PMC8173698</pub-id></element-citation><mixed-citation id="mc-CR161" publication-type="journal">Hwang D, Ramsey JD, Kabanov AV. Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. Adv Drug Deliv Rev. 2020;156:80&#8211;118.<pub-id pub-id-type="pmid">32980449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2020.09.009</pub-id><pub-id pub-id-type="pmcid">PMC8173698</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><mixed-citation publication-type="other">Eligard. Tiny implant fights prostate cancer. Nursing. 2002;32(5):18.<pub-id pub-id-type="pmid">12035639</pub-id></mixed-citation></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mu</surname><given-names>W</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name></person-group><article-title>A review on nano-based drug delivery system for cancer chemoimmunotherapy</article-title><source>Nanomicro Lett</source><year>2020</year><volume>12</volume><issue>1</issue><fpage>142</fpage><pub-id pub-id-type="pmid">34138136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40820-020-00482-6</pub-id><pub-id pub-id-type="pmcid">PMC7770879</pub-id></element-citation><mixed-citation id="mc-CR163" publication-type="journal">Mu W, Chu Q, Liu Y, Zhang N. A review on nano-based drug delivery system for cancer chemoimmunotherapy. Nanomicro Lett. 2020;12(1):142.<pub-id pub-id-type="pmid">34138136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40820-020-00482-6</pub-id><pub-id pub-id-type="pmcid">PMC7770879</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hunter</surname><given-names>FW</given-names></name><name name-style="western"><surname>Barker</surname><given-names>HR</given-names></name><name name-style="western"><surname>Lipert</surname><given-names>B</given-names></name><name name-style="western"><surname>Rothe</surname><given-names>F</given-names></name><name name-style="western"><surname>Gebhart</surname><given-names>G</given-names></name><name name-style="western"><surname>Piccart-Gebhart</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer</article-title><source>Br J Cancer</source><year>2020</year><volume>122</volume><issue>5</issue><fpage>603</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1038/s41416-019-0635-y</pub-id><pub-id pub-id-type="pmid">31839676</pub-id><pub-id pub-id-type="pmcid">PMC7054312</pub-id></element-citation><mixed-citation id="mc-CR164" publication-type="journal">Hunter FW, Barker HR, Lipert B, Rothe F, Gebhart G, Piccart-Gebhart MJ, et al. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br J Cancer. 2020;122(5):603&#8211;12.<pub-id pub-id-type="pmid">31839676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-019-0635-y</pub-id><pub-id pub-id-type="pmcid">PMC7054312</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fraguas-Sanchez</surname><given-names>AI</given-names></name><name name-style="western"><surname>Lozza</surname><given-names>I</given-names></name><name name-style="western"><surname>Torres-Suarez</surname><given-names>AI</given-names></name></person-group><article-title>Actively targeted nanomedicines in breast cancer: from pre-clinal investigation to clinic</article-title><source>Cancers (Basel)</source><year>2022</year><volume>14</volume><issue>5</issue><fpage>1198</fpage><pub-id pub-id-type="doi">10.3390/cancers14051198</pub-id><pub-id pub-id-type="pmid">35267507</pub-id><pub-id pub-id-type="pmcid">PMC8909490</pub-id></element-citation><mixed-citation id="mc-CR165" publication-type="journal">Fraguas-Sanchez AI, Lozza I, Torres-Suarez AI. Actively targeted nanomedicines in breast cancer: from pre-clinal investigation to clinic. Cancers (Basel). 2022;14(5):1198.<pub-id pub-id-type="pmid">35267507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14051198</pub-id><pub-id pub-id-type="pmcid">PMC8909490</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keam</surname><given-names>SJ</given-names></name></person-group><article-title>Trastuzumab deruxtecan: first approval</article-title><source>Drugs</source><year>2020</year><volume>80</volume><issue>5</issue><fpage>501</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1007/s40265-020-01281-4</pub-id><pub-id pub-id-type="pmid">32144719</pub-id></element-citation><mixed-citation id="mc-CR166" publication-type="journal">Keam SJ. Trastuzumab deruxtecan: first approval. Drugs. 2020;80(5):501&#8211;8.<pub-id pub-id-type="pmid">32144719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-020-01281-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heo</surname><given-names>YA</given-names></name><name name-style="western"><surname>Syed</surname><given-names>YY</given-names></name><name name-style="western"><surname>Keam</surname><given-names>SJ</given-names></name></person-group><article-title>Pegaspargase: a review in acute lymphoblastic leukaemia</article-title><source>Drugs</source><year>2019</year><volume>79</volume><issue>7</issue><fpage>767</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1007/s40265-019-01120-1</pub-id><pub-id pub-id-type="pmid">31030380</pub-id><pub-id pub-id-type="pmcid">PMC6531401</pub-id></element-citation><mixed-citation id="mc-CR167" publication-type="journal">Heo YA, Syed YY, Keam SJ. Pegaspargase: a review in acute lymphoblastic leukaemia. Drugs. 2019;79(7):767&#8211;77.<pub-id pub-id-type="pmid">31030380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-019-01120-1</pub-id><pub-id pub-id-type="pmcid">PMC6531401</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>S</given-names></name><name name-style="western"><surname>Choi</surname><given-names>DW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HN</given-names></name><name name-style="western"><surname>Park</surname><given-names>CG</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W</given-names></name><name name-style="western"><surname>Park</surname><given-names>HH</given-names></name></person-group><article-title>Protein-based nanoparticles as drug delivery systems</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><issue>7</issue><fpage>604</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics12070604</pub-id><pub-id pub-id-type="pmid">32610448</pub-id><pub-id pub-id-type="pmcid">PMC7407889</pub-id></element-citation><mixed-citation id="mc-CR168" publication-type="journal">Hong S, Choi DW, Kim HN, Park CG, Lee W, Park HH. Protein-based nanoparticles as drug delivery systems. Pharmaceutics. 2020;12(7):604.<pub-id pub-id-type="pmid">32610448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics12070604</pub-id><pub-id pub-id-type="pmcid">PMC7407889</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>F</given-names></name><name name-style="western"><surname>Caruana</surname><given-names>P</given-names></name><name name-style="western"><surname>De la Fuente</surname><given-names>N</given-names></name><name name-style="western"><surname>Espanol</surname><given-names>P</given-names></name><name name-style="western"><surname>Gamez</surname><given-names>M</given-names></name><name name-style="western"><surname>Balart</surname><given-names>J</given-names></name><etal/></person-group><article-title>Nano-based approved pharmaceuticals for cancer treatment: present and future challenges</article-title><source>Biomolecules</source><year>2022</year><volume>12</volume><issue>6</issue><fpage>784</fpage><pub-id pub-id-type="doi">10.3390/biom12060784</pub-id><pub-id pub-id-type="pmid">35740909</pub-id><pub-id pub-id-type="pmcid">PMC9221343</pub-id></element-citation><mixed-citation id="mc-CR169" publication-type="journal">Rodriguez F, Caruana P, De la Fuente N, Espanol P, Gamez M, Balart J, et al. Nano-based approved pharmaceuticals for cancer treatment: present and future challenges. Biomolecules. 2022;12(6):784.<pub-id pub-id-type="pmid">35740909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom12060784</pub-id><pub-id pub-id-type="pmcid">PMC9221343</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duvic</surname><given-names>M</given-names></name><name name-style="western"><surname>Talpur</surname><given-names>R</given-names></name></person-group><article-title>Optimizing denileukin diftitox (Ontak) therapy</article-title><source>Future Oncol</source><year>2008</year><volume>4</volume><issue>4</issue><fpage>457</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.2217/14796694.4.4.457</pub-id><pub-id pub-id-type="pmid">18684057</pub-id></element-citation><mixed-citation id="mc-CR170" publication-type="journal">Duvic M, Talpur R. Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008;4(4):457&#8211;69.<pub-id pub-id-type="pmid">18684057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/14796694.4.4.457</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jahangir</surname><given-names>MA</given-names></name><name name-style="western"><surname>Taleuzzaman</surname><given-names>M</given-names></name><name name-style="western"><surname>Kala</surname><given-names>C</given-names></name><name name-style="western"><surname>Gilani</surname><given-names>SJ</given-names></name></person-group><article-title>Advancements in polymer and lipid-based nanotherapeutics for cancer drug targeting</article-title><source>Curr Pharm Des</source><year>2020</year><volume>26</volume><issue>40</issue><fpage>5119</fpage><lpage>5127</lpage><pub-id pub-id-type="doi">10.2174/1381612826999200820173253</pub-id><pub-id pub-id-type="pmid">32867646</pub-id></element-citation><mixed-citation id="mc-CR171" publication-type="journal">Jahangir MA, Taleuzzaman M, Kala C, Gilani SJ. Advancements in polymer and lipid-based nanotherapeutics for cancer drug targeting. Curr Pharm Des. 2020;26(40):5119&#8211;27.<pub-id pub-id-type="pmid">32867646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1381612826999200820173253</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>CH</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>JK</given-names></name></person-group><article-title>Diagnostic and therapeutic roles of iron oxide nanoparticles in biomedicine</article-title><source>Tzu Chi Med J</source><year>2023</year><volume>35</volume><issue>1</issue><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.4103/tcmj.tcmj_65_22</pub-id><pub-id pub-id-type="pmid">36866343</pub-id><pub-id pub-id-type="pmcid">PMC9972926</pub-id></element-citation><mixed-citation id="mc-CR172" publication-type="journal">Lu CH, Hsiao JK. Diagnostic and therapeutic roles of iron oxide nanoparticles in biomedicine. Tzu Chi Med J. 2023;35(1):11&#8211;7.<pub-id pub-id-type="pmid">36866343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/tcmj.tcmj_65_22</pub-id><pub-id pub-id-type="pmcid">PMC9972926</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><citation-alternatives><element-citation id="ec-CR173" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maier-Hauff</surname><given-names>K</given-names></name><name name-style="western"><surname>Ulrich</surname><given-names>F</given-names></name><name name-style="western"><surname>Nestler</surname><given-names>D</given-names></name><name name-style="western"><surname>Niehoff</surname><given-names>H</given-names></name><name name-style="western"><surname>Wust</surname><given-names>P</given-names></name><name name-style="western"><surname>Thiesen</surname><given-names>B</given-names></name><etal/></person-group><article-title>Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme</article-title><source>J Neurooncol</source><year>2011</year><volume>103</volume><issue>2</issue><fpage>317</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1007/s11060-010-0389-0</pub-id><pub-id pub-id-type="pmid">20845061</pub-id><pub-id pub-id-type="pmcid">PMC3097345</pub-id></element-citation><mixed-citation id="mc-CR173" publication-type="journal">Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011;103(2):317&#8211;24.<pub-id pub-id-type="pmid">20845061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11060-010-0389-0</pub-id><pub-id pub-id-type="pmcid">PMC3097345</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR174"><label>174.</label><citation-alternatives><element-citation id="ec-CR174" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivera Gil</surname><given-names>P</given-names></name><name name-style="western"><surname>Huhn</surname><given-names>D</given-names></name><name name-style="western"><surname>del Mercato</surname><given-names>LL</given-names></name><name name-style="western"><surname>Sasse</surname><given-names>D</given-names></name><name name-style="western"><surname>Parak</surname><given-names>WJ</given-names></name></person-group><article-title>Nanopharmacy: inorganic nanoscale devices as vectors and active compounds</article-title><source>Pharmacol Res</source><year>2010</year><volume>62</volume><issue>2</issue><fpage>115</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2010.01.009</pub-id><pub-id pub-id-type="pmid">20097288</pub-id></element-citation><mixed-citation id="mc-CR174" publication-type="journal">Rivera Gil P, Huhn D, del Mercato LL, Sasse D, Parak WJ. Nanopharmacy: inorganic nanoscale devices as vectors and active compounds. Pharmacol Res. 2010;62(2):115&#8211;25.<pub-id pub-id-type="pmid">20097288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2010.01.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR175"><label>175.</label><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Gao</surname><given-names>K</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>In situ modification of the tumor cell surface with immunomodulating nanoparticles for effective suppression of tumor growth in mice</article-title><source>Adv Mater</source><year>2019</year><volume>31</volume><issue>32</issue><fpage>e1902542</fpage><pub-id pub-id-type="doi">10.1002/adma.201902542</pub-id><pub-id pub-id-type="pmid">31183900</pub-id></element-citation><mixed-citation id="mc-CR175" publication-type="journal">Zheng C, Wang Q, Wang Y, Zhao X, Gao K, Liu Q, et al. In situ modification of the tumor cell surface with immunomodulating nanoparticles for effective suppression of tumor growth in mice. Adv Mater. 2019;31(32):e1902542.<pub-id pub-id-type="pmid">31183900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.201902542</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR176"><label>176.</label><citation-alternatives><element-citation id="ec-CR176" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wei</surname><given-names>G</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><issue>19</issue><fpage>5542</fpage><lpage>5557</lpage><pub-id pub-id-type="doi">10.7150/thno.35343</pub-id><pub-id pub-id-type="pmid">31534502</pub-id><pub-id pub-id-type="pmcid">PMC6735384</pub-id></element-citation><mixed-citation id="mc-CR176" publication-type="journal">Huang Z, Wei G, Zeng Z, Huang Y, Huang L, Shen Y, et al. Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor. Theranostics. 2019;9(19):5542&#8211;57.<pub-id pub-id-type="pmid">31534502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.35343</pub-id><pub-id pub-id-type="pmcid">PMC6735384</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR177"><label>177.</label><citation-alternatives><element-citation id="ec-CR177" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ren</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Tumor size-dependent abscopal effect of polydopamine-coated all-in-one nanoparticles for immunochemo-photothermal therapy of early- and late-stage metastatic cancer</article-title><source>Biomaterials</source><year>2021</year><volume>269</volume><fpage>120629</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.120629</pub-id><pub-id pub-id-type="pmid">33387938</pub-id><pub-id pub-id-type="pmcid">PMC8466812</pub-id></element-citation><mixed-citation id="mc-CR177" publication-type="journal">Sun J, Wan Z, Xu J, Luo Z, Ren P, Zhang B, et al. Tumor size-dependent abscopal effect of polydopamine-coated all-in-one nanoparticles for immunochemo-photothermal therapy of early- and late-stage metastatic cancer. Biomaterials. 2021;269:120629.<pub-id pub-id-type="pmid">33387938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2020.120629</pub-id><pub-id pub-id-type="pmcid">PMC8466812</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR178"><label>178.</label><citation-alternatives><element-citation id="ec-CR178" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Won</surname><given-names>JE</given-names></name><name name-style="western"><surname>Byeon</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wi</surname><given-names>TI</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kang</surname><given-names>TH</given-names></name><etal/></person-group><article-title>Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches</article-title><source>J Immunother Cancer</source><year>2022</year><volume>10</volume><issue>2</issue><fpage>e003928</fpage><pub-id pub-id-type="doi">10.1136/jitc-2021-003928</pub-id><pub-id pub-id-type="pmid">35228265</pub-id><pub-id pub-id-type="pmcid">PMC8886443</pub-id></element-citation><mixed-citation id="mc-CR178" publication-type="journal">Won JE, Byeon Y, Wi TI, Lee CM, Lee JH, Kang TH, et al. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches. J Immunother Cancer. 2022;10(2):e003928.<pub-id pub-id-type="pmid">35228265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2021-003928</pub-id><pub-id pub-id-type="pmcid">PMC8886443</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR179"><label>179.</label><citation-alternatives><element-citation id="ec-CR179" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thiramanas</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Landfester</surname><given-names>K</given-names></name><name name-style="western"><surname>Mailander</surname><given-names>V</given-names></name></person-group><article-title>Cellular uptake of siRNA-loaded nanocarriers to knockdown PD-L1: strategies to improve T-cell functions</article-title><source>Cells</source><year>2020</year><volume>9</volume><issue>9</issue><fpage>2043</fpage><pub-id pub-id-type="doi">10.3390/cells9092043</pub-id><pub-id pub-id-type="pmid">32906726</pub-id><pub-id pub-id-type="pmcid">PMC7565787</pub-id></element-citation><mixed-citation id="mc-CR179" publication-type="journal">Thiramanas R, Li M, Jiang S, Landfester K, Mailander V. Cellular uptake of siRNA-loaded nanocarriers to knockdown PD-L1: strategies to improve T-cell functions. Cells. 2020;9(9):2043.<pub-id pub-id-type="pmid">32906726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells9092043</pub-id><pub-id pub-id-type="pmcid">PMC7565787</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR180"><label>180.</label><citation-alternatives><element-citation id="ec-CR180" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Du</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Co-inhibition of the TGF-beta pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti-tumor immunotherapy</article-title><source>Biomater Sci</source><year>2020</year><volume>8</volume><issue>18</issue><fpage>5121</fpage><lpage>5132</lpage><pub-id pub-id-type="doi">10.1039/D0BM00916D</pub-id><pub-id pub-id-type="pmid">32820750</pub-id></element-citation><mixed-citation id="mc-CR180" publication-type="journal">Wang Y, Gao Z, Du X, Chen S, Zhang W, Wang J, et al. Co-inhibition of the TGF-beta pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti-tumor immunotherapy. Biomater Sci. 2020;8(18):5121&#8211;32.<pub-id pub-id-type="pmid">32820750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d0bm00916d</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR181"><label>181.</label><citation-alternatives><element-citation id="ec-CR181" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galstyan</surname><given-names>A</given-names></name><name name-style="western"><surname>Markman</surname><given-names>JL</given-names></name><name name-style="western"><surname>Shatalova</surname><given-names>ES</given-names></name><name name-style="western"><surname>Chiechi</surname><given-names>A</given-names></name><name name-style="western"><surname>Korman</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Patil</surname><given-names>R</given-names></name><etal/></person-group><article-title>Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>3850</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-11719-3</pub-id><pub-id pub-id-type="pmid">31462642</pub-id><pub-id pub-id-type="pmcid">PMC6713723</pub-id></element-citation><mixed-citation id="mc-CR181" publication-type="journal">Galstyan A, Markman JL, Shatalova ES, Chiechi A, Korman AJ, Patil R, et al. Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy. Nat Commun. 2019;10(1):3850.<pub-id pub-id-type="pmid">31462642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-11719-3</pub-id><pub-id pub-id-type="pmcid">PMC6713723</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR182"><label>182.</label><citation-alternatives><element-citation id="ec-CR182" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>L</given-names></name><name name-style="western"><surname>Pan</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Min</surname><given-names>Y</given-names></name></person-group><article-title>Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy</article-title><source>Acta Biomater</source><year>2023</year><volume>158</volume><fpage>698</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2022.12.039</pub-id><pub-id pub-id-type="pmid">36563773</pub-id></element-citation><mixed-citation id="mc-CR182" publication-type="journal">Su L, Pan W, Li X, Zhou X, Ma X, Min Y. Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy. Acta Biomater. 2023;158:698&#8211;707.<pub-id pub-id-type="pmid">36563773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2022.12.039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR183"><label>183.</label><citation-alternatives><element-citation id="ec-CR183" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Han</surname><given-names>X</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X</given-names></name><etal/></person-group><article-title>Cancer cell membrane-coated gambogic acid nanoparticles for effective anticancer vaccination by activating dendritic cells</article-title><source>Int J Nanomedicine</source><year>2023</year><volume>18</volume><fpage>2261</fpage><lpage>2273</lpage><pub-id pub-id-type="doi">10.2147/IJN.S408521</pub-id><pub-id pub-id-type="pmid">37159807</pub-id><pub-id pub-id-type="pmcid">PMC10163893</pub-id></element-citation><mixed-citation id="mc-CR183" publication-type="journal">Huang F, Zhang Q, Xiao J, Zhang X, Han X, Shi X, et al. Cancer cell membrane-coated gambogic acid nanoparticles for effective anticancer vaccination by activating dendritic cells. Int J Nanomedicine. 2023;18:2261&#8211;73.<pub-id pub-id-type="pmid">37159807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S408521</pub-id><pub-id pub-id-type="pmcid">PMC10163893</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR184"><label>184.</label><citation-alternatives><element-citation id="ec-CR184" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>L</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liao</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>The potentiated checkpoint blockade immunotherapy by ROS-responsive nanocarrier-mediated cascade chemo-photodynamic therapy</article-title><source>Biomaterials</source><year>2019</year><volume>223</volume><fpage>119469</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.119469</pub-id><pub-id pub-id-type="pmid">31520886</pub-id></element-citation><mixed-citation id="mc-CR184" publication-type="journal">Hu L, Cao Z, Ma L, Liu Z, Liao G, Wang J, et al. The potentiated checkpoint blockade immunotherapy by ROS-responsive nanocarrier-mediated cascade chemo-photodynamic therapy. Biomaterials. 2019;223:119469.<pub-id pub-id-type="pmid">31520886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2019.119469</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR185"><label>185.</label><citation-alternatives><element-citation id="ec-CR185" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M</given-names></name><name name-style="western"><surname>Yong</surname><given-names>SB</given-names></name><name name-style="western"><surname>Han</surname><given-names>H</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S</given-names></name><name name-style="western"><surname>Lahiji</surname><given-names>SF</given-names></name><etal/></person-group><article-title>Engineering TGF-beta inhibitor-encapsulated macrophage-inspired multi-functional nanoparticles for combination cancer immunotherapy</article-title><source>Biomater Res</source><year>2023</year><volume>27</volume><issue>1</issue><fpage>136</fpage><pub-id pub-id-type="doi">10.1186/s40824-023-00470-y</pub-id><pub-id pub-id-type="pmid">38111068</pub-id><pub-id pub-id-type="pmcid">PMC10729390</pub-id></element-citation><mixed-citation id="mc-CR185" publication-type="journal">Kim J, Kim M, Yong SB, Han H, Kang S, Lahiji SF, et al. Engineering TGF-beta inhibitor-encapsulated macrophage-inspired multi-functional nanoparticles for combination cancer immunotherapy. Biomater Res. 2023;27(1):136.<pub-id pub-id-type="pmid">38111068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40824-023-00470-y</pub-id><pub-id pub-id-type="pmcid">PMC10729390</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR186"><label>186.</label><citation-alternatives><element-citation id="ec-CR186" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>K</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H</given-names></name><name name-style="western"><surname>Jia</surname><given-names>M</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment</article-title><source>Biomed Pharmacother</source><year>2023</year><volume>161</volume><fpage>114567</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2023.114567</pub-id><pub-id pub-id-type="pmid">36963362</pub-id></element-citation><mixed-citation id="mc-CR186" publication-type="journal">Lin Z, Huang K, Guo H, Jia M, Sun Q, Chen X, et al. Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment. Biomed Pharmacother. 2023;161:114567.<pub-id pub-id-type="pmid">36963362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2023.114567</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR187"><label>187.</label><citation-alternatives><element-citation id="ec-CR187" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fan</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Targeted codelivery of an antigen and dual agonists by hybrid nanoparticles for enhanced cancer immunotherapy</article-title><source>Nano Lett</source><year>2019</year><volume>19</volume><issue>7</issue><fpage>4237</fpage><lpage>4249</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.9b00030</pub-id><pub-id pub-id-type="pmid">30868883</pub-id></element-citation><mixed-citation id="mc-CR187" publication-type="journal">Zhang L, Wu S, Qin Y, Fan F, Zhang Z, Huang C, et al. Targeted codelivery of an antigen and dual agonists by hybrid nanoparticles for enhanced cancer immunotherapy. Nano Lett. 2019;19(7):4237&#8211;49.<pub-id pub-id-type="pmid">30868883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.9b00030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR188"><label>188.</label><citation-alternatives><element-citation id="ec-CR188" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Cui</surname><given-names>X</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>CD16 CAR-T cells enhance antitumor activity of CpG ODN-loaded nanoparticle-adjuvanted tumor antigen-derived vaccinevia ADCC approach</article-title><source>J Nanobiotechnology</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>159</fpage><pub-id pub-id-type="doi">10.1186/s12951-023-01900-8</pub-id><pub-id pub-id-type="pmid">37208748</pub-id><pub-id pub-id-type="pmcid">PMC10199637</pub-id></element-citation><mixed-citation id="mc-CR188" publication-type="journal">Zhang X, Hu Q, He X, Cui X, Liang Z, Wang L, et al. CD16 CAR-T cells enhance antitumor activity of CpG ODN-loaded nanoparticle-adjuvanted tumor antigen-derived vaccinevia ADCC approach. J Nanobiotechnology. 2023;21(1):159.<pub-id pub-id-type="pmid">37208748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-023-01900-8</pub-id><pub-id pub-id-type="pmcid">PMC10199637</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR189"><label>189.</label><citation-alternatives><element-citation id="ec-CR189" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Traini</surname><given-names>G</given-names></name><name name-style="western"><surname>Ruiz-de-Angulo</surname><given-names>A</given-names></name><name name-style="western"><surname>Blanco-Canosa</surname><given-names>JB</given-names></name><name name-style="western"><surname>Zamacola Bascaran</surname><given-names>K</given-names></name><name name-style="western"><surname>Molinaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Silipo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cancer Immunotherapy of TLR4 agonist-antigen constructs enhanced with pathogen-mimicking magnetite nanoparticles and checkpoint blockade of PD-L1</article-title><source>Small</source><year>2019</year><volume>15</volume><issue>4</issue><fpage>e1803993</fpage><pub-id pub-id-type="doi">10.1002/smll.201803993</pub-id><pub-id pub-id-type="pmid">30569516</pub-id></element-citation><mixed-citation id="mc-CR189" publication-type="journal">Traini G, Ruiz-de-Angulo A, Blanco-Canosa JB, Zamacola Bascaran K, Molinaro A, Silipo A, et al. Cancer Immunotherapy of TLR4 agonist-antigen constructs enhanced with pathogen-mimicking magnetite nanoparticles and checkpoint blockade of PD-L1. Small. 2019;15(4):e1803993.<pub-id pub-id-type="pmid">30569516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.201803993</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR190"><label>190.</label><citation-alternatives><element-citation id="ec-CR190" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Dong</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Lv</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>N</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Surgically derived cancer cell membrane-coated R837-Loaded Poly(2-Oxazoline) nanoparticles for prostate cancer immunotherapy</article-title><source>ACS Appl Mater Interfaces</source><year>2023</year><volume>15</volume><issue>6</issue><fpage>7878</fpage><lpage>7886</lpage><pub-id pub-id-type="doi">10.1021/acsami.2c22363</pub-id><pub-id pub-id-type="pmid">36738473</pub-id><pub-id pub-id-type="pmcid">PMC9940722</pub-id></element-citation><mixed-citation id="mc-CR190" publication-type="journal">Li S, Dong S, Wu J, Lv X, Yang N, Wei Q, et al. Surgically derived cancer cell membrane-coated R837-Loaded Poly(2-Oxazoline) nanoparticles for prostate cancer immunotherapy. ACS Appl Mater Interfaces. 2023;15(6):7878&#8211;86.<pub-id pub-id-type="pmid">36738473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsami.2c22363</pub-id><pub-id pub-id-type="pmcid">PMC9940722</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR191"><label>191.</label><citation-alternatives><element-citation id="ec-CR191" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manna</surname><given-names>S</given-names></name><name name-style="western"><surname>Maiti</surname><given-names>S</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>A</given-names></name><name name-style="western"><surname>Mulder</surname><given-names>E</given-names></name><name name-style="western"><surname>Du</surname><given-names>W</given-names></name><etal/></person-group><article-title>Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity</article-title><source>Biomaterials</source><year>2023</year><volume>296</volume><fpage>122062</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2023.122062</pub-id><pub-id pub-id-type="pmid">36863071</pub-id><pub-id pub-id-type="pmcid">PMC10085859</pub-id></element-citation><mixed-citation id="mc-CR191" publication-type="journal">Manna S, Maiti S, Shen J, Weiss A, Mulder E, Du W, et al. Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity. Biomaterials. 2023;296:122062.<pub-id pub-id-type="pmid">36863071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2023.122062</pub-id><pub-id pub-id-type="pmcid">PMC10085859</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR192"><label>192.</label><citation-alternatives><element-citation id="ec-CR192" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>V</given-names></name><name name-style="western"><surname>Kucaba</surname><given-names>TA</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Sehgal</surname><given-names>D</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>DM</given-names></name><etal/></person-group><article-title>TLR7/8 agonist-loaded nanoparticles augment NK cell-mediated antibody-based cancer immunotherapy</article-title><source>Mol Pharm</source><year>2020</year><volume>17</volume><issue>6</issue><fpage>2109</fpage><lpage>2124</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.0c00271</pub-id><pub-id pub-id-type="pmid">32383885</pub-id></element-citation><mixed-citation id="mc-CR192" publication-type="journal">Kim H, Khanna V, Kucaba TA, Zhang W, Sehgal D, Ferguson DM, et al. TLR7/8 agonist-loaded nanoparticles augment NK cell-mediated antibody-based cancer immunotherapy. Mol Pharm. 2020;17(6):2109&#8211;24.<pub-id pub-id-type="pmid">32383885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.0c00271</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR193"><label>193.</label><citation-alternatives><element-citation id="ec-CR193" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Hao</surname><given-names>C</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The development of chiral nanoparticles to target NK cells and CD8(+) T cells for cancer immunotherapy</article-title><source>Adv Mater</source><year>2022</year><volume>34</volume><issue>16</issue><fpage>e2109354</fpage><pub-id pub-id-type="doi">10.1002/adma.202109354</pub-id><pub-id pub-id-type="pmid">35176181</pub-id></element-citation><mixed-citation id="mc-CR193" publication-type="journal">Wang W, Zhao J, Hao C, Hu S, Chen C, Cao Y, et al. The development of chiral nanoparticles to target NK cells and CD8(+) T cells for cancer immunotherapy. Adv Mater. 2022;34(16):e2109354.<pub-id pub-id-type="pmid">35176181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202109354</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR194"><label>194.</label><citation-alternatives><element-citation id="ec-CR194" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoo</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Eun</surname><given-names>R</given-names></name><name name-style="western"><surname>Park</surname><given-names>HM</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Park</surname><given-names>SH</given-names></name><name name-style="western"><surname>Heo</surname><given-names>J</given-names></name><etal/></person-group><article-title>Nanoengineered macrophages armed with TLR7/8 agonist enhance remodeling of immunosuppressive tumor microenvironment</article-title><source>Small</source><year>2023</year><volume>20</volume><fpage>e2307694</fpage><pub-id pub-id-type="doi">10.1002/smll.202307694</pub-id><pub-id pub-id-type="pmid">37967333</pub-id></element-citation><mixed-citation id="mc-CR194" publication-type="journal">Yoo YJ, Eun R, Park HM, Kim S, Park SH, Heo J, et al. Nanoengineered macrophages armed with TLR7/8 agonist enhance remodeling of immunosuppressive tumor microenvironment. Small. 2023;20:e2307694.<pub-id pub-id-type="pmid">37967333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202307694</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR195"><label>195.</label><citation-alternatives><element-citation id="ec-CR195" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biber</surname><given-names>G</given-names></name><name name-style="western"><surname>Sabag</surname><given-names>B</given-names></name><name name-style="western"><surname>Raiff</surname><given-names>A</given-names></name><name name-style="western"><surname>Ben-Shmuel</surname><given-names>A</given-names></name><name name-style="western"><surname>Puthenveetil</surname><given-names>A</given-names></name><name name-style="western"><surname>Benichou</surname><given-names>JIC</given-names></name><etal/></person-group><article-title>Modulation of intrinsic inhibitory checkpoints using nano-carriers to unleash NK cell activity</article-title><source>EMBO Mol Med</source><year>2022</year><volume>14</volume><issue>1</issue><fpage>e14073</fpage><pub-id pub-id-type="doi">10.15252/emmm.202114073</pub-id><pub-id pub-id-type="pmid">34725941</pub-id><pub-id pub-id-type="pmcid">PMC8749471</pub-id></element-citation><mixed-citation id="mc-CR195" publication-type="journal">Biber G, Sabag B, Raiff A, Ben-Shmuel A, Puthenveetil A, Benichou JIC, et al. Modulation of intrinsic inhibitory checkpoints using nano-carriers to unleash NK cell activity. EMBO Mol Med. 2022;14(1):e14073.<pub-id pub-id-type="pmid">34725941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.202114073</pub-id><pub-id pub-id-type="pmcid">PMC8749471</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR196"><label>196.</label><citation-alternatives><element-citation id="ec-CR196" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>KS</given-names></name><name name-style="western"><surname>Han</surname><given-names>JH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>SH</given-names></name><name name-style="western"><surname>Jung</surname><given-names>HY</given-names></name><name name-style="western"><surname>Park</surname><given-names>JD</given-names></name><name name-style="western"><surname>An</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Cationic nanoparticle-mediated activation of natural killer cells for effective cancer immunotherapy</article-title><source>ACS Appl Mater Interfaces</source><year>2020</year><volume>12</volume><issue>51</issue><fpage>56731</fpage><lpage>56740</lpage><pub-id pub-id-type="doi">10.1021/acsami.0c16357</pub-id><pub-id pub-id-type="pmid">33290037</pub-id></element-citation><mixed-citation id="mc-CR196" publication-type="journal">Kim KS, Han JH, Choi SH, Jung HY, Park JD, An HJ, et al. Cationic nanoparticle-mediated activation of natural killer cells for effective cancer immunotherapy. ACS Appl Mater Interfaces. 2020;12(51):56731&#8211;40.<pub-id pub-id-type="pmid">33290037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsami.0c16357</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR197"><label>197.</label><citation-alternatives><element-citation id="ec-CR197" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>TT</given-names></name><name name-style="western"><surname>Stephan</surname><given-names>SB</given-names></name><name name-style="western"><surname>Moffett</surname><given-names>HF</given-names></name><name name-style="western"><surname>McKnight</surname><given-names>LE</given-names></name><name name-style="western"><surname>Ji</surname><given-names>W</given-names></name><name name-style="western"><surname>Reiman</surname><given-names>D</given-names></name><etal/></person-group><article-title>In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers</article-title><source>Nat Nanotechnol</source><year>2017</year><volume>12</volume><issue>8</issue><fpage>813</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1038/nnano.2017.57</pub-id><pub-id pub-id-type="pmid">28416815</pub-id><pub-id pub-id-type="pmcid">PMC5646367</pub-id></element-citation><mixed-citation id="mc-CR197" publication-type="journal">Smith TT, Stephan SB, Moffett HF, McKnight LE, Ji W, Reiman D, et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 2017;12(8):813&#8211;20.<pub-id pub-id-type="pmid">28416815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nnano.2017.57</pub-id><pub-id pub-id-type="pmcid">PMC5646367</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR198"><label>198.</label><citation-alternatives><element-citation id="ec-CR198" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Shi</surname><given-names>S</given-names></name><name name-style="western"><surname>Sun</surname><given-names>K</given-names></name><etal/></person-group><article-title>Self-assembled nanoparticles prepared from low-molecular-weight PEI and low-generation PAMAM for EGFRvIII-chimeric antigen receptor gene loading and T-cell transient modification</article-title><source>Int J Nanomedicine</source><year>2020</year><volume>15</volume><fpage>483</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.2147/IJN.S229858</pub-id><pub-id pub-id-type="pmid">32158206</pub-id><pub-id pub-id-type="pmcid">PMC6986680</pub-id></element-citation><mixed-citation id="mc-CR198" publication-type="journal">Yu Q, Zhang M, Chen Y, Chen X, Shi S, Sun K, et al. Self-assembled nanoparticles prepared from low-molecular-weight PEI and low-generation PAMAM for EGFRvIII-chimeric antigen receptor gene loading and T-cell transient modification. Int J Nanomedicine. 2020;15:483&#8211;95.<pub-id pub-id-type="pmid">32158206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S229858</pub-id><pub-id pub-id-type="pmcid">PMC6986680</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR199"><label>199.</label><citation-alternatives><element-citation id="ec-CR199" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Melo</surname><given-names>MB</given-names></name><name name-style="western"><surname>Mabardi</surname><given-names>L</given-names></name><name name-style="western"><surname>Castano</surname><given-names>AP</given-names></name><name name-style="western"><surname>Xie</surname><given-names>YQ</given-names></name><etal/></person-group><article-title>Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery</article-title><source>Nat Biotechnol</source><year>2018</year><volume>36</volume><issue>8</issue><fpage>707</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1038/nbt.4181</pub-id><pub-id pub-id-type="pmid">29985479</pub-id><pub-id pub-id-type="pmcid">PMC6078803</pub-id></element-citation><mixed-citation id="mc-CR199" publication-type="journal">Tang L, Zheng Y, Melo MB, Mabardi L, Castano AP, Xie YQ, et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol. 2018;36(8):707&#8211;16.<pub-id pub-id-type="pmid">29985479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.4181</pub-id><pub-id pub-id-type="pmcid">PMC6078803</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR200"><label>200.</label><citation-alternatives><element-citation id="ec-CR200" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L</given-names></name><name name-style="western"><surname>Mabardi</surname><given-names>L</given-names></name><name name-style="western"><surname>Kumari</surname><given-names>S</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>DJ</given-names></name></person-group><article-title>enhancing adoptive cell therapy of cancer through targeted delivery of small-molecule immunomodulators to internalizing or noninternalizing receptors</article-title><source>ACS Nano</source><year>2017</year><volume>11</volume><issue>3</issue><fpage>3089</fpage><lpage>3100</lpage><pub-id pub-id-type="doi">10.1021/acsnano.7b00078</pub-id><pub-id pub-id-type="pmid">28231431</pub-id><pub-id pub-id-type="pmcid">PMC5647839</pub-id></element-citation><mixed-citation id="mc-CR200" publication-type="journal">Zheng Y, Tang L, Mabardi L, Kumari S, Irvine DJ. enhancing adoptive cell therapy of cancer through targeted delivery of small-molecule immunomodulators to internalizing or noninternalizing receptors. ACS Nano. 2017;11(3):3089&#8211;100.<pub-id pub-id-type="pmid">28231431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.7b00078</pub-id><pub-id pub-id-type="pmcid">PMC5647839</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR201"><label>201.</label><citation-alternatives><element-citation id="ec-CR201" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gal</surname><given-names>O</given-names></name><name name-style="western"><surname>Betzer</surname><given-names>O</given-names></name><name name-style="western"><surname>Rousso-Noori</surname><given-names>L</given-names></name><name name-style="western"><surname>Sadan</surname><given-names>T</given-names></name><name name-style="western"><surname>Motiei</surname><given-names>M</given-names></name><name name-style="western"><surname>Nikitin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Antibody delivery into the brain by radiosensitizer nanoparticles for targeted glioblastoma therapy</article-title><source>J Nanotheranostics</source><year>2022</year><volume>3</volume><issue>4</issue><fpage>177</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.3390/jnt3040012</pub-id><pub-id pub-id-type="pmid">36324626</pub-id><pub-id pub-id-type="pmcid">PMC7613745</pub-id></element-citation><mixed-citation id="mc-CR201" publication-type="journal">Gal O, Betzer O, Rousso-Noori L, Sadan T, Motiei M, Nikitin M, et al. Antibody delivery into the brain by radiosensitizer nanoparticles for targeted glioblastoma therapy. J Nanotheranostics. 2022;3(4):177&#8211;88.<pub-id pub-id-type="pmid">36324626</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jnt3040012</pub-id><pub-id pub-id-type="pmcid">PMC7613745</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR202"><label>202.</label><citation-alternatives><element-citation id="ec-CR202" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lin</surname><given-names>M</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Phototherapy and anti-GITR antibody-based therapy synergistically reinvigorate immunogenic cell death and reject established cancers</article-title><source>Biomaterials</source><year>2021</year><volume>269</volume><fpage>120648</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.120648</pub-id><pub-id pub-id-type="pmid">33445099</pub-id></element-citation><mixed-citation id="mc-CR202" publication-type="journal">Sun Q, Yang Z, Lin M, Peng Y, Wang R, Du Y, et al. Phototherapy and anti-GITR antibody-based therapy synergistically reinvigorate immunogenic cell death and reject established cancers. Biomaterials. 2021;269:120648.<pub-id pub-id-type="pmid">33445099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2020.120648</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR203"><label>203.</label><citation-alternatives><element-citation id="ec-CR203" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>CT</given-names></name><name name-style="western"><surname>Chen</surname><given-names>KG</given-names></name><name name-style="western"><surname>Liu</surname><given-names>A</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Fan</surname><given-names>YN</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>DK</given-names></name><etal/></person-group><article-title>Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><issue>1</issue><fpage>1359</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-21497-6</pub-id><pub-id pub-id-type="pmid">33649336</pub-id><pub-id pub-id-type="pmcid">PMC7921676</pub-id></element-citation><mixed-citation id="mc-CR203" publication-type="journal">Jiang CT, Chen KG, Liu A, Huang H, Fan YN, Zhao DK, et al. Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy. Nat Commun. 2021;12(1):1359.<pub-id pub-id-type="pmid">33649336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-21497-6</pub-id><pub-id pub-id-type="pmcid">PMC7921676</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR204"><label>204.</label><citation-alternatives><element-citation id="ec-CR204" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Go</surname><given-names>S</given-names></name><name name-style="western"><surname>Jung</surname><given-names>M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Moon</surname><given-names>S</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C</given-names></name><etal/></person-group><article-title>A Personalized cancer nanovaccine that enhances t-cell responses and efficacy through dual interactions with dendritic cells and T cells</article-title><source>Adv Mater</source><year>2023</year><volume>35</volume><issue>49</issue><fpage>e2303979</fpage><pub-id pub-id-type="doi">10.1002/adma.202303979</pub-id><pub-id pub-id-type="pmid">37515819</pub-id></element-citation><mixed-citation id="mc-CR204" publication-type="journal">Go S, Jung M, Lee S, Moon S, Hong J, Kim C, et al. A Personalized cancer nanovaccine that enhances t-cell responses and efficacy through dual interactions with dendritic cells and T cells. Adv Mater. 2023;35(49):e2303979.<pub-id pub-id-type="pmid">37515819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202303979</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR205"><label>205.</label><citation-alternatives><element-citation id="ec-CR205" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Tian</surname><given-names>J</given-names></name><name name-style="western"><surname>Qi</surname><given-names>C</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yan</surname><given-names>W</given-names></name><etal/></person-group><article-title>Intravenous delivery of RNA encoding Anti-PD-1 human monoclonal antibody for treating intestinal cancer</article-title><source>J Cancer</source><year>2022</year><volume>13</volume><issue>2</issue><fpage>579</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.7150/jca.63991</pub-id><pub-id pub-id-type="pmid">35069904</pub-id><pub-id pub-id-type="pmcid">PMC8771528</pub-id></element-citation><mixed-citation id="mc-CR205" publication-type="journal">Wu L, Wang W, Tian J, Qi C, Cai Z, Yan W, et al. Intravenous delivery of RNA encoding Anti-PD-1 human monoclonal antibody for treating intestinal cancer. J Cancer. 2022;13(2):579&#8211;88.<pub-id pub-id-type="pmid">35069904</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/jca.63991</pub-id><pub-id pub-id-type="pmcid">PMC8771528</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR206"><label>206.</label><citation-alternatives><element-citation id="ec-CR206" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stater</surname><given-names>EP</given-names></name><name name-style="western"><surname>Morcos</surname><given-names>G</given-names></name><name name-style="western"><surname>Isaac</surname><given-names>E</given-names></name><name name-style="western"><surname>Ogirala</surname><given-names>A</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>HT</given-names></name><name name-style="western"><surname>Longo</surname><given-names>VA</given-names></name><etal/></person-group><article-title>Translatable drug-loaded iron oxide nanophore sensitizes murine melanoma tumors to monoclonal antibody immunotherapy</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><issue>7</issue><fpage>6178</fpage><lpage>6192</lpage><pub-id pub-id-type="doi">10.1021/acsnano.2c05800</pub-id><pub-id pub-id-type="pmid">36971591</pub-id><pub-id pub-id-type="pmcid">PMC10324163</pub-id></element-citation><mixed-citation id="mc-CR206" publication-type="journal">Stater EP, Morcos G, Isaac E, Ogirala A, Hsu HT, Longo VA, et al. Translatable drug-loaded iron oxide nanophore sensitizes murine melanoma tumors to monoclonal antibody immunotherapy. ACS Nano. 2023;17(7):6178&#8211;92.<pub-id pub-id-type="pmid">36971591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.2c05800</pub-id><pub-id pub-id-type="pmcid">PMC10324163</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR207"><label>207.</label><citation-alternatives><element-citation id="ec-CR207" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy</article-title><source>Acta Pharm Sin B</source><year>2023</year><volume>13</volume><issue>3</issue><fpage>955</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2022.09.021</pub-id><pub-id pub-id-type="pmid">36970191</pub-id><pub-id pub-id-type="pmcid">PMC10031380</pub-id></element-citation><mixed-citation id="mc-CR207" publication-type="journal">Dong Z, Huang Z, Li S, Wang Y, Yao Y, Yang X, et al. Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy. Acta Pharm Sin B. 2023;13(3):955&#8211;66.<pub-id pub-id-type="pmid">36970191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2022.09.021</pub-id><pub-id pub-id-type="pmcid">PMC10031380</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR208"><label>208.</label><citation-alternatives><element-citation id="ec-CR208" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T</given-names></name><name name-style="western"><surname>Qin</surname><given-names>X</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Tumor lysate-loaded lipid hybrid nanovaccine collaborated with an immune checkpoint antagonist for combination immunotherapy</article-title><source>Adv Healthc Mater</source><year>2019</year><volume>8</volume><issue>1</issue><fpage>e1800837</fpage><pub-id pub-id-type="doi">10.1002/adhm.201800837</pub-id><pub-id pub-id-type="pmid">30506847</pub-id></element-citation><mixed-citation id="mc-CR208" publication-type="journal">Hu X, Wu T, Qin X, Qi Y, Qiao Q, Yang C, et al. Tumor lysate-loaded lipid hybrid nanovaccine collaborated with an immune checkpoint antagonist for combination immunotherapy. Adv Healthc Mater. 2019;8(1):e1800837.<pub-id pub-id-type="pmid">30506847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.201800837</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR209"><label>209.</label><citation-alternatives><element-citation id="ec-CR209" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ding</surname><given-names>H</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Si</surname><given-names>G</given-names></name><etal/></person-group><article-title>Magnetic delivery of antigen-loaded magnetic liposomes for active lymph node targeting and enhanced anti-tumor immunity</article-title><source>Adv Healthc Mater</source><year>2023</year><volume>12</volume><issue>32</issue><fpage>e2301232</fpage><pub-id pub-id-type="doi">10.1002/adhm.202301232</pub-id><pub-id pub-id-type="pmid">37709487</pub-id></element-citation><mixed-citation id="mc-CR209" publication-type="journal">Sheng J, Liu Y, Ding H, Wu L, Liu L, Si G, et al. Magnetic delivery of antigen-loaded magnetic liposomes for active lymph node targeting and enhanced anti-tumor immunity. Adv Healthc Mater. 2023;12(32):e2301232.<pub-id pub-id-type="pmid">37709487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202301232</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR210"><label>210.</label><citation-alternatives><element-citation id="ec-CR210" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Construction of pH-sensitive nanovaccines encapsulating tumor cell lysates and immune adjuvants for breast cancer therapy</article-title><source>Small</source><year>2023</year><volume>19</volume><issue>37</issue><fpage>e2301420</fpage><pub-id pub-id-type="doi">10.1002/smll.202301420</pub-id><pub-id pub-id-type="pmid">37154213</pub-id></element-citation><mixed-citation id="mc-CR210" publication-type="journal">Ding Y, Yang J, Wei H, Wang J, Huang S, Yang S, et al. Construction of pH-sensitive nanovaccines encapsulating tumor cell lysates and immune adjuvants for breast cancer therapy. Small. 2023;19(37):e2301420.<pub-id pub-id-type="pmid">37154213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202301420</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR211"><label>211.</label><citation-alternatives><element-citation id="ec-CR211" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>He</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>F</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Personalized bacteria loaded with autoantigens for the enhancement of tumor immunotherapy</article-title><source>Adv Healthc Mater</source><year>2023</year><volume>12</volume><issue>11</issue><fpage>e2203026</fpage><pub-id pub-id-type="doi">10.1002/adhm.202203026</pub-id><pub-id pub-id-type="pmid">36602466</pub-id></element-citation><mixed-citation id="mc-CR211" publication-type="journal">Wu C, He W, Chen Y, Cai J, Zeng F, Lu Z, et al. Personalized bacteria loaded with autoantigens for the enhancement of tumor immunotherapy. Adv Healthc Mater. 2023;12(11):e2203026.<pub-id pub-id-type="pmid">36602466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202203026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR212"><label>212.</label><citation-alternatives><element-citation id="ec-CR212" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ding</surname><given-names>M</given-names></name><name name-style="western"><surname>Xiu</surname><given-names>W</given-names></name><name name-style="western"><surname>Shan</surname><given-names>J</given-names></name><name name-style="western"><surname>Yuwen</surname><given-names>L</given-names></name><etal/></person-group><article-title>Endogenous/exogenous nanovaccines synergistically enhance dendritic cell-mediated tumor immunotherapy</article-title><source>Adv Healthc Mater</source><year>2023</year><volume>12</volume><issue>17</issue><fpage>e2203028</fpage><pub-id pub-id-type="doi">10.1002/adhm.202203028</pub-id><pub-id pub-id-type="pmid">36807733</pub-id><pub-id pub-id-type="pmcid">PMC11468714</pub-id></element-citation><mixed-citation id="mc-CR212" publication-type="journal">Zhang Y, Li Q, Ding M, Xiu W, Shan J, Yuwen L, et al. Endogenous/exogenous nanovaccines synergistically enhance dendritic cell-mediated tumor immunotherapy. Adv Healthc Mater. 2023;12(17):e2203028.<pub-id pub-id-type="pmid">36807733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202203028</pub-id><pub-id pub-id-type="pmcid">PMC11468714</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR213"><label>213.</label><citation-alternatives><element-citation id="ec-CR213" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>H</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S</given-names></name><name name-style="western"><surname>Chae</surname><given-names>SY</given-names></name><name name-style="western"><surname>Won</surname><given-names>C</given-names></name><name name-style="western"><surname>Min</surname><given-names>DH</given-names></name></person-group><article-title>Development of a cancer nanovaccine to induce antigen-specific immune responses based on large-sized porous silica nanoparticles</article-title><source>ACS Appl Mater Interfaces</source><year>2023</year><volume>15</volume><issue>11</issue><fpage>13860</fpage><lpage>8</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsami.2c19526</pub-id><pub-id pub-id-type="pmid">36913611</pub-id></element-citation><mixed-citation id="mc-CR213" publication-type="journal">Shin H, Kang S, Chae SY, Won C, Min DH. Development of a cancer nanovaccine to induce antigen-specific immune responses based on large-sized porous silica nanoparticles. ACS Appl Mater Interfaces. 2023;15(11):13860&#8211;8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsami.2c19526</pub-id><pub-id pub-id-type="pmid">36913611</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR214"><label>214.</label><citation-alternatives><element-citation id="ec-CR214" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Dong</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Dual-responsive PEG-lipid polyester nanoparticles for siRNA and vaccine delivery elicit anti-cancer immune responses by modulating tumor microenvironment</article-title><source>Biomater Sci</source><year>2023</year><volume>11</volume><issue>19</issue><fpage>6619</fpage><lpage>6634</lpage><pub-id pub-id-type="doi">10.1039/D3BM01265D</pub-id><pub-id pub-id-type="pmid">37608695</pub-id></element-citation><mixed-citation id="mc-CR214" publication-type="journal">Liu Z, Zhao L, Feng Y, Wang Q, Dong N, Zhang Y, et al. Dual-responsive PEG-lipid polyester nanoparticles for siRNA and vaccine delivery elicit anti-cancer immune responses by modulating tumor microenvironment. Biomater Sci. 2023;11(19):6619&#8211;34.<pub-id pub-id-type="pmid">37608695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d3bm01265d</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR215"><label>215.</label><citation-alternatives><element-citation id="ec-CR215" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lafuente-Gomez</surname><given-names>N</given-names></name><name name-style="western"><surname>de Lazaro</surname><given-names>I</given-names></name><name name-style="western"><surname>Dhanjani</surname><given-names>M</given-names></name><name name-style="western"><surname>Garcia-Soriano</surname><given-names>D</given-names></name><name name-style="western"><surname>Sobral</surname><given-names>MC</given-names></name><name name-style="western"><surname>Salas</surname><given-names>G</given-names></name><etal/></person-group><article-title>Multifunctional magnetic nanoparticles elicit anti-tumor immunity in a mouse melanoma model</article-title><source>Mater Today Bio</source><year>2023</year><volume>23</volume><fpage>100817</fpage><pub-id pub-id-type="doi">10.1016/j.mtbio.2023.100817</pub-id><pub-id pub-id-type="pmid">37822453</pub-id><pub-id pub-id-type="pmcid">PMC10562177</pub-id></element-citation><mixed-citation id="mc-CR215" publication-type="journal">Lafuente-Gomez N, de Lazaro I, Dhanjani M, Garcia-Soriano D, Sobral MC, Salas G, et al. Multifunctional magnetic nanoparticles elicit anti-tumor immunity in a mouse melanoma model. Mater Today Bio. 2023;23:100817.<pub-id pub-id-type="pmid">37822453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mtbio.2023.100817</pub-id><pub-id pub-id-type="pmcid">PMC10562177</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR216"><label>216.</label><citation-alternatives><element-citation id="ec-CR216" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Poria cocos polysaccharide-functionalized graphene oxide nanosheet induces efficient cancer immunotherapy in mice</article-title><source>Front Bioeng Biotechnol</source><year>2022</year><volume>10</volume><fpage>1050077</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2022.1050077</pub-id><pub-id pub-id-type="pmid">36727039</pub-id><pub-id pub-id-type="pmcid">PMC9885324</pub-id></element-citation><mixed-citation id="mc-CR216" publication-type="journal">Yang J, Dong X, Li B, Chen T, Yu B, Wang X, et al. Poria cocos polysaccharide-functionalized graphene oxide nanosheet induces efficient cancer immunotherapy in mice. Front Bioeng Biotechnol. 2022;10:1050077.<pub-id pub-id-type="pmid">36727039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fbioe.2022.1050077</pub-id><pub-id pub-id-type="pmcid">PMC9885324</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR217"><label>217.</label><citation-alternatives><element-citation id="ec-CR217" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>W</given-names></name><name name-style="western"><surname>Tong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Qian</surname><given-names>H</given-names></name></person-group><article-title>Development of novel self-assembled vaccines based on tumour-specific antigenic peptide and TLR2 agonist for effective breast cancer immunotherapy via activating CD8(+) T cells and enhancing their function</article-title><source>Immunology</source><year>2023</year><volume>169</volume><issue>4</issue><fpage>454</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1111/imm.13643</pub-id><pub-id pub-id-type="pmid">36946150</pub-id></element-citation><mixed-citation id="mc-CR217" publication-type="journal">Shi W, Tong Z, Chen S, Qiu Q, Zhou J, Qian H. Development of novel self-assembled vaccines based on tumour-specific antigenic peptide and TLR2 agonist for effective breast cancer immunotherapy via activating CD8(+) T cells and enhancing their function. Immunology. 2023;169(4):454&#8211;66.<pub-id pub-id-type="pmid">36946150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imm.13643</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR218"><label>218.</label><citation-alternatives><element-citation id="ec-CR218" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gheybi</surname><given-names>E</given-names></name><name name-style="western"><surname>Asoodeh</surname><given-names>A</given-names></name><name name-style="western"><surname>Amani</surname><given-names>J</given-names></name></person-group><article-title>Preparation of chitosan nanoparticle containing recombinant CD44v antigen and evaluation of its immunization capacity against breast cancer in BALB/c mice</article-title><source>BMC Cancer</source><year>2023</year><volume>23</volume><issue>1</issue><fpage>134</fpage><pub-id pub-id-type="doi">10.1186/s12885-023-10614-x</pub-id><pub-id pub-id-type="pmid">36759786</pub-id><pub-id pub-id-type="pmcid">PMC9912563</pub-id></element-citation><mixed-citation id="mc-CR218" publication-type="journal">Gheybi E, Asoodeh A, Amani J. Preparation of chitosan nanoparticle containing recombinant CD44v antigen and evaluation of its immunization capacity against breast cancer in BALB/c mice. BMC Cancer. 2023;23(1):134.<pub-id pub-id-type="pmid">36759786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-023-10614-x</pub-id><pub-id pub-id-type="pmcid">PMC9912563</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR219"><label>219.</label><citation-alternatives><element-citation id="ec-CR219" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>H</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jon</surname><given-names>S</given-names></name></person-group><article-title>Nanovaccine displaying immunodominant T Cell epitopes of fibroblast activation protein is effective against desmoplastic tumors</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><issue>11</issue><fpage>10337</fpage><lpage>10352</lpage><pub-id pub-id-type="doi">10.1021/acsnano.3c00764</pub-id><pub-id pub-id-type="pmid">37184372</pub-id></element-citation><mixed-citation id="mc-CR219" publication-type="journal">Shin H, Kim Y, Jon S. Nanovaccine displaying immunodominant T Cell epitopes of fibroblast activation protein is effective against desmoplastic tumors. ACS Nano. 2023;17(11):10337&#8211;52.<pub-id pub-id-type="pmid">37184372</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c00764</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR220"><label>220.</label><citation-alternatives><element-citation id="ec-CR220" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>C</given-names></name><name name-style="western"><surname>You</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A nanovaccine based on adjuvant peptide FK-13 and l-phenylalanine poly(ester amide) enhances CD8(+) T cell-mediated antitumor immunity</article-title><source>Adv Sci (Weinh)</source><year>2023</year><volume>10</volume><issue>20</issue><fpage>e2300418</fpage><pub-id pub-id-type="doi">10.1002/advs.202300418</pub-id><pub-id pub-id-type="pmid">37162249</pub-id><pub-id pub-id-type="pmcid">PMC10369282</pub-id></element-citation><mixed-citation id="mc-CR220" publication-type="journal">Xie C, You X, Zhang H, Li J, Wang L, Liu Y, et al. A nanovaccine based on adjuvant peptide FK-13 and l-phenylalanine poly(ester amide) enhances CD8(+) T cell-mediated antitumor immunity. Adv Sci (Weinh). 2023;10(20):e2300418.<pub-id pub-id-type="pmid">37162249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202300418</pub-id><pub-id pub-id-type="pmcid">PMC10369282</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR221"><label>221.</label><citation-alternatives><element-citation id="ec-CR221" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L</given-names></name><name name-style="western"><surname>Quan</surname><given-names>J</given-names></name><name name-style="western"><surname>Gu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Self-assembled nanoparticles based on DNA origami and a nitrated T helper cell epitope as a platform for the development of personalized cancer vaccines</article-title><source>Cancer Immunol Immunother</source><year>2023</year><volume>72</volume><issue>8</issue><fpage>2741</fpage><lpage>2755</lpage><pub-id pub-id-type="doi">10.1007/s00262-023-03446-y</pub-id><pub-id pub-id-type="pmid">37119260</pub-id><pub-id pub-id-type="pmcid">PMC10992429</pub-id></element-citation><mixed-citation id="mc-CR221" publication-type="journal">Kang Y, Zhang W, Yu Q, Gao L, Quan J, Gu F, et al. Self-assembled nanoparticles based on DNA origami and a nitrated T helper cell epitope as a platform for the development of personalized cancer vaccines. Cancer Immunol Immunother. 2023;72(8):2741&#8211;55.<pub-id pub-id-type="pmid">37119260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-023-03446-y</pub-id><pub-id pub-id-type="pmcid">PMC10992429</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR222"><label>222.</label><citation-alternatives><element-citation id="ec-CR222" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G</given-names></name></person-group><article-title>Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy</article-title><source>Bioact Mater</source><year>2023</year><volume>26</volume><fpage>169</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">36883121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2023.02.016</pub-id><pub-id pub-id-type="pmcid">PMC9982230</pub-id></element-citation><mixed-citation id="mc-CR222" publication-type="journal">Su T, Liu X, Lin S, Cheng F, Zhu G. Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy. Bioact Mater. 2023;26:169&#8211;80.<pub-id pub-id-type="pmid">36883121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2023.02.016</pub-id><pub-id pub-id-type="pmcid">PMC9982230</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR223"><label>223.</label><citation-alternatives><element-citation id="ec-CR223" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>K</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J</given-names></name></person-group><article-title>Vaccination of TLR7/8 agonist-conjugated antigen nanoparticles for cancer immunotherapy</article-title><source>Adv Healthc Mater</source><year>2023</year><volume>12</volume><issue>22</issue><fpage>e2300249</fpage><pub-id pub-id-type="doi">10.1002/adhm.202300249</pub-id><pub-id pub-id-type="pmid">37016572</pub-id></element-citation><mixed-citation id="mc-CR223" publication-type="journal">Wang N, Zhang G, Zhang P, Zhao K, Tian Y, Cui J. Vaccination of TLR7/8 agonist-conjugated antigen nanoparticles for cancer immunotherapy. Adv Healthc Mater. 2023;12(22):e2300249.<pub-id pub-id-type="pmid">37016572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202300249</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR224"><label>224.</label><citation-alternatives><element-citation id="ec-CR224" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name></person-group><article-title>Antigen-capturing dendritic-cell-targeting nanoparticles for enhanced tumor immunotherapy based on photothermal-therapy-induced in situ vaccination</article-title><source>Adv Healthc Mater</source><year>2023</year><volume>12</volume><issue>22</issue><fpage>e2202871</fpage><pub-id pub-id-type="doi">10.1002/adhm.202202871</pub-id><pub-id pub-id-type="pmid">37276021</pub-id></element-citation><mixed-citation id="mc-CR224" publication-type="journal">Li Y, Luo Y, Hou L, Huang Z, Wang Y, Zhou S. Antigen-capturing dendritic-cell-targeting nanoparticles for enhanced tumor immunotherapy based on photothermal-therapy-induced in situ vaccination. Adv Healthc Mater. 2023;12(22):e2202871.<pub-id pub-id-type="pmid">37276021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202202871</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR225"><label>225.</label><citation-alternatives><element-citation id="ec-CR225" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nahar</surname><given-names>S</given-names></name><name name-style="western"><surname>Alam</surname><given-names>MM</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S</given-names></name><name name-style="western"><surname>McVicar</surname><given-names>DW</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D</given-names></name></person-group><article-title>reactive oxygen species-sensitive biodegradable mesoporous silica nanoparticles harboring theravac elicit tumor-specific immunity for colon tumor treatment</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><issue>20</issue><fpage>19740</fpage><lpage>19752</lpage><pub-id pub-id-type="doi">10.1021/acsnano.3c03195</pub-id><pub-id pub-id-type="pmid">37831945</pub-id></element-citation><mixed-citation id="mc-CR225" publication-type="journal">Huang Y, Nahar S, Alam MM, Hu S, McVicar DW, Yang D. reactive oxygen species-sensitive biodegradable mesoporous silica nanoparticles harboring theravac elicit tumor-specific immunity for colon tumor treatment. ACS Nano. 2023;17(20):19740&#8211;52.<pub-id pub-id-type="pmid">37831945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c03195</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR226"><label>226.</label><citation-alternatives><element-citation id="ec-CR226" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donkor</surname><given-names>M</given-names></name><name name-style="western"><surname>Choe</surname><given-names>J</given-names></name><name name-style="western"><surname>Reid</surname><given-names>DM</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>B</given-names></name><name name-style="western"><surname>Pulse</surname><given-names>M</given-names></name><name name-style="western"><surname>Ranjan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Nasal tumor vaccination protects against lung tumor development by induction of resident effector and memory anti-tumor immune responses</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><issue>2</issue><fpage>445</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics15020445</pub-id><pub-id pub-id-type="pmid">36839766</pub-id><pub-id pub-id-type="pmcid">PMC9958580</pub-id></element-citation><mixed-citation id="mc-CR226" publication-type="journal">Donkor M, Choe J, Reid DM, Quinn B, Pulse M, Ranjan A, et al. Nasal tumor vaccination protects against lung tumor development by induction of resident effector and memory anti-tumor immune responses. Pharmaceutics. 2023;15(2):445.<pub-id pub-id-type="pmid">36839766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15020445</pub-id><pub-id pub-id-type="pmcid">PMC9958580</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR227"><label>227.</label><citation-alternatives><element-citation id="ec-CR227" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>W</given-names></name><name name-style="western"><surname>Feng</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Ferroptosis and necroptosis produced autologous tumor cell lysates co-delivering with combined immnoadjuvants as personalized in situ nanovaccines for antitumor immunity</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><issue>15</issue><fpage>14475</fpage><lpage>14493</lpage><pub-id pub-id-type="doi">10.1021/acsnano.3c00901</pub-id><pub-id pub-id-type="pmid">37466500</pub-id></element-citation><mixed-citation id="mc-CR227" publication-type="journal">Shi W, Feng W, Li S, Cui Y, Liu S, Jiang H, et al. Ferroptosis and necroptosis produced autologous tumor cell lysates co-delivering with combined immnoadjuvants as personalized in situ nanovaccines for antitumor immunity. ACS Nano. 2023;17(15):14475&#8211;93.<pub-id pub-id-type="pmid">37466500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c00901</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR228"><label>228.</label><citation-alternatives><element-citation id="ec-CR228" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>K</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><etal/></person-group><article-title>Regulating the surface topography of CpG nanoadjuvants via coordination-driven self-assembly for enhanced tumor immunotherapy</article-title><source>Nanoscale Adv</source><year>2023</year><volume>5</volume><issue>18</issue><fpage>4758</fpage><lpage>4769</lpage><pub-id pub-id-type="doi">10.1039/D3NA00322A</pub-id><pub-id pub-id-type="pmid">37705793</pub-id><pub-id pub-id-type="pmcid">PMC10496906</pub-id></element-citation><mixed-citation id="mc-CR228" publication-type="journal">Zhang L, Zhang L, Wang Y, Jiang K, Gao C, Zhang P, et al. Regulating the surface topography of CpG nanoadjuvants via coordination-driven self-assembly for enhanced tumor immunotherapy. Nanoscale Adv. 2023;5(18):4758&#8211;69.<pub-id pub-id-type="pmid">37705793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d3na00322a</pub-id><pub-id pub-id-type="pmcid">PMC10496906</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR229"><label>229.</label><citation-alternatives><element-citation id="ec-CR229" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>J</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Rui</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Hou</surname><given-names>C</given-names></name><name name-style="western"><surname>Leng</surname><given-names>X</given-names></name><etal/></person-group><article-title>A Universal cyclodextrin-based nanovaccine platform delivers epitope peptides for enhanced antitumor immunity</article-title><source>Adv Healthc Mater</source><year>2023</year><volume>12</volume><issue>27</issue><fpage>e2301099</fpage><pub-id pub-id-type="doi">10.1002/adhm.202301099</pub-id><pub-id pub-id-type="pmid">37602523</pub-id></element-citation><mixed-citation id="mc-CR229" publication-type="journal">Mao J, Jin Z, Rui X, Li L, Hou C, Leng X, et al. A Universal cyclodextrin-based nanovaccine platform delivers epitope peptides for enhanced antitumor immunity. Adv Healthc Mater. 2023;12(27):e2301099.<pub-id pub-id-type="pmid">37602523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202301099</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR230"><label>230.</label><citation-alternatives><element-citation id="ec-CR230" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Firdaus</surname><given-names>FZ</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>S</given-names></name><name name-style="western"><surname>Hussein</surname><given-names>WM</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wright</surname><given-names>Q</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Liposomal formulations of a polyleucine-antigen conjugate as therapeutic vaccines against cervical cancer</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><issue>2</issue><fpage>602</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics15020602</pub-id><pub-id pub-id-type="pmid">36839923</pub-id><pub-id pub-id-type="pmcid">PMC9965676</pub-id></element-citation><mixed-citation id="mc-CR230" publication-type="journal">Firdaus FZ, Bartlett S, Hussein WM, Lu L, Wright Q, Huang W, et al. Liposomal formulations of a polyleucine-antigen conjugate as therapeutic vaccines against cervical cancer. Pharmaceutics. 2023;15(2):602.<pub-id pub-id-type="pmid">36839923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15020602</pub-id><pub-id pub-id-type="pmcid">PMC9965676</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR231"><label>231.</label><citation-alternatives><element-citation id="ec-CR231" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>P</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A "trained immunity" inducer-adjuvanted nanovaccine reverses the growth of established tumors in mice</article-title><source>J Nanobiotechnology</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>74</fpage><pub-id pub-id-type="doi">10.1186/s12951-023-01832-3</pub-id><pub-id pub-id-type="pmid">36864424</pub-id><pub-id pub-id-type="pmcid">PMC9980871</pub-id></element-citation><mixed-citation id="mc-CR231" publication-type="journal">Li D, Li W, Zheng P, Yang Y, Liu Q, Hu Y, et al. A &#8220;trained immunity&#8221; inducer-adjuvanted nanovaccine reverses the growth of established tumors in mice. J Nanobiotechnology. 2023;21(1):74.<pub-id pub-id-type="pmid">36864424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-023-01832-3</pub-id><pub-id pub-id-type="pmcid">PMC9980871</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR232"><label>232.</label><citation-alternatives><element-citation id="ec-CR232" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramos da Silva</surname><given-names>J</given-names></name><name name-style="western"><surname>Bitencourt Rodrigues</surname><given-names>K</given-names></name><name name-style="western"><surname>FormosoPelegrin</surname><given-names>G</given-names></name><name name-style="western"><surname>Silva Sales</surname><given-names>N</given-names></name><name name-style="western"><surname>Muramatsu</surname><given-names>H</given-names></name><name name-style="western"><surname>de Oliveirasilva</surname><given-names>M</given-names></name><etal/></person-group><article-title>Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice</article-title><source>Sci Transl Med</source><year>2023</year><volume>15</volume><issue>686</issue><fpage>eabn3464</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.abn3464</pub-id><pub-id pub-id-type="pmid">36867683</pub-id></element-citation><mixed-citation id="mc-CR232" publication-type="journal">Ramos da Silva J, Bitencourt Rodrigues K, FormosoPelegrin G, Silva Sales N, Muramatsu H, de Oliveirasilva M, et al. Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice. Sci Transl Med. 2023;15(686):eabn3464.<pub-id pub-id-type="pmid">36867683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.abn3464</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR233"><label>233.</label><citation-alternatives><element-citation id="ec-CR233" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>K</given-names></name><name name-style="western"><surname>Duan</surname><given-names>X</given-names></name><name name-style="western"><surname>Mao</surname><given-names>M</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Rao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>D</given-names></name><etal/></person-group><article-title>mRNA-LNP vaccination-based immunotherapy augments CD8(+) T cell responses against HPV-positive oropharyngeal cancer</article-title><source>NPJ Vaccines</source><year>2023</year><volume>8</volume><issue>1</issue><fpage>144</fpage><pub-id pub-id-type="doi">10.1038/s41541-023-00733-8</pub-id><pub-id pub-id-type="pmid">37773254</pub-id><pub-id pub-id-type="pmcid">PMC10542330</pub-id></element-citation><mixed-citation id="mc-CR233" publication-type="journal">Qiu K, Duan X, Mao M, Song Y, Rao Y, Cheng D, et al. mRNA-LNP vaccination-based immunotherapy augments CD8(+) T cell responses against HPV-positive oropharyngeal cancer. NPJ Vaccines. 2023;8(1):144.<pub-id pub-id-type="pmid">37773254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-023-00733-8</pub-id><pub-id pub-id-type="pmcid">PMC10542330</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR234"><label>234.</label><citation-alternatives><element-citation id="ec-CR234" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>P</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Exploiting immunostimulatory mechanisms of immunogenic cell death to develop membrane-encapsulated nanoparticles as a potent tumor vaccine</article-title><source>J Nanobiotechnology</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>326</fpage><pub-id pub-id-type="doi">10.1186/s12951-023-02031-w</pub-id><pub-id pub-id-type="pmid">37684628</pub-id><pub-id pub-id-type="pmcid">PMC10492316</pub-id></element-citation><mixed-citation id="mc-CR234" publication-type="journal">Liu Q, Hu Y, Zheng P, Yang Y, Fu Y, Yang Y, et al. Exploiting immunostimulatory mechanisms of immunogenic cell death to develop membrane-encapsulated nanoparticles as a potent tumor vaccine. J Nanobiotechnology. 2023;21(1):326.<pub-id pub-id-type="pmid">37684628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-023-02031-w</pub-id><pub-id pub-id-type="pmcid">PMC10492316</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR235"><label>235.</label><citation-alternatives><element-citation id="ec-CR235" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma</article-title><source>Theranostics</source><year>2023</year><volume>13</volume><issue>12</issue><fpage>4166</fpage><lpage>4181</lpage><pub-id pub-id-type="doi">10.7150/thno.85843</pub-id><pub-id pub-id-type="pmid">37554274</pub-id><pub-id pub-id-type="pmcid">PMC10405843</pub-id></element-citation><mixed-citation id="mc-CR235" publication-type="journal">Lin Z, Jiang C, Wang P, Chen Q, Wang B, Fu X, et al. Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma. Theranostics. 2023;13(12):4166&#8211;81.<pub-id pub-id-type="pmid">37554274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.85843</pub-id><pub-id pub-id-type="pmcid">PMC10405843</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR236"><label>236.</label><citation-alternatives><element-citation id="ec-CR236" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>M</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Spleen-targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma</article-title><source>EMBO Mol Med</source><year>2023</year><volume>15</volume><issue>10</issue><fpage>e16836</fpage><pub-id pub-id-type="doi">10.15252/emmm.202216836</pub-id><pub-id pub-id-type="pmid">37552209</pub-id><pub-id pub-id-type="pmcid">PMC10565630</pub-id></element-citation><mixed-citation id="mc-CR236" publication-type="journal">Wu M, Luo Z, Cai Z, Mao Q, Li Z, Li H, et al. Spleen-targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma. EMBO Mol Med. 2023;15(10):e16836.<pub-id pub-id-type="pmid">37552209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.202216836</pub-id><pub-id pub-id-type="pmcid">PMC10565630</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR237"><label>237.</label><citation-alternatives><element-citation id="ec-CR237" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tian</surname><given-names>M</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion</article-title><source>J Nanobiotechnology</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>324</fpage><pub-id pub-id-type="doi">10.1186/s12951-023-02069-w</pub-id><pub-id pub-id-type="pmid">37679769</pub-id><pub-id pub-id-type="pmcid">PMC10486025</pub-id></element-citation><mixed-citation id="mc-CR237" publication-type="journal">Xiang Y, Tian M, Huang J, Li Y, Li G, Li X, et al. LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion. J Nanobiotechnology. 2023;21(1):324.<pub-id pub-id-type="pmid">37679769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-023-02069-w</pub-id><pub-id pub-id-type="pmcid">PMC10486025</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR238"><label>238.</label><citation-alternatives><element-citation id="ec-CR238" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Han</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>DS</given-names></name><name name-style="western"><surname>Hong</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>K</given-names></name><etal/></person-group><article-title>ROS-responsive nanoparticle delivery of mRNA and photosensitizer for combinatorial cancer therapy</article-title><source>Nano Lett</source><year>2023</year><volume>23</volume><issue>9</issue><fpage>3661</fpage><lpage>3668</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.2c03784</pub-id><pub-id pub-id-type="pmid">37093620</pub-id></element-citation><mixed-citation id="mc-CR238" publication-type="journal">Zhou H, Liao Y, Han X, Chen DS, Hong X, Zhou K, et al. ROS-responsive nanoparticle delivery of mRNA and photosensitizer for combinatorial cancer therapy. Nano Lett. 2023;23(9):3661&#8211;8.<pub-id pub-id-type="pmid">37093620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.2c03784</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR239"><label>239.</label><citation-alternatives><element-citation id="ec-CR239" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>P</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H</given-names></name><name name-style="western"><surname>Ding</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name><etal/></person-group><article-title>An integrated polymeric mrna vaccine without inflammation side effects for cellular immunity mediated cancer therapy</article-title><source>Adv Mater</source><year>2023</year><volume>35</volume><issue>3</issue><fpage>e2207471</fpage><pub-id pub-id-type="doi">10.1002/adma.202207471</pub-id><pub-id pub-id-type="pmid">36326183</pub-id></element-citation><mixed-citation id="mc-CR239" publication-type="journal">Huang P, Jiang L, Pan H, Ding L, Zhou B, Zhao M, et al. An integrated polymeric mrna vaccine without inflammation side effects for cellular immunity mediated cancer therapy. Adv Mater. 2023;35(3):e2207471.<pub-id pub-id-type="pmid">36326183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202207471</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR240"><label>240.</label><citation-alternatives><element-citation id="ec-CR240" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Shen</surname><given-names>R</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity</article-title><source>Nat Biomed Eng</source><year>2023</year><volume>8</volume><issue>5</issue><fpage>544</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1038/s41551-023-01131-0</pub-id><pub-id pub-id-type="pmid">38082180</pub-id><pub-id pub-id-type="pmcid">PMC11162325</pub-id></element-citation><mixed-citation id="mc-CR240" publication-type="journal">Zhu Y, Ma J, Shen R, Lin J, Li S, Lu X, et al. Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity. Nat Biomed Eng. 2023;8(5):544&#8211;60.<pub-id pub-id-type="pmid">38082180</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41551-023-01131-0</pub-id><pub-id pub-id-type="pmcid">PMC11162325</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR241"><label>241.</label><citation-alternatives><element-citation id="ec-CR241" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben-Akiva</surname><given-names>E</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>J</given-names></name><name name-style="western"><surname>Hemmati</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name><name name-style="western"><surname>Tzeng</surname><given-names>SY</given-names></name><name name-style="western"><surname>Pardoll</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination</article-title><source>Proc Natl Acad Sci U S A</source><year>2023</year><volume>120</volume><issue>26</issue><fpage>e2301606120</fpage><pub-id pub-id-type="doi">10.1073/pnas.2301606120</pub-id><pub-id pub-id-type="pmid">37339211</pub-id><pub-id pub-id-type="pmcid">PMC10293809</pub-id></element-citation><mixed-citation id="mc-CR241" publication-type="journal">Ben-Akiva E, Karlsson J, Hemmati S, Yu H, Tzeng SY, Pardoll DM, et al. Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination. Proc Natl Acad Sci U S A. 2023;120(26):e2301606120.<pub-id pub-id-type="pmid">37339211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2301606120</pub-id><pub-id pub-id-type="pmcid">PMC10293809</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR242"><label>242.</label><citation-alternatives><element-citation id="ec-CR242" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oyama</surname><given-names>R</given-names></name><name name-style="western"><surname>Ishigame</surname><given-names>H</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>H</given-names></name><name name-style="western"><surname>Tateshita</surname><given-names>N</given-names></name><name name-style="western"><surname>Itazawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Imai</surname><given-names>R</given-names></name><etal/></person-group><article-title>An ionizable lipid material with a vitamin E scaffold as an mRNA vaccine platform for efficient cytotoxic T cell responses</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><issue>19</issue><fpage>18758</fpage><lpage>18774</lpage><pub-id pub-id-type="doi">10.1021/acsnano.3c02251</pub-id><pub-id pub-id-type="pmid">37814788</pub-id><pub-id pub-id-type="pmcid">PMC10569098</pub-id></element-citation><mixed-citation id="mc-CR242" publication-type="journal">Oyama R, Ishigame H, Tanaka H, Tateshita N, Itazawa M, Imai R, et al. An ionizable lipid material with a vitamin E scaffold as an mRNA vaccine platform for efficient cytotoxic T cell responses. ACS Nano. 2023;17(19):18758&#8211;74.<pub-id pub-id-type="pmid">37814788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c02251</pub-id><pub-id pub-id-type="pmcid">PMC10569098</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR243"><label>243.</label><citation-alternatives><element-citation id="ec-CR243" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>K</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SY</given-names></name><name name-style="western"><surname>Seo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MH</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name></person-group><article-title>Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy</article-title><source>Biomater Sci</source><year>2020</year><volume>8</volume><issue>4</issue><fpage>1101</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1039/C9BM01564G</pub-id><pub-id pub-id-type="pmid">31793928</pub-id></element-citation><mixed-citation id="mc-CR243" publication-type="journal">Lee K, Kim SY, Seo Y, Kim MH, Chang J, Lee H. Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy. Biomater Sci. 2020;8(4):1101&#8211;5.<pub-id pub-id-type="pmid">31793928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c9bm01564g</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR244"><label>244.</label><citation-alternatives><element-citation id="ec-CR244" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granot-Matok</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ezra</surname><given-names>A</given-names></name><name name-style="western"><surname>Ramishetti</surname><given-names>S</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name><name name-style="western"><surname>Naidu</surname><given-names>GS</given-names></name><name name-style="western"><surname>Benhar</surname><given-names>I</given-names></name><etal/></person-group><article-title>Lipid nanoparticles-loaded with toxin mRNA represents a new strategy for the treatment of solid tumors</article-title><source>Theranostics</source><year>2023</year><volume>13</volume><issue>11</issue><fpage>3497</fpage><lpage>3508</lpage><pub-id pub-id-type="doi">10.7150/thno.82228</pub-id><pub-id pub-id-type="pmid">37441597</pub-id><pub-id pub-id-type="pmcid">PMC10334842</pub-id></element-citation><mixed-citation id="mc-CR244" publication-type="journal">Granot-Matok Y, Ezra A, Ramishetti S, Sharma P, Naidu GS, Benhar I, et al. Lipid nanoparticles-loaded with toxin mRNA represents a new strategy for the treatment of solid tumors. Theranostics. 2023;13(11):3497&#8211;508.<pub-id pub-id-type="pmid">37441597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.82228</pub-id><pub-id pub-id-type="pmcid">PMC10334842</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR245"><label>245.</label><citation-alternatives><element-citation id="ec-CR245" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thran</surname><given-names>M</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>J</given-names></name><name name-style="western"><surname>Ponisch</surname><given-names>M</given-names></name><name name-style="western"><surname>Fiedler</surname><given-names>K</given-names></name><name name-style="western"><surname>Thess</surname><given-names>A</given-names></name><name name-style="western"><surname>Mui</surname><given-names>BL</given-names></name><etal/></person-group><article-title>mRNA mediates passive vaccination against infectious agents, toxins, and tumors</article-title><source>EMBO Mol Med</source><year>2017</year><volume>9</volume><issue>10</issue><fpage>1434</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.15252/emmm.201707678</pub-id><pub-id pub-id-type="pmid">28794134</pub-id><pub-id pub-id-type="pmcid">PMC5623855</pub-id></element-citation><mixed-citation id="mc-CR245" publication-type="journal">Thran M, Mukherjee J, Ponisch M, Fiedler K, Thess A, Mui BL, et al. mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Mol Med. 2017;9(10):1434&#8211;47.<pub-id pub-id-type="pmid">28794134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.201707678</pub-id><pub-id pub-id-type="pmcid">PMC5623855</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR246"><label>246.</label><citation-alternatives><element-citation id="ec-CR246" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>JQ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>C</given-names></name><name name-style="western"><surname>Talebian</surname><given-names>F</given-names></name><etal/></person-group><article-title>Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy</article-title><source>J Control Release</source><year>2022</year><volume>345</volume><fpage>306</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.03.021</pub-id><pub-id pub-id-type="pmid">35301053</pub-id><pub-id pub-id-type="pmcid">PMC9133152</pub-id></element-citation><mixed-citation id="mc-CR246" publication-type="journal">Liu JQ, Zhang C, Zhang X, Yan J, Zeng C, Talebian F, et al. Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. J Control Release. 2022;345:306&#8211;13.<pub-id pub-id-type="pmid">35301053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.03.021</pub-id><pub-id pub-id-type="pmcid">PMC9133152</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR247"><label>247.</label><citation-alternatives><element-citation id="ec-CR247" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ran</surname><given-names>H</given-names></name><name name-style="western"><surname>Quan</surname><given-names>G</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><etal/></person-group><article-title>The practical self-targeted oncolytic adenoviral nanosphere based on immuno-obstruction method via polyprotein surface precipitation technique enhances transfection efficiency for virotherapy</article-title><source>Biochem Biophys Res Commun</source><year>2019</year><volume>508</volume><issue>3</issue><fpage>791</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2018.10.162</pub-id><pub-id pub-id-type="pmid">30528388</pub-id></element-citation><mixed-citation id="mc-CR247" publication-type="journal">Ran H, Quan G, Huang Y, Zhu C, Lu C, Liu W, et al. The practical self-targeted oncolytic adenoviral nanosphere based on immuno-obstruction method via polyprotein surface precipitation technique enhances transfection efficiency for virotherapy. Biochem Biophys Res Commun. 2019;508(3):791&#8211;6.<pub-id pub-id-type="pmid">30528388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2018.10.162</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR248"><label>248.</label><citation-alternatives><element-citation id="ec-CR248" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>L</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Combination immunotherapy of oncolytic virus nanovesicles and PD-1 blockade effectively enhances therapeutic effects and boosts antitumour immune response</article-title><source>J Drug Target</source><year>2020</year><volume>28</volume><issue>9</issue><fpage>982</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1080/1061186X.2020.1766473</pub-id><pub-id pub-id-type="pmid">32379004</pub-id></element-citation><mixed-citation id="mc-CR248" publication-type="journal">Ji W, Li L, Zhou S, Qiu L, Qian Z, Zhang H, et al. Combination immunotherapy of oncolytic virus nanovesicles and PD-1 blockade effectively enhances therapeutic effects and boosts antitumour immune response. J Drug Target. 2020;28(9):982&#8211;90.<pub-id pub-id-type="pmid">32379004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/1061186X.2020.1766473</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR249"><label>249.</label><citation-alternatives><element-citation id="ec-CR249" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fusciello</surname><given-names>M</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>F</given-names></name><name name-style="western"><surname>Tahtinen</surname><given-names>S</given-names></name><name name-style="western"><surname>Capasso</surname><given-names>C</given-names></name><name name-style="western"><surname>Feola</surname><given-names>S</given-names></name><name name-style="western"><surname>Martins</surname><given-names>B</given-names></name><etal/></person-group><article-title>Artificially cloaked viral nanovaccine for cancer immunotherapy</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>5747</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-13744-8</pub-id><pub-id pub-id-type="pmid">31848338</pub-id><pub-id pub-id-type="pmcid">PMC6917704</pub-id></element-citation><mixed-citation id="mc-CR249" publication-type="journal">Fusciello M, Fontana F, Tahtinen S, Capasso C, Feola S, Martins B, et al. Artificially cloaked viral nanovaccine for cancer immunotherapy. Nat Commun. 2019;10(1):5747.<pub-id pub-id-type="pmid">31848338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-13744-8</pub-id><pub-id pub-id-type="pmcid">PMC6917704</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR250"><label>250.</label><citation-alternatives><element-citation id="ec-CR250" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brugada-Vila</surname><given-names>P</given-names></name><name name-style="western"><surname>Cascante</surname><given-names>A</given-names></name><name name-style="western"><surname>Lazaro</surname><given-names>MA</given-names></name><name name-style="western"><surname>Castells-Sala</surname><given-names>C</given-names></name><name name-style="western"><surname>Fornaguera</surname><given-names>C</given-names></name><name name-style="western"><surname>Rovira-Rigau</surname><given-names>M</given-names></name><etal/></person-group><article-title>Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><issue>6</issue><fpage>2744</fpage><lpage>2758</lpage><pub-id pub-id-type="doi">10.7150/thno.40902</pub-id><pub-id pub-id-type="pmid">32194832</pub-id><pub-id pub-id-type="pmcid">PMC7052890</pub-id></element-citation><mixed-citation id="mc-CR250" publication-type="journal">Brugada-Vila P, Cascante A, Lazaro MA, Castells-Sala C, Fornaguera C, Rovira-Rigau M, et al. Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses. Theranostics. 2020;10(6):2744&#8211;58.<pub-id pub-id-type="pmid">32194832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.40902</pub-id><pub-id pub-id-type="pmcid">PMC7052890</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR251"><label>251.</label><citation-alternatives><element-citation id="ec-CR251" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kennedy</surname><given-names>EM</given-names></name><name name-style="western"><surname>Denslow</surname><given-names>A</given-names></name><name name-style="western"><surname>Hewett</surname><given-names>J</given-names></name><name name-style="western"><surname>Kong</surname><given-names>L</given-names></name><name name-style="western"><surname>De Almeida</surname><given-names>A</given-names></name><name name-style="western"><surname>Bryant</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>5907</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-33599-w</pub-id><pub-id pub-id-type="pmid">36207308</pub-id><pub-id pub-id-type="pmcid">PMC9546900</pub-id></element-citation><mixed-citation id="mc-CR251" publication-type="journal">Kennedy EM, Denslow A, Hewett J, Kong L, De Almeida A, Bryant JD, et al. Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer. Nat Commun. 2022;13(1):5907.<pub-id pub-id-type="pmid">36207308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-33599-w</pub-id><pub-id pub-id-type="pmcid">PMC9546900</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR252"><label>252.</label><citation-alternatives><element-citation id="ec-CR252" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carneiro</surname><given-names>BA</given-names></name><name name-style="western"><surname>Zamarin</surname><given-names>D</given-names></name><name name-style="western"><surname>Marron</surname><given-names>T</given-names></name><name name-style="western"><surname>Mehmi</surname><given-names>I</given-names></name><name name-style="western"><surname>Patel</surname><given-names>SP</given-names></name><name name-style="western"><surname>Subbiah</surname><given-names>V</given-names></name><etal/></person-group><article-title>First-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors</article-title><source>Cancer Res</source><year>2022</year><volume>82</volume><issue>12</issue><fpage>CT183-</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2022-CT183</pub-id></element-citation><mixed-citation id="mc-CR252" publication-type="journal">Carneiro BA, Zamarin D, Marron T, Mehmi I, Patel SP, Subbiah V, et al. First-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors. Cancer Res. 2022;82(12):CT183-.</mixed-citation></citation-alternatives></ref><ref id="CR253"><label>253.</label><citation-alternatives><element-citation id="ec-CR253" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>P</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>He</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><etal/></person-group><article-title>Engineered norovirus-derived nanoparticles as a plug-and-play cancer vaccine platform</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><issue>4</issue><fpage>3412</fpage><lpage>3429</lpage><pub-id pub-id-type="doi">10.1021/acsnano.2c08840</pub-id><pub-id pub-id-type="pmid">36779845</pub-id></element-citation><mixed-citation id="mc-CR253" publication-type="journal">Zheng P, Yang Y, Fu Y, He J, Hu Y, Zheng X, et al. Engineered norovirus-derived nanoparticles as a plug-and-play cancer vaccine platform. ACS Nano. 2023;17(4):3412&#8211;29.<pub-id pub-id-type="pmid">36779845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.2c08840</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR254"><label>254.</label><citation-alternatives><element-citation id="ec-CR254" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KW</given-names></name><name name-style="western"><surname>Heo</surname><given-names>MG</given-names></name><name name-style="western"><surname>Park</surname><given-names>DI</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Nanoparticle delivery of recombinant IL-2 (BALLkine-2) achieves durable tumor control with less systemic adverse effects in cancer immunotherapy</article-title><source>Biomaterials</source><year>2022</year><volume>280</volume><fpage>121257</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.121257</pub-id><pub-id pub-id-type="pmid">34839122</pub-id></element-citation><mixed-citation id="mc-CR254" publication-type="journal">Kim J, Kang S, Kim KW, Heo MG, Park DI, Lee JH, et al. Nanoparticle delivery of recombinant IL-2 (BALLkine-2) achieves durable tumor control with less systemic adverse effects in cancer immunotherapy. Biomaterials. 2022;280:121257.<pub-id pub-id-type="pmid">34839122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2021.121257</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR255"><label>255.</label><citation-alternatives><element-citation id="ec-CR255" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akkin</surname><given-names>S</given-names></name><name name-style="western"><surname>Varan</surname><given-names>G</given-names></name><name name-style="western"><surname>Isik</surname><given-names>A</given-names></name><name name-style="western"><surname>Goksen</surname><given-names>S</given-names></name><name name-style="western"><surname>Karakoc</surname><given-names>E</given-names></name><name name-style="western"><surname>Malanga</surname><given-names>M</given-names></name><etal/></person-group><article-title>Synergistic antitumor potency of a self-assembling cyclodextrin nanoplex for the co-delivery of 5-fluorouracil and interleukin-2 in the treatment of colorectal cancer</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><issue>2</issue><fpage>314</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics15020314</pub-id><pub-id pub-id-type="pmid">36839637</pub-id><pub-id pub-id-type="pmcid">PMC9963231</pub-id></element-citation><mixed-citation id="mc-CR255" publication-type="journal">Akkin S, Varan G, Isik A, Goksen S, Karakoc E, Malanga M, et al. Synergistic antitumor potency of a self-assembling cyclodextrin nanoplex for the co-delivery of 5-fluorouracil and interleukin-2 in the treatment of colorectal cancer. Pharmaceutics. 2023;15(2):314.<pub-id pub-id-type="pmid">36839637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15020314</pub-id><pub-id pub-id-type="pmcid">PMC9963231</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR256"><label>256.</label><citation-alternatives><element-citation id="ec-CR256" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charych</surname><given-names>DH</given-names></name><name name-style="western"><surname>Hoch</surname><given-names>U</given-names></name><name name-style="western"><surname>Langowski</surname><given-names>JL</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SR</given-names></name><name name-style="western"><surname>Addepalli</surname><given-names>MK</given-names></name><name name-style="western"><surname>Kirk</surname><given-names>PB</given-names></name><etal/></person-group><article-title>NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models</article-title><source>Clin Cancer Res</source><year>2016</year><volume>22</volume><issue>3</issue><fpage>680</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-1631</pub-id><pub-id pub-id-type="pmid">26832745</pub-id></element-citation><mixed-citation id="mc-CR256" publication-type="journal">Charych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, Kirk PB, et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res. 2016;22(3):680&#8211;90.<pub-id pub-id-type="pmid">26832745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-15-1631</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR257"><label>257.</label><citation-alternatives><element-citation id="ec-CR257" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charych</surname><given-names>D</given-names></name><name name-style="western"><surname>Khalili</surname><given-names>S</given-names></name><name name-style="western"><surname>Dixit</surname><given-names>V</given-names></name><name name-style="western"><surname>Kirk</surname><given-names>P</given-names></name><name name-style="western"><surname>Chang</surname><given-names>T</given-names></name><name name-style="western"><surname>Langowski</surname><given-names>J</given-names></name><etal/></person-group><article-title>Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><issue>7</issue><fpage>e0179431</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0179431</pub-id><pub-id pub-id-type="pmid">28678791</pub-id><pub-id pub-id-type="pmcid">PMC5497954</pub-id></element-citation><mixed-citation id="mc-CR257" publication-type="journal">Charych D, Khalili S, Dixit V, Kirk P, Chang T, Langowski J, et al. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLoS ONE. 2017;12(7):e0179431.<pub-id pub-id-type="pmid">28678791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0179431</pub-id><pub-id pub-id-type="pmcid">PMC5497954</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR258"><label>258.</label><citation-alternatives><element-citation id="ec-CR258" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bentebibel</surname><given-names>SE</given-names></name><name name-style="western"><surname>Hurwitz</surname><given-names>ME</given-names></name><name name-style="western"><surname>Bernatchez</surname><given-names>C</given-names></name><name name-style="western"><surname>Haymaker</surname><given-names>C</given-names></name><name name-style="western"><surname>Hudgens</surname><given-names>CW</given-names></name><name name-style="western"><surname>Kluger</surname><given-names>HM</given-names></name><etal/></person-group><article-title>A first-in-human study and biomarker analysis of NKTR-214, a novel IL2Rbetagamma-biased cytokine, in patients with advanced or metastatic solid tumors</article-title><source>Cancer Discov</source><year>2019</year><volume>9</volume><issue>6</issue><fpage>711</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-1495</pub-id><pub-id pub-id-type="pmid">30988166</pub-id></element-citation><mixed-citation id="mc-CR258" publication-type="journal">Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker C, Hudgens CW, Kluger HM, et al. A first-in-human study and biomarker analysis of NKTR-214, a novel IL2Rbetagamma-biased cytokine, in patients with advanced or metastatic solid tumors. Cancer Discov. 2019;9(6):711&#8211;21.<pub-id pub-id-type="pmid">30988166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-18-1495</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR259"><label>259.</label><citation-alternatives><element-citation id="ec-CR259" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eggermont</surname><given-names>AM</given-names></name><name name-style="western"><surname>Ascierto</surname><given-names>PA</given-names></name><name name-style="western"><surname>Khushalani</surname><given-names>NI</given-names></name><name name-style="western"><surname>Schadendorf</surname><given-names>D</given-names></name><name name-style="western"><surname>Boland</surname><given-names>G</given-names></name><name name-style="western"><surname>Weber</surname><given-names>J</given-names></name><etal/></person-group><article-title>PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence</article-title><source>Future Oncol</source><year>2022</year><volume>18</volume><issue>8</issue><fpage>903</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.2217/fon-2021-1286</pub-id><pub-id pub-id-type="pmid">35073733</pub-id></element-citation><mixed-citation id="mc-CR259" publication-type="journal">Eggermont AM, Ascierto PA, Khushalani NI, Schadendorf D, Boland G, Weber J, et al. PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Future Oncol. 2022;18(8):903&#8211;13.<pub-id pub-id-type="pmid">35073733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/fon-2021-1286</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR260"><label>260.</label><citation-alternatives><element-citation id="ec-CR260" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tannir</surname><given-names>NM</given-names></name><name name-style="western"><surname>Cho</surname><given-names>DC</given-names></name><name name-style="western"><surname>Diab</surname><given-names>A</given-names></name><name name-style="western"><surname>Sznol</surname><given-names>M</given-names></name><name name-style="western"><surname>Bilen</surname><given-names>MA</given-names></name><name name-style="western"><surname>Balar</surname><given-names>AV</given-names></name><etal/></person-group><article-title>Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study</article-title><source>J Immunother Cancer</source><year>2022</year><volume>10</volume><issue>4</issue><fpage>e004419</fpage><pub-id pub-id-type="doi">10.1136/jitc-2021-004419</pub-id><pub-id pub-id-type="pmid">35444058</pub-id><pub-id pub-id-type="pmcid">PMC9021810</pub-id></element-citation><mixed-citation id="mc-CR260" publication-type="journal">Tannir NM, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, et al. Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. J Immunother Cancer. 2022;10(4):e004419.<pub-id pub-id-type="pmid">35444058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2021-004419</pub-id><pub-id pub-id-type="pmcid">PMC9021810</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR261"><label>261.</label><citation-alternatives><element-citation id="ec-CR261" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ptacin</surname><given-names>JL</given-names></name><name name-style="western"><surname>Caffaro</surname><given-names>CE</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>San Jose Gall</surname><given-names>KM</given-names></name><name name-style="western"><surname>Aerni</surname><given-names>HR</given-names></name><name name-style="western"><surname>Acuff</surname><given-names>NV</given-names></name><etal/></person-group><article-title>An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><issue>1</issue><fpage>4785</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-24987-9</pub-id><pub-id pub-id-type="pmid">34373459</pub-id><pub-id pub-id-type="pmcid">PMC8352909</pub-id></element-citation><mixed-citation id="mc-CR261" publication-type="journal">Ptacin JL, Caffaro CE, Ma L, San Jose Gall KM, Aerni HR, Acuff NV, et al. An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism. Nat Commun. 2021;12(1):4785.<pub-id pub-id-type="pmid">34373459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-24987-9</pub-id><pub-id pub-id-type="pmcid">PMC8352909</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR262"><label>262.</label><citation-alternatives><element-citation id="ec-CR262" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falchook</surname><given-names>G</given-names></name><name name-style="western"><surname>Gan</surname><given-names>H</given-names></name><name name-style="western"><surname>Fu</surname><given-names>SQ</given-names></name><name name-style="western"><surname>McKean</surname><given-names>M</given-names></name><name name-style="western"><surname>Azad</surname><given-names>A</given-names></name><name name-style="western"><surname>Sommerhalder</surname><given-names>D</given-names></name><etal/></person-group><article-title>Phase 1/2 Study of Thor-707 (Sar444245), a Pegylated Recombinant Non-Alpha Il-2, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients (Pts) with Advanced Solid Tumors</article-title><source>J Immunother Cancer</source><year>2021</year><volume>9</volume><fpage>A511</fpage><lpage>A</lpage></element-citation><mixed-citation id="mc-CR262" publication-type="journal">Falchook G, Gan H, Fu SQ, McKean M, Azad A, Sommerhalder D, et al. Phase 1/2 Study of Thor-707 (Sar444245), a Pegylated Recombinant Non-Alpha Il-2, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients (Pts) with Advanced Solid Tumors. J Immunother Cancer. 2021;9:A511&#8211;A.</mixed-citation></citation-alternatives></ref><ref id="CR263"><label>263.</label><citation-alternatives><element-citation id="ec-CR263" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janku</surname><given-names>F</given-names></name><name name-style="western"><surname>Abdul-Karim</surname><given-names>R</given-names></name><name name-style="western"><surname>Azad</surname><given-names>A</given-names></name><name name-style="western"><surname>Bendell</surname><given-names>J</given-names></name><name name-style="western"><surname>Falchook</surname><given-names>G</given-names></name><name name-style="western"><surname>Gan</surname><given-names>HK</given-names></name><etal/></person-group><article-title>THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced / metastatic solid tumors: Interim results from HAMMER, an open-label, multicenter phase 1/2 Study</article-title><source>Cancer Res</source><year>2021</year><volume>81</volume><issue>13</issue><fpage>2021</fpage><lpage>04</lpage></element-citation><mixed-citation id="mc-CR263" publication-type="journal">Janku F, Abdul-Karim R, Azad A, Bendell J, Falchook G, Gan HK, et al. THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced / metastatic solid tumors: Interim results from HAMMER, an open-label, multicenter phase 1/2 Study. Cancer Res. 2021;81(13):2021&#8211;04.</mixed-citation></citation-alternatives></ref><ref id="CR264"><label>264.</label><citation-alternatives><element-citation id="ec-CR264" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neelapu</surname><given-names>SS</given-names></name><name name-style="western"><surname>Gause</surname><given-names>BL</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>L</given-names></name><name name-style="western"><surname>Lee</surname><given-names>ST</given-names></name><name name-style="western"><surname>Frye</surname><given-names>AR</given-names></name><name name-style="western"><surname>Horton</surname><given-names>J</given-names></name><etal/></person-group><article-title>A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma</article-title><source>Blood</source><year>2007</year><volume>109</volume><issue>12</issue><fpage>5160</fpage><lpage>5163</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-12-063594</pub-id><pub-id pub-id-type="pmid">17339422</pub-id><pub-id pub-id-type="pmcid">PMC1941785</pub-id></element-citation><mixed-citation id="mc-CR264" publication-type="journal">Neelapu SS, Gause BL, Harvey L, Lee ST, Frye AR, Horton J, et al. A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood. 2007;109(12):5160&#8211;3.<pub-id pub-id-type="pmid">17339422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2006-12-063594</pub-id><pub-id pub-id-type="pmcid">PMC1941785</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR265"><label>265.</label><citation-alternatives><element-citation id="ec-CR265" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barberio</surname><given-names>AE</given-names></name><name name-style="western"><surname>Smith</surname><given-names>SG</given-names></name><name name-style="western"><surname>Pires</surname><given-names>IS</given-names></name><name name-style="western"><surname>Iyer</surname><given-names>S</given-names></name><name name-style="western"><surname>Reinhardt</surname><given-names>F</given-names></name><name name-style="western"><surname>Melo</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Layer-by-layer interleukin-12 nanoparticles drive a safe and effective response in ovarian tumors</article-title><source>Bioeng Transl Med</source><year>2023</year><volume>8</volume><issue>2</issue><fpage>e10453</fpage><pub-id pub-id-type="doi">10.1002/btm2.10453</pub-id><pub-id pub-id-type="pmid">36925719</pub-id><pub-id pub-id-type="pmcid">PMC10013828</pub-id></element-citation><mixed-citation id="mc-CR265" publication-type="journal">Barberio AE, Smith SG, Pires IS, Iyer S, Reinhardt F, Melo MB, et al. Layer-by-layer interleukin-12 nanoparticles drive a safe and effective response in ovarian tumors. Bioeng Transl Med. 2023;8(2):e10453.<pub-id pub-id-type="pmid">36925719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/btm2.10453</pub-id><pub-id pub-id-type="pmcid">PMC10013828</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR266"><label>266.</label><citation-alternatives><element-citation id="ec-CR266" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lacinski</surname><given-names>RA</given-names></name><name name-style="western"><surname>Markel</surname><given-names>JE</given-names></name><name name-style="western"><surname>Pratt</surname><given-names>HG</given-names></name><name name-style="western"><surname>Reinbeau</surname><given-names>RM</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>A</given-names></name><name name-style="western"><surname>Santiago</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Optimizing the synthesis of interleukin-12-loaded PLGA nanospheres (rmIL-12ns) via ultrasonication for treatment of metastatic osteosarcoma</article-title><source>J Orthop Res</source><year>2023</year><volume>41</volume><issue>7</issue><fpage>1565</fpage><lpage>1581</lpage><pub-id pub-id-type="doi">10.1002/jor.25491</pub-id><pub-id pub-id-type="pmid">36453532</pub-id><pub-id pub-id-type="pmcid">PMC10232680</pub-id></element-citation><mixed-citation id="mc-CR266" publication-type="journal">Lacinski RA, Markel JE, Pratt HG, Reinbeau RM, Stewart A, Santiago SP, et al. Optimizing the synthesis of interleukin-12-loaded PLGA nanospheres (rmIL-12ns) via ultrasonication for treatment of metastatic osteosarcoma. J Orthop Res. 2023;41(7):1565&#8211;81.<pub-id pub-id-type="pmid">36453532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jor.25491</pub-id><pub-id pub-id-type="pmcid">PMC10232680</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR267"><label>267.</label><citation-alternatives><element-citation id="ec-CR267" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>H</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S</given-names></name><name name-style="western"><surname>Won</surname><given-names>C</given-names></name><name name-style="western"><surname>Min</surname><given-names>DH</given-names></name></person-group><article-title>Enhanced local delivery of engineered IL-2 mRNA by porous silica nanoparticles to promote effective antitumor immunity</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><issue>17</issue><fpage>17554</fpage><lpage>17567</lpage><pub-id pub-id-type="doi">10.1021/acsnano.3c06733</pub-id><pub-id pub-id-type="pmid">37643221</pub-id></element-citation><mixed-citation id="mc-CR267" publication-type="journal">Shin H, Kang S, Won C, Min DH. Enhanced local delivery of engineered IL-2 mRNA by porous silica nanoparticles to promote effective antitumor immunity. ACS Nano. 2023;17(17):17554&#8211;67.<pub-id pub-id-type="pmid">37643221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c06733</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR268"><label>268.</label><citation-alternatives><element-citation id="ec-CR268" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sun</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Pan</surname><given-names>F</given-names></name><name name-style="western"><surname>Ma</surname><given-names>A</given-names></name><etal/></person-group><article-title>IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy</article-title><source>Biomaterials</source><year>2022</year><volume>281</volume><fpage>121341</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.121341</pub-id><pub-id pub-id-type="pmid">34995901</pub-id></element-citation><mixed-citation id="mc-CR268" publication-type="journal">Luo Y, Chen Z, Sun M, Li B, Pan F, Ma A, et al. IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy. Biomaterials. 2022;281:121341.<pub-id pub-id-type="pmid">34995901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2021.121341</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR269"><label>269.</label><citation-alternatives><element-citation id="ec-CR269" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>P</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Tao</surname><given-names>A</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>G</given-names></name><etal/></person-group><article-title>Biomimetic calcium carbonate nanoparticles delivered IL-12 mRNA for targeted glioblastoma sono-immunotherapy by ultrasound-induced necroptosis</article-title><source>J Nanobiotechnology</source><year>2022</year><volume>20</volume><issue>1</issue><fpage>525</fpage><pub-id pub-id-type="doi">10.1186/s12951-022-01731-z</pub-id><pub-id pub-id-type="pmid">36496387</pub-id><pub-id pub-id-type="pmcid">PMC9741778</pub-id></element-citation><mixed-citation id="mc-CR269" publication-type="journal">Zhao P, Tian Y, Lu Y, Zhang J, Tao A, Xiang G, et al. Biomimetic calcium carbonate nanoparticles delivered IL-12 mRNA for targeted glioblastoma sono-immunotherapy by ultrasound-induced necroptosis. J Nanobiotechnology. 2022;20(1):525.<pub-id pub-id-type="pmid">36496387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-022-01731-z</pub-id><pub-id pub-id-type="pmcid">PMC9741778</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR270"><label>270.</label><citation-alternatives><element-citation id="ec-CR270" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>R</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Co-delivery of IL-12 cytokine gene and cisplatin prodrug by a polymetformin-conjugated nanosystem for lung cancer chemo-gene treatment through chemotherapy sensitization and tumor microenvironment modulation</article-title><source>Acta Biomater</source><year>2021</year><volume>128</volume><fpage>447</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2021.04.034</pub-id><pub-id pub-id-type="pmid">33894351</pub-id></element-citation><mixed-citation id="mc-CR270" publication-type="journal">Sun Y, Yang J, Yang T, Li Y, Zhu R, Hou Y, et al. Co-delivery of IL-12 cytokine gene and cisplatin prodrug by a polymetformin-conjugated nanosystem for lung cancer chemo-gene treatment through chemotherapy sensitization and tumor microenvironment modulation. Acta Biomater. 2021;128:447&#8211;61.<pub-id pub-id-type="pmid">33894351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2021.04.034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR271"><label>271.</label><citation-alternatives><element-citation id="ec-CR271" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>Co-delivery of Interleukin-12 and doxorubicin loaded Nano-delivery system for enhanced immunotherapy with polarization toward M1-type macrophages</article-title><source>Eur J Pharm Biopharm</source><year>2022</year><volume>177</volume><fpage>175</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2022.07.002</pub-id><pub-id pub-id-type="pmid">35811038</pub-id></element-citation><mixed-citation id="mc-CR271" publication-type="journal">Li T, Liu Z, Fu X, Chen Y, Zhu S, Zhang J. Co-delivery of Interleukin-12 and doxorubicin loaded Nano-delivery system for enhanced immunotherapy with polarization toward M1-type macrophages. Eur J Pharm Biopharm. 2022;177:175&#8211;83.<pub-id pub-id-type="pmid">35811038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejpb.2022.07.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR272"><label>272.</label><citation-alternatives><element-citation id="ec-CR272" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fewell</surname><given-names>JG</given-names></name><name name-style="western"><surname>Matar</surname><given-names>M</given-names></name><name name-style="western"><surname>Slobodkin</surname><given-names>G</given-names></name><name name-style="western"><surname>Han</surname><given-names>SO</given-names></name><name name-style="western"><surname>Rice</surname><given-names>J</given-names></name><name name-style="western"><surname>Hovanes</surname><given-names>B</given-names></name><etal/></person-group><article-title>Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer</article-title><source>J Control Release</source><year>2005</year><volume>109</volume><issue>1&#8211;3</issue><fpage>288</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2005.09.024</pub-id><pub-id pub-id-type="pmid">16269201</pub-id></element-citation><mixed-citation id="mc-CR272" publication-type="journal">Fewell JG, Matar M, Slobodkin G, Han SO, Rice J, Hovanes B, et al. Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer. J Control Release. 2005;109(1&#8211;3):288&#8211;98.<pub-id pub-id-type="pmid">16269201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2005.09.024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR273"><label>273.</label><citation-alternatives><element-citation id="ec-CR273" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sonabend</surname><given-names>AM</given-names></name><name name-style="western"><surname>Velicu</surname><given-names>S</given-names></name><name name-style="western"><surname>Ulasov</surname><given-names>IV</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tyler</surname><given-names>B</given-names></name><name name-style="western"><surname>Brem</surname><given-names>H</given-names></name><etal/></person-group><article-title>A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma</article-title><source>Anticancer Drugs</source><year>2008</year><volume>19</volume><issue>2</issue><fpage>133</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1097/CAD.0b013e3282f24017</pub-id><pub-id pub-id-type="pmid">18176109</pub-id></element-citation><mixed-citation id="mc-CR273" publication-type="journal">Sonabend AM, Velicu S, Ulasov IV, Han Y, Tyler B, Brem H, et al. A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma. Anticancer Drugs. 2008;19(2):133&#8211;42.<pub-id pub-id-type="pmid">18176109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CAD.0b013e3282f24017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR274"><label>274.</label><citation-alternatives><element-citation id="ec-CR274" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alvarez</surname><given-names>RD</given-names></name><name name-style="western"><surname>Sill</surname><given-names>MW</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>SA</given-names></name><name name-style="western"><surname>Muller</surname><given-names>CY</given-names></name><name name-style="western"><surname>Bender</surname><given-names>DP</given-names></name><name name-style="western"><surname>DeBernardo</surname><given-names>RL</given-names></name><etal/></person-group><article-title>A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study</article-title><source>Gynecol Oncol</source><year>2014</year><volume>133</volume><issue>3</issue><fpage>433</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2014.03.571</pub-id><pub-id pub-id-type="pmid">24708919</pub-id><pub-id pub-id-type="pmcid">PMC4057915</pub-id></element-citation><mixed-citation id="mc-CR274" publication-type="journal">Alvarez RD, Sill MW, Davidson SA, Muller CY, Bender DP, DeBernardo RL, et al. A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2014;133(3):433&#8211;8.<pub-id pub-id-type="pmid">24708919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygyno.2014.03.571</pub-id><pub-id pub-id-type="pmcid">PMC4057915</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR275"><label>275.</label><citation-alternatives><element-citation id="ec-CR275" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anwer</surname><given-names>K</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Chu</surname><given-names>C</given-names></name><name name-style="western"><surname>Fewell</surname><given-names>JG</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>D</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>RD</given-names></name></person-group><article-title>Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer</article-title><source>Gynecol Oncol</source><year>2013</year><volume>131</volume><issue>1</issue><fpage>169</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2013.07.081</pub-id><pub-id pub-id-type="pmid">23863356</pub-id></element-citation><mixed-citation id="mc-CR275" publication-type="journal">Anwer K, Kelly FJ, Chu C, Fewell JG, Lewis D, Alvarez RD. Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2013;131(1):169&#8211;73.<pub-id pub-id-type="pmid">23863356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygyno.2013.07.081</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR276"><label>276.</label><citation-alternatives><element-citation id="ec-CR276" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thaker</surname><given-names>PH</given-names></name><name name-style="western"><surname>Brady</surname><given-names>WE</given-names></name><name name-style="western"><surname>Lankes</surname><given-names>HA</given-names></name><name name-style="western"><surname>Odunsi</surname><given-names>K</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>WH</given-names></name><name name-style="western"><surname>Moore</surname><given-names>KN</given-names></name><etal/></person-group><article-title>A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study</article-title><source>Gynecol Oncol</source><year>2017</year><volume>147</volume><issue>2</issue><fpage>283</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2017.08.001</pub-id><pub-id pub-id-type="pmid">28802766</pub-id><pub-id pub-id-type="pmcid">PMC5704992</pub-id></element-citation><mixed-citation id="mc-CR276" publication-type="journal">Thaker PH, Brady WE, Lankes HA, Odunsi K, Bradley WH, Moore KN, et al. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;147(2):283&#8211;90.<pub-id pub-id-type="pmid">28802766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygyno.2017.08.001</pub-id><pub-id pub-id-type="pmcid">PMC5704992</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR277"><label>277.</label><citation-alternatives><element-citation id="ec-CR277" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hewitt</surname><given-names>SL</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>D</given-names></name><name name-style="western"><surname>Zielinski</surname><given-names>J</given-names></name><name name-style="western"><surname>Apte</surname><given-names>A</given-names></name><name name-style="western"><surname>Musenge</surname><given-names>F</given-names></name><name name-style="western"><surname>Karp</surname><given-names>R</given-names></name><etal/></person-group><article-title>Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment</article-title><source>Clin Cancer Res</source><year>2020</year><volume>26</volume><issue>23</issue><fpage>6284</fpage><lpage>6298</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-0472</pub-id><pub-id pub-id-type="pmid">32817076</pub-id></element-citation><mixed-citation id="mc-CR277" publication-type="journal">Hewitt SL, Bailey D, Zielinski J, Apte A, Musenge F, Karp R, et al. Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment. Clin Cancer Res. 2020;26(23):6284&#8211;98.<pub-id pub-id-type="pmid">32817076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-20-0472</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR278"><label>278.</label><citation-alternatives><element-citation id="ec-CR278" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Mao</surname><given-names>L</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><etal/></person-group><article-title>Intravenous administration of IL-12 encoding self-replicating RNA-lipid nanoparticle complex leads to safe and effective antitumor responses</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>7366</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-57997-w</pub-id><pub-id pub-id-type="pmid">38548896</pub-id><pub-id pub-id-type="pmcid">PMC10978917</pub-id></element-citation><mixed-citation id="mc-CR278" publication-type="journal">Wang Z, Chen Y, Wu H, Wang M, Mao L, Guo X, et al. Intravenous administration of IL-12 encoding self-replicating RNA-lipid nanoparticle complex leads to safe and effective antitumor responses. Sci Rep. 2024;14(1):7366.<pub-id pub-id-type="pmid">38548896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-57997-w</pub-id><pub-id pub-id-type="pmcid">PMC10978917</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR279"><label>279.</label><citation-alternatives><element-citation id="ec-CR279" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujimura</surname><given-names>NA</given-names></name><name name-style="western"><surname>Fatima</surname><given-names>SE</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>N</given-names></name><name name-style="western"><surname>Akram</surname><given-names>M</given-names></name><name name-style="western"><surname>Tahir</surname><given-names>S</given-names></name><name name-style="western"><surname>Khan</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Evaluation of exosomes encapsulated recombinant Interleukin-29 for its in vitro anticancer studies</article-title><source>J Biotechnol</source><year>2023</year><volume>373</volume><fpage>24</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2023.06.008</pub-id><pub-id pub-id-type="pmid">37394182</pub-id></element-citation><mixed-citation id="mc-CR279" publication-type="journal">Fujimura NA, Fatima SE, Ahmed N, Akram M, Tahir S, Khan MA, et al. Evaluation of exosomes encapsulated recombinant Interleukin-29 for its in vitro anticancer studies. J Biotechnol. 2023;373:24&#8211;33.<pub-id pub-id-type="pmid">37394182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbiotec.2023.06.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR280"><label>280.</label><citation-alternatives><element-citation id="ec-CR280" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kateh Shamshiri</surname><given-names>M</given-names></name><name name-style="western"><surname>Jaafari</surname><given-names>MR</given-names></name><name name-style="western"><surname>Badiee</surname><given-names>A</given-names></name></person-group><article-title>Preparation of liposomes containing IFN-gamma and their potentials in cancer immunotherapy: in vitro and in vivo studies in a colon cancer mouse model</article-title><source>Life Sci</source><year>2021</year><volume>264</volume><fpage>118605</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2020.118605</pub-id><pub-id pub-id-type="pmid">33096119</pub-id></element-citation><mixed-citation id="mc-CR280" publication-type="journal">Kateh Shamshiri M, Jaafari MR, Badiee A. Preparation of liposomes containing IFN-gamma and their potentials in cancer immunotherapy: in vitro and in vivo studies in a colon cancer mouse model. Life Sci. 2021;264:118605.<pub-id pub-id-type="pmid">33096119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2020.118605</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR281"><label>281.</label><citation-alternatives><element-citation id="ec-CR281" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chang</surname><given-names>S</given-names></name></person-group><article-title>Chitosan nanoparticles loaded with TGF-beta1 inhibit cervical cancer cell progression through down-regulation of MicroRNA-155 and activation of Tim-3 pathway</article-title><source>J Biomed Nanotechnol</source><year>2021</year><volume>17</volume><issue>9</issue><fpage>1850</fpage><lpage>1857</lpage><pub-id pub-id-type="doi">10.1166/jbn.2021.3146</pub-id><pub-id pub-id-type="pmid">34688330</pub-id></element-citation><mixed-citation id="mc-CR281" publication-type="journal">Yan M, Zhang Y, Chang S. Chitosan nanoparticles loaded with TGF-beta1 inhibit cervical cancer cell progression through down-regulation of MicroRNA-155 and activation of Tim-3 pathway. J Biomed Nanotechnol. 2021;17(9):1850&#8211;7.<pub-id pub-id-type="pmid">34688330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1166/jbn.2021.3146</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR282"><label>282.</label><citation-alternatives><element-citation id="ec-CR282" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alghamri</surname><given-names>MS</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>K</given-names></name><name name-style="western"><surname>Mujeeb</surname><given-names>AA</given-names></name><name name-style="western"><surname>Mauser</surname><given-names>A</given-names></name><name name-style="western"><surname>Taher</surname><given-names>A</given-names></name><name name-style="western"><surname>Thalla</surname><given-names>R</given-names></name><etal/></person-group><article-title>Systemic delivery of an adjuvant CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy</article-title><source>ACS Nano</source><year>2022</year><volume>16</volume><issue>6</issue><fpage>8729</fpage><lpage>8750</lpage><pub-id pub-id-type="doi">10.1021/acsnano.1c07492</pub-id><pub-id pub-id-type="pmid">35616289</pub-id><pub-id pub-id-type="pmcid">PMC9649873</pub-id></element-citation><mixed-citation id="mc-CR282" publication-type="journal">Alghamri MS, Banerjee K, Mujeeb AA, Mauser A, Taher A, Thalla R, et al. Systemic delivery of an adjuvant CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy. ACS Nano. 2022;16(6):8729&#8211;50.<pub-id pub-id-type="pmid">35616289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.1c07492</pub-id><pub-id pub-id-type="pmcid">PMC9649873</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR283"><label>283.</label><citation-alternatives><element-citation id="ec-CR283" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ukidve</surname><given-names>A</given-names></name><name name-style="western"><surname>Krishnan</surname><given-names>V</given-names></name><name name-style="western"><surname>Fehnel</surname><given-names>A</given-names></name><name name-style="western"><surname>Pan</surname><given-names>DC</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Systemic tumour suppression via the preferential accumulation of erythrocyte-anchored chemokine-encapsulating nanoparticles in lung metastases</article-title><source>Nat Biomed Eng</source><year>2021</year><volume>5</volume><issue>5</issue><fpage>441</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1038/s41551-020-00644-2</pub-id><pub-id pub-id-type="pmid">33199847</pub-id></element-citation><mixed-citation id="mc-CR283" publication-type="journal">Zhao Z, Ukidve A, Krishnan V, Fehnel A, Pan DC, Gao Y, et al. Systemic tumour suppression via the preferential accumulation of erythrocyte-anchored chemokine-encapsulating nanoparticles in lung metastases. Nat Biomed Eng. 2021;5(5):441&#8211;54.<pub-id pub-id-type="pmid">33199847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41551-020-00644-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR284"><label>284.</label><citation-alternatives><element-citation id="ec-CR284" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fonseca-Santos</surname><given-names>B</given-names></name><name name-style="western"><surname>Gremiao</surname><given-names>MP</given-names></name><name name-style="western"><surname>Chorilli</surname><given-names>M</given-names></name></person-group><article-title>Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease</article-title><source>Int J Nanomedicine</source><year>2015</year><volume>10</volume><fpage>4981</fpage><lpage>5003</lpage><pub-id pub-id-type="doi">10.2147/IJN.S87148</pub-id><pub-id pub-id-type="pmid">26345528</pub-id><pub-id pub-id-type="pmcid">PMC4531021</pub-id></element-citation><mixed-citation id="mc-CR284" publication-type="journal">Fonseca-Santos B, Gremiao MP, Chorilli M. Nanotechnology-based drug delivery systems for the treatment of Alzheimer&#8217;s disease. Int J Nanomedicine. 2015;10:4981&#8211;5003.<pub-id pub-id-type="pmid">26345528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S87148</pub-id><pub-id pub-id-type="pmcid">PMC4531021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR285"><label>285.</label><citation-alternatives><element-citation id="ec-CR285" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shinde</surname><given-names>VR</given-names></name><name name-style="western"><surname>Revi</surname><given-names>N</given-names></name><name name-style="western"><surname>Murugappan</surname><given-names>S</given-names></name><name name-style="western"><surname>Singh</surname><given-names>SP</given-names></name><name name-style="western"><surname>Rengan</surname><given-names>AK</given-names></name></person-group><article-title>Enhanced permeability and retention effect: a key facilitator for solid tumor targeting by nanoparticles</article-title><source>Photodiagnosis Photodyn Ther</source><year>2022</year><volume>39</volume><fpage>102915</fpage><pub-id pub-id-type="doi">10.1016/j.pdpdt.2022.102915</pub-id><pub-id pub-id-type="pmid">35597441</pub-id></element-citation><mixed-citation id="mc-CR285" publication-type="journal">Shinde VR, Revi N, Murugappan S, Singh SP, Rengan AK. Enhanced permeability and retention effect: a key facilitator for solid tumor targeting by nanoparticles. Photodiagnosis Photodyn Ther. 2022;39:102915.<pub-id pub-id-type="pmid">35597441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pdpdt.2022.102915</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR286"><label>286.</label><citation-alternatives><element-citation id="ec-CR286" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bockamp</surname><given-names>E</given-names></name><name name-style="western"><surname>Rosigkeit</surname><given-names>S</given-names></name><name name-style="western"><surname>Siegl</surname><given-names>D</given-names></name><name name-style="western"><surname>Schuppan</surname><given-names>D</given-names></name></person-group><article-title>Nano-enhanced cancer immunotherapy: immunology encounters nanotechnology</article-title><source>Cells</source><year>2020</year><volume>9</volume><issue>9</issue><fpage>2102</fpage><pub-id pub-id-type="doi">10.3390/cells9092102</pub-id><pub-id pub-id-type="pmid">32942725</pub-id><pub-id pub-id-type="pmcid">PMC7565449</pub-id></element-citation><mixed-citation id="mc-CR286" publication-type="journal">Bockamp E, Rosigkeit S, Siegl D, Schuppan D. Nano-enhanced cancer immunotherapy: immunology encounters nanotechnology. Cells. 2020;9(9):2102.<pub-id pub-id-type="pmid">32942725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells9092102</pub-id><pub-id pub-id-type="pmcid">PMC7565449</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR287"><label>287.</label><citation-alternatives><element-citation id="ec-CR287" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>N</given-names></name><name name-style="western"><surname>Sheppard</surname><given-names>NC</given-names></name><name name-style="western"><surname>Billingsley</surname><given-names>MM</given-names></name><name name-style="western"><surname>June</surname><given-names>CH</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>MJ</given-names></name></person-group><article-title>Nanomaterials for T-cell cancer immunotherapy</article-title><source>Nat Nanotechnol</source><year>2021</year><volume>16</volume><issue>1</issue><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1038/s41565-020-00822-y</pub-id><pub-id pub-id-type="pmid">33437036</pub-id></element-citation><mixed-citation id="mc-CR287" publication-type="journal">Gong N, Sheppard NC, Billingsley MM, June CH, Mitchell MJ. Nanomaterials for T-cell cancer immunotherapy. Nat Nanotechnol. 2021;16(1):25&#8211;36.<pub-id pub-id-type="pmid">33437036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41565-020-00822-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR288"><label>288.</label><citation-alternatives><element-citation id="ec-CR288" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Allen</surname><given-names>ME</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kyriakakis</surname><given-names>P</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Engineering light-controllable CAR T cells for cancer immunotherapy</article-title><source>Sci Adv</source><year>2020</year><volume>6</volume><issue>8</issue><fpage>eaay9209</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aay9209</pub-id><pub-id pub-id-type="pmid">32128416</pub-id><pub-id pub-id-type="pmcid">PMC7030928</pub-id></element-citation><mixed-citation id="mc-CR288" publication-type="journal">Huang Z, Wu Y, Allen ME, Pan Y, Kyriakakis P, Lu S, et al. Engineering light-controllable CAR T cells for cancer immunotherapy. Sci Adv. 2020;6(8):eaay9209.<pub-id pub-id-type="pmid">32128416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.aay9209</pub-id><pub-id pub-id-type="pmcid">PMC7030928</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR289"><label>289.</label><citation-alternatives><element-citation id="ec-CR289" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amoozgar</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kloepper</surname><given-names>J</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J</given-names></name><name name-style="western"><surname>Tay</surname><given-names>RE</given-names></name><name name-style="western"><surname>Kazer</surname><given-names>SW</given-names></name><name name-style="western"><surname>Kiner</surname><given-names>E</given-names></name><etal/></person-group><article-title>Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><issue>1</issue><fpage>2582</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-22885-8</pub-id><pub-id pub-id-type="pmid">33976133</pub-id><pub-id pub-id-type="pmcid">PMC8113440</pub-id></element-citation><mixed-citation id="mc-CR289" publication-type="journal">Amoozgar Z, Kloepper J, Ren J, Tay RE, Kazer SW, Kiner E, et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat Commun. 2021;12(1):2582.<pub-id pub-id-type="pmid">33976133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-22885-8</pub-id><pub-id pub-id-type="pmcid">PMC8113440</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR290"><label>290.</label><citation-alternatives><element-citation id="ec-CR290" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maadi</surname><given-names>H</given-names></name><name name-style="western"><surname>Soheilifar</surname><given-names>MH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>WS</given-names></name><name name-style="western"><surname>Moshtaghian</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title>Trastuzumab mechanism of action; 20 years of research to unravel a dilemma</article-title><source>Cancers (Basel)</source><year>2021</year><volume>13</volume><issue>14</issue><fpage>3540</fpage><pub-id pub-id-type="doi">10.3390/cancers13143540</pub-id><pub-id pub-id-type="pmid">34298754</pub-id><pub-id pub-id-type="pmcid">PMC8303665</pub-id></element-citation><mixed-citation id="mc-CR290" publication-type="journal">Maadi H, Soheilifar MH, Choi WS, Moshtaghian A, Wang Z. Trastuzumab mechanism of action; 20 years of research to unravel a dilemma. Cancers (Basel). 2021;13(14):3540.<pub-id pub-id-type="pmid">34298754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13143540</pub-id><pub-id pub-id-type="pmcid">PMC8303665</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR291"><label>291.</label><citation-alternatives><element-citation id="ec-CR291" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Al Zaki</surname><given-names>A</given-names></name><name name-style="western"><surname>Hui</surname><given-names>JZ</given-names></name><name name-style="western"><surname>Muzykantov</surname><given-names>VR</given-names></name><name name-style="western"><surname>Tsourkas</surname><given-names>A</given-names></name></person-group><article-title>Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities</article-title><source>Science</source><year>2012</year><volume>338</volume><issue>6109</issue><fpage>903</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1126/science.1226338</pub-id><pub-id pub-id-type="pmid">23161990</pub-id><pub-id pub-id-type="pmcid">PMC3660151</pub-id></element-citation><mixed-citation id="mc-CR291" publication-type="journal">Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science. 2012;338(6109):903&#8211;10.<pub-id pub-id-type="pmid">23161990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1226338</pub-id><pub-id pub-id-type="pmcid">PMC3660151</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR292"><label>292.</label><citation-alternatives><element-citation id="ec-CR292" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirpotin</surname><given-names>DB</given-names></name><name name-style="western"><surname>Drummond</surname><given-names>DC</given-names></name><name name-style="western"><surname>Shao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shalaby</surname><given-names>MR</given-names></name><name name-style="western"><surname>Hong</surname><given-names>K</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>UB</given-names></name><etal/></person-group><article-title>Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><issue>13</issue><fpage>6732</fpage><lpage>6740</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-4199</pub-id><pub-id pub-id-type="pmid">16818648</pub-id></element-citation><mixed-citation id="mc-CR292" publication-type="journal">Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66(13):6732&#8211;40.<pub-id pub-id-type="pmid">16818648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-05-4199</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR293"><label>293.</label><citation-alternatives><element-citation id="ec-CR293" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>SY</given-names></name><name name-style="western"><surname>Wu</surname><given-names>FG</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Antibody-Incorporated Nanomedicines for Cancer Therapy</article-title><source>Adv Mater</source><year>2022</year><volume>34</volume><issue>24</issue><fpage>e2109210</fpage><pub-id pub-id-type="doi">10.1002/adma.202109210</pub-id><pub-id pub-id-type="pmid">35142395</pub-id></element-citation><mixed-citation id="mc-CR293" publication-type="journal">Wu SY, Wu FG, Chen X. Antibody-Incorporated Nanomedicines for Cancer Therapy. Adv Mater. 2022;34(24):e2109210.<pub-id pub-id-type="pmid">35142395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202109210</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR294"><label>294.</label><citation-alternatives><element-citation id="ec-CR294" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XY</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G</given-names></name></person-group><article-title>Nanovaccines for cancer immunotherapy</article-title><source>Wiley Interdiscip Rev Nanomed Nanobiotechnol</source><year>2019</year><volume>11</volume><issue>5</issue><fpage>e1559</fpage><pub-id pub-id-type="doi">10.1002/wnan.1559</pub-id><pub-id pub-id-type="pmid">31172659</pub-id><pub-id pub-id-type="pmcid">PMC7040494</pub-id></element-citation><mixed-citation id="mc-CR294" publication-type="journal">Zhang Y, Lin S, Wang XY, Zhu G. Nanovaccines for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11(5):e1559.<pub-id pub-id-type="pmid">31172659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/wnan.1559</pub-id><pub-id pub-id-type="pmcid">PMC7040494</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR295"><label>295.</label><citation-alternatives><element-citation id="ec-CR295" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurunathan</surname><given-names>S</given-names></name><name name-style="western"><surname>Thangaraj</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name></person-group><article-title>Nanovaccines: an effective therapeutic approach for cancer therapy</article-title><source>Biomed Pharmacother</source><year>2024</year><volume>170</volume><fpage>115992</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2023.115992</pub-id><pub-id pub-id-type="pmid">38070247</pub-id></element-citation><mixed-citation id="mc-CR295" publication-type="journal">Gurunathan S, Thangaraj P, Wang L, Cao Q, Kim JH. Nanovaccines: an effective therapeutic approach for cancer therapy. Biomed Pharmacother. 2024;170:115992.<pub-id pub-id-type="pmid">38070247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2023.115992</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR296"><label>296.</label><citation-alternatives><element-citation id="ec-CR296" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aikins</surname><given-names>ME</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Moon</surname><given-names>JJ</given-names></name></person-group><article-title>Engineered nanoparticles for cancer vaccination and immunotherapy</article-title><source>Acc Chem Res</source><year>2020</year><volume>53</volume><issue>10</issue><fpage>2094</fpage><lpage>2105</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.0c00456</pub-id><pub-id pub-id-type="pmid">33017150</pub-id><pub-id pub-id-type="pmcid">PMC7871038</pub-id></element-citation><mixed-citation id="mc-CR296" publication-type="journal">Aikins ME, Xu C, Moon JJ. Engineered nanoparticles for cancer vaccination and immunotherapy. Acc Chem Res. 2020;53(10):2094&#8211;105.<pub-id pub-id-type="pmid">33017150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.accounts.0c00456</pub-id><pub-id pub-id-type="pmcid">PMC7871038</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR297"><label>297.</label><citation-alternatives><element-citation id="ec-CR297" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diao</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name></person-group><article-title>Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell</article-title><source>Adv Sci (Weinh)</source><year>2023</year><volume>10</volume><issue>22</issue><fpage>e2300121</fpage><pub-id pub-id-type="doi">10.1002/advs.202300121</pub-id><pub-id pub-id-type="pmid">37254712</pub-id><pub-id pub-id-type="pmcid">PMC10401146</pub-id></element-citation><mixed-citation id="mc-CR297" publication-type="journal">Diao L, Liu M. Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell. Adv Sci (Weinh). 2023;10(22):e2300121.<pub-id pub-id-type="pmid">37254712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202300121</pub-id><pub-id pub-id-type="pmcid">PMC10401146</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR298"><label>298.</label><citation-alternatives><element-citation id="ec-CR298" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hernandez</surname><given-names>R</given-names></name><name name-style="western"><surname>Malek</surname><given-names>TR</given-names></name></person-group><article-title>Fueling cancer vaccines to improve T cell-mediated antitumor immunity</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>878377</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.878377</pub-id><pub-id pub-id-type="pmid">35651800</pub-id><pub-id pub-id-type="pmcid">PMC9150178</pub-id></element-citation><mixed-citation id="mc-CR298" publication-type="journal">Hernandez R, Malek TR. Fueling cancer vaccines to improve T cell-mediated antitumor immunity. Front Oncol. 2022;12:878377.<pub-id pub-id-type="pmid">35651800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2022.878377</pub-id><pub-id pub-id-type="pmcid">PMC9150178</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR299"><label>299.</label><citation-alternatives><element-citation id="ec-CR299" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaiser</surname><given-names>J</given-names></name></person-group><article-title>Personalized tumor vaccines keep cancer in check</article-title><source>Science</source><year>2017</year><volume>356</volume><issue>6334</issue><fpage>122</fpage><pub-id pub-id-type="doi">10.1126/science.356.6334.122</pub-id><pub-id pub-id-type="pmid">28408552</pub-id></element-citation><mixed-citation id="mc-CR299" publication-type="journal">Kaiser J. Personalized tumor vaccines keep cancer in check. Science. 2017;356(6334):122.<pub-id pub-id-type="pmid">28408552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.356.6334.122</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR300"><label>300.</label><citation-alternatives><element-citation id="ec-CR300" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>Peptide-based therapeutic cancer vaccine: current trends in clinical application</article-title><source>Cell Prolif</source><year>2021</year><volume>54</volume><issue>5</issue><fpage>e13025</fpage><pub-id pub-id-type="doi">10.1111/cpr.13025</pub-id><pub-id pub-id-type="pmid">33754407</pub-id><pub-id pub-id-type="pmcid">PMC8088465</pub-id></element-citation><mixed-citation id="mc-CR300" publication-type="journal">Liu W, Tang H, Li L, Wang X, Yu Z, Li J. Peptide-based therapeutic cancer vaccine: current trends in clinical application. Cell Prolif. 2021;54(5):e13025.<pub-id pub-id-type="pmid">33754407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cpr.13025</pub-id><pub-id pub-id-type="pmcid">PMC8088465</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR301"><label>301.</label><citation-alternatives><element-citation id="ec-CR301" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>X</given-names></name><name name-style="western"><surname>Zaks</surname><given-names>T</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name></person-group><article-title>Lipid nanoparticles for mRNA delivery</article-title><source>Nat Rev Mater</source><year>2021</year><volume>6</volume><issue>12</issue><fpage>1078</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1038/s41578-021-00358-0</pub-id><pub-id pub-id-type="pmid">34394960</pub-id><pub-id pub-id-type="pmcid">PMC8353930</pub-id></element-citation><mixed-citation id="mc-CR301" publication-type="journal">Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078&#8211;94.<pub-id pub-id-type="pmid">34394960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41578-021-00358-0</pub-id><pub-id pub-id-type="pmcid">PMC8353930</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR302"><label>302.</label><citation-alternatives><element-citation id="ec-CR302" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kowalski</surname><given-names>PS</given-names></name><name name-style="western"><surname>Rudra</surname><given-names>A</given-names></name><name name-style="western"><surname>Miao</surname><given-names>L</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>DG</given-names></name></person-group><article-title>Delivering the messenger: advances in technologies for therapeutic mRNA delivery</article-title><source>Mol Ther</source><year>2019</year><volume>27</volume><issue>4</issue><fpage>710</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2019.02.012</pub-id><pub-id pub-id-type="pmid">30846391</pub-id><pub-id pub-id-type="pmcid">PMC6453548</pub-id></element-citation><mixed-citation id="mc-CR302" publication-type="journal">Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27(4):710&#8211;28.<pub-id pub-id-type="pmid">30846391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2019.02.012</pub-id><pub-id pub-id-type="pmcid">PMC6453548</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR303"><label>303.</label><citation-alternatives><element-citation id="ec-CR303" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>He</surname><given-names>G</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name></person-group><article-title>Development of mRNA Lipid Nanoparticles: targeting and therapeutic aspects</article-title><source>Int J Mol Sci</source><year>2024</year><volume>25</volume><issue>18</issue><fpage>10166</fpage><pub-id pub-id-type="doi">10.3390/ijms251810166</pub-id><pub-id pub-id-type="pmid">39337651</pub-id><pub-id pub-id-type="pmcid">PMC11432440</pub-id></element-citation><mixed-citation id="mc-CR303" publication-type="journal">Liu Y, Huang Y, He G, Guo C, Dong J, Wu L. Development of mRNA Lipid Nanoparticles: targeting and therapeutic aspects. Int J Mol Sci. 2024;25(18):10166.<pub-id pub-id-type="pmid">39337651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms251810166</pub-id><pub-id pub-id-type="pmcid">PMC11432440</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR304"><label>304.</label><citation-alternatives><element-citation id="ec-CR304" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Serrano</surname><given-names>LO</given-names></name><name name-style="western"><surname>Burkhart</surname><given-names>DJ</given-names></name></person-group><article-title>Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines</article-title><source>J Nanobiotechnology</source><year>2017</year><volume>15</volume><issue>1</issue><fpage>83</fpage><pub-id pub-id-type="doi">10.1186/s12951-017-0319-9</pub-id><pub-id pub-id-type="pmid">29149896</pub-id><pub-id pub-id-type="pmcid">PMC5693489</pub-id></element-citation><mixed-citation id="mc-CR304" publication-type="journal">De Serrano LO, Burkhart DJ. Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines. J Nanobiotechnology. 2017;15(1):83.<pub-id pub-id-type="pmid">29149896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-017-0319-9</pub-id><pub-id pub-id-type="pmcid">PMC5693489</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR305"><label>305.</label><citation-alternatives><element-citation id="ec-CR305" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>MS</given-names></name><name name-style="western"><surname>Ramishetti</surname><given-names>S</given-names></name><name name-style="western"><surname>Landesman-Milo</surname><given-names>D</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>M</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>S</given-names></name><name name-style="western"><surname>Palakuri</surname><given-names>R</given-names></name><etal/></person-group><article-title>Therapeutic gene silencing using targeted lipid nanoparticles in metastatic ovarian cancer</article-title><source>Small</source><year>2021</year><volume>17</volume><issue>19</issue><fpage>e2100287</fpage><pub-id pub-id-type="doi">10.1002/smll.202100287</pub-id><pub-id pub-id-type="pmid">33825318</pub-id></element-citation><mixed-citation id="mc-CR305" publication-type="journal">Singh MS, Ramishetti S, Landesman-Milo D, Goldsmith M, Chatterjee S, Palakuri R, et al. Therapeutic gene silencing using targeted lipid nanoparticles in metastatic ovarian cancer. Small. 2021;17(19):e2100287.<pub-id pub-id-type="pmid">33825318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202100287</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR306"><label>306.</label><citation-alternatives><element-citation id="ec-CR306" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name></person-group><article-title>mRNA vaccine for cancer immunotherapy</article-title><source>Mol Cancer</source><year>2021</year><volume>20</volume><issue>1</issue><fpage>41</fpage><pub-id pub-id-type="doi">10.1186/s12943-021-01335-5</pub-id><pub-id pub-id-type="pmid">33632261</pub-id><pub-id pub-id-type="pmcid">PMC7905014</pub-id></element-citation><mixed-citation id="mc-CR306" publication-type="journal">Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20(1):41.<pub-id pub-id-type="pmid">33632261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-021-01335-5</pub-id><pub-id pub-id-type="pmcid">PMC7905014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR307"><label>307.</label><citation-alternatives><element-citation id="ec-CR307" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fritsch</surname><given-names>EF</given-names></name><name name-style="western"><surname>Hacohen</surname><given-names>N</given-names></name><name name-style="western"><surname>Wu</surname><given-names>CJ</given-names></name></person-group><article-title>Personal neoantigen cancer vaccines: the momentum builds</article-title><source>Oncoimmunology</source><year>2014</year><volume>3</volume><fpage>e29311</fpage><pub-id pub-id-type="doi">10.4161/onci.29311</pub-id><pub-id pub-id-type="pmid">25101225</pub-id><pub-id pub-id-type="pmcid">PMC4121338</pub-id></element-citation><mixed-citation id="mc-CR307" publication-type="journal">Fritsch EF, Hacohen N, Wu CJ. Personal neoantigen cancer vaccines: the momentum builds. Oncoimmunology. 2014;3:e29311.<pub-id pub-id-type="pmid">25101225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/onci.29311</pub-id><pub-id pub-id-type="pmcid">PMC4121338</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR308"><label>308.</label><citation-alternatives><element-citation id="ec-CR308" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fritsch</surname><given-names>EF</given-names></name><name name-style="western"><surname>Ott</surname><given-names>PA</given-names></name></person-group><article-title>Personalized cancer vaccines directed against tumor mutations: building evidence from mice to humans</article-title><source>Cancer Res</source><year>2024</year><volume>84</volume><issue>7</issue><fpage>953</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-24-0565</pub-id><pub-id pub-id-type="pmid">38558128</pub-id></element-citation><mixed-citation id="mc-CR308" publication-type="journal">Fritsch EF, Ott PA. Personalized cancer vaccines directed against tumor mutations: building evidence from mice to humans. Cancer Res. 2024;84(7):953&#8211;5.<pub-id pub-id-type="pmid">38558128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-24-0565</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR309"><label>309.</label><citation-alternatives><element-citation id="ec-CR309" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howard</surname><given-names>FHN</given-names></name><name name-style="western"><surname>Al-Janabi</surname><given-names>H</given-names></name><name name-style="western"><surname>Patel</surname><given-names>P</given-names></name><name name-style="western"><surname>Cox</surname><given-names>K</given-names></name><name name-style="western"><surname>Smith</surname><given-names>E</given-names></name><name name-style="western"><surname>Vadakekolathu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Nanobugs as drugs: bacterial derived nanomagnets enhance tumor targeting and oncolytic activity of HSV-1 virus</article-title><source>Small</source><year>2022</year><volume>18</volume><issue>13</issue><fpage>e2104763</fpage><pub-id pub-id-type="doi">10.1002/smll.202104763</pub-id><pub-id pub-id-type="pmid">35076148</pub-id></element-citation><mixed-citation id="mc-CR309" publication-type="journal">Howard FHN, Al-Janabi H, Patel P, Cox K, Smith E, Vadakekolathu J, et al. Nanobugs as drugs: bacterial derived nanomagnets enhance tumor targeting and oncolytic activity of HSV-1 virus. Small. 2022;18(13):e2104763.<pub-id pub-id-type="pmid">35076148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202104763</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR310"><label>310.</label><citation-alternatives><element-citation id="ec-CR310" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>C</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Song</surname><given-names>L</given-names></name><name name-style="western"><surname>Peng</surname><given-names>B</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B</given-names></name><etal/></person-group><article-title>Emerging nano-/biotechnology drives oncolytic virus-activated and combined cancer immunotherapy</article-title><source>Research (Wash D C)</source><year>2023</year><volume>6</volume><fpage>0108</fpage><pub-id pub-id-type="pmid">37040283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.34133/research.0108</pub-id><pub-id pub-id-type="pmcid">PMC10079287</pub-id></element-citation><mixed-citation id="mc-CR310" publication-type="journal">Fang C, Xiao G, Wang T, Song L, Peng B, Xu B, et al. Emerging nano-/biotechnology drives oncolytic virus-activated and combined cancer immunotherapy. Research (Wash D C). 2023;6:0108.<pub-id pub-id-type="pmid">37040283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.34133/research.0108</pub-id><pub-id pub-id-type="pmcid">PMC10079287</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR311"><label>311.</label><citation-alternatives><element-citation id="ec-CR311" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>F</given-names></name><name name-style="western"><surname>Gabrilovich</surname><given-names>D</given-names></name><name name-style="western"><surname>Sotomayor</surname><given-names>EM</given-names></name></person-group><article-title>Immune tolerance in breast cancer</article-title><source>Breast Dis</source><year>2004</year><volume>20</volume><fpage>93</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.3233/BD-2004-20111</pub-id><pub-id pub-id-type="pmid">15687711</pub-id></element-citation><mixed-citation id="mc-CR311" publication-type="journal">Cheng F, Gabrilovich D, Sotomayor EM. Immune tolerance in breast cancer. Breast Dis. 2004;20:93&#8211;103.<pub-id pub-id-type="pmid">15687711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/bd-2004-20111</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR312"><label>312.</label><mixed-citation publication-type="other">Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther. 2002;13(1):3-13.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/10430340152712629</pub-id><pub-id pub-id-type="pmid">11779411</pub-id></mixed-citation></ref><ref id="CR313"><label>313.</label><citation-alternatives><element-citation id="ec-CR313" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neff-LaFord</surname><given-names>HD</given-names></name><name name-style="western"><surname>Vorderstrasse</surname><given-names>BA</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>BP</given-names></name></person-group><article-title>Fewer CTL, not enhanced NK cells, are sufficient for viral clearance from the lungs of immunocompromised mice</article-title><source>Cell Immunol</source><year>2003</year><volume>226</volume><issue>1</issue><fpage>54</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2003.11.005</pub-id><pub-id pub-id-type="pmid">14746808</pub-id></element-citation><mixed-citation id="mc-CR313" publication-type="journal">Neff-LaFord HD, Vorderstrasse BA, Lawrence BP. Fewer CTL, not enhanced NK cells, are sufficient for viral clearance from the lungs of immunocompromised mice. Cell Immunol. 2003;226(1):54&#8211;64.<pub-id pub-id-type="pmid">14746808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cellimm.2003.11.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR314"><label>314.</label><citation-alternatives><element-citation id="ec-CR314" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rana</surname><given-names>I</given-names></name><name name-style="western"><surname>Oh</surname><given-names>J</given-names></name><name name-style="western"><surname>Baig</surname><given-names>J</given-names></name><name name-style="western"><surname>Moon</surname><given-names>JH</given-names></name><name name-style="western"><surname>Son</surname><given-names>S</given-names></name><name name-style="western"><surname>Nam</surname><given-names>J</given-names></name></person-group><article-title>Nanocarriers for cancer nano-immunotherapy</article-title><source>Drug Deliv Transl Res</source><year>2023</year><volume>13</volume><issue>7</issue><fpage>1936</fpage><lpage>1954</lpage><pub-id pub-id-type="doi">10.1007/s13346-022-01241-3</pub-id><pub-id pub-id-type="pmid">36190661</pub-id><pub-id pub-id-type="pmcid">PMC9528883</pub-id></element-citation><mixed-citation id="mc-CR314" publication-type="journal">Rana I, Oh J, Baig J, Moon JH, Son S, Nam J. Nanocarriers for cancer nano-immunotherapy. Drug Deliv Transl Res. 2023;13(7):1936&#8211;54.<pub-id pub-id-type="pmid">36190661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13346-022-01241-3</pub-id><pub-id pub-id-type="pmcid">PMC9528883</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR315"><label>315.</label><citation-alternatives><element-citation id="ec-CR315" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>P</given-names></name><name name-style="western"><surname>Paraiso</surname><given-names>WKD</given-names></name><name name-style="western"><surname>Cabral</surname><given-names>H</given-names></name></person-group><article-title>Revitalizing cytokine-based cancer immunotherapy through advanced delivery systems</article-title><source>Macromol Biosci</source><year>2023</year><volume>23</volume><issue>12</issue><fpage>e2300275</fpage><pub-id pub-id-type="doi">10.1002/mabi.202300275</pub-id><pub-id pub-id-type="pmid">37565723</pub-id></element-citation><mixed-citation id="mc-CR315" publication-type="journal">Chen P, Paraiso WKD, Cabral H. Revitalizing cytokine-based cancer immunotherapy through advanced delivery systems. Macromol Biosci. 2023;23(12):e2300275.<pub-id pub-id-type="pmid">37565723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mabi.202300275</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR316"><label>316.</label><citation-alternatives><element-citation id="ec-CR316" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>KG</given-names></name><name name-style="western"><surname>Vrabel</surname><given-names>MR</given-names></name><name name-style="western"><surname>Mantooth</surname><given-names>SM</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>ES</given-names></name><name name-style="western"><surname>Gabaldon</surname><given-names>TA</given-names></name><etal/></person-group><article-title>Localized interleukin-12 for cancer immunotherapy</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>575597</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.575597</pub-id><pub-id pub-id-type="pmid">33178203</pub-id><pub-id pub-id-type="pmcid">PMC7593768</pub-id></element-citation><mixed-citation id="mc-CR316" publication-type="journal">Nguyen KG, Vrabel MR, Mantooth SM, Hopkins JJ, Wagner ES, Gabaldon TA, et al. Localized interleukin-12 for cancer immunotherapy. Front Immunol. 2020;11:575597.<pub-id pub-id-type="pmid">33178203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.575597</pub-id><pub-id pub-id-type="pmcid">PMC7593768</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR317"><label>317.</label><citation-alternatives><element-citation id="ec-CR317" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lian</surname><given-names>H</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hua</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cytokine therapy combined with nanomaterials participates in cancer immunotherapy</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><issue>12</issue><fpage>2606</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics14122606</pub-id><pub-id pub-id-type="pmid">36559100</pub-id><pub-id pub-id-type="pmcid">PMC9788370</pub-id></element-citation><mixed-citation id="mc-CR317" publication-type="journal">Lian H, Ma S, Zhao D, Zhao W, Cui Y, Hua Y, et al. Cytokine therapy combined with nanomaterials participates in cancer immunotherapy. Pharmaceutics. 2022;14(12):2606.<pub-id pub-id-type="pmid">36559100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics14122606</pub-id><pub-id pub-id-type="pmcid">PMC9788370</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR318"><label>318.</label><citation-alternatives><element-citation id="ec-CR318" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><name name-style="western"><surname>Yue</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name></person-group><article-title>Targeted cancer immunotherapy: nanoformulation engineering and clinical translation</article-title><source>Adv Sci (Weinh)</source><year>2022</year><volume>9</volume><issue>35</issue><fpage>e2204335</fpage><pub-id pub-id-type="doi">10.1002/advs.202204335</pub-id><pub-id pub-id-type="pmid">36257824</pub-id><pub-id pub-id-type="pmcid">PMC9762307</pub-id></element-citation><mixed-citation id="mc-CR318" publication-type="journal">Yu M, Yang W, Yue W, Chen Y. Targeted cancer immunotherapy: nanoformulation engineering and clinical translation. Adv Sci (Weinh). 2022;9(35):e2204335.<pub-id pub-id-type="pmid">36257824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202204335</pub-id><pub-id pub-id-type="pmcid">PMC9762307</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR319"><label>319.</label><citation-alternatives><element-citation id="ec-CR319" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Q</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X</given-names></name><name name-style="western"><surname>Sofias</surname><given-names>AM</given-names></name><name name-style="western"><surname>van der Meel</surname><given-names>R</given-names></name><name name-style="western"><surname>Ruiz-Hernandez</surname><given-names>E</given-names></name><name name-style="western"><surname>Storm</surname><given-names>G</given-names></name><etal/></person-group><article-title>Cancer nanomedicine meets immunotherapy: opportunities and challenges</article-title><source>Acta Pharmacol Sin</source><year>2020</year><volume>41</volume><issue>7</issue><fpage>954</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1038/s41401-020-0448-9</pub-id><pub-id pub-id-type="pmid">32555445</pub-id><pub-id pub-id-type="pmcid">PMC7470866</pub-id></element-citation><mixed-citation id="mc-CR319" publication-type="journal">Sun Q, Bai X, Sofias AM, van der Meel R, Ruiz-Hernandez E, Storm G, et al. Cancer nanomedicine meets immunotherapy: opportunities and challenges. Acta Pharmacol Sin. 2020;41(7):954&#8211;8.<pub-id pub-id-type="pmid">32555445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41401-020-0448-9</pub-id><pub-id pub-id-type="pmcid">PMC7470866</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR320"><label>320.</label><citation-alternatives><element-citation id="ec-CR320" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmid</surname><given-names>P</given-names></name><name name-style="western"><surname>Rugo</surname><given-names>HS</given-names></name><name name-style="western"><surname>Adams</surname><given-names>S</given-names></name><name name-style="western"><surname>Schneeweiss</surname><given-names>A</given-names></name><name name-style="western"><surname>Barrios</surname><given-names>CH</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>H</given-names></name><etal/></person-group><article-title>Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>Lancet Oncol</source><year>2020</year><volume>21</volume><issue>1</issue><fpage>44</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(19)30689-8</pub-id><pub-id pub-id-type="pmid">31786121</pub-id></element-citation><mixed-citation id="mc-CR320" publication-type="journal">Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44&#8211;59.<pub-id pub-id-type="pmid">31786121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(19)30689-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR321"><label>321.</label><citation-alternatives><element-citation id="ec-CR321" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yam</surname><given-names>C</given-names></name><name name-style="western"><surname>Mittendorf</surname><given-names>EA</given-names></name><name name-style="western"><surname>Garber</surname><given-names>HR</given-names></name><name name-style="western"><surname>Sun</surname><given-names>R</given-names></name><name name-style="western"><surname>Damodaran</surname><given-names>S</given-names></name><name name-style="western"><surname>Murthy</surname><given-names>RK</given-names></name><etal/></person-group><article-title>A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2023</year><volume>199</volume><issue>3</issue><fpage>457</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1007/s10549-023-06929-9</pub-id><pub-id pub-id-type="pmid">37061619</pub-id><pub-id pub-id-type="pmcid">PMC12247189</pub-id></element-citation><mixed-citation id="mc-CR321" publication-type="journal">Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, et al. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2023;199(3):457&#8211;69.<pub-id pub-id-type="pmid">37061619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-023-06929-9</pub-id><pub-id pub-id-type="pmcid">PMC12247189</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR322"><label>322.</label><citation-alternatives><element-citation id="ec-CR322" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loibl</surname><given-names>S</given-names></name><name name-style="western"><surname>Schneeweiss</surname><given-names>A</given-names></name><name name-style="western"><surname>Huober</surname><given-names>J</given-names></name><name name-style="western"><surname>Braun</surname><given-names>M</given-names></name><name name-style="western"><surname>Rey</surname><given-names>J</given-names></name><name name-style="western"><surname>Blohmer</surname><given-names>JU</given-names></name><etal/></person-group><article-title>Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response</article-title><source>Ann Oncol</source><year>2022</year><volume>33</volume><issue>11</issue><fpage>1149</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2022.07.1940</pub-id><pub-id pub-id-type="pmid">35961599</pub-id></element-citation><mixed-citation id="mc-CR322" publication-type="journal">Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 2022;33(11):1149&#8211;58.<pub-id pub-id-type="pmid">35961599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2022.07.1940</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR323"><label>323.</label><citation-alternatives><element-citation id="ec-CR323" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sonoda</surname><given-names>T</given-names></name><name name-style="western"><surname>Umeda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Demura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tada</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakashima</surname><given-names>K</given-names></name><name name-style="western"><surname>Anzai</surname><given-names>M</given-names></name><etal/></person-group><article-title>Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: a multicenter Phase 2 clinical trial</article-title><source>Cancer Med</source><year>2023</year><volume>12</volume><issue>12</issue><fpage>13041</fpage><lpage>13053</lpage><pub-id pub-id-type="doi">10.1002/cam4.5978</pub-id><pub-id pub-id-type="pmid">37081729</pub-id><pub-id pub-id-type="pmcid">PMC10315716</pub-id></element-citation><mixed-citation id="mc-CR323" publication-type="journal">Sonoda T, Umeda Y, Demura Y, Tada T, Nakashima K, Anzai M, et al. Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: a multicenter Phase 2 clinical trial. Cancer Med. 2023;12(12):13041&#8211;53.<pub-id pub-id-type="pmid">37081729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.5978</pub-id><pub-id pub-id-type="pmcid">PMC10315716</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR324"><label>324.</label><citation-alternatives><element-citation id="ec-CR324" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gentzler</surname><given-names>RD</given-names></name><name name-style="western"><surname>Mohindra</surname><given-names>NA</given-names></name><name name-style="western"><surname>Jalal</surname><given-names>SI</given-names></name><name name-style="western"><surname>Reckamp</surname><given-names>KL</given-names></name><name name-style="western"><surname>Hall</surname><given-names>RD</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>NH</given-names></name><etal/></person-group><article-title>Phase I/II trial of carboplatin, nab-paclitaxel, and pembrolizumab for advanced non-small cell lung cancer: hoosier cancer research network LUN13-175</article-title><source>Oncologist</source><year>2024</year><volume>29</volume><issue>1</issue><fpage>47</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1093/oncolo/oyad180</pub-id><pub-id pub-id-type="pmid">37390616</pub-id><pub-id pub-id-type="pmcid">PMC10769801</pub-id></element-citation><mixed-citation id="mc-CR324" publication-type="journal">Gentzler RD, Mohindra NA, Jalal SI, Reckamp KL, Hall RD, Hanna NH, et al. Phase I/II trial of carboplatin, nab-paclitaxel, and pembrolizumab for advanced non-small cell lung cancer: hoosier cancer research network LUN13-175. Oncologist. 2024;29(1):47&#8211;56.<pub-id pub-id-type="pmid">37390616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/oncolo/oyad180</pub-id><pub-id pub-id-type="pmcid">PMC10769801</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR325"><label>325.</label><citation-alternatives><element-citation id="ec-CR325" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilkerson</surname><given-names>AD</given-names></name><name name-style="western"><surname>Parthasarathy</surname><given-names>PB</given-names></name><name name-style="western"><surname>Stabellini</surname><given-names>N</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>C</given-names></name><name name-style="western"><surname>Pavicic</surname><given-names>PG</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Fu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Phase II clinical trial of pembrolizumab and chemotherapy reveals distinct transcriptomic profiles by radiologic response in metastatic triple-negative breast cancer</article-title><source>Clin Cancer Res</source><year>2024</year><volume>30</volume><issue>1</issue><fpage>82</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-23-1349</pub-id><pub-id pub-id-type="pmid">37882661</pub-id><pub-id pub-id-type="pmcid">PMC10767305</pub-id></element-citation><mixed-citation id="mc-CR325" publication-type="journal">Wilkerson AD, Parthasarathy PB, Stabellini N, Mitchell C, Pavicic PG Jr, Fu P, et al. Phase II clinical trial of pembrolizumab and chemotherapy reveals distinct transcriptomic profiles by radiologic response in metastatic triple-negative breast cancer. Clin Cancer Res. 2024;30(1):82&#8211;93.<pub-id pub-id-type="pmid">37882661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-23-1349</pub-id><pub-id pub-id-type="pmcid">PMC10767305</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR326"><label>326.</label><citation-alternatives><element-citation id="ec-CR326" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X</given-names></name><name name-style="western"><surname>Cai</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma</article-title><source>J Immunother Cancer</source><year>2022</year><volume>10</volume><issue>3</issue><fpage>e004291</fpage><pub-id pub-id-type="doi">10.1136/jitc-2021-004291</pub-id><pub-id pub-id-type="pmid">35338088</pub-id><pub-id pub-id-type="pmcid">PMC8961177</pub-id></element-citation><mixed-citation id="mc-CR326" publication-type="journal">Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H, et al. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer. 2022;10(3):e004291.<pub-id pub-id-type="pmid">35338088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2021-004291</pub-id><pub-id pub-id-type="pmcid">PMC8961177</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR327"><label>327.</label><citation-alternatives><element-citation id="ec-CR327" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B</given-names></name><etal/></person-group><article-title>Two-year outcomes of clinical N2&#8211;3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study</article-title><source>J Thorac Cardiovasc Surg</source><year>2024</year><volume>167</volume><issue>3</issue><fpage>838</fpage><lpage>47 e1</lpage><pub-id pub-id-type="doi">10.1016/j.jtcvs.2023.08.056</pub-id><pub-id pub-id-type="pmid">37696429</pub-id></element-citation><mixed-citation id="mc-CR327" publication-type="journal">Yang Y, Liu J, Liu Z, Zhu L, Chen H, Yu B, et al. Two-year outcomes of clinical N2&#8211;3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study. J Thorac Cardiovasc Surg. 2024;167(3):838&#8211;47 e1.<pub-id pub-id-type="pmid">37696429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtcvs.2023.08.056</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR328"><label>328.</label><citation-alternatives><element-citation id="ec-CR328" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>G</given-names></name><name name-style="western"><surname>Su</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Luo</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cai</surname><given-names>P</given-names></name><etal/></person-group><article-title>Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial</article-title><source>J Transl Med</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>411</fpage><pub-id pub-id-type="doi">10.1186/s12967-023-04273-6</pub-id><pub-id pub-id-type="pmid">37355621</pub-id><pub-id pub-id-type="pmcid">PMC10290378</pub-id></element-citation><mixed-citation id="mc-CR328" publication-type="journal">Yang G, Su X, Huang Y, Luo G, Wang Z, Cai P, et al. Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial. J Transl Med. 2023;21(1):411.<pub-id pub-id-type="pmid">37355621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-023-04273-6</pub-id><pub-id pub-id-type="pmcid">PMC10290378</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR329"><label>329.</label><citation-alternatives><element-citation id="ec-CR329" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>6654</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-42479-w</pub-id><pub-id pub-id-type="pmid">37863916</pub-id><pub-id pub-id-type="pmcid">PMC10589334</pub-id></element-citation><mixed-citation id="mc-CR329" publication-type="journal">Wang C, Liu Z, Chen X, Qiao J, Lu Z, Li L, et al. Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial. Nat Commun. 2023;14(1):6654.<pub-id pub-id-type="pmid">37863916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-42479-w</pub-id><pub-id pub-id-type="pmcid">PMC10589334</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR330"><label>330.</label><citation-alternatives><element-citation id="ec-CR330" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YZ</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><etal/></person-group><article-title>Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial</article-title><source>Lancet Oncol</source><year>2024</year><volume>25</volume><issue>1</issue><fpage>76</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(23)00531-4</pub-id><pub-id pub-id-type="pmid">38048802</pub-id></element-citation><mixed-citation id="mc-CR330" publication-type="journal">Li K, Chen J, Hu Y, Wang YZ, Shen Y, Chen G, et al. Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024;25(1):76&#8211;85.<pub-id pub-id-type="pmid">38048802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(23)00531-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR331"><label>331.</label><citation-alternatives><element-citation id="ec-CR331" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>X</given-names></name><name name-style="western"><surname>Duan</surname><given-names>H</given-names></name><name name-style="western"><surname>Ni</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Qi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)</article-title><source>Int J Surg</source><year>2022</year><volume>103</volume><fpage>106680</fpage><pub-id pub-id-type="doi">10.1016/j.ijsu.2022.106680</pub-id><pub-id pub-id-type="pmid">35595021</pub-id></element-citation><mixed-citation id="mc-CR331" publication-type="journal">Yan X, Duan H, Ni Y, Zhou Y, Wang X, Qi H, et al. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE). Int J Surg. 2022;103:106680.<pub-id pub-id-type="pmid">35595021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijsu.2022.106680</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR332"><label>332.</label><citation-alternatives><element-citation id="ec-CR332" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Feng</surname><given-names>K</given-names></name><name name-style="western"><surname>Tong</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase i clinical trial</article-title><source>Cytotherapy</source><year>2020</year><volume>22</volume><issue>10</issue><fpage>573</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1016/j.jcyt.2020.04.088</pub-id><pub-id pub-id-type="pmid">32527643</pub-id></element-citation><mixed-citation id="mc-CR332" publication-type="journal">Liu Y, Guo Y, Wu Z, Feng K, Tong C, Wang Y, et al. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase i clinical trial. Cytotherapy. 2020;22(10):573&#8211;80.<pub-id pub-id-type="pmid">32527643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcyt.2020.04.088</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR333"><label>333.</label><citation-alternatives><element-citation id="ec-CR333" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ota</surname><given-names>S</given-names></name><name name-style="western"><surname>Miyashita</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamagishi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ogasawara</surname><given-names>M</given-names></name></person-group><article-title>Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy</article-title><source>Hum Vaccin Immunother</source><year>2021</year><volume>17</volume><issue>12</issue><fpage>5563</fpage><lpage>5572</lpage><pub-id pub-id-type="doi">10.1080/21645515.2021.2003645</pub-id><pub-id pub-id-type="pmid">34919493</pub-id><pub-id pub-id-type="pmcid">PMC8903979</pub-id></element-citation><mixed-citation id="mc-CR333" publication-type="journal">Ota S, Miyashita M, Yamagishi Y, Ogasawara M. Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy. Hum Vaccin Immunother. 2021;17(12):5563&#8211;72.<pub-id pub-id-type="pmid">34919493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2021.2003645</pub-id><pub-id pub-id-type="pmcid">PMC8903979</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR334"><label>334.</label><citation-alternatives><element-citation id="ec-CR334" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'Hara</surname><given-names>MH</given-names></name><name name-style="western"><surname>O'Reilly</surname><given-names>EM</given-names></name><name name-style="western"><surname>Varadhachary</surname><given-names>G</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>RA</given-names></name><name name-style="western"><surname>Wainberg</surname><given-names>ZA</given-names></name><name name-style="western"><surname>Ko</surname><given-names>AH</given-names></name><etal/></person-group><article-title>CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study</article-title><source>Lancet Oncol</source><year>2021</year><volume>22</volume><issue>1</issue><fpage>118</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(20)30532-5</pub-id><pub-id pub-id-type="pmid">33387490</pub-id></element-citation><mixed-citation id="mc-CR334" publication-type="journal">O&#8217;Hara MH, O&#8217;Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021;22(1):118&#8211;31.<pub-id pub-id-type="pmid">33387490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(20)30532-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR335"><label>335.</label><citation-alternatives><element-citation id="ec-CR335" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mei</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Rasko</surname><given-names>JEJ</given-names></name><name name-style="western"><surname>Nie</surname><given-names>J</given-names></name><etal/></person-group><article-title>Camrelizumab plus gemcitabine, vinorelbine, and pegylated liposomal doxorubicin in relapsed/refractory primary mediastinal b-cell lymphoma: a single-arm, open-label</article-title><source>Phase II Trial Clin Cancer Res</source><year>2020</year><volume>26</volume><issue>17</issue><fpage>4521</fpage><lpage>4530</lpage><pub-id pub-id-type="pmid">32499235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-20-0514</pub-id></element-citation><mixed-citation id="mc-CR335" publication-type="journal">Mei Q, Zhang W, Liu Y, Yang Q, Rasko JEJ, Nie J, et al. Camrelizumab plus gemcitabine, vinorelbine, and pegylated liposomal doxorubicin in relapsed/refractory primary mediastinal b-cell lymphoma: a single-arm, open-label. Phase II Trial Clin Cancer Res. 2020;26(17):4521&#8211;30.<pub-id pub-id-type="pmid">32499235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-20-0514</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR336"><label>336.</label><citation-alternatives><element-citation id="ec-CR336" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Little</surname><given-names>RF</given-names></name><name name-style="western"><surname>Aleman</surname><given-names>K</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P</given-names></name><name name-style="western"><surname>Wyvill</surname><given-names>KM</given-names></name><name name-style="western"><surname>Pluda</surname><given-names>JM</given-names></name><name name-style="western"><surname>Read-Connole</surname><given-names>E</given-names></name><etal/></person-group><article-title>Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma</article-title><source>Blood</source><year>2007</year><volume>110</volume><issue>13</issue><fpage>4165</fpage><lpage>4171</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-06-097568</pub-id><pub-id pub-id-type="pmid">17846226</pub-id><pub-id pub-id-type="pmcid">PMC2234790</pub-id></element-citation><mixed-citation id="mc-CR336" publication-type="journal">Little RF, Aleman K, Kumar P, Wyvill KM, Pluda JM, Read-Connole E, et al. Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma. Blood. 2007;110(13):4165&#8211;71.<pub-id pub-id-type="pmid">17846226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2007-06-097568</pub-id><pub-id pub-id-type="pmcid">PMC2234790</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR337"><label>337.</label><citation-alternatives><element-citation id="ec-CR337" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simpkins</surname><given-names>F</given-names></name><name name-style="western"><surname>Flores</surname><given-names>AM</given-names></name><name name-style="western"><surname>Chu</surname><given-names>C</given-names></name><name name-style="western"><surname>Lucci</surname><given-names>JA</given-names></name><name name-style="western"><surname>Berek</surname><given-names>JS</given-names></name><name name-style="western"><surname>Coukos</surname><given-names>G</given-names></name><etal/></person-group><article-title>A phase I, dose escalation trial to assess the safety and biological activity of recombinant human interleukin-18 (SB-485232) in combination with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><issue>15_suppl</issue><fpage>5065-</fpage><pub-id pub-id-type="doi">10.1200/jco.2012.30.15_suppl.5065</pub-id></element-citation><mixed-citation id="mc-CR337" publication-type="journal">Simpkins F, Flores AM, Chu C, Lucci JA, Berek JS, Coukos G, et al. A phase I, dose escalation trial to assess the safety and biological activity of recombinant human interleukin-18 (SB-485232) in combination with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer. J Clin Oncol. 2012;30(15_suppl):5065-.</mixed-citation></citation-alternatives></ref><ref id="CR338"><label>338.</label><citation-alternatives><element-citation id="ec-CR338" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>CD</given-names></name><name name-style="western"><surname>Rappaport</surname><given-names>AR</given-names></name><name name-style="western"><surname>Davis</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Hart</surname><given-names>MG</given-names></name><name name-style="western"><surname>Scallan</surname><given-names>CD</given-names></name><name name-style="western"><surname>Hong</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><issue>8</issue><fpage>1619</fpage><lpage>1629</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01937-6</pub-id><pub-id pub-id-type="pmid">35970920</pub-id></element-citation><mixed-citation id="mc-CR338" publication-type="journal">Palmer CD, Rappaport AR, Davis MJ, Hart MG, Scallan CD, Hong SJ, et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2022;28(8):1619&#8211;29.<pub-id pub-id-type="pmid">35970920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-01937-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR339"><label>339.</label><citation-alternatives><element-citation id="ec-CR339" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cafri</surname><given-names>G</given-names></name><name name-style="western"><surname>Gartner</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Zaks</surname><given-names>T</given-names></name><name name-style="western"><surname>Hopson</surname><given-names>K</given-names></name><name name-style="western"><surname>Levin</surname><given-names>N</given-names></name><name name-style="western"><surname>Paria</surname><given-names>BC</given-names></name><etal/></person-group><article-title>mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer</article-title><source>J Clin Invest</source><year>2020</year><volume>130</volume><issue>11</issue><fpage>5976</fpage><lpage>5988</lpage><pub-id pub-id-type="doi">10.1172/JCI134915</pub-id><pub-id pub-id-type="pmid">33016924</pub-id><pub-id pub-id-type="pmcid">PMC7598064</pub-id></element-citation><mixed-citation id="mc-CR339" publication-type="journal">Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, et al. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest. 2020;130(11):5976&#8211;88.<pub-id pub-id-type="pmid">33016924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI134915</pub-id><pub-id pub-id-type="pmcid">PMC7598064</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR340"><label>340.</label><citation-alternatives><element-citation id="ec-CR340" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burris</surname><given-names>HA</given-names></name><name name-style="western"><surname>Patel</surname><given-names>MR</given-names></name><name name-style="western"><surname>Cho</surname><given-names>DC</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>JM</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>M</given-names></name><name name-style="western"><surname>Zaks</surname><given-names>TZ</given-names></name><etal/></person-group><article-title>A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors</article-title><source>J Clin Oncol</source><year>2019</year><volume>37</volume><issue>15_suppl</issue><fpage>2523-</fpage><pub-id pub-id-type="doi">10.1200/JCO.2019.37.15_suppl.2523</pub-id></element-citation><mixed-citation id="mc-CR340" publication-type="journal">Burris HA, Patel MR, Cho DC, Clarke JM, Gutierrez M, Zaks TZ, et al. A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors. J Clin Oncol. 2019;37(15_suppl):2523-.</mixed-citation></citation-alternatives></ref><ref id="CR341"><label>341.</label><citation-alternatives><element-citation id="ec-CR341" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>JS</given-names></name><name name-style="western"><surname>Carlino</surname><given-names>MS</given-names></name><name name-style="western"><surname>Khattak</surname><given-names>A</given-names></name><name name-style="western"><surname>Meniawy</surname><given-names>T</given-names></name><name name-style="western"><surname>Ansstas</surname><given-names>G</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study</article-title><source>Lancet</source><year>2024</year><volume>403</volume><issue>10427</issue><fpage>632</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)02268-7</pub-id><pub-id pub-id-type="pmid">38246194</pub-id></element-citation><mixed-citation id="mc-CR341" publication-type="journal">Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632&#8211;44.<pub-id pub-id-type="pmid">38246194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(23)02268-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR342"><label>342.</label><citation-alternatives><element-citation id="ec-CR342" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jimeno</surname><given-names>A</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>R</given-names></name><name name-style="western"><surname>Do</surname><given-names>KT</given-names></name><name name-style="western"><surname>Akerley</surname><given-names>WL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><etal/></person-group><article-title>A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies</article-title><source>Cancer Res</source><year>2020</year><volume>80</volume><issue>16</issue><fpage>283</fpage><lpage>299</lpage></element-citation><mixed-citation id="mc-CR342" publication-type="journal">Jimeno A, Gupta S, Sullivan R, Do KT, Akerley WL, Wang D, et al. A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies. Cancer Res. 2020;80(16):283&#8211;99.</mixed-citation></citation-alternatives></ref><ref id="CR343"><label>343.</label><mixed-citation publication-type="other">Patel MR, Bauer TM, Jimeno A, Wang D, LoRusso P, Do KT, et al. A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36&#947;, for intratumoral (iTu) injection alone and in combination with durvalumab. Journal of Clinical Oncology. 2020;38(15).</mixed-citation></ref><ref id="CR344"><label>344.</label><citation-alternatives><element-citation id="ec-CR344" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olson</surname><given-names>D</given-names></name><name name-style="western"><surname>Daud</surname><given-names>A</given-names></name><name name-style="western"><surname>Shapira-Frommer</surname><given-names>R</given-names></name><name name-style="western"><surname>Jimeno</surname><given-names>A</given-names></name><name name-style="western"><surname>Reagan</surname><given-names>P</given-names></name><name name-style="western"><surname>Kummar</surname><given-names>S</given-names></name><etal/></person-group><article-title>Safety and Preliminary Efficacy of mRNA-2752, A Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36&#947; for Intratumoral (ITu) Injection, and Durvalumab (IV) in TNBC, HNSCC, and melanoma</article-title><source>J Immunother Cancer</source><year>2022</year><volume>10</volume><fpage>A798-A</fpage></element-citation><mixed-citation id="mc-CR344" publication-type="journal">Olson D, Daud A, Shapira-Frommer R, Jimeno A, Reagan P, Kummar S, et al. Safety and Preliminary Efficacy of mRNA-2752, A Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36&#947; for Intratumoral (ITu) Injection, and Durvalumab (IV) in TNBC, HNSCC, and melanoma. J Immunother Cancer. 2022;10:A798-A.</mixed-citation></citation-alternatives></ref><ref id="CR345"><label>345.</label><citation-alternatives><element-citation id="ec-CR345" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><name name-style="western"><surname>Oehm</surname><given-names>P</given-names></name><name name-style="western"><surname>Derhovanessian</surname><given-names>E</given-names></name><name name-style="western"><surname>Jabulowsky</surname><given-names>RA</given-names></name><name name-style="western"><surname>Vormehr</surname><given-names>M</given-names></name><name name-style="western"><surname>Gold</surname><given-names>M</given-names></name><etal/></person-group><article-title>An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma</article-title><source>Nature</source><year>2020</year><volume>585</volume><issue>7823</issue><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2537-9</pub-id><pub-id pub-id-type="pmid">32728218</pub-id></element-citation><mixed-citation id="mc-CR345" publication-type="journal">Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585(7823):107&#8211;12.<pub-id pub-id-type="pmid">32728218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2537-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR346"><label>346.</label><citation-alternatives><element-citation id="ec-CR346" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linch</surname><given-names>M</given-names></name><name name-style="western"><surname>Papai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Takacs</surname><given-names>I</given-names></name><name name-style="western"><surname>Imedio</surname><given-names>ER</given-names></name><name name-style="western"><surname>K&#252;hnle</surname><given-names>MC</given-names></name><name name-style="western"><surname>Derhovanessian</surname><given-names>E</given-names></name><etal/></person-group><article-title>A First-in-Human (FIH) Phase I/IIa Clinical Trial Assessing a Ribonucleic Acid Lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT</article-title><source>J Immunother Cancer</source><year>2021</year><volume>9</volume><fpage>A451</fpage><lpage>A</lpage></element-citation><mixed-citation id="mc-CR346" publication-type="journal">Linch M, Papai Z, Takacs I, Imedio ER, K&#252;hnle MC, Derhovanessian E, et al. A First-in-Human (FIH) Phase I/IIa Clinical Trial Assessing a Ribonucleic Acid Lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT. J Immunother Cancer. 2021;9:A451&#8211;A.</mixed-citation></citation-alternatives></ref><ref id="CR347"><label>347.</label><citation-alternatives><element-citation id="ec-CR347" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>MR</given-names></name><name name-style="western"><surname>Manikhas</surname><given-names>GM</given-names></name><name name-style="western"><surname>Orlov</surname><given-names>S</given-names></name><name name-style="western"><surname>Afanasyev</surname><given-names>B</given-names></name><name name-style="western"><surname>Makhson</surname><given-names>AM</given-names></name><name name-style="western"><surname>Bhar</surname><given-names>P</given-names></name><etal/></person-group><article-title>Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer</article-title><source>Ann Oncol</source><year>2006</year><volume>17</volume><issue>8</issue><fpage>1263</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdl104</pub-id><pub-id pub-id-type="pmid">16740598</pub-id></element-citation><mixed-citation id="mc-CR347" publication-type="journal">Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006;17(8):1263&#8211;8.<pub-id pub-id-type="pmid">16740598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdl104</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR348"><label>348.</label><citation-alternatives><element-citation id="ec-CR348" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herbst</surname><given-names>RS</given-names></name><name name-style="western"><surname>Giaccone</surname><given-names>G</given-names></name><name name-style="western"><surname>de Marinis</surname><given-names>F</given-names></name><name name-style="western"><surname>Reinmuth</surname><given-names>N</given-names></name><name name-style="western"><surname>Vergnenegre</surname><given-names>A</given-names></name><name name-style="western"><surname>Barrios</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><issue>14</issue><fpage>1328</fpage><lpage>1339</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1917346</pub-id><pub-id pub-id-type="pmid">32997907</pub-id></element-citation><mixed-citation id="mc-CR348" publication-type="journal">Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383(14):1328&#8211;39.<pub-id pub-id-type="pmid">32997907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1917346</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR349"><label>349.</label><citation-alternatives><element-citation id="ec-CR349" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barenholz</surname><given-names>Y</given-names></name></person-group><article-title>Doxil(R)&#8211;the first FDA-approved nano-drug: lessons learned</article-title><source>J Control Release</source><year>2012</year><volume>160</volume><issue>2</issue><fpage>117</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2012.03.020</pub-id><pub-id pub-id-type="pmid">22484195</pub-id></element-citation><mixed-citation id="mc-CR349" publication-type="journal">Barenholz Y. Doxil(R)&#8211;the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117&#8211;34.<pub-id pub-id-type="pmid">22484195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2012.03.020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR350"><label>350.</label><citation-alternatives><element-citation id="ec-CR350" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thaker</surname><given-names>PH</given-names></name><name name-style="western"><surname>Borys</surname><given-names>N</given-names></name><name name-style="western"><surname>Fewell</surname><given-names>J</given-names></name><name name-style="western"><surname>Anwer</surname><given-names>K</given-names></name></person-group><article-title>GEN-1 immunotherapy for the treatment of ovarian cancer</article-title><source>Future Oncol</source><year>2019</year><volume>15</volume><issue>4</issue><fpage>421</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.2217/fon-2018-0423</pub-id><pub-id pub-id-type="pmid">30325199</pub-id></element-citation><mixed-citation id="mc-CR350" publication-type="journal">Thaker PH, Borys N, Fewell J, Anwer K. GEN-1 immunotherapy for the treatment of ovarian cancer. Future Oncol. 2019;15(4):421&#8211;38.<pub-id pub-id-type="pmid">30325199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/fon-2018-0423</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR351"><label>351.</label><citation-alternatives><element-citation id="ec-CR351" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blass</surname><given-names>E</given-names></name><name name-style="western"><surname>Ott</surname><given-names>PA</given-names></name></person-group><article-title>Advances in the development of personalized neoantigen-based therapeutic cancer vaccines</article-title><source>Nat Rev Clin Oncol</source><year>2021</year><volume>18</volume><issue>4</issue><fpage>215</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1038/s41571-020-00460-2</pub-id><pub-id pub-id-type="pmid">33473220</pub-id><pub-id pub-id-type="pmcid">PMC7816749</pub-id></element-citation><mixed-citation id="mc-CR351" publication-type="journal">Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215&#8211;29.<pub-id pub-id-type="pmid">33473220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-020-00460-2</pub-id><pub-id pub-id-type="pmcid">PMC7816749</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR352"><label>352.</label><citation-alternatives><element-citation id="ec-CR352" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorentzen</surname><given-names>CL</given-names></name><name name-style="western"><surname>Haanen</surname><given-names>JB</given-names></name><name name-style="western"><surname>Met</surname><given-names>O</given-names></name><name name-style="western"><surname>Svane</surname><given-names>IM</given-names></name></person-group><article-title>Clinical advances and ongoing trials on mRNA vaccines for cancer treatment</article-title><source>Lancet Oncol</source><year>2022</year><volume>23</volume><issue>10</issue><fpage>e450</fpage><lpage>e458</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(22)00372-2</pub-id><pub-id pub-id-type="pmid">36174631</pub-id><pub-id pub-id-type="pmcid">PMC9512276</pub-id></element-citation><mixed-citation id="mc-CR352" publication-type="journal">Lorentzen CL, Haanen JB, Met O, Svane IM. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022;23(10):e450&#8211;8.<pub-id pub-id-type="pmid">36174631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(22)00372-2</pub-id><pub-id pub-id-type="pmcid">PMC9512276</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR353"><label>353.</label><citation-alternatives><element-citation id="ec-CR353" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ji</surname><given-names>M</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><etal/></person-group><article-title>The quest for nanoparticle-powered vaccines in cancer immunotherapy</article-title><source>J Nanobiotechnology</source><year>2024</year><volume>22</volume><issue>1</issue><fpage>61</fpage><pub-id pub-id-type="doi">10.1186/s12951-024-02311-z</pub-id><pub-id pub-id-type="pmid">38355548</pub-id><pub-id pub-id-type="pmcid">PMC10865557</pub-id></element-citation><mixed-citation id="mc-CR353" publication-type="journal">Sun Z, Zhao H, Ma L, Shi Y, Ji M, Sun X, et al. The quest for nanoparticle-powered vaccines in cancer immunotherapy. J Nanobiotechnology. 2024;22(1):61.<pub-id pub-id-type="pmid">38355548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-024-02311-z</pub-id><pub-id pub-id-type="pmcid">PMC10865557</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR354"><label>354.</label><citation-alternatives><element-citation id="ec-CR354" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Cui</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X</given-names></name><etal/></person-group><article-title>Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy</article-title><source>J Adv Res</source><year>2022</year><volume>35</volume><fpage>49</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.jare.2021.08.011</pub-id><pub-id pub-id-type="pmid">35003793</pub-id><pub-id pub-id-type="pmcid">PMC8721234</pub-id></element-citation><mixed-citation id="mc-CR354" publication-type="journal">Jiang M, Zhao L, Cui X, Wu X, Zhang Y, Guan X, et al. Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy. J Adv Res. 2022;35:49&#8211;60.<pub-id pub-id-type="pmid">35003793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jare.2021.08.011</pub-id><pub-id pub-id-type="pmcid">PMC8721234</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR355"><label>355.</label><citation-alternatives><element-citation id="ec-CR355" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name></person-group><article-title>mRNA-based therapeutics in cancer treatment</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><issue>2</issue><fpage>622</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics15020622</pub-id><pub-id pub-id-type="pmid">36839944</pub-id><pub-id pub-id-type="pmcid">PMC9964383</pub-id></element-citation><mixed-citation id="mc-CR355" publication-type="journal">Sun H, Zhang Y, Wang G, Yang W, Xu Y. mRNA-based therapeutics in cancer treatment. Pharmaceutics. 2023;15(2):622.<pub-id pub-id-type="pmid">36839944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15020622</pub-id><pub-id pub-id-type="pmcid">PMC9964383</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR356"><label>356.</label><citation-alternatives><element-citation id="ec-CR356" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Ma</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R</given-names></name><etal/></person-group><article-title>In Situ Transforming RNA Nanovaccines from Polyethylenimine Functionalized Graphene Oxide Hydrogel for Durable Cancer Immunotherapy</article-title><source>Nano Lett</source><year>2021</year><volume>21</volume><issue>5</issue><fpage>2224</fpage><lpage>2231</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.0c05039</pub-id><pub-id pub-id-type="pmid">33594887</pub-id></element-citation><mixed-citation id="mc-CR356" publication-type="journal">Yin Y, Li X, Ma H, Zhang J, Yu D, Zhao R, et al. In Situ Transforming RNA Nanovaccines from Polyethylenimine Functionalized Graphene Oxide Hydrogel for Durable Cancer Immunotherapy. Nano Lett. 2021;21(5):2224&#8211;31.<pub-id pub-id-type="pmid">33594887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.0c05039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR357"><label>357.</label><mixed-citation publication-type="other">Orlandini von Niessen AG, Poleganov MA, Rechner C, Plaschke A, Kranz LM, Fesser S, et al. Improving mRNA-based therapeutic gene delivery by expression-augmenting 3' UTRs identified by cellular library screening. Mol Ther. 2019;27(4):824&#8211;36.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2018.12.011</pub-id><pub-id pub-id-type="pmcid">PMC6453560</pub-id><pub-id pub-id-type="pmid">30638957</pub-id></mixed-citation></ref><ref id="CR358"><label>358.</label><citation-alternatives><element-citation id="ec-CR358" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S</given-names></name><name name-style="western"><surname>Shin</surname><given-names>H</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><etal/></person-group><article-title>Sequential and timely combination of a cancer nanovaccine with immune checkpoint blockade effectively inhibits tumor growth and relapse</article-title><source>Angew Chem Int Ed Engl</source><year>2020</year><volume>59</volume><issue>34</issue><fpage>14628</fpage><lpage>14638</lpage><pub-id pub-id-type="doi">10.1002/anie.202006117</pub-id><pub-id pub-id-type="pmid">32430981</pub-id></element-citation><mixed-citation id="mc-CR358" publication-type="journal">Kim Y, Kang S, Shin H, Kim T, Yu B, Kim J, et al. Sequential and timely combination of a cancer nanovaccine with immune checkpoint blockade effectively inhibits tumor growth and relapse. Angew Chem Int Ed Engl. 2020;59(34):14628&#8211;38.<pub-id pub-id-type="pmid">32430981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.202006117</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR359"><label>359.</label><citation-alternatives><element-citation id="ec-CR359" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name></person-group><article-title>Engineering customized nanovaccines for enhanced cancer immunotherapy</article-title><source>Bioact Mater</source><year>2024</year><volume>36</volume><fpage>330</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">38496036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2024.02.028</pub-id><pub-id pub-id-type="pmcid">PMC10940734</pub-id></element-citation><mixed-citation id="mc-CR359" publication-type="journal">Guo J, Liu C, Qi Z, Qiu T, Zhang J, Yang H. Engineering customized nanovaccines for enhanced cancer immunotherapy. Bioact Mater. 2024;36:330&#8211;57.<pub-id pub-id-type="pmid">38496036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2024.02.028</pub-id><pub-id pub-id-type="pmcid">PMC10940734</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR360"><label>360.</label><citation-alternatives><element-citation id="ec-CR360" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lane</surname><given-names>LA</given-names></name><name name-style="western"><surname>Qian</surname><given-names>X</given-names></name><name name-style="western"><surname>Smith</surname><given-names>AM</given-names></name><name name-style="western"><surname>Nie</surname><given-names>S</given-names></name></person-group><article-title>Physical chemistry of nanomedicine: understanding the complex behaviors of nanoparticles in vivo</article-title><source>Annu Rev Phys Chem</source><year>2015</year><volume>66</volume><fpage>521</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1146/annurev-physchem-040513-103718</pub-id><pub-id pub-id-type="pmid">25622189</pub-id><pub-id pub-id-type="pmcid">PMC8590374</pub-id></element-citation><mixed-citation id="mc-CR360" publication-type="journal">Lane LA, Qian X, Smith AM, Nie S. Physical chemistry of nanomedicine: understanding the complex behaviors of nanoparticles in vivo. Annu Rev Phys Chem. 2015;66:521&#8211;47.<pub-id pub-id-type="pmid">25622189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-physchem-040513-103718</pub-id><pub-id pub-id-type="pmcid">PMC8590374</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR361"><label>361.</label><citation-alternatives><element-citation id="ec-CR361" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>XQ</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>N</given-names></name><name name-style="western"><surname>Pridgen</surname><given-names>E</given-names></name><name name-style="western"><surname>Swami</surname><given-names>A</given-names></name><name name-style="western"><surname>Farokhzad</surname><given-names>OC</given-names></name></person-group><article-title>Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine</article-title><source>Adv Drug Deliv Rev</source><year>2012</year><volume>64</volume><issue>13</issue><fpage>1363</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2012.08.005</pub-id><pub-id pub-id-type="pmid">22917779</pub-id><pub-id pub-id-type="pmcid">PMC3517211</pub-id></element-citation><mixed-citation id="mc-CR361" publication-type="journal">Zhang XQ, Xu X, Bertrand N, Pridgen E, Swami A, Farokhzad OC. Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev. 2012;64(13):1363&#8211;84.<pub-id pub-id-type="pmid">22917779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2012.08.005</pub-id><pub-id pub-id-type="pmcid">PMC3517211</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR362"><label>362.</label><citation-alternatives><element-citation id="ec-CR362" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poon</surname><given-names>W</given-names></name><name name-style="western"><surname>Kingston</surname><given-names>BR</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>B</given-names></name><name name-style="western"><surname>Ngo</surname><given-names>W</given-names></name><name name-style="western"><surname>Chan</surname><given-names>WCW</given-names></name></person-group><article-title>A framework for designing delivery systems</article-title><source>Nat Nanotechnol</source><year>2020</year><volume>15</volume><issue>10</issue><fpage>819</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1038/s41565-020-0759-5</pub-id><pub-id pub-id-type="pmid">32895522</pub-id></element-citation><mixed-citation id="mc-CR362" publication-type="journal">Poon W, Kingston BR, Ouyang B, Ngo W, Chan WCW. A framework for designing delivery systems. Nat Nanotechnol. 2020;15(10):819&#8211;29.<pub-id pub-id-type="pmid">32895522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41565-020-0759-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR363"><label>363.</label><citation-alternatives><element-citation id="ec-CR363" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Nie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liao</surname><given-names>G</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Overcoming the reticuloendothelial system barrier to drug delivery with a "Don't-Eat-Us" strategy</article-title><source>ACS Nano</source><year>2019</year><volume>13</volume><issue>11</issue><fpage>13015</fpage><lpage>13026</lpage><pub-id pub-id-type="doi">10.1021/acsnano.9b05679</pub-id><pub-id pub-id-type="pmid">31689086</pub-id></element-citation><mixed-citation id="mc-CR363" publication-type="journal">Tang Y, Wang X, Li J, Nie Y, Liao G, Yu Y, et al. Overcoming the reticuloendothelial system barrier to drug delivery with a &#8220;Don&#8217;t-Eat-Us&#8221; strategy. ACS Nano. 2019;13(11):13015&#8211;26.<pub-id pub-id-type="pmid">31689086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.9b05679</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR364"><label>364.</label><citation-alternatives><element-citation id="ec-CR364" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danhier</surname><given-names>F</given-names></name><name name-style="western"><surname>Feron</surname><given-names>O</given-names></name><name name-style="western"><surname>Preat</surname><given-names>V</given-names></name></person-group><article-title>To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery</article-title><source>J Control Release</source><year>2010</year><volume>148</volume><issue>2</issue><fpage>135</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2010.08.027</pub-id><pub-id pub-id-type="pmid">20797419</pub-id></element-citation><mixed-citation id="mc-CR364" publication-type="journal">Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148(2):135&#8211;46.<pub-id pub-id-type="pmid">20797419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2010.08.027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR365"><label>365.</label><citation-alternatives><element-citation id="ec-CR365" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>R</given-names></name><name name-style="western"><surname>Hemmati</surname><given-names>HD</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R</given-names></name><name name-style="western"><surname>Kohane</surname><given-names>DS</given-names></name></person-group><article-title>Photoswitchable nanoparticles for triggered tissue penetration and drug delivery</article-title><source>J Am Chem Soc</source><year>2012</year><volume>134</volume><issue>21</issue><fpage>8848</fpage><lpage>8855</lpage><pub-id pub-id-type="doi">10.1021/ja211888a</pub-id><pub-id pub-id-type="pmid">22385538</pub-id><pub-id pub-id-type="pmcid">PMC3363369</pub-id></element-citation><mixed-citation id="mc-CR365" publication-type="journal">Tong R, Hemmati HD, Langer R, Kohane DS. Photoswitchable nanoparticles for triggered tissue penetration and drug delivery. J Am Chem Soc. 2012;134(21):8848&#8211;55.<pub-id pub-id-type="pmid">22385538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ja211888a</pub-id><pub-id pub-id-type="pmcid">PMC3363369</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR366"><label>366.</label><citation-alternatives><element-citation id="ec-CR366" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blanco</surname><given-names>E</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>M</given-names></name></person-group><article-title>Principles of nanoparticle design for overcoming biological barriers to drug delivery</article-title><source>Nat Biotechnol</source><year>2015</year><volume>33</volume><issue>9</issue><fpage>941</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1038/nbt.3330</pub-id><pub-id pub-id-type="pmid">26348965</pub-id><pub-id pub-id-type="pmcid">PMC4978509</pub-id></element-citation><mixed-citation id="mc-CR366" publication-type="journal">Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941&#8211;51.<pub-id pub-id-type="pmid">26348965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.3330</pub-id><pub-id pub-id-type="pmcid">PMC4978509</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR367"><label>367.</label><citation-alternatives><element-citation id="ec-CR367" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niculescu</surname><given-names>AG</given-names></name><name name-style="western"><surname>Grumezescu</surname><given-names>AM</given-names></name></person-group><article-title>Novel tumor-targeting nanoparticles for cancer treatment-a review</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>9</issue><fpage>5253</fpage><pub-id pub-id-type="doi">10.3390/ijms23095253</pub-id><pub-id pub-id-type="pmid">35563645</pub-id><pub-id pub-id-type="pmcid">PMC9101878</pub-id></element-citation><mixed-citation id="mc-CR367" publication-type="journal">Niculescu AG, Grumezescu AM. Novel tumor-targeting nanoparticles for cancer treatment-a review. Int J Mol Sci. 2022;23(9):5253.<pub-id pub-id-type="pmid">35563645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23095253</pub-id><pub-id pub-id-type="pmcid">PMC9101878</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR368"><label>368.</label><citation-alternatives><element-citation id="ec-CR368" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mi</surname><given-names>P</given-names></name></person-group><article-title>Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><issue>10</issue><fpage>4557</fpage><lpage>4588</lpage><pub-id pub-id-type="doi">10.7150/thno.38069</pub-id><pub-id pub-id-type="pmid">32292515</pub-id><pub-id pub-id-type="pmcid">PMC7150471</pub-id></element-citation><mixed-citation id="mc-CR368" publication-type="journal">Mi P. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. Theranostics. 2020;10(10):4557&#8211;88.<pub-id pub-id-type="pmid">32292515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.38069</pub-id><pub-id pub-id-type="pmcid">PMC7150471</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR369"><label>369.</label><citation-alternatives><element-citation id="ec-CR369" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Mettenbrink</surname><given-names>EM</given-names></name><name name-style="western"><surname>DeAngelis</surname><given-names>PL</given-names></name><name name-style="western"><surname>Wilhelm</surname><given-names>S</given-names></name></person-group><article-title>Nanoparticle toxicology</article-title><source>Annu Rev Pharmacol Toxicol</source><year>2021</year><volume>61</volume><fpage>269</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-032320-110338</pub-id><pub-id pub-id-type="pmid">32841092</pub-id></element-citation><mixed-citation id="mc-CR369" publication-type="journal">Yang W, Wang L, Mettenbrink EM, DeAngelis PL, Wilhelm S. Nanoparticle toxicology. Annu Rev Pharmacol Toxicol. 2021;61:269&#8211;89.<pub-id pub-id-type="pmid">32841092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-pharmtox-032320-110338</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>